Substituted 2-azabicycles and their use as orexin receptor modulators

ABSTRACT

The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.61/780,378, filed Mar. 13, 2013, which is incorporated herein byreference in its entirety.

TECHNICAL FIELD

The present invention is directed to substituted 2-azabicycliccompounds, pharmaceutical compositions comprising them, methods ofmaking them, and methods of using them for the modulation of the orexinreceptor for the treatment of disease states, disorders, and conditionsmediated by orexin receptor activity.

BACKGROUND

Orexin/hypocretin signaling is mediated by two receptors and two peptideagonists. The peptides (orexin-A and orexin-B) are cleavage products ofthe same gene, pre-pro orexin. In the central nervous system, neuronsproducing pre-pro orexin are found solely in the perifornical nucleus,the dorsal hypothalamus, and the lateral hypothalamus (Peyron et al.,1998, J. Neurosci. 18: 9996-10015). Orexigenic cells in these regionsproject to many areas of the brain, extending rostrally to the olfactorybulbs and caudally to the spinal cord (Van den Pol, 1999, J. Neurosci.19: 3171-3182).

The orexins bind to two high affinity receptors, referred to as orexin-1and orexin-2 receptors. Orexin-1 and orexin-2 receptors areG-protein-coupled, seven transmembrane receptors that share over 64%amino acid sequence identity with one another. Both receptors aregenerally excitatory, the common cellular response to orexin-inducedreceptor activation being increases in intracellular calcium. Homologybetween the species orthologs is high and there are no knownpharmacological differences. Orexin-A and -B are usually consideredequal ligands for orexin-2 receptor but orexin-B is thought to be 5- to100-fold weaker ligand than orexin-A at the orexin-1 receptor (Sakuraiet al., 1998, Cell 92: 573-585; Ammoun et al., 2003, J. Pharmacol. Exp.Ther. 305: 507-514).

Many regions of the brain have fairly selective expression of theorexin-1 or orexin-2 receptors (Marcus et al., 2001, J. Comp Neurology435, 6-25; Trivedi et al., 1998, FEBS Letters, 438, 71-75). Orexin-1receptors are selective for the limbic system (bed nucleus of the striaterminalis and amygdala), cingulate cortex and noradrenergic neurons inthe locus coeruleus. Conversely, the orexin-2 receptor is almost theexclusive orexin receptor in the histaminergic neurons in thetuberomammilary nucleus which play a critical role in wake promotion; inparaventricular neurons and the parabrachial nucleus. In other brainregions like the dorsal raphe, the ventral tegmental area or theprefontal cortex both receptors are coexpressed.

The broad CNS distribution of cells producing orexin, as well as cellsexpressing the orexin receptors, suggests involvement of orexin in anumber of physiological functions, including feeding and metabolism,regulation of wakefulness and sleep, sympathetic activation and stressresponse (de Lecea, 2012, Progress in Brain Research, 198, 15-24;Kukkonen, 2013, Am J. Physiol. Cell Physiol., 304, C2-C32). Orexin alsoplays a key role regulating motivation and reward associated with foodintake and with drugs of abuse (Mahler et al., 2012, Progress in BrainResearch, 198, 79-121).

Several lines of evidence indicate that the orexin system is animportant modulator of arousal. Rodents administered orexinintracerebroventricularly spend more time awake (Piper et al., 2000, J.Neurosci. 12: 726-730. Orexin-mediated effects on arousal have beenlinked to orexin neuronal projections to histaminergic neurons in thetuberomammillary nucleus (Yamanaka et al., 2002, Biochem. Biophys. Res.Comm. 290: 1237-1245). Rodents whose pre-pro orexin gene has beenknocked out, or whose orexigenic neurons have been killed, displayaltered sleep/wake cycles similar to narcolepsy (Chemelli et al., 1999,Cell 98: 437-451; Hara et al., 2001, Neuron 30: 345-354). Dog models ofnarcolepsy have been shown to have mutant or non-functional orexin-2receptors (Lin et al., 1999, Cell 98: 365-376). Orexin signaling as atarget for sleep-promoting therapies was further validated clinically byfindings of attenuated orexin levels and loss of orexinergic neurons inhuman narcoleptic patients (Mignot et al., 2001, Am. J. Hum. Genet. 68:686-699; Minot & Thorsby, 2001, New England J. Med. 344: 692) or, inrare cases, to mutations in the orexin-2 gene (Peyron et al., 2000,Nature Med. 6: 991-997). Disorders of the sleep-wake cycle are thereforelikely targets for orexin-2 receptor modulator activity. Examples ofsleep-wake disorders that may be treated by agonists or other modulatorsthat up-regulate orexin-2 receptor-mediated processes includenarcolepsy, jet lag (sleepiness) and sleep disorders secondary toneurological disorders such as depression. Examples of disorders thatmay be treated by antagonists or other modulators that down-regulateorexin-2 receptor-mediated processes include insomnia, restless legsyndrome, jet lag (wakefulness) and sleep disorders secondary toneurological disorders such as mania, schizophrenia, pain syndromes andthe like.

Evidence has accumulated to demonstrate a clear involvement of orexinsignaling in reward pathways associated with drug dependence (Mahler etal., 2012, Progress in Brain Research, 198, 79-121). Orexinergic neuronssend projections to the ventral tegmental area and other brain regionsinvolved in reward processing. Orexin ligands mediate reward behavior,and antagonizing these effects with a selective orexin-1 receptorantagonist in various preclinical model of addiction has suggested thatthese actions are mediated through orexin-1 receptor. Specifically, aselective orexin-1 antagonist attenuates morphine conditioned placepreference and reinstatement (Harris et al., 2005, Nature, 437,556-5599; Narita et al., 2006, J Neurosci., 26, 398-405; Harris et al.,2007, Behav Brain Res, 183, 43-51), stress-induced cocainereinstatement, cocaine-induced behavioral and synaptic plasticity(Borgland et al., 2006, Neuron, 49, 589-601), and intake and cue andstress-induced reinstatement of ethanol (Lawrence et al., 2006, Br JPharmacol, 148, 752-759), in addition to attenuating precipitatedmorphine withdrawal (Sharf et al., 2008, Biol Psychiatry, 64, 175-183)and nicotine self-administration (Hollander et al., 2008, Proc Natl AcadSci USA., 105, 19480-19485). Another recent study has also suggested arole for OX2R (Shoblock et al., 2011, Psychopharmacology, 215, 191-203).

Orexin's role in more complex emotional behavior is also emerging(Johnson et al., 2012, Progress in Brain Research, 198, 133-161).Changes in orexin levels in patients with panic and posttraumatic stressdisorders have been noted as have changes in the prevalence of anxietybehaviors in narcoleptic patients (Johnson et al., 2010, NatureMedicine, 16, 111-115; Fortuyn et al., 2010, General HospitalPsychiatry, 32, 49-56; Strawn et al., 2010, Psychoneuroendocrinology,35, 1001-1007). Lactate infusion or acute hypercapnia, which causespanic in humans, and are used as an animal model of panic, activatesorexin neurons in the perifornical hypothalamus. This activationcorrelates with anxiety in the social interaction test or open fieldtest. Blocking orexin signaling with either siRNA or selective orexin-1receptor antagonists attenuates panic-like responses to lactate (Johnsonet al., 2010, Nature Medicine, 16, 111-115; Johnson et al., 2012,Neuropsychopharmacology, 37, 1911, 1922).

Cerebral spinal fluid (CSF) levels of orexin are lower in depressed orsuicidal patients, and the level of orexin inversely correlates withillness severity (Brundin et al., 2007, EuropeanNeuropsychopharmacology, 17, 573-579; Salomon et al., 2003, BiolPsychiatry, 54, 96-104). A positive correlation between orexin-1receptor mRNA in the amygdala and depressive behavior in the forced swimtest in mice has been reported (Arendt, 2013, Behavioral Neuroscience,127, 86-94).

The orexin system also interacts with brain dopamine systems.Intracerebroventricular injections of orexin in mice increase locomotoractivity, grooming and stereotypy; these behavioral effects are reversedby administration of D2 dopamine receptor antagonists (Nakamura et al.,2000, Brain Res. 873: 181-187). Therefore, orexin receptor modulatorsmay be useful to treat various neurological disorders; e.g., agonists orup-regulators to treat catatonia, antagonists or down-regulators totreat Parkinson's disease, Tourette's syndrome, anxiety, delerium anddementias.

Orexins and their receptors have been found in both the myenteric andsubmucosal plexus of the enteric nervous system, where orexins have beenshown to increase motility in vitro (Kirchgessner & Liu, 1999, Neuron24: 941-951) and to stimulate gastric acid secretion in vitro (Takahashiet al., 1999, Biochem. Biophys. Res. Comm. 254: 623-627). Orexin effectson the gut may be driven by a projection via the vagus nerve (van denPol, 1999, supra), as vagotomy or atropine prevent the effect of anintracerebroventricular injection of orexin on gastric acid secretion(Takahashi et al., 1999, supra). Orexin receptor antagonists or otherdown-regulators of orexin receptor-mediated systems are thereforepotential treatments for ulcers, irritable bowel syndrome, diarrhea andgastroesophageal reflux.

Body weight may also be affected by orexin-mediated regulation ofappetite and metabolism. Some effects of orexin on metabolism andappetite may be mediated in the gut, where, as mentioned, orexins altergastric motility and gastric acid secretion. Orexin antagoniststherefore are likely to be useful in treatment of overweight or obesityand conditions related to overweight or obesity, such as insulinresistance/type II diabetes, hyperlipidemia, gallstones, angina,hypertension, breathlessness, tachycardia, infertility, sleep apnea,back and joint pain, varicose veins and osteoarthritis. Conversely,orexin agonists are likely to be useful in treatment of underweight andrelated conditions such as hypotension, bradycardia, ammenorrhea andrelated infertility, and eating disorders such as anorexia and bulimia.

Intracerebroventricularly administered orexins have been shown toincrease mean arterial pressure and heart rate in freely moving (awake)animals (Samson et al., 1999, Brain Res. 831: 248-253; Shirasaka et al.,1999, Am. J. Physiol. 277: R1780-R1785) and in urethane-anesthetizedanimals (Chen et al., 2000, Am. J. Physiol. 278: R692-R697), withsimilar results. Orexin receptor agonists may therefore be candidatesfor treatment of hypotension, bradycardia and heart failure relatedthereto, while orexin receptor antagonists may be useful for treatmentof hypertension, tachycardia and other arrhythmias, angina pectoris andacute heart failure.

From the foregoing discussion, it can be seen that the identification oforexin receptor modulators, will be of great advantage in thedevelopment of therapeutic agents for the treatment of a wide variety ofdisorders that are mediated through these receptor systems.

SUMMARY

The present invention is directed to compounds of Formula I:

wherein X is N or CR₁; Y is N or CR₂; R₁ is H, alkoxy, halo, triazolyl,thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl,pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl orpyrazolyl is optionally substituted with up to two substituents selectedfrom halo and alkyl; R₂ is H, alkyl, alkoxy, or halo; Z is NH, N—CH₃,N—CH₂CH₃, N—CH₂-cyclopropyl, N—C(═O)CH₃, N—CH₂CH₂OCH₃ or O; R₃ is H,alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl,oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, whereintriazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted withup to two substituents selected from halo and alkyl; R₄ is H or alkyl;or R₃ and R₄, together with the atoms to which they are attached, form a6-membered aryl ring or a 5-membered or 6-membered heteroaryl ring; R₅is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl orpyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl,naphthyridinyl or pyrimidinyl is optionally substituted with up to twogroups selected from halo, alkoxy, hydroxymethyl and alkyl; and n is 1or 2. Enantiomers and diastereomers of the compounds of Formula I arealso described, as well as the pharmaceutically acceptable salts.

Methods of making the compounds of Formula I are also described. Theinvention also relates to pharmaceutical compositions comprisingtherapeutically effective amounts of compounds of Formula I. Methods ofusing the compounds of the invention are also within the scope of theinvention.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 depicts an Oak Ridge Thermal Ellipsoid Plot Program (ORTEP),shown at 40% probability level, of one embodiment of the invention,Example 13.

FIG. 2 depicts an ORTEP, shown at 40% probability level, of oneembodiment of the invention, Example 14.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The invention may be more fully appreciated by reference to thefollowing description, including the following glossary of terms and theconcluding examples.

The term “alkyl” refers to a straight- or branched-chain alkyl grouphaving from 1 to 12 carbon atoms in the chain. In some embodiments, analkyl group is a C₁-C₆ alkyl group. In some embodiments, an alkyl groupis a C₁-C₄ alkyl group. Examples of alkyl groups include methyl (Me)ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl(tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups thatin light of the ordinary skill in the art and the teachings providedherein would be considered equivalent to any one of the foregoingexamples. Alkyl groups of the invention can be substituted with, forexample, halogen atoms. One exemplary substitutent is fluoro. Preferredsubstituted alkyl groups of the invention include trihalogenated alkylgroups such as trifluoromethyl groups.

Alkyl groups of the invention can also refer to “cycloalkyl” moieties.Cycloalkyl refers to monocyclic, non-aromatic hydrocarbon groups havingfrom 3 to 7 carbon atoms. Examples of cycloalkyl groups include, forexample, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,1-methylcyclopropyl, 2-methylcyclopentyl, and the like.

The term “alkoxy” includes a straight chain or branched alkyl group witha terminal oxygen linking the alkyl group to the rest of the molecule.In some embodiments, an alkoxy group is a C₁-C₆ alkoxy group. In someembodiments, an alkoxy group is a C₁-C₄ alkoxy group. Alkoxy includesmethoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and soon.

The term “aryl ring” represents” a mono- or bi-cyclic aromatic,hydrocarbon ring structure. Aryl rings can have 6 or 10 carbon atoms inthe ring.

The term “halogen” represents chlorine, fluorine, bromine, or iodine.The term “halo” represents chloro, fluoro, bromo, or iodo.

The term “heteroaryl ring” represents a mono- or bicyclic aromatic ringstructure including carbon atoms as well as up to four heteroatomsselected from nitrogen, oxygen, and sulfur. Heteroaryl rings can includea total of 5, 6, 9, or 10 ring atoms.

The term “isoxazolyl” represents the following moiety:

The term “isoxazolyl” represents the following moiety:

The isoxazolyl moiety can be attached through any one of the 3-, 4-, or5-position carbon atoms. Isoxazolyl groups of the invention can beoptionally substituted with, for example, one or two alkyl groups, forexample, one or two methyl groups.

The term “oxazolyl” represents the following moiety:

The oxazolyl moiety can be attached through any one of the carbon atoms.

The term “oxadiazolyl” represents a 1,2,3-oxadiazole, 1,2,4-oxadiazole,1,2,5-oxadiazole, or 1,3,4-oxadiazole moiety:

The oxadiazolyl moieties can be attached through any one of the carbonor nitrogen atoms. Within the scope of the invention, “oxadiazolyl”groups can be substituted with an alkyl or halo group, preferably amethyl group.

The term “pyridyl” represents the following moiety:

The pyridyl moiety can be attached through any one of the 2-, 3-, 4-,5-, or 6-position carbon atoms.

The term “pyrimidinyl” represents the following moiety:

The pyrimidinyl moiety can be attached through any one of the 2-, 4-,5-, or 6-position carbon atoms. Within the scope of the invention,“pyrimidinyl” groups of the invention can be substituted with halogen,for example fluoro, or alkyl, for example methyl.

The term “pyrazinyl” represents the following moiety:

The pyrazinyl moiety can be attached through any one of the 2-, 3-, 5-,or 6-position carbon atoms.

The term “pyridazinyl” represents the following moiety:

The pyridazinyl moiety can be attached through any one of the 3-, 4-,5-, or 6-position carbon atoms.

The term “pyrazolyl” represents the following moiety:

The pyrazolyl moiety can be attached through any one of the 1-, 2-, 3-,4-, or 5-position carbon atoms. Pyrazolyl groups of the invention can beoptionally substituted with, for example, one or two alkyl groups, forexample, one or two methyl groups.

The term “triazolyl” represents a 1,2,3-triazole or a 1,2,4-triazolemoiety:

The triazolyl moieties can be attached through any one of their atoms.

The term “imidazolyl” represents the following moiety:

The imidazolyl moiety can be attached through any one of the 2-, 4-, or5-position carbon atoms, or via the N-1 nitrogen atom. Imidazolyl groupsof the invention can be optionally substituted with, for example, one ortwo alkyl groups, for example, one or two methyl groups.

The term “thiazolyl” represents the following moiety:

The thiazolyl moiety can be attached through any one of the carbonatoms. Thiazolyl groups of the invention can be optionally substitutedwith, for example, one or two alkyl groups, for example, one or twomethyl groups.

The term “naphthyridinyl” represents the following moiety:

The naphthyridinyl moiety can be attached through any one of the carbonatoms. Naphthyridinyl groups of the invention can be optionallysubstituted with, for example, one or two alkyl groups, for example, oneor two methyl groups, or halo groups.

The term “imidazothiazolyl” represents the following moiety:

The imidazothiazolyl moiety can be attached through any one of thecarbon atoms. imidazothiazolyl groups of the invention can be optionallysubstituted with, for example, one or two alkyl groups, for example, oneor two methyl groups.

“Pharmaceutically acceptable” means approved or approvable by aregulatory agency of the Federal or a state government or thecorresponding agency in countries other than the United States, or thatis listed in the U.S. Pharmacopoeia or other generally recognizedpharmacopoeia for use in animals, and more particularly, in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of theinvention that is pharmaceutically acceptable and that possesses thedesired pharmacological activity of the parent compound. In particular,such salts are non-toxic may be inorganic or organic acid addition saltsand base addition salts. Specifically, such salts include: (1) acidaddition salts, formed with inorganic acids such as hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and thelike; or formed with organic acids such as acetic acid, propionic acid,hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid,lactic acid, malonic acid, succinic acid, malic acid, maleic acid,fumaric acid, tartaric acid, citric acid, benzoic acid,3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid,methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid,2-hydroxyethanesulfonic acid, benzenesulfonic acid,4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,4-toluenesulfonic acid, camphorsulfonic acid,4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid,3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid,lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoicacid, salicylic acid, stearic acid, muconic acid, and the like; or (2)salts formed when an acidic proton present in the parent compound eitheris replaced by a metal ion, e.g., an alkali metal ion, an alkaline earthion, or an aluminum ion; or coordinates with an organic base such asethanolamine, diethanolamine, triethanolamine, N-methylglucamine and thelike. Salts further include, by way of example only, sodium, potassium,calcium, magnesium, ammonium, tetraalkylammonium, and the like; and whenthe compound contains a basic functionality, salts of non toxic organicor inorganic acids, such as hydrochloride, hydrobromide, tartrate,mesylate, acetate, maleate, oxalate and the like.

“Pharmaceutically acceptable vehicle” refers to a diluent, adjuvant,excipient or carrier with which a compound of the invention isadministered. A “pharmaceutically acceptable excipient” refers to asubstance that is non-toxic, biologically tolerable, and otherwisebiologically suitable for administration to a subject, such as an inertsubstance, added to a pharmacological composition or otherwise used as avehicle, carrier, or diluent to facilitate administration of a agent andthat is compatible therewith. Examples of excipients include calciumcarbonate, calcium phosphate, various sugars and types of starch,cellulose derivatives, gelatin, vegetable oils, and polyethyleneglycols.

“Subject” includes humans. The terms “human,” “patient,” and “subject”are used interchangeably herein.

“Treating” or “treatment” of any disease or disorder refers, in oneembodiment, to ameliorating the disease or disorder (i.e., arresting orreducing the development of the disease or at least one of the clinicalsymptoms thereof). In another embodiment “treating” or “treatment”refers to ameliorating at least one physical parameter, which may not bediscernible by the subject. In yet another embodiment, “treating” or“treatment” refers to modulating the disease or disorder, eitherphysically, (e.g., stabilization of a discernible symptom),physiologically, (e.g., stabilization of a physical parameter), or both.In yet another embodiment, “treating” or “treatment” refers to delayingthe onset of the disease or disorder.

In treatment methods according to the invention, a therapeuticallyeffective amount of a pharmaceutical agent according to the invention isadministered to a subject suffering from or diagnosed as having such adisease, disorder, or condition. A “therapeutically effective amount”means an amount or dose sufficient to generally bring about the desiredtherapeutic or prophylactic benefit in patients in need of suchtreatment for the designated disease, disorder, or condition. Effectiveamounts or doses of the compounds of the present invention may beascertained by routine methods such as modeling, dose escalation studiesor clinical trials, and by taking into consideration routine factors,e.g., the mode or route of administration or drug delivery, thepharmacokinetics of the compound, the severity and course of thedisease, disorder, or condition, the subject's previous or ongoingtherapy, the subject's health status and response to drugs, and thejudgment of the treating physician. An example of a dose is in the rangeof from about 0.001 to about 200 mg of compound per kg of subject's bodyweight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). Fora 70-kg human, an illustrative range for a suitable dosage amount isfrom about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

“Compounds of the present invention,” and equivalent expressions, aremeant to embrace compounds of the Formula (I) as described herein, whichexpression includes the pharmaceutically acceptable salts, and thesolvates, e.g., hydrates, where the context so permits. Similarly,reference to intermediates, whether or not they themselves are claimed,is meant to embrace their salts, and solvates, where the context sopermits.

As used herein, the term “isotopic variant” refers to a compound thatcontains unnatural proportions of isotopes at one or more of the atomsthat constitute such compound. For example, an “isotopic variant” of acompound can be radiolabeled, that is, contain one or morenon-radioactive or radioactive isotopes, such as for example, deuterium(²H or D), carbon-13 (¹³C), nitrogen-15 (¹⁵N), or the like. It will beunderstood that, in a compound where such isotopic substitution is made,the following atoms, where present, may vary, so that for example, anyhydrogen may be ²H/D, any carbon may be ¹³C, or any nitrogen may be ¹⁵N,and that the presence and placement of such atoms may be determinedwithin the skill of the art. Likewise, the invention may include thepreparation of isotopic variants with radioisotopes, in the instance forexample, where the resulting compounds may be used for drug and/orsubstrate tissue distribution studies. Radiolabeled compounds of theinvention can be used in diagnostic methods such as Single-photonemission computed tomography (SPECT). The radioactive isotopes tritium,i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for their easeof incorporation and ready means of detection. Further, compounds may beprepared that are substituted with positron emitting isotopes, such as¹¹C, ¹⁸F, ¹⁵O and ¹³N, and would be useful in Positron EmissionTopography (PET) studies for examining substrate receptor occupancy.

All isotopic variants of the compounds of the invention, radioactive ornot, are intended to be encompassed within the scope of the invention.In one aspect, provided herein are deuterated analogs of compounds ofFormula I as described in the Examples section. In one embodiment,deuterated analogs of compounds of Formula I comprise deuterium atomsattached to one or more positions on the 2-azabicyclic ring, such asbridgehead carbons, or non-bridgehead carbons of the 2-azabicyclic ring,and preferably comprise one or more deuterium atoms attached tonon-bridgehead carbons of the 2-azabicyclic ring. Also contemplatedwithin the scope of embodiments described herein are compounds in whicha single proton in compounds of Formula I is replaced with a deuterium,or 2 protons in compounds of Formula I are replaced with deuterium, ormore than 2 protons in compounds of Formula I are replaced withdeuterium. Deuteration of a compound of Formula I may also be effectedon one or more substituents (such as e.g., ring A, R¹, R², or R⁵)present on the 2-azabicyclic ring.

It is also to be understood that compounds that have the same molecularformula but differ in the nature or sequence of bonding of their atomsor the arrangement of their atoms in space are termed “isomers.” Isomersthat differ in the arrangement of their atoms in space are termed“stereoisomers.”

Stereoisomers that are not mirror images of one another are termed“diastereomers” and those that are non-superimposable mirror images ofeach other are termed “enantiomers.” When a compound has an asymmetriccenter, for example, it is bonded to four different groups, a pair ofenantiomers is possible. An enantiomer can be characterized by theabsolute configuration of its asymmetric center and is described by theR- and S-sequencing rules of Cahn and Prelog, or by the manner in whichthe molecule rotates the plane of polarized light and designated asdextrorotatory or levorotatory (i.e., as (+) or (−)-isomersrespectively). A chiral compound can exist as either individualenantiomer or as a mixture thereof. A mixture containing equalproportions of the enantiomers is called a “racemic mixture.”

“Tautomers” refer to compounds that are interchangeable forms of aparticular compound structure, and that vary in the displacement ofhydrogen atoms and electrons. Thus, two structures may be in equilibriumthrough the movement of π electrons and an atom (usually H). Forexample, enols and ketones are tautomers because they are rapidlyinterconverted by treatment with either acid or base. Another example oftautomerism is the acid- and nitro-forms of phenyl nitromethane, thatare likewise formed by treatment with acid or base.

Tautomeric forms may be relevant to the attainment of the optimalchemical reactivity and biological activity of a compound of interest.

Compounds of the invention may also exist as “rotamers,” that is,conformational isomers that occur when the rotation leading to differentconformations is hindered, resulting a rotational energy barrier to beovercome to convert from one conformational isomer to another.

The compounds of this invention may possess one or more asymmetriccenters; such compounds can therefore be produced as individual (R)- or(S)-stereoisomers or as mixtures thereof.

Unless indicated otherwise, the description or naming of a particularcompound in the specification and claims is intended to include bothindividual enantiomers and mixtures, racemic or otherwise, thereof. Themethods for the determination of stereochemistry and the separation ofstereoisomers are well-known in the art.

The present invention is directed to compounds of Formula I:

wherein

-   -   X is N or CR₁    -   Y is N or CR₂    -   R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl is optionally substituted with up to two        substituents selected from halo and alkyl;    -   R₂ is H, alkyl, alkoxy, or halo;    -   Z is NH, N—CH₃, N—CH₂CH₃, N—CH₂-cyclopropyl, N—C(═O)CH₃,        N—CH₂CH₂OCH₃ or O;    -   R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl is optionally substituted with up to two        substituents selected from halo and alkyl;    -   R₄ is H or alkyl;        -   or R₃ and R₄, together with the atoms to which they are            attached, form a 6-membered aryl ring or a 5- or 6-membered            heteroaryl ring;    -   R₅ is phenyl, pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl,        naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl,        benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is        optionally substituted with up to two groups selected from halo,        alkoxy, hydroxymethyl and alkyl; and    -   n is 1 or 2.

In one aspect, the invention is directed to compounds of Formula I:

wherein

-   -   X is N or CR₁    -   Y is N or CR₂    -   R₁ is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl,        isoxazolyl, oxadiazolyl, or pyrazolyl;    -   R₂ is H, alkyl, alkoxy, or halo;    -   Z is NH, or O;    -   R₃ is H, alkyl, alkoxy, halo, or triazolyl;    -   R₄ is H or alkyl;        -   or R₃ and R₄, together with the atoms to which they are            attached, form a 6-membered aryl ring or a 5- or 6-membered            heteroaryl ring; R₅ is pyridyl, pyrazinyl, or pyrimidinyl,            wherein the pyridyl, pyrazinyl, or pyrimidinyl is        -   optionally substituted with halo or alkyl; and    -   n is 1 or 2.

Enantiomers and diastereomers of the compounds of Formula I are alsowithin the scope of the invention. Also within the scope of theinvention are the pharmaceutically acceptable salts of the compounds ofFormula I, as well as the pharmaceutically acceptable salts of theenantiomers and diastereomers of the compounds of Formula I. Also withinthe scope of the invention are isotopic variations of compounds ofFormula I, such as, e.g., deuterated compounds of Formula I.

In preferred embodiments, Z is NH. In other embodiments, Z is O. In yetother embodiments, Z is NH, N—CH₃, N—CH₂CH₃, N—CH₂-cyclopropyl,N—C(═O)CH₃, or N—CH₂CH₂OCH₃.

In preferred embodiments, X is CR₁ and Y is CR₂.

In other embodiments, X is CR₁ and Y is N.

In yet other embodiments, X is N and Y is CR₂.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is H. In other embodiments, R₁ isalkoxy, for example, C₁₋₆alkoxy such as methoxy or ethoxy.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is halo, preferably F, Cl, or Br.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is triazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, with1,2,3-triazolyl being preferred. In preferred embodiments, the1,2,3-triazolyl is attached through the 2-position nitrogen atom. Inother embodiments, the 1,2,3-triazolyl is attached through the1-position nitrogen atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is pyrimidinyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is oxazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is isoxazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is oxadiazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom. The oxadiazolyl group canoptionally be substituted with alkyl, for example methyl. In exemplaryembodiments, the substituted oxadiazolyl moiety is 1,2,4-oxadiazolylsubstituted with methyl.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is pyridyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom. The pyridyl group can optionally besubstituted with alkyl, for example methyl or halo.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is imidazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom. The imidazolyl group can optionallybe substituted with alkyl, for example methyl or halo.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is phenyl, optionally substituted withup to two substituents selected from halo and alkyl, which can beattached through any available atom. The phenyl group can optionally besubstituted with alkyl, for example methyl or halo.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is pyrazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom. The pyrazolyl group can optionallybe substituted with one or two C₁₋₆alkyl, for example methyl.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is thiazolyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom.

In those embodiments wherein X is CR₁, for example, where X is CR₁ and Yis CR₂ or X is CR₁ and Y is N, R₁ is pyridazinyl, optionally substitutedwith up to two substituents selected from halo and alkyl, which can beattached through any available atom.

In preferred embodiments wherein Y is CR₂, for example, X is CR₁ and Yis CR₂ or X is N and Y is CR₂, R₂ is H. In other embodiments, R₂ isalkyl, for example C₁₋₆alkyl such as methyl.

In those embodiments wherein Y is CR₂, for example, X is CR₁ and Y isCR₂ or X is N and Y is CR₂, R₂ is alkoxy, for example, C₁₋₆alkoxy suchas methoxy or ethoxy.

In those embodiments wherein Y is CR₂, for example, X is CR₁ and Y isCR₂ or X is N and Y is CR₂, R₂ is halo, preferably one of F, Cl, or Br.

In preferred embodiments, R₃ is H. In other embodiments, R₃ is alkyl,for example, C₁₋₆alkyl such as methyl.

In yet other embodiments, R₃ is alkoxy, for example, C₁₋₆alkoxy such asmethoxy or ethoxy.

In still other embodiments, R₃ is halo, preferably F, Cl, or Br.

In other embodiments, R₃ is triazolyl, with 1,2,3-triazolyl beingpreferred. In preferred embodiments, the 1,2,3-triazolyl is attachedthrough the 2-position nitrogen atom. In other embodiments, the1,2,3-triazolyl is attached through the 1-position nitrogen atom.

In preferred embodiments, R₄ is H. In other embodiments, R₃ is alkyl,for example C₁₋₆alkyl such as methyl.

In alternative embodiments, R₃ and R₄, together with the atoms to whichthey are attached, form a 6-membered aryl ring.

In other embodiments, R₃ and R₄, together with the atoms to which theyare attached, form a 5-membered heteroaryl ring. Preferably, the5-membered heteroaryl ring includes one nitrogen atom.

In other embodiments, R₃ and R₄, together with the atoms to which theyare attached, form a 6-membered heteroaryl ring. Preferably, the6-membered heteroaryl ring includes one nitrogen atom.

In some embodiments of the invention, R₅ is a phenyl ring optionallysubstituted with a one or two substituents independently selected fromthe group consisting of alkyl, cyano, alkoxy, and halo, or from thegroup consisting of alkyl and halo. In some embodiments of theinvention, R₅ is a heteroaryl ring. In some of such embodiments, R₅ is aheteroaryl optionally substituted with a one or two substituentsindependently selected from the group consisting of alkyl, cyano,alkoxy, and halo, or from the group consisting of alkyl and halo. Inpreferred embodiments, R₅ is pyridyl, which can be attached through anyavailable atom, optionally substituted with halo (preferably F, Cl, orBr) or alkyl. In some embodiments, the alkyl is substituted with one ormore halogen atoms. A preferred substituted alkyl group is trihaloalkylsuch as trifluoromethyl. Other substituted alkyl groups includedifluoromethyl or monofluoromethyl. Preferably, R₅ is pyridylsubstituted at any available position with trifluoromethyl.

In preferred embodiments, R₅ is pyrazinyl, which can be attached throughany available atom, optionally substituted with halo (preferably F, Cl,or Br) or alkyl. In some embodiments, the alkyl is substituted with oneor more halogen atoms. A preferred substituted alkyl group istrihaloalkyl such as trifluoromethyl. Other substituted alkyl groupsinclude difluoromethyl or monofluoromethyl. Preferably, R₅ is pyrazinylsubstituted at any available position with trifluoromethyl.

In preferred embodiments, R₅ is pyrimidinyl, which can be attachedthrough any available atom, optionally substituted with halo (preferablyF, Cl, or Br) or alkyl. In some embodiments, the alkyl is substitutedwith one or more halogen atoms. A preferred substituted alkyl group istrihaloalkyl such as trifluoromethyl. Other substituted alkyl groupsinclude difluoromethyl or monofluoromethyl. Preferably, R₅ ispyrimidinyl substituted at any available position with trifluoromethyl.

In other embodiments, R₅ is benzoxazolyl which can be attached throughany available atom, optionally substituted with halo (preferably F, Cl,or Br) or alkyl. In some embodiments, the alkyl is substituted with oneor more halogen atoms. A preferred substituted alkyl group istrifluoromethyl. Other substituted alkyl groups include difluoromethylor monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, ornaphthyridinyl substituted at any available position withtrifluoromethyl.

In other embodiments, R₅ is pyridazinyl which can be attached throughany available atom, optionally substituted with halo (preferably F, Cl,or Br) or alkyl. In some embodiments, the alkyl is substituted with oneor more halogen atoms. A preferred substituted alkyl group istrifluoromethyl. Other substituted alkyl groups include difluoromethylor monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, ornaphthyridinyl substituted at any available position withtrifluoromethyl.

In other embodiments, R₅ is naphthyridinyl which can be attached throughany available atom, optionally substituted with halo (preferably F, Cl,or Br) or alkyl. In some embodiments, the alkyl is substituted with oneor more halogen atoms. A preferred substituted alkyl group istrifluoromethyl. Other substituted alkyl groups include difluoromethylor monofluoromethyl. Preferably, R₅ is benzoxazolyl, pyridazinyl, ornaphthyridinyl substituted at any available position withtrifluoromethyl.

In preferred embodiments, n is 1. In other embodiments, n is 2.

In some embodiments of Formula I, R₁ is H and R₃ is as defined above forFormula I, preferably R₃ is triazolyl, oxazolyl, pyridyl or pyrimidinyl.In other embodiments of Formula I, R₃ is H and R₁ is as defined abovefor Formula I, preferably R₁ is triazolyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl or pyrimidinyl.

In some embodiments of Formula I, the group

is a pyridyl group, preferably X is N, R₃ is a ring selected fromtriazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl orpyridyl or pyrimidinyl; R₄ is H or alkyl, preferably methyl; Z is NH orO, preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridylor pyrazinyl. In some of such embodiments, R₃ is a ring at the orthoposition relative to the carbonyl group in Formula I, and R₄ is at theortho, meta or para position on the relative to the carbonyl group inFormula I, preferably R₄ is at the meta position adjacent to R₃. In someother such embodiments, R₃ is a ring at the ortho position relative tothe carbonyl group in Formula I, and R₄ is at the ortho, meta or paraposition relative to the carbonyl group in Formula I, preferably R₄ isat the meta position not adjacent to R₃. R₃ and R₅ are optionallysubstituted as described above.

In some embodiments of Formula I, the group

is a pyridyl group, preferably Y is N, R₁ is a ring selected fromtriazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl, phenyl or pyrazolyl; preferably triazolyl orpyridyl or pyrimidinyl; R₄ is H or alkyl, preferably methyl; Z is NH orO, preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridylor pyrazinyl. In some of such embodiments, R₁ is a ring at the orthoposition relative to the carbonyl group in Formula I, and R₄ is at theortho, meta or para position on the relative to the carbonyl group inFormula I, preferably R₄ is at the meta position adjacent to R₁. In someother such embodiments, R₁ is a ring at the ortho position relative tothe carbonyl group in Formula I, and R₄ is at the ortho, meta or paraposition relative to the carbonyl group in Formula I, preferably R₄ isat the meta position not adjacent to R₁. R₁ and R₅ are optionallysubstituted as described above.

In some embodiments of Formula I, the group

is a phenyl group, R₃ is a ring selected from triazolyl, thiazolyl,pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl,phenyl or pyrazolyl; preferably triazolyl or pyridyl or pyrimidinyl atthe ortho position; R₄ is H or alkyl, preferably methyl; Z is NH or O,preferably O; preferably NH, R₅ is a heteroaryl, preferably pyridyl orpyrazinyl. In some of such embodiments, R₃ is a ring at the orthoposition relative to the carbonyl group in Formula I, and R₄ is at theortho, meta or para position on the relative to the carbonyl group inFormula I, preferably R₄ is at the meta position adjacent to R₃. In someother such embodiments, R₃ is a ring at the ortho position relative tothe carbonyl group in Formula I, and R₄ is at the ortho, meta or paraposition relative to the carbonyl group in Formula I, preferably R₄ isat the meta position not adjacent to R₃. R₃ and R₅ are optionallysubstituted as described above.

Also provided herein is a compound of Formula IA:

wherein

-   -   ring A is a heteroaryl ring selected from furanyl, thiazolyl,        imidazothiazolyl, and pyrazinyl;    -   R₁ is H, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl,        or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl is optionally substituted with up to two        substituents selected from halo and alkyl;    -   R₂ is H, alkyl, alkoxy, or halo;    -   Z is NH, N—CH₃, N—CH₂CH₃, N—CH₂-cyclopropyl, N—C(═O)CH₃,        N—CH₂CH₂OCH₃ or O;    -   R₃ is H, alkyl, alkoxy, halo, triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl,        or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,        pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl        or pyrazolyl is optionally substituted with up to two        substituents selected from halo and alkyl;    -   R₄ is H or alkyl;        -   or R₃ and R₄, together with the atoms to which they are            attached, form a 6-membered aryl ring or a 5- or 6-membered            heteroaryl ring;    -   R₅ is pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl,        naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl,        benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is        optionally substituted with up to two substituents selected from        halo, alkoxy, hydroxymethyl and alkyl; and    -   n is 1 or 2.

Enantiomers and diastereomers of the compounds of Formula IA are alsowithin the scope of the invention. Also within the scope of theinvention are the pharmaceutically acceptable salts of the compounds ofFormula IA, as well as the pharmaceutically acceptable salts of theenantiomers and diastereomers of the compounds of Formula IA. Alsowithin the scope of the invention are isotopic variations of compoundsof Formula IA, such as, e.g., deuterated compounds of Formula IA.

In some embodiments, ring A is a furanyl ring. In some embodiments, ringA is a thiazolyl ring. In some embodiments, ring A is a imidazothiazolylring. In other embodiments, ring A is a pyrazinyl ring.

All of the embodiments described for Formula I above, with respect tothe variables R₁, R₂, Z, R₃, R₄, R₅ and n, also apply for Formula IA,and are expressly contemplated herein.

The invention relates to methods of using the compounds described hereinto treat subjects diagnosed with or suffering from a disease, disorder,or condition mediated by orexin receptor activity. These methods areaccomplished by administering to the subject a compound of theinvention. In some embodiments, the compounds described herein areselective for orexin-1 receptor activity. In some embodiments, thecompounds described herein are selective for orexin-1 receptor activityover orexin-2 receptor activity.

Diseases, disorders, and conditions mediated by orexin receptor activityinclude disorders of the sleep-wake cycle, insomnia, restless legssyndrome, jet-lag, disturbed sleep, sleep disorders secondary toneurological disorders, mania, depression, manic depression,schizophrenia, pain syndromes, fibromyalgia, neuropathic pain,catatonia, Parkinson's disease, Tourette's syndrome, anxiety, delirium,dementia, overweight, obesity, or conditions related to overweight orobesity, insulin resistance, type II diabetes, hyperlipidemia,gallstones, angina, hypertension, breathlessness, tachycardia,infertility, sleep apnea, back and joint pain, varicose veins,osteoarthritis, hypertension, tachycardia, arrhythmias, angina pectoris,acute heart failure, ulcers, irritable bowel syndrome, diarrheagastroesophageal reflux, mood disorders, post-traumatic stress disorder,panic disorders, attention deficit disorders, cognitive deficiencies, orsubstance abuse.

Compounds of the invention are particularly suited for the treatment ofmood disorders, post-traumatic stress disorder, panic disorders,attention deficit disorders, cognitive deficiencies, or substance abuse.

In one aspect, compounds of the invention are particularly suited forthe treatment of mood disorders. Non-limiting examples of mood disordersinclude anxiety-related mood disorders, depression, panic-related mooddisorders, stress related mood disorders and the like. In anotheraspect, compounds of the invention are suitable for the treatment ofpost-traumatic stress disorder, panic disorders, attention deficitdisorders, cognitive deficiencies, or substance abuse (e.g., morphineabuse, cocaine abuse, alcohol abuse and the like). It will be understoodthat certain disorders such as, for example, depression and/orschizophrenia and/or substance abuse and/or cognitive impairments alsohave elements of anxiety and/or panic and/or stress associated with themand the treatment of such conditions and/or combinations of conditionsare also contemplated within the scope of embodiments presented herein.In some embodiments, advantageously, compounds of the invention treat amood disorder (e.g., anxiety) with reduced concomitant sedation and/orwith reduced effect on sleep (e.g. attenuated arousal effects). In oneembodiment, compounds of the invention are particularly suited for thetreatment of anxious depression. In another embodiment, compounds of theinvention are particularly suited for the treatment of panic,schizophrenia, and substance abuse.

Sleep disorders include, but are not limited to, sleep-wake transitiondisorders, insomnia, restless legs syndrome, jet-lag, disturbed sleep,and sleep disorders secondary to neurological disorders (e g, manias,depressions, manic depression, schizophrenia, and pain syndromes (e.g.,fibromyalgia, neuropathic).

Metabolic disorders include, but are not limited to, overweight orobesity and conditions related to overweight or obesity, such as insulinresistance, type II diabetes, hyperlipidemia, gallstones, angina,hypertension, breathlessness, tachycardia, infertility, sleep apnea,back and joint pain, varicose veins and osteoarthritis.

Neurological disorders include, but are not limited to, Parkinson'sdisease, Alzheimer's disease, Tourette's Syndrome, catatonia, anxiety,delirium and dementias.

In treatment methods according to the invention, a therapeuticallyeffective amount of a pharmaceutical agent according to the invention isadministered to a subject suffering from or diagnosed as having such adisease, disorder, or condition. A “therapeutically effective amount”means an amount or dose sufficient to generally bring about the desiredtherapeutic or prophylactic benefit in patients in need of suchtreatment for the designated disease, disorder, or condition. Effectiveamounts or doses of the compounds of the present invention may beascertained by routine methods such as modeling, dose escalation studiesor clinical trials, and by taking into consideration routine factors,e.g., the mode or route of administration or drug delivery, thepharmacokinetics of the compound, the severity and course of thedisease, disorder, or condition, the subject's previous or ongoingtherapy, the subject's health status and response to drugs, and thejudgment of the treating physician. An example of a dose is in the rangeof from about 0.001 to about 200 mg of compound per kg of subject's bodyweight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID). Fora 70-kg human, an illustrative range for a suitable dosage amount isfrom about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.

Once improvement of the patient's disease, disorder, or condition hasoccurred, the dose may be adjusted for preventative or maintenancetreatment. For example, the dosage or the frequency of administration,or both, may be reduced as a function of the symptoms, to a level atwhich the desired therapeutic or prophylactic effect is maintained. Ofcourse, if symptoms have been alleviated to an appropriate level,treatment may cease. Patients may, however, require intermittenttreatment on a long-term basis upon any recurrence of symptoms.

In addition, the compounds of the invention may be used in combinationwith additional active ingredients in the treatment of the aboveconditions. The additional active ingredients may be coadministeredseparately with a compound of the invention or included with such anagent in a pharmaceutical composition according to the invention. In anexemplary embodiment, additional active ingredients are those that areknown or discovered to be effective in the treatment of conditions,disorders, or diseases mediated by orexin activity, such as anotherorexin modulator or a compound active against another target associatedwith the particular condition, disorder, or disease. The combination mayserve to increase efficacy (e.g., by including in the combination acompound potentiating the potency or effectiveness of an active agentaccording to the invention), decrease one or more side effects, ordecrease the required dose of the active agent according to theinvention.

The compounds of the invention are used, alone or in combination withone or more additional active ingredients, to formulate pharmaceuticalcompositions of the invention. A pharmaceutical composition of theinvention comprises: (a) an effective amount of at least one compound inaccordance with the invention; and (b) a pharmaceutically acceptableexcipient.

Delivery forms of the pharmaceutical compositions containing one or moredosage units of the active agents may be prepared using suitablepharmaceutical excipients and compounding techniques known or thatbecome available to those skilled in the art. The compositions may beadministered in the inventive methods by a suitable route of delivery,e.g., oral, parenteral, rectal, topical, or ocular routes, or byinhalation.

The preparation may be in the form of tablets, capsules, sachets,dragees, powders, granules, lozenges, powders for reconstitution, liquidpreparations, or suppositories. Preferably, the compositions areformulated for intravenous infusion, topical administration, or oraladministration.

For oral administration, the compounds of the invention can be providedin the form of tablets or capsules, or as a solution, emulsion, orsuspension. To prepare the oral compositions, the compounds may beformulated to yield a dosage of, e.g., from about 0.05 to about 100mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about0.1 to about 10 mg/kg daily. For example, a total daily dosage of about5 mg to 5 g daily may be accomplished by dosing once, twice, three, orfour times per day.

Oral tablets may include a compound according to the invention mixedwith pharmaceutically acceptable excipients such as inert diluents,disintegrating agents, binding agents, lubricating agents, sweeteningagents, flavoring agents, coloring agents and preservative agents.Suitable inert fillers include sodium and calcium carbonate, sodium andcalcium phosphate, lactose, starch, sugar, glucose, methyl cellulose,magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquidoral excipients include ethanol, glycerol, water, and the like. Starch,polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystallinecellulose, and alginic acid are suitable disintegrating agents. Bindingagents may include starch and gelatin. The lubricating agent, ifpresent, may be magnesium stearate, stearic acid or talc. If desired,the tablets may be coated with a material such as glyceryl monostearateor glyceryl distearate to delay absorption in the gastrointestinaltract, or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin capsules.To prepare hard gelatin capsules, compounds of the invention may bemixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsulesmay be prepared by mixing the compound of the invention with water, anoil such as peanut oil or olive oil, liquid paraffin, a mixture of monoand di-glycerides of short chain fatty acids, polyethylene glycol 400,or propylene glycol.

Liquids for oral administration may be in the form of suspensions,solutions, emulsions or syrups or may be lyophilized or presented as adry product for reconstitution with water or other suitable vehiclebefore use. Such liquid compositions may optionally contain:pharmaceutically-acceptable excipients such as suspending agents (forexample, sorbitol, methyl cellulose, sodium alginate, gelatin,hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel andthe like); non-aqueous vehicles, e.g., oil (for example, almond oil orfractionated coconut oil), propylene glycol, ethyl alcohol, or water;preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbicacid); wetting agents such as lecithin; and, if desired, flavoring orcoloring agents.

The active agents of this invention may also be administered by non-oralroutes. For example, the compositions may be formulated for rectaladministration as a suppository. For parenteral use, includingintravenous, intramuscular, intraperitoneal, or subcutaneous routes, thecompounds of the invention may be provided in sterile aqueous solutionsor suspensions, buffered to an appropriate pH and isotonicity or inparenterally acceptable oil. Suitable aqueous vehicles include Ringer'ssolution and isotonic sodium chloride. Such forms will be presented inunit-dose form such as ampules or disposable injection devices, inmulti-dose forms such as vials from which the appropriate dose may bewithdrawn, or in a solid form or pre-concentrate that can be used toprepare an injectable formulation. Illustrative infusion doses may rangefrom about 1 to 1000 .mu.g/kg/minute of compound, admixed with apharmaceutical carrier over a period ranging from several minutes toseveral days.

For topical administration, the compounds may be mixed with apharmaceutical carrier at a concentration of about 0.1% to about 10% ofdrug to vehicle. Another mode of administering the compounds of theinvention may utilize a patch formulation to affect transdermaldelivery.

Compounds of the invention may alternatively be administered in methodsof this invention by inhalation, via the nasal or oral routes, e.g., ina spray formulation also containing a suitable carrier.

Exemplary compounds useful in methods of the invention will now bedescribed by reference to the illustrative synthetic schemes for theirgeneral preparation below and the specific examples that follow.Artisans will recognize that, to obtain the various compounds herein,starting materials may be suitably selected so that the ultimatelydesired substituents will be carried through the reaction scheme with orwithout protection as appropriate to yield the desired product.Alternatively, it may be necessary or desirable to employ, in the placeof the ultimately desired substituent, a suitable group that may becarried through the reaction scheme and replaced as appropriate with thedesired substituent. Unless otherwise specified, the variables are asdefined above in reference to Formula (I). Reactions may be performedbetween the melting point and the reflux temperature of the solvent, andpreferably between 0° C. and the reflux temperature of the solvent.Reactions may be heated employing conventional heating or microwaveheating. Reactions may also be conducted in sealed pressure vesselsabove the normal reflux temperature of the solvent.

The synthesis of exemplary intermediates having the structure

is described in Schemes 1-6 below and in the Examples section below(Intermediates A-1 to A-59).

Intermediate compounds of formula (IIIa) and (IIIb) can be prepared asoutlined in Scheme 1 from commercially available or syntheticallyaccessible compounds of formula (A) where R_(3A), R_(4A) are —H, halo,—C₁₋₄alkyl, —C₁₋₄alkoxy or R_(3A) and R_(4A) together with the atoms towhich they are attached form a 6-membered aryl or 6 membered heteroarylring and X and Y are as defined in formula (I) as above. Compounds offormula (IIa) and (IIIb), are obtained by reacting a compound of formula(A), with commercially available 1,2,3-triazole, in the presence K₂CO₃in DMF or dioxane, at temperatures ranging from about 60° C. to about100° C. Compounds of formula (IIIa) and (IIIb) are obtained by reactingcompounds of formula (II) in the presence of a base such as NaOH in asolvent such as EtOH at temperatures ranging from about 80° C. to about100° C. One skilled in the art will recognize that 1,2,3-triazole canexist in two tautomeric forms defined as 2H-[1,2,3]triazole and1H-[1,2,3]triazole thus accounting for the formation of (IIIa) and(IIIb).

Intermediate compounds of formula (III) can be prepared as outlined inScheme 2 from commercially available or synthetically accessiblecompounds of formula (IV_(a-c)). Compounds of formula (Va) and (Vb) areobtained by reacting compounds of formula (IVa), (IVb) and (IVc) whereHal is —Br, or —I; W is CO₂H, CO₂Alkyl, or CN and R_(3A) and R_(4A) are—H, halo, —C₁₋₄alkyl, —C₁₋₄ alkoxy or R_(3A) and R_(4A) together withthe atoms to which they are attached form a 6-membered aryl or 6membered heteroaryl ring, and X and Y are as defined in Formula I above,with commercially available 1,2,3-triazole, in the presence of, forexample, copper(I)iodide, Cs₂CO₃ andtrans-N,N′-dimethyl-1,2-cyclohexanediamine in, for example, DMF ordioxane, at temperatures ranging from about 60° C. to about 120° C.Compounds of formula (IVc) can be converted to the corresponding esters(Vb) by treatment with, for example, alkyl iodide in the presence of abase such as K₂CO₃ in a solvent such as DMF. Compounds of formula (III)are obtained by reacting a compound of formula (Va) and (Vb) in thepresence of a base such as NaOH in a solvent such as EtOH attemperatures ranging from about 80° C. to about 100° C. One skilled inthe art will recognize that 1,2,3-triazole can exist in two tautomericforms defined as 2H-[1,2,3]triazole and 1H-[1,2,3]triazole thuscompounds of formula (Va), (Vb), and (III) can also exist as the N1linked variant (structure not shown). It will be understood that theheterocycle in (Va) and (Vb) is not limited to triazole and may be anyother suitable heterocycle.

Intermediate compounds of formula (IX) can be prepared as outlined inScheme 3 from commercially available or synthetically accessiblecompounds of formula (VI) where R_(3A), R_(4A) are —H, halo, —C₁₋₄alkyl,—C₁₋₄alkoxy or R_(3A) and R_(4A) together with the atoms to which theyare attached form a 6-membered aryl or 6 membered heteroaryl ring, and Xand Y are as defined in formula (I) as above, G is SnBu₃, or 4,4,5,5tetramethyl-1,dioxaboralane, and HAL is Cl, or Br, preferably Br.Compounds of formula (VIII) are obtained by reacting a compound offormula (VI) with commercially available (VII) in the presence of acatalyst such as 1,1′-Bis(di-tert-butylphosphino)ferrocene palladiumdichloride and a base such as Na₂CO₃ in a solvent such as 2-MeTHF or THFat temperatures ranging from about 60° C. to about 90° C. Compounds offormula (IX) are obtained by reacting a compound of formula (VIII) inthe presence of a base such as NaOH in a solvent such as MeOH attemperatures ranging from about 80° C. to about 100° C. or acids such asH₂SO₄ in solvents such as H₂O at temperatures ranging from about 80° C.to about 100° C. It will be understood that the heterocycle in (VII) isnot limited to pyrimidine and may be any other suitable heterocycle.

Intermediate compound of formula (XIV) can be prepared as outlined inScheme 4 from commercially available compound (X). Compound (XI) isobtained by reacting compound (X) with commercially available acroleinin a solvent such as 1,4 dioxane at temperatures of about 200° C. in,for example, a microwave reactor. Compound (XII) can be prepared fromcompound (XI) by treatment with an acid such as HBr in a solvent such astoluene at a temperature of about 90° C. Compound (XIII) can be obtainedby treatment of compound (XII) with, for example, commercially availableiodoethane and a base such as K₂CO₃ in a solvent such as DMF attemperatures ranging from about 45° C. to about 65° C. Compound (XIV) isobtained by treating compound (XIII) with a base such as NaOH in asolvent such as MeOH at temperatures ranging from about 80° C. to about100° C.

Intermediate compounds of formula (XVI) are prepared as outlined inScheme 5 from commercially available or synthetically accessiblecompounds of formula (XIV) where R_(2B) is —H, —C₁₋₄alkyl, or—C₁₋₄alkoxy, or R_(2B) is —H, halo, —C₁₋₄alkyl, or —C₁₋₄alkoxy, and HALis halo, preferably Cl, or Br. Compounds of formula (XV) are obtained byreacting a compound of formula (XIV) with commercially available (VII)in the presence of a catalyst such as Pd(dppf)Cl₂ and a base such asNa₂CO₃ in a solvent such as 2-MeTHF at temperatures ranging from about75° C. to about 150° C. Compounds of formula (XVI) are obtained byreacting a compound of formula (XV) in the presence of a base such asNaOH in a solvent such as MeOH at temperatures ranging from about 80° C.to about 100° C. It will be understood that the heterocycle in (VII) isnot limited to pyrimidine and may be any other suitable heterocycle.

Intermediate compounds of formula (XXI) can be prepared as outlined inScheme 6 from commercially available or synthetically accessiblecompounds of formula (XVII) where Hal is Br or I; and where R_(3A) andR_(4A) are —H, halo, —C₁₋₄alkyl, —C₁₋₄alkoxy, or R_(3A) and R_(4A)together with the atoms to which they are attached form a 6-memberedaryl or 6 membered heteroaryl ring. Compounds of formula (XVIIIa) can beconverted to the corresponding ester (XVIIIb) by treatment with, forexample, thionyl chloride in a solvent such as MeOH. Compounds of theformula (XX) are obtained by reacting compounds of formula (XVIIIb) withcommercially available compounds of the formula XIX where L is aheterocycle such as pyrazole, pyridyl, or oxazole or any otherheterocycle described herein; G is SnBu₃ or 4,4,5,5tetramethyl-1,dioxaboralane and R_(1A) and R_(2A) are —H, —C₁₋₄alkyl, or—C₁₋₄alkoxy, or R_(1A) and R_(2A) are —H, halo, —C₁₋₄alkyl, or—C₁₋₄alkoxy; in the presence of a catalyst such as Pd(Ph₃P)₄ and a basesuch as Na₂CO₃ in a mixture of solvents such as DME and H₂O attemperatures ranging from about 100° C. to about 150° C. Compounds offormula (XXI) are obtained by reacting a compound of formula (XX) in thepresence of a base such as NaOH in a solvent such as MeOH attemperatures ranging from about 80° C. to about 100° C.

According to Scheme 7, compound (XXV), where n is 1 or 2, is obtained byreaction of (XXII), (XXIII) where PG of H₂N-PG is H, benzyl (Bn), methylbenzyl, and the like, and (XXIV) in an aqueous medium where H⁺ is HCl,AcOH and the like as described in C. Chiu et al. SyntheticCommunications 1996, 26, 577-584 and S. Larsen et al. J. Am. Chem. Soc.1985, 107, 1768-1769. In a particularly preferred embodiment, a compoundof formula (XXV), where n is 1, is obtained by reacting, for example,commercially available cyclopentadiene, (+)-α-methyl-benzylamine andformaldehyde in an aqueous medium with AcOH. Enantio-enriched compoundsof formula (XXVa) and (XXVb) are obtained by chiral resolution of (XXV)using a chiral acid, such as commercially available L or D-dibenzoyltartaric acid and the like, followed by formation of the free base usinga base such as aqueous NaOH and the like, as described in C. Chiu et al.Synthetic Communications 1996, 26, 577-584. In a preferred embodiment, acompound of formula (XXV) is treated with, for example, D-dibenzoyltartaric acid followed by a base such as aqueous NaOH to afford anenantio-enriched compound of formula (XXVa). Compound (XXVII) isobtained from (XXVa) through a hydroboration/oxidation sequence of theolefin to install the hydroxyl group; followed by, for example, anoptional one-pot palladium-mediated hydrogenolysis and PG “swap” (i.e.methyl benzyl to Boc); and subsequent oxidation of the hydroxyl groupusing an oxidant such as IBX, SO₃-pyridine, Swern conditions [(COCl)₂,DMSO, Et₃N], and the like, in a solvent such as EtOAc, DMSO, DCM, andthe like, at temperatures ranging from about −78° C. to room temperature(about 23° C.). In a preferred embodiment, a compound of formula (XXVa)where PG is methyl benzyl, is treated with, for example, BH₃ followed byH₂O₂ and NaOH to install the hydroxyl group, and, for example, a one-potpalladium mediated hydrogenolysis using hydrogen gas (1 atm), Pd/C, andBoc₂O, in EtOH at room temperature (23° C.) exchanges the methyl benzylfor a Boc group. The Boc-protected intermediate is oxidized with, forexample, IBX in refluxing such as, for example, EtOAc to afford acompound of formula (XXVII). Compound (XXVb) could also be subjected tothe same set of transformations as compound (XXVa) to obtain thecorresponding opposite enantiomer (structure not shown).

A compound of formula (XXVIII) where Z is OH, is obtained from reduction([R]) of the ketone in a compound of formula (XXVII), with a reducingagent such as L-Selectride, NaBH₄ and the like, in a solvent such asTHF, MeOH and the like at temperatures ranging from about −78° C. toroom temperature (about 23° C.). Alternatively, the racemic form of acompound of formula (XXVIII) can be obtained from reduction ofcommercially available (R/S)-tert-butyl6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate as described in R. Nenckaet al. Tetrahedron 2012, 68, 1286-1298.

An alternative route to a compound of formula (XXVII) can be preparedfrom commercially available (1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one(XXVI). A compound of formula (XXV) is obtained from treatment ofcompound (XXVI) with a reducing agent such as LiAlH₄ and the like,followed by protection of the free amine with a suitable protectinggroup. A compound of formula (XXVII) is obtained from a compound offormula (XXV) by a hydroboration/oxidation sequence of the olefin toinstall the hydroxyl group; followed by oxidation of the hydroxyl groupusing an oxidant such as IBX, SO₃-pyridine, Swern conditions [(COCl)₂,DMSO, Et₃N], and the like, in a solvent such as EtOAc, DMSO, DCM, andthe like at temperatures ranging from about −78° C. to room temperature(about 23° C.); and, optionally, a one-pot palladium mediatedhydrogenolysis and PG “swap” (i.e. Bn to Boc). In a preferredembodiment, a compound of formula (XXV) where PG is Bn is subjected tothe conditions described in F. Carroll et al. J. of Med. Chem. 1992, 35,2184-2191, followed by PG swap (Bn to Boc) to obtain a compound offormula (XXVII) where PG is Boc.

A compound of formula (XXVIII) where Z is NH₂, is obtained by reacting acompound of formula (XXVII) with an amine NH₂-Q, where Q is OH or Bn,followed by reduction of the corresponding oxime or imine with asuitable reducing agent such as NaBH₄ (with or without a metal saltadditive such as NiCl₂ and the like), Raney Ni (H₂ atm), Zn(BH₄)₂, andthe like in a solvent such as MeOH and the like. In a particularembodiment, the oxime intermediate from reaction of a compound offormula (XXVII) with an amine NH₂-Q, where Q is OH, is obtained byreacting a compound of formula (XXVII) with commercially availablehydroxylamine hydrochloride and triethylamine in EtOH at temperaturesranging from room temperature (about 23° C.) to reflux. The oximeintermediate is reduced with NaBH₄ in combination with NiCl₂ in MeOH togive a compound of formula (XXVIII) where Z is NH₂. Alternatively, theimine intermediate from reaction of a compound of formula (XXVII) withan amine NH₂-Q, where Q is Bn, is obtained by reacting a compound offormula (XXVII) with commercially available benzylamine In-situreduction of the imine intermediate with a reducing agent such as sodiumtriacetoxyborohydride and the like, followed by debenzylation under, forexample, palladium mediated hydrogenolysis affords a compound of formula(XXVIII) where Z is NH₂.

Referring to Scheme 7, the synthesis of compounds wherein n is 2 isdescribed in the Examples section, for instance in IntermediatesC-1-C-11, and in Examples 248-283.

According to Scheme 8, a compound of formula (XXIX), where Z is O or NH,is obtained from a compound of formula (XXVIII), by a S_(N)Ar reactionor metal mediated cross-coupling reaction with a compound R₅—U; whereR₅—U is a suitable commercially available or synthetically accessiblehalogen-substituted heteroaryl compound, where R₅ is defined in formula(I) as above and W is F, Cl, Br, I, or OTf. A compound of formula (XXIX)where Z is O, is obtained from a compound of formula (XXVIII), where Zis OH, by S_(N)Ar coupling with a compound R₅—W as described above, inthe presence of a base, such as NaH, K₂CO₃ and the like, in a solventsuch as DMF at temperatures ranging from room temperature (about 23° C.)to about 90° C. In a preferred embodiment the base is NaH and thesolvent is DMF. A compound of formula (XXIX), where Z is NH, is obtainedfrom a compound of formula (XXVIII), where Z is NH₂, by metal mediatedcross-coupling with a compound R₅—W as described above, in the presenceof a palladium catalyst, a phosphine ligand such as BINAP and the like,a base such as NaOtBu and the like, in a solvent such as toluene, DME,and DMF, at temperatures ranging from room temperature (about 23° C.) toabout 100° C. In a preferred embodiment the palladium catalyst isPd(OAc)₂, the ligand is BINAP, the base is NaOtBu, and the solvent istoluene. Alternatively, a compound of formula (XXIX) where Z is NH, isobtained from a compound of formula (XXVIII), where Z is NH₂, by S_(N)Arcoupling with a compound R₅—W as described above, in the presence of abase, such as NaH, K₂CO₃ in a solvent such as DMF at temperaturesranging from room temperature (about 23° C.) to about 90° C. In apreferred embodiment the base is K₂CO₃ and the solvent is DMF. Removalof PG (where PG is Boc, Bn, methyl benzyl, and the like) in compounds offormula (XXIX) is accomplished using methods known to one skilled in theart to give compounds of formula (XXX). In a preferred embodiment, wherePG is Boc in a compound of formula (XXIX) and Z is O or NH, is treatedwith, for example, HCl in dioxane to afford a compound of formula (XXX).

A compound of formula (XXXI) is obtained from a compound of formula(XXX), by reaction of a compound of formula (XXX) with a compound offormula (XXXII), under amide bond formation conditions. Compounds offormula (XXXII), where X, Y, R₃, and R₄ are as defined in formula (I),are commercially available, as described, or synthetically accessibleappropriately substituted aryl or heteroaryl carboxylic acids or acidsalts. A compound of formula (XXX), either as a free base or as an acidsalt, is reacted with a compound of formula (XXXII) in the presence of adehydrating agent such as HOBt/EDAC, CDI, HATU, HOAT, T₃P; a suitablyselected base such as DIPEA, TEA; in an organic solvent or mixturethereof, such as toluene, MeCN, EtOAc, DMF, THF, DCM to afford acompound of formula (XXXI). In a particularly preferred embodiment acompound of formula (XXXI) is obtained using, for example, thedehydrating agent HATU, the base DIPEA, and the solvent DMF; or thedehydrating agent T₃P, the base Et₃N, and the solvent mixture ofDCM/DMF. Alternatively, one skilled in the art can transform a compoundof formula (XXXII) to the corresponding acid chloride or an activatedester before amide formation with a compound of formula (XXX).

Referring to Scheme 8, the synthesis of compounds wherein n is 2 isdescribed in the Examples section, for instance in IntermediatesC-1-C-11, and in Examples 248-283.

In one group of embodiments, provided herein is a compound of Formula Iof Examples 1-84 with structures and names as set forth in the Examplessection. In another group of embodiments, provided herein is a compoundof Formula I of Examples 1-4, 7-92, 94-204, 206, 208-660 with structuresand names as set forth in the Examples section below. In yet anotherembodiment, provided herein is a compound of Formula I of Examples85-92, 94-204, 206, 208-660 with structures and names as set forth inthe Examples section below. In one group of embodiments, provided hereinis a compound of Formula IA selected from Examples 5, 6, 93, 205, and207 having the structures and names as set forth in the Examples sectionbelow. In one group of embodiments, provided herein is a compound ofFormula I or Formula IA having structures and names as set forth inTable 2 below.

EXAMPLES Abbreviations

Term Acronym Acetic Acid HOAc Acetonitrile ACN Apparent app Aqueous aqAtmosphere atm 2-(1H-9-Azobenzotriazole-1-yl)-1,1,3,3- HATUtetramethylaminium hexafluorophosphate Benzyl Bn2,2′-bis(diphenylphosphino)-1,1′-binaphthalene BINAP [1,1′-Bis(di-tert-PdCl₂(dtbpf) butylphosphino)ferrocene]dichloropalladium(II) Broad brtert-Butylcarbamoyl Boc/Boc Dichloromethane DCM DiisopropylethylamineDIPEA 1,2-Dimethoxyethane DME N,N-Dimethylformamide DMFDimethylsulfoxide DMSO Doublet d Electrospray ionization ESIEnantiomeric excess ee Ethanol EtOH Ethyl Acetate EtOAc, or EA Grams gHertz Hz High-pressure liquid chromatography HPLC Hours h Liquidchromatography and mass spectrometry LCMS Mass spectrometry MS Mass tocharge ratio m/z Methanol MeOH Microliter μL Milligrams mg Milliliter mLMillimoles mmol Minute min Molar M Multiplet m Normal N Nuclear magneticresonance NMR Palladium on carbon Pd/C Palladium hydroxide on carbonPd(OH)₂/C Parts per million ppm Phenyl Ph Propylphosphonic anhydride T₃PRetention time R_(t) Room temperature rt Quartet q Singlet SSupercritical Fluid Chromatography SFC Temperature T Thin layerchromatography TLC Times X Triethylamine TEA Trifluoroacetic acid TFATriplet t

Chemistry:

In obtaining the compounds described in the examples below and thecorresponding analytical data, the following experimental and analyticalprotocols were followed unless otherwise indicated.

Unless otherwise stated, reaction mixtures were magnetically stirred atroom temperature (rt) under a nitrogen atmosphere. Where solutions were“dried,” they were generally dried over a drying agent such as Na₂SO₄ orMgSO₄. Where mixtures, solutions, and extracts were “concentrated”, theywere typically concentrated on a rotary evaporator under reducedpressure. Reactions under microwave irradiation conditions were carriedout in a Biotage Initiator or CEM Discover instrument.

Where compounds were “purified via silica gel chromatography”normal-phase flash column chromatography was performed on silica gel(SiO₂) using prepackaged cartridges, eluting with the indicatedsolvents.

Where compounds were purified by “Shimadzu Method X” the method employedwas either:

Preparative reverse-phase high performance liquid chromatography (HPLC)was performed on a Shimadzu LC-8A Series HPLC with an Inertsil ODS-3column (3 μm, 30×100 mm, T=45° C.), mobile phase of 5% ACN in H₂O (bothwith 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.

or

Preparative reverse-phase high performance liquid chromatography (HPLC)was performed on a Shimadzu LC-8A Series HPLC with an XBridge C18 OBDcolumn (5 μm, 50×100 mm), mobile phase of 5% ACN in H₂O (both with 0.05%TFA) was held for 1 min, then a gradient of 5-99% ACN over 14 min, thenheld at 99% ACN for 10 min, with a flow rate of 80 mL/min.

Where compounds were purified by “Agilent Prep Method X” the methodemployed was either:

Preparative reverse-phase high performance liquid chromatography (HPLC)was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBDcolumn (5 μm, 30×100 mm), mobile phase of 5% ACN in 20 mM NH₄OH was heldfor 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99%ACN for 5 min, with a flow rate of 40 mL/min.

or

Preparative reverse-phase high performance liquid chromatography (HPLC)was performed on a Agilent 1100 Series HPLC with an XBridge C18 OBDcolumn (5 μm, 50×100 mm), mobile phase of 5% ACN in 20 mM NH₄OH was heldfor 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99%ACN for 5 min, with a flow rate of 80 mL/min.

Where compounds were purified by “Gilson Prep Method X” the methodemployed was: Preparative reverse-phase high performance liquidchromatography (HPLC) was performed on a Gilson HPLC with an XBridge C18column (5 μm, 100×50 mm), mobile phase of 5-99% ACN in 20 mM NH₄OH over10 min and then hold at 99 ACN for 2 min, at a flow rate of 80 mL/min.

Mass spectra (MS) were obtained on an Agilent series 1100 MSD usingelectrospray ionization (ESI) in positive mode unless otherwiseindicated. Calculated (calcd.) mass corresponds to the exact mass.

Where acids are employed for amide bond coupling the free acid or acidsalt may be used interchangeably.

Nuclear magnetic resonance (NMR) spectra were obtained on Bruker modelDRX spectrometers. The format of the ¹H NMR data below is: chemicalshift in ppm downfield of the tetramethylsilane reference (multiplicity,coupling constant J in Hz, integration). Definitions for multiplicityare as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet,br=broad. For compounds that are present as a mixture of rotamers theratio is represented so that the total is 1, e.g. 0.80:0.20.Alternatively, ¹H NMR data may be reported for only the major rotamer asindicated, or the data may be reported for one or more rotamers suchthat the total is less than 1. It will be understood that for compoundscomprising an exchangeable proton, said proton may or may not be visibleon an NMR spectrum depending on the choice of solvent used for runningthe NMR spectrum and the concentration of the compound in the solution.

Chemical names were generated using ChemDraw Ultra 12.0 (CambridgeSoftCorp., Cambridge, Mass.) or ACD/Name Version 10.01 (Advanced Chemistry).

Compounds designated (R/S) are racemic compounds where the relativestereochemistry is as drawn.

Examples 63-65, 68-72, 75, 78-79, 81-82, 84, 164-165, 303-419, 421-660are suitable for preparation using methods analogous to the methodsdescribed in the synthetic schemes and in the Examples section.

Intermediates

Intermediate Name Structure Reference A-1  2-(2H-1,2,3-triazol-2-yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 2 A-2  3-fluoro-2-(pyrimidin-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 50 A-3 6-methyl-2-(2H- 1,2,3-triazol-2- yl)nicotinic acid

Prepared according to WO 2011/050198 Intermediate 70 A-4 6-methyl-2-(1H- 1,2,3-triazol-1- yl)nicotinic acid

Prepared according to WO 2011/050198 Intermediate 71 A-5 4-methoxy-2-(2H- 1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 54 A-6  2-fluoro-6-(pyrimidin-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 14 A-7  5-fluoro-2-(pyrimidin-2- yl)benzoic acid.

Prepared according to WO 2011/050198 Intermediate 13 A-8  3-ethoxy-6-methylpicolinic acid

WO 2010/063663 Description 39 A-9  2-(4H-1,2,4-triazol- 4-yl)benzoicacid

Commercially available, CAS 167626-65-5 A-10 5-fluoro-2-(2H-1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 1 A-11 2-fluoro-6-(2H-1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 12 A-124-fluoro-2-(2H- 1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 4 A-132-methoxy-6-(2H- 1,2,3-triazol-2- yl)benzoic acid

Prepared analogous to Intermediate A-X using 2-bromo-6-(2H-1,2,3-triazol-2- yl)benzoic acid A-14 5-(4-fluorophenyl)-2-methylthiazole-4- carboxylic acid

Commercially available, CAS 433283-22-8 A-15 4-methoxy-2- (pyrimidin-2-yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 88 A-163-fluoro-2-(2H- 1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 5 A-17 6-methylimidazo[2,1- b]thiazole-5- carboxylic acid

Commercially available, CAS 77628-51-4 A-18 3-fluoro-2- methoxybenzoicacid

Commercially available, CAS 106428-05-1

Synthesis of 3-fluoro-2-(pyrimidin-2-yl)benzonitrile (Intermediate inthe synthesis of intermediate A-2)

To a solution of3-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(4.98 g, 19.1 mmol) and 2-bromopyrimidine (3.85 g, 23 mmol) in THF (96mL) was added Na₂CO₃ (6 g, 57.4 mmol) followed by water (43 mL). Thereaction mixture was degassed with N₂ for 10 minutes. PdCl₂(dtbpf) (374mg, 0.57 mmol) was added and the reaction mixture was stirred at 80° C.for 5 h. The solution was cooled to room temperature and a mixture ofEtOAc and water was added. The aqueous was extracted twice with EtOAcand the combined organic layers were dried over MgSO4, filtered andevaporated. The title compound was precipitated by dissolving theresidue in a minimum amount of EtOAc and then adding hexanes. The solidwas filtered, washed with hexanes and dried to afford the title compound(2.46 g, 64%). MS (ESI) mass calcd. for C₁₁H₆FN₃, 199.1. m/z found 200.1[M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 9.02-8.91 (m, 2H), 7.65 (dt,J=7.7, 1.0 Hz, 1H), 7.60-7.52 (m, 1H), 7.51-7.43 (m, 1H), 7.41 (t, J=4.9Hz, 1H).

Intermediate A-19: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid

Step A: 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To3-bromo-5-methylpicolinic acid (1.5 g, 7.6 mmol) in DMF (19 mL) wasadded K₂CO₃ (1.2 g, 8.4 mmol) and 2H-1,2,3-triazole (440 μL, 7.6 mmol).The mixture was heated to 100° C. for 16 h, cooled to room temperatureand extracted with EtOAc (2×). The combined organics were dried (Na₂SO₄)and concentrated. Purification via silica gel chromatography (5-60%EtOAc in hexanes) gave the title compound (490 mg, 35%)¹H NMR (500 MHz,Chloroform-d) 8.58-8.53 (m, 1H), 8.29-8.24 (m, 1H), 7.98 (s, 2H), 2.54(s, 3H) and 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile (387 mg,27%).

Step B: (sodium 5-methyl-3-(2H-1,2,3-triazol-2-yl)picolinate). To asolution of the title compound of Step A (489 mg, 2.6 mmol) in EtOH (7mL) was added 4 N NaOH (660 μL, 2.6 mmol). The mixture was heated at100° C. for 24 h. The reaction mixture was concentrated in vacuo to awhite solid which was used without further purification in subsequentsteps. MS (ESI) mass calcd. for C₉H₈N₄O₂, 204.1. m/z found 205.0 [M+H]⁺.

Intermediate A-20: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid

Step A: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinonitrile. To3-bromo-6-methylpicolinonitrile (2.2 g, 11 mmol) in DMF (28 mL) wasadded K₂CO₃ (1.7 g, 12 mmol) and 2H-1,2,3-triazole (650 μL, 11 mmol).The mixture was heated to 100° C. for 36 h, cooled to rt and extractedwith EtOAc. The combined organics were dried (Na₂SO₄) and concentrated.Purification via silica gel chromatography (10-100% EtOAc in hexanes)gave the title compound (1 g, 48%).

Step B: 6-methyl-3-(2H-1,2,3-triazol-2-yl)picolinic acid. To a solutionof the title compound of Step A (730 mg, 4 mmol) in EtOH (10 mL) wasadded 4 N NaOH (1 mL, 4 mmol). The mixture was heated at 100° C. for 24h. The reaction mixture was concentrated in vacuo to a white solid whichwas used without further purification in subsequent steps. MS (ESI) masscalcd. for C₉H₈N₄O₂, 204.1. m/z found 205.1 [M+H]⁺.

Intermediate A-21: 3-ethoxyisoquinoline-4-carboxylic acid

Step A: ethyl 3-hydroxyisoquinoline-4-carboxylate. To a suspension ofethyl 3-aminoisoquinoline-4-carboxylate (583 mg, 2.70 mmol) in 6.8 mL ofH₂SO₄ 5N cooled to 0° C. was added sodium nitrite (223 mg, 3.24 mmol,dissolved in 1 mL of water). The reaction mixture was stirred at 0° C.for 2.5 h and then NaOH_((aq)) 1N was added until pH=7. The aqueousphase was extracted twice with DCM and the combined organic phases weredried over MgSO₄, filtered and evaporated to give the title compound ofStep A which was used without further purification in the next step (583mg, 99%). MS (ESI) mass calcd. for C₁₂H₁₁NO₃, 217.1. m/z found 218.1[M+H]⁺.

Step B: ethyl 3-ethoxyisoquinoline-4-carboxylate. To the title compoundof Step A (583 mg, 2.68 mmol) in THF (13 mL) was addedtriphenylphosphine (1.06 g, 4.03 mmol), ethanol (0.24 mL, 4.03 mmol) andDIAD (0.79 mL, 4.03 mmol). The reaction mixture was stirred at roomtemperature for 16 h and then the solvent was evaporated. The crude waspurified via silica gel chromatography (0-30% EtOAc in hexanes) toafford the title compound of Step B (498 mg, 76%). MS (ESI) mass calcd.for C₁₄H₁₅NO₃, 245.1. m/z found 246.1 [M+H]⁺. ¹H NMR (500 MHz,Chloroform-d) δ 8.97 (s, 1H), 7.91-7.82 (m, 2H), 7.65-7.60 (m, 1H),7.42-7.36 (m, 1H), 4.59-4.48 (m, 4H), 1.48-1.39 (m, 6H).

Step C: 3-ethoxyisoquinoline-4-carboxylic acid. The title compound ofStep B (492 mg, 2 mmol) dissolved in MeOH (15 mL) was added NaOH_((aq))2M (2.5 mL). The reaction mixture was stirred at 60° C. for 16 h andthen NaOH_((aq)) 4M (2 mL) was added and the mixture was stirred at 70°C. for 4 h. MeOH was evaporated and the aqueous phase was cooled to 0°C. and acidified with the addition of HCl_((aq)) 6N. The solid wasfiltered, washed with cold water and dried to afford the title compound(285 mg, 65%). MS (ESI) mass calcd. for C₁₂H₁₁NO₃, 217.1. m/z found218.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d6) δ 13.36 (s, 1H), 9.15 (s, 1H),8.13-8.06 (m, 1H), 7.82-7.70 (m, 2H), 7.54-7.47 (m, 1H), 4.50 (q, J=7.0Hz, 2H), 1.35 (t, J=7.0 Hz, 3H).

Intermediate Name Structure Reference A-22 3-methyl- 2-(2H- 1,2,3-triazol-2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 82 A-23 4-fluoro- 2-(pyrimidin- 2- yl)benzoic acid

Prepared according to WO 2011/050198 Intermediate 87

Intermediate A-24: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid

Step A: Methyl 2-methoxy-6-(pyrimidin-2-yl)benzoate. In a microwave vialwas dissolved methyl2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS1146214-77-8) (500 mg, 1.71 mmol) and 2-bromopyrimidine (344 mg, 2.05mmol) in THF (8.5 mL). Na₂CO₃ (544 mg, 5.14 mmol) was then addedfollowed by water (4 mL) and the reaction mixture was degassed with N₂for 10 minutes. PdCl₂(dtbpf) (CAS 95408-45-0) (45 mg, 0.069 mmol) wasthen added and the reaction mixture was heated at 80° C. for 4 h. Themixture was cooled to room temperature and water and EtOAc added. Thereaction mixture was extracted with EtOAc (3×). The combined organiclayers were dried over Na₂SO₄, filtered and concentrated. The crude waspurified via silica gel chromatography (0-70% EtOAc in hexanes) toafford the title compound (265 mg, 63%). MS (ESI) mass calcd. forC₁₃H₁₂N₂O₃, 244.1. m/z found 245.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d) δ 8.78 (d, J=4.9 Hz, 2H), 7.99 (dd, J=7.9, 0.9 Hz, 1H),7.49 (t, J=8.1 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 7.09 (dd, J=8.3, 0.9 Hz,1H), 3.90 (s, 3H), 3.89 (s, 3H).

Step B: 2-methoxy-6-(pyrimidin-2-yl)benzoic acid. To a solution of thetitle compound of Step A (265 mg, 1.09 mmol) in THF (4 mL) was added 2 MNaOH (2 mL). The mixture was heated at 50° C. for 72 h. The reactionmixture was cooled to room temperature and concentrated in vacuo toremove THF. Then, 1 M HCl_((aq)) was added and the aqueous was extractedwith 10:1 DCM/2,2,2-trifluoroethanol (3×). The combined organic layerswere dried over Na₂SO₄, filtered and concentrated to give intermediateA-24, which was used without further purification in subsequent steps.MS (ESI) mass calcd. for C₁₂H₁₀N₂O₃, 230.1. m/z found 231.1 [M+H]⁺. ¹HNMR (500 MHz, DMSO-d₆) δ 12.63 (s, 1H), 8.86 (d, J=4.9 Hz, 2H), 7.77(dd, J=7.9, 1.0 Hz, 1H), 7.51 (t, J=8.1 Hz, 1H), 7.45 (t, J=4.9 Hz, 1H),7.25 (dd, J=8.4, 1.0 Hz, 1H), 3.83 (s, 3H).

Intermediate A-25: 7-ethoxyquinoline-8-carboxylic acid

Step A: 7-methoxyquinoline-8-carboxylic acid. In separate batches (1 g)a mixture of 2-amino-6-methoxybenzoic acid (11 g, 66 mmol) and acrolein(4.8 mL, 72 mmol) in 1,4-dioxane (66 mL) was heated in a microwavereactor for 20 min at 200° C. After combining the reactions, the mixturewas concentrated and purified via silica gel chromatography (0-10% MeOHin DCM) to give the title compound (2.8 g, 20%). MS (ESI) mass calcd.for C₁₁H₁₉NO₃, 203.1. m/z found 204.0 [M+H]⁺.

Step B: 7-hydroxyquinoline-8-carboxylic acid. The title compound of StepA (2.9 g, 14.1 mmol) in HBr (14 mL) was heated at 90° C. for 1 h. Themixture was then concentrated washed with PhCH₃ and used without furtherpurification in subsequent steps.

Step C: ethyl 7-ethoxyquinoline-8-carboxylate. To the title compound ofStep B (800 mg, 3.9 mmol) and K₂CO₃ (1.4 g, 10.4 mmol) in DMF (15 mL)was added iodoethane (560 mL, 6.9 mmol). After stirring overnight atroom temperature, the reaction was concentrated and purified via silicagel chromatography (0-30% EtOAc in hexanes) to give the title compound.MS (ESI) mass calcd. for C₁₄H₁₅NO₃, 245.1. m/z found 246.0 [M+H]⁺.

Step D: 7-ethoxyquinoline-8-carboxylic acid. To the title compound ofStep C (1.3 g, 5.4 mmol) in THF (22 mL) and H₂O (11 mL) was added LiOHhydrate (675 mg, 16.5 mmol) and MeOH. The mixture was heated at 67° C.for 12 h. Additional LiOH hydrate (675 mg, 16.5 mmol) was added and theheating was continued at 70° C. for 1 day. Additional LiOH hydrate (1.4g, 33 mmol) was added and the heating was continued at 75° C. for 1 day.The reaction was allowed to cool to room temperature, acidified to pH=3with 1 N HCl_((aq)) and concentrated. Purification via prep HPLC gavethe title compound (1 g, 84%). MS (ESI) mass calcd. for C₁₂H₁₁NO₃,217.1. m/z found 218.0 [M+H]⁺.

Intermediate A-27: 3-methyl-2-(oxazol-2-yl)benzoic acid

Step A: ethyl 3-methyl-2-(oxazol-2-yl)benzoate. In a microwave vial wasdissolved ethyl 2-iodo-3-methylbenzoate (627 mg, 2.16 mmol) and2-(tributylstannyl)oxazole (0.54 mL, 0.07 mmol) in DME (2.59 mL). Thesolution was degassed with N₂ for 5 minutes then CuI (21 mg, 0.11 mmol)and Pd(PPh₃)₄ (125 mg, 0.11 mmol) were added. The reaction was purgedwith N₂ and heated at 150° C. for 1 h. The reaction was cooled to roomtemperature, filtered through a pad of Celite and purified via silicagel chromatography (0-40% EtOAc in hexanes) to give the title compoundof step A (333 mg, 67%). MS (ESI) mass calcd. for C₁₃H₁₃NO₃, 231.1. m/zfound 232.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.89-7.82 (m, 1H),7.79 (d, J=0.8 Hz, 1H), 7.48-7.43 (m, 2H), 7.30 (d, J=0.9 Hz, 1H), 4.17(q, J=7.1 Hz, 2H), 2.27 (s, 3H), 1.18 (t, J=7.1 Hz, 3H).

Step B: 3-methyl-2-(oxazol-2-yl)benzoic acid. To the title compound ofstep A (166 mg, 0.72 mmol) was added MeOH (7.2 mL) and 1M NaOH_((aq))(7.2 mL). MeOH was evaporated and then 1 M HCl_((aq)) was added. To thesolution was added DCM and the aqueous was extracted with DCM (3×). Thecombined organic layers were dried over MgSO₄, filtered and evaporatedto give the title compound (145 mg). MS (ESI) mass calcd. for C₁₁H₉NO₃,203.1. m/z found 204.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 8.20 (s, 1H),7.79-7.68 (m, 1H), 7.65-7.49 (m, 2H), 7.35 (s, 1H), 4.34 (s, 1H), 2.20(s, 3H).

Intermediate Name Structure Reference A-28 3-(2H- 1,2,3- triazol- 2-yl)picolinic acid

Prepared according to WO 2011/050198 Intermediate 72 A-29 1H-indole- 7-carboxylic acid

Commercially available, CAS 1670-83-3

Intermediate A-30: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid

Step A: Ethyl 2-methoxy-6-(1H-pyrazol-5-yl)benzoate. In a microwave vialwas dissolved ethyl 2-bromo-6-methoxybenzoate (500 mg, 1.54 mmol) and5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (330 mg,1.70 mmol) in DME (10 mL) and water (2 mL). Na₂CO₃ (259 mg, 3.09 mmol)was then added followed by Pd(PPh₃)₄ (89 mg, 0.077 mmol) and thereaction mixture was degassed with N₂ for 10 minutes. The reactionmixture was then heated at 100° C. for 1 h in the microwave. The mixturewas cooled to room temperature, filtered through Celite and washed withEtOAc and DCM. The crude solution was concentrated in vacuo and directlypurified via silica gel chromatography (10-80% EtOAc in hexanes) toafford the title compound (125 mg, 33%). MS (ESI) mass calcd. forC₁₃H₁₄N₂O₃, 246.3. m/z found 247.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d) δ 7.63 (d, J=2.2 Hz, 1H), 7.44-7.37 (m, 1H), 7.24 (d,J=8.1 Hz, 1H), 6.94 (dd, J=8.3, 0.9 Hz, 1H), 6.53 (d, J=2.3 Hz, 1H),4.29 (q, J=7.2 Hz, 2H), 3.88 (s, 3H), 1.25-1.16 (m, 3H).

Step B: 2-methoxy-6-(1H-pyrazol-5-yl)benzoic acid. Prepared analogous tointermediate A-24 step B to give title compound. MS (ESI) mass calcd.for C₁₁H₁₀N₂O₃, 218.1. m/z found 219.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆)δ 12.85 (br. s, 1H), 7.71 (d, J=2.2 Hz, 1H), 7.39 (t, J=8.0 Hz, 1H),7.35-7.28 (m, 1H), 7.04 (dd, J=8.3, 1.0 Hz, 1H), 6.51 (d, J=2.3 Hz, 1H),3.80 (s, 3H).

Intermediate A-31: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid

Step A: Methyl 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoate. Preparedanalogous to intermediate A-30 step A to give title compound. MS (ESI)mass calcd. for C₁₃H₁₄N₂O₂, 230.1. m/z found 231.1 [M+H]⁺. ¹H NMR (400MHz, Chloroform-d) δ 8.04 (dd, J=7.8, 1.5 Hz, 1H), 7.61 (td, J=7.5, 1.5Hz, 1H), 7.53 (td, J=7.7, 1.4 Hz, 1H), 7.35 (s, 1H), 7.28 (dd, J=7.6,1.4 Hz, 1H), 3.71 (s, 3H), 3.58 (s, 3H), 1.84 (s, 3H).

Step B: 2-(1,4-dimethyl-1H-pyrazol-5-yl)benzoic acid. To a solution ofthe title compound of Step A (680 mg, 2.95 mmol) in MeOH (15 mL) wasadded 4 M LiOH (4 mL). The mixture was heated at 50° C. overnight. MeOHwas removed and HCl added until pH=2. White solids precipitated from thereaction mixture and the precipitate was filtered, washed with EtOAc andcollected to give intermediate A-31, which was used without furtherpurification in subsequent steps. MS (ESI) mass calcd. for C₁₂H₁₂N₂O₂,216.1. m/z found 217.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 12.87 (s,1H), 7.95 (dd, J=7.8, 1.5 Hz, 1H), 7.67 (td, J=7.5, 1.5 Hz, 1H), 7.59(td, J=7.6, 1.4 Hz, 1H), 7.33 (dd, J=7.6, 1.4 Hz, 1H), 7.25 (s, 1H),3.48 (s, 3H), 1.77 (s, 3H).

Intermediate Name Structure Reference A-33 2-bromo-3- fluorobenzoic acid

Commercially available, CAS 132715-69-6

Intermediate A-33: 3-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid

To 3-fluoro-2-iodobenzoic acid (4.5 g, 16.9 mmol) dissolved in dioxane(33.8 mL) and H₂O (0.09 mL) was added Cs₂CO₃ (11.02 g, 33.8 mmol), CuI(161 mg, 0.85 mmol), 2H-1,2,3-triazole (1.96 mL, 33.8 mmol), andtrans-N,N-dimethyl-1,2-cyclohexanediamine (0.53 mL, 3.38 mmol). Themixture was then heated to 100° C. overnight, cooled to roomtemperature, diluted with H₂O, and extracted with EtOAc. The aqueouslayer was then acidified and extracted with EtOAc. The combined organicswere dried and concentrated. From this concentrate a solid precipitatedto provide intermediate A-33 (285 mg, 8%). MS (ESI) mass calcd forC₉H₆FN₃O₂, 207.0. m/z found 208.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄)δ 6.81-6.77 (m, 1H), 6.46-6.40 (m, 2H), 6.30-6.23 (m, 1H), 6.18-6.12 (m,1H).

Intermediate A-34: 2-(5-fluoropyrimidin-2-yl)benzoic acid

Step A: 5-fluoro-2-iodopyrimidine. To a solution of2-chloro-5-fluoropyrimidine (4 mL, 32 mmol) in propionitrile (33 mL) wasadded chlorotrimethylsilane (12 mL, 97 mmol) and sodium iodide (15 g, 97mmol), and the reaction mixture was heated to 150° C. for 1 h. Uponcompletion of the reaction, the reaction mixture was cooled to roomtemperature and the solvent removed. The residue was taken up in EtOAcand a solution of saturated NaHCO₃. The organic layer was dried overMgSO₄, filtered and evaporated. Purification via silica gelchromatography (0-20% EtOAc in hexanes) gave the title compound (2.82 g,39%).

Step B: 2-(5-fluoropyrimidin-2-yl)benzonitrile. In a microwave vial wasdissolved 2-cyanophenylboronic acid (500 mg, 3.40 mmol) in THF (15 mL),and the reaction mixture was degassed with N₂. Then, the title compoundof step A (915 mg, 4.08 mmol), Na₂CO₃ (1.08 g, 10.2 mmol), water (5 mL),and PdCl₂(dtbpf) (CAS 95408-45-0) (89 mg, 0.14 mmol) were added, and thereaction mixture was stirred at room temperature for 1 h and then heatedvia microwave heating to 75° C. for 2 h. The mixture was cooled to roomtemperature and water and EtOAc added. The reaction mixture wasextracted with EtOAc. The combined organic layers were dried over MgSO₄,filtered and concentrated. The crude was purified via silica gelchromatography (0-30% EtOAc in hexanes) to afford the title compound(280 mg, 41%). MS (ESI) mass calcd. for C₁₁H₆FN₃, 199.1. m/z found 200.0[M+H]⁺.

Step C: 2-(5-fluoropyrimidin-2-yl)benzoic acid. A solution of the titlecompound of step B (1.24 g, 6.22 mmol) in H₂SO₄ (6 mL) and water (6 mL)was stirred at 80° C. for 1 h. Then, the reaction mixture was cooled to0° C. and the aqueous phase extracted with DCM (2×). A solution of 20 MNaOH (11 mL) was added to the aqueous layer until pH ˜3-4. The aqueouslayer was extracted again with EtOAc and DCM. The combined organiclayers were dried over MgSO₄, filtered and concentrated to afford thetitle compound (672 mg, 50%). MS (ESI) mass calcd. for C₁₁H₇FN₂O₂,218.1. m/z found 219.1 [M+H]⁺.

Intermediate A-35: 3-fluoro-2-(5-fluoropyrimidin-2-yl)benzoic acid

Prepared analogous to Intermediate A-34, substituting2-cyanophenylboronic acid with (2-cyano-6-fluorophenyl)boronic acid (CAS656235-44-8). MS (ESI) mass calcd. for C₁₁H₆F₂N₂O₂, 236.0. m/z found237.1 [M+H]⁺.

Intermediate A-36: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid

Step A: Methyl 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoate. A solutionof methyl3-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS887234-98-2) (3 g, 11 mmol) in THF (30 mL) was degassed with N₂. Then,2-chloro-5-fluoropyrimidine (1.6 mL, 13.04 mmol), Na₂CO₃ (3.45 g, 32.6mmol), water (10 mL), and Pd(dppf)Cl₂ (354 mg, 0.434 mmol) were added,and the reaction mixture was stirred at 100° C. overnight. The mixturewas cooled to room temperature and water and EtOAc added. The reactionmixture was extracted with EtOAc. The combined organic layers were driedover MgSO₄, filtered and concentrated. The crude was purified via silicagel chromatography (0-40% EtOAc in hexanes) to afford the title compound(1.07 g, 40%).

Step B: 2-(5-fluoropyrimidin-2-yl)-3-methylbenzoic acid. To a solutionof the title compound of Step A (1.46 g, 5.93 mmol) in MeOH (20 mL) wasadded 1 M NaOH (12 mL), and the reaction mixture was stirred at roomtemperature overnight. The solvent was removed and the crude was dilutedwith water until pH=10. The aqueous layer was extracted with EtOAc. Theaqueous layer was further acidified with 12 M HCl_((aq)) until pH=2 andextracted with EtOAc. The combined organic layers were dried over MgSO₄,filtered and concentrated to afford the title compound (1.19 g, 83%). MS(ESI) mass calcd. for C₁₂H₉FN₂O₂, 232.1. m/z found 233.1 [M+H]⁺.

Intermediate Name Structure Reference A-37 2-(pyrimidin-2- yl)benzoicacid

Comercially available, CAS 400892-62-8 A-38 5-methyl-2-(2H-1,2,3-triazol-2- yl)nicotinic acid

Prepared analogous to WO 2011/050200 Intermediate 47, Example 160 A-392-(2H-1,2,3-triazol- 2-yl)nicotinic acid

Comercially available, CAS 1369497-44-8 A-40 6-methyl-3-(2H-1,2,3-triazol-2- yl)picolinic acid

2012/089606 Intermediate D40. A-41 6-methyl-3- (pyrimidin-2-yl)picolinic acid

WO 2010/122151 Intermediate D28 A-42 3-(pyrimidin-2- yl)picolinic acid

WO 2010/122151 Intermediate D105 A-43 3-phenylpyrazine- 2-carboxylicacid

Comercially available, CAS 2881- 85-8 A-44 1H-indazole-7- carboxylicacid

Comercially available, CAS 677304-69-7 A-45 3-phenylfuran-2- carboxylicacid

Comercially available, CAS169772-63-8

Intermediate A-46: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid

Step A: Methyl 5-methyl-2-(pyrimidin-2-yl)nicotinate. To a sealed tubecontaining methyl 2-chloro-5-methylnicotinate (CAS 65169-43-9) (745 mg,4.01 mmol), CuI (38 mg, 0.2 mmol), LiCl (169 mg, 4.01 mmol), andPd(PPh₃)₄(231 mg, 0.2 mmol) in toluene (15 mL) was added2-(tributylstannyl)pyrimidine (1.5 mL, 4.4 mmol), and the reactionmixture was heated at 120° C. overnight. The reaction mixture wasdiluted with water and extracted with DCM. The combined organic layerswere dried over MgSO₄, filtered and evaporated. Purification via silicagel chromatography (0-50% EtOAc in hexanes) gave the title compound (494mg, 52%). MS (ESI) mass calcd. for C₁₂H₁₁N₃O₂, 229.1. m/z found 229.99.

Step B: 5-methyl-2-(pyrimidin-2-yl)nicotinic acid. To a solution of thetitle compound of step A (466 mg, 2.03 mmol) in MeOH (10 mL) was added10 M NaOH (1 mL), and the reaction mixture was stirred at roomtemperature for 2 h. The solvent was removed and the crude was dilutedwith water and acidified with 6 M HCl_((aq)) until pH=3. The aqueouslayer was saturated with solid NaCl and extracted with 20% iPrOH inCHCl₃ (3×). The combined organic layers were dried over MgSO₄, filteredand concentrated to afford the title compound (432 mg, 99%). MS (ESI)mass calcd. for C₁₁H₉N₃O₂, 215.1. m/z found 216.1 [M+H]⁺. ¹H NMR (500MHz, Methanol-d₄) δ 8.90 (br. s, 2H), 8.64 (br. s, 1H), 8.17 (s, 1H),7.55 (br. s, 1H), 2.51 (s, 3H).

Intermediate A-47: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate

Step A: Methyl 5-methyl-3-(pyrimidin-2-yl)picolinate. Prepared analogousto intermediate A-46, step A substituting methyl2-chloro-5-methylnicotinate with methyl 3-bromo-5-methylpicolinate. MS(ESI) mass calcd. for C₁₂H₁₁N₃O₂, 229.1. m/z found 230.0 [M+H]⁺.

Step B: Lithium 5-methyl-3-(pyrimidin-2-yl)picolinate. To a solution ofthe title compound of step A (592 mg, 2.58 mmol) in THF (5 mL) was added4 M LiOH (0.8 mL) and water (1.5 mL), and the reaction mixture wasstirred at room temperature for 2.5 h. The solvent was removed and thecrude reaction mixture placed under vacuum overnight to give the titlecompound (591 mg), which was used in the next step without furtherpurification. MS (ESI) mass calcd. for C₁₁H₉N₃O₂, 215.1. m/z found 216.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 8.83 (d, J=4.9 Hz, 2H), 8.39(br. s, 1H), 8.23-8.18 (m, 1H), 7.38 (t, J=4.9 Hz, 1H), 2.44 (s, 3H).

Intermediate A-48: 3-fluoro-2-(oxazol-2-yl)benzoic acid

Step A: 2-bromo-N-(2,2-dimethoxyethyl)-6-fluorobenzamide To a solutionof 2-bromo-6-fluorobenzoic acid (2 g, 9.1 mmol) in DMF (27 mL) was addedHBTU (5.20 g, 13.7 mmol) and DIPEA (4.7 mL, 27 mmol), and the reactionmixture was stirred for 10 min. Then, 2,2-dimethoxyethylamine (1.3 mL,11.9 mmol) was added and the reaction mixture stirred at roomtemperature for 12 h. The reaction mixture was diluted with EtOAc andwashed with saturated aqueous NaHCO₃. The combined organic layers weredried over MgSO₄, filtered and concentrated. Purification via silica gelchromatography (0-25% EtOAc in hexanes) gave the title compound (2.3 g,82%).

Step B: 2-(2-bromo-6-fluorophenyl)oxazole. To P₂O₅ (6.4 g, 22.6 mmol)was added methanesulfonic acid (52 mL, 801 mmol), and the reactionmixture was stirred at room temperature for 1 h. Then, the titlecompound of step A (2.3 g, 7.54 mmol) was added to the reaction mixture,and the mixture heated to 140° C. for 2 h. DCM was added and the mixturewas slowly poured into a saturated solution of aqueous NaHCO₃ on ice.The mixture was extracted with DCM. The combined organic layers weredried over MgSO₄, filtered and concentrated. Purification via silica gelchromatography (0-10% EtOAc in hexanes) gave the title compound (1.5 g,82%). MS (ESI) mass calcd. for C₉H₅BrFNO, 240.95. m/z found 242.0[M+H]⁺.

Step C: Methyl 3-fluoro-2-(oxazol-2-yl)benzoate. A solution of the titlecompound of step B (2.18 g, 8.99 mmol), Pd(OAc)₂ (40 mg, 0.18 mmol),1,1′-bis(diphenylphosphino)ferrocene (199 mg, 0.36 mmol), and Et₃N (3.7mL, 27 mmol) in 1:1 MeOH/1,4-dioxane (36 mL) was degassed with N₂ for 15min. Then, the mixture was stirred at 95° C. under an atmosphere ofcarbon monoxide overnight. The reaction mixture was diluted with EtOAcand washed with a solution of NaHCO₃. The organic layer was separated,dried over MgSO₄, filtered, and concentrated. Purification via silicagel chromatography (0-12% EtOAc in hexanes) gave the title compound (1.7g, 83%). MS (ESI) mass calcd. for C₁₁H₈FNO₃, 221.1. m/z found 222.0[M+H]⁺.

Step D: 3-fluoro-2-(oxazol-2-yl)benzoic acid. To a solution of the titlecompound of step C (1.65 g, 7.46 mmol) in MeOH (22 mL) was added 2 MNaOH (7.5 mL), and the reaction mixture was stirred at room temperatureovernight. The reaction mixture was acidified with 1 M HCl_((aq)) andthe solvents evaporated in vacuo. The mixture was diluted with water andextracted with DCM. The combined organic were dried over MgSO₄, filteredand concentrated to afford the title compound (905 mg, 58%). MS (ESI)mass calcd. for C₁₀H₆FNO₃, 207.0. m/z found 208.0 [M+H]⁺. MP=182° C.

Intermediate A-49: 5-fluoro-2-(oxazol-2-yl)benzoic acid

Step A: Methyl 5-fluoro-2-(oxazol-2-yl)benzoate. To a solution of methyl2-bromo-5-fluorobenzoate (1.1 g, 4.8 mmol) and2-(tri-n-butylstannyl)oxazole (1.3 mL, 6.2 mmol) in toluene (14 mL) wasadded Pd(PPh₃)₄ (550 mg, 0.476 mmol), and the reaction mixture washeated via microwave heating to 150° C. for 30 min. The reaction mixturewas diluted with water and extracted with EtOAc. The combined organiclayers were dried over MgSO₄, filtered and concentrated. Purificationvia silica gel chromatography (0-40% EtOAc in hexanes, followed by asecond column 0-10% EtOAc in hexanes) gave the title compound (553 mg,52%). MS (ESI) mass calcd. for C₁₁H₆FNO₃, 221.1. m/z found 222.1 [M+H]⁺.

Step B: 5-fluoro-2-(oxazol-2-yl)benzoic acid. Prepared analogous tointermediate 48, step D, to give the title compound (858 mg, 99%). MS(ESI) mass calcd. for C₁₀H₆FNO₃, 207.0. m/z found 208.1 [M+H]⁺.

Intermediate A-50: 2-fluoro-6-(oxazol-2-yl)benzoic acid

Prepared analogous to intermediate 48, substituting2-bromo-6-fluorobenzoic acid with 2-bromo-3-fluorobenzoic acid. MS (ESI)mass calcd. for C₁₀H₆FNO₃, 207.0. m/z found 208.0 [M+H]⁺.

Intermediate A-51: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoicacid

Step A: 5-(2-bromo-5-fluorophenyl)-3-methyl-1,2,4-oxadiazole. To asolution of bromo-5-fluorobenzoyl chloride (2.17 g, 9.13 mmol) in THF(18 mL) was added DIPEA (1.7 mL, 10 mmol). Then, acetamide oxime (676mg, 9.13 mmol) was added portionwise, and the reaction mixture wasstirred at 70° C. for 16 h. The reaction mixture was diluted with EtOAcand washed with a saturated solution of NaHCO₃. The combined organiclayers were dried over MgSO₄, filtered and concentrated. Purificationvia silica gel chromatography (0-20% EtOAc in hexanes) gave the titlecompound (2.35 g, 57%). MS (ESI) mass calcd. for C₉H₆BrFN₂O, 255.96. m/zfound 257.0 [M+H]⁺.

Step B: 4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid. Preparedanalogous to intermediate 48, steps C and D, to give the title compound.MS (ESI) mass calcd. for C₁₀H₇FN₂O₃, 222.0. m/z found 223.0 [M+H]⁺.

Enantiopure Route A (2-azabicyclo[2.2.1]heptan-6-ol) Intermediate B-1:(1S,4R)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]hept-5-ene

Intermediate B-1 was prepared according to the procedure of C. Chiu etal. [Synthetic Communications 1996, 26, 577-584] with the substitutionof (+)-α-Methyl-benzylamine for (−)-α-Methyl-benzylamine and D-dibenzoyltartaric acid for L-dibenzoyl tartaric acid. MS (ESI) mass calcd. forC₁₄H₁₇N, 199.1. m/z found 200.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ7.36-7.25 (m, 4H), 7.23-7.17 (m, 1H), 6.35-6.30 (m, 1H), 6.11 (dd,J=5.7, 2.0 Hz, 1H), 4.16-4.12 (m, 1H), 3.05 (q, J=6.5 Hz, 1H), 2.89 (dd,J=8.9, 3.1 Hz, 1H), 2.85-2.81 (m, 1H), 1.65-1.59 (m, 1H), 1.48-1.43 (m,1H), 1.37-1.31 (m, 4H).

Intermediate B-2:(1S,4R,6S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.1]heptan-6-ol

Intermediate B-2 was synthesized according to the procedure of F.Carroll et al. [J Med. Chem. 1992, 35, 2184-2191] on a similarsubstrate. A 1 M solution of BH₃-THF (1 M BH₃-THF in THF, 359.3 mL,359.3 mmol) was added dropwise via addition funnel to a stirred solutionof intermediate B-1 (35.8 g, 179.6 mmol) in THF (359 mL) at 0° C. Uponcomplete addition of BH₃-THF, the reaction mixture was stirred at 0° C.for 2 h. Then, excess BH₃ was quenched with a solution of THF-H₂O. A 3 MNaOH (132 mL) solution was added followed by the dropwise addition ofH₂O₂ (30% w/w in H₂O, 140 mL), and the reaction mixture was warmed to40° C. and stirred for 1.5 h. The biphasic mixture was then cooled toroom temperature and K₂CO₃ (17 g) added in one portion. The resultingmixture was concentrated under reduced pressure to remove THF andre-dissolved in DCM. The crude reaction mixture was washed with H₂O andthe aqueous phase extracted with DCM (3×). The combined organics werethen washed with brine, dried with Na₂SO₄, filtered, and concentrated togive a clear oil, which was further purified by silica gelchromatography (5-10% MeOH (with 10% 2 M NH₃) in DCM) to giveintermediate B-2 as a clear oil (20.2 g, 93.0 mmol, 52%). MS (ESI) masscalcd. for C₁₄H₁₉NO, 217.2. m/z found 218.1 [M+H]⁺. ¹H NMR (500 MHz,Chloroform-d) δ 7.34-7.27 (m, 4H), 7.24-7.19 (m, 1H), 4.03 (d, J=6.9 Hz,1H), 3.46 (q, J=6.5 Hz, 1H), 3.01 (s, 1H), 2.56-2.48 (m, 1H), 2.42-2.33(m, 1H), 2.25 (dd, J=8.8, 1.3 Hz, 1H), 1.82 (ddd, J=13.1, 6.9, 2.2 Hz,1H), 1.53-1.43 (m, 2H), 1.33-1.28 (m, 1H), 1.27 (d, J=6.5 Hz, 3H).

Intermediate B-3: (1S,4R,6S)-tert-butyl6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate

To a solution of intermediate B-2 (500 mg, 2.3 mmol) in EtOH (11.5 mL)was added Boc₂O (603 mg, 2.76 mmol) and 10 wt % Pd/C wet Degussa (490mg, 0.46 mmol). The reaction mixture was stirred under an atmosphere ofH₂ (balloon) at room temperature for 22 h. Then, the reaction mixturewas filtered through a pad of Celite and washed with EtOAc. The filtratewas concentrated to a clear oil to give the title compound inquantitative yield, which was used without further purification. MS(ESI) mass calcd. for C₁₁H₁₉NO₃, 213.1. m/z found 158.1 [M+2H-tBu]⁺. ¹HNMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ4.08-3.99 (m, 1H), 3.99-3.92 (m, 1H), 3.18-3.09 (m, 1H), 2.80 (dd,J=28.1, 9.2 Hz, 1H), 2.18-1.37 (m, 14H).

Intermediate B-4: (1S,4R)-tert-butyl6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate

To a solution of intermediate B-3 (7 g, 33 mmol) in EtOAc (219 mL) wasadded IBX (24.5 g, 39.4 mmol), and the heterogeneous reaction mixturewas stirred at 80° C. overnight. Upon completion, the reaction mixturewas then filtered through Celite, washed with EtOAc and concentrated toa white solid. The crude reaction mixture was re-dissolved in EtOAc andwashed once with a 5% aqueous Na₂CO₃ solution. The aqueous layer wasfurther extracted with EtOAc (2×) and the combined organics were washedwith brine, dried with Na₂SO₄, filtered, and concentrated to affordintermediate B-4 as a light yellow solid (6.12 g, 28.9 mmol, 88%), whichwas used in the next step without further purification. MS (ESI) masscalcd. for C₁₁H₁₂NO₃, 211.1. m/z found 156.1 [M+2H-tBu]⁺. ¹H NMR (400MHz, Chloroform-d) δ 4.32-4.04 (m, 1H), 3.45 (ddd, J=9.6, 3.1, 1.8 Hz,1H), 3.25-3.04 (m, 1H), 2.89-2.77 (m, 1H), 2.21 (ddd, J=18.0, 4.6, 1.8Hz, 1H), 2.04-1.96 (m, 1H), 1.95-1.82 (m, 1H), 1.75-1.66 (m, 1H), 1.45(s, 9H).

Intermediate B-5: (1S,4R,6R)-tert-butyl6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate

A 1 M solution of L-Selectride (1 M in THF, 19.8 mL, 19.8 mmol) wasadded to a solution of intermediate B-4 (1.67 g, 7.91 mmol) in dry THF(40 mL) at −78° C., and the reaction mixture was stirred at thattemperature for 3 h. Then, the reaction mixture was warmed to 0° C. anda 3 M NaOH (8.4 mL) solution was added followed by a solution of H₂O₂(30% w/w in H₂O, 4.3 mL). The resulting mixture was warmed to roomtemperature and stirred for 2 h. The biphasic mixture was thenconcentrated in vacuo to remove THF and the aqueous layer extracted withDCM (3×). The combined organics were washed with brine, dried withNa₂SO₄, filtered, and concentrated to an oil, which was further purifiedby silica gel chromatography (10-90% EtOAc in hexanes), to giveintermediate B-2 as a white solid (1.16 g, 5.44 mmol, 67%). MS (ESI)mass calcd. for C₁₁H₁₉NO₃, 213.1. m/z found 158.1 [M+2H-tBu]⁺. ¹H NMR(400 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ4.38-4.10 (m, 2H), 3.36 (br. s, 1H), 3.09 (dd, J=9.6, 1.4 Hz, 1H),2.54-1.38 (m, 14H), 1.16-1.00 (m, 1H).

Intermediate B-5 can also be prepared from commercially available(1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one. The procedure is as follows:

Enantiopure Route B (2-azabicyclo[2.2.1]heptan-6-ol) Intermediate B-6:(1S,4R,6S)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol

To a round bottom flask containing commercially available,(1S,4R)-2-azabicyclo[2.2.1]hept-5-en-3-one (2.0 g, 18.3 mmol), in THF(100 mL) at 0° C. was added a solution of LiAlH₄ (1 M in THF, 40.3 mL,40.3 mmol), and the reaction mixture was refluxed overnight. Thereaction mixture was then cooled to 0° C. and carefully quenched by thedropwise addition of H₂O (15 mL). Celite and solid Na₂CO₃ were added tothe slurry and the reaction mixture was vigorously stirred at roomtemperature for 3 h. The slurry was then filtered and the solids washedwith THF. Benzyl bromide (2.4 mL, 20.2 mmol) and an aqueous solution ofNa₂CO₃ (3.2 g in 30 mL H₂O) were added to the filtrate and the reactionmixture stirred at room temperature overnight. Upon completion of thereaction, the reaction mixture was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered, and concentrated to provide crude(1S,4R)-2-benzyl-2-azabicyclo[2.2.1]hept-5-ene as a yellow oil, whichwas directly hydroborated according to the procedure of F. Carroll etal. [J. Med. Chem. 1992, 35, 2184-2191]. The crude alcohol was purifiedby silica gel chromatography (0-15% MeOH (with 5% NH₄OH) in DCM) to giveintermediate B-6 as a clear oil (2.66 g, 13.1 mmol, 71% over 3 steps).MS (ESI) mass calcd for C₁₃H₁₇NO, 203.1. m/z found 204.1 [M+H]⁺. ¹H NMR(500 MHz, Chloroform-d) δ 7.39-7.28 (m, 4H), 7.26-7.21 (m, 1H),4.18-4.09 (m, 1H), 3.76-3.66 (m, 2H), 3.06 (br. s, 1H), 2.51 (dt, J=9.0,3.0 Hz, 1H), 2.44-2.35 (m, 2H), 1.90-1.81 (m, 1H), 1.68-1.53 (m, 2H),1.38-1.30 (m, 1H).

Intermediate B-7: (1S,4R,6R)-2-benzyl-2-azabicyclo[2.2.1]heptan-6-ol

Intermediate B-7 was prepared from intermediate B-6 according to theprocedure of F. Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191]. MS(ESI) mass calcd for C₁₃H₁₇NO, 203.1. m/z found 204.1 [M+H]⁺. ¹H NMR(500 MHz, Chloroform-d) δ 7.37-7.22 (m, 5H), 4.56 (s, 1H), 4.05-3.94 (m,1H), 3.80 (d, J=13.0 Hz, 1H), 3.62 (d, J=12.9 Hz, 1H), 3.20-3.11 (m,1H), 2.77 (d, J=9.2 Hz, 1H), 2.45-2.34 (m, 2H), 1.88-1.79 (m, 1H),1.76-1.64 (m, 1H), 1.30 (d, J=10.4 Hz, 1H), 0.99 (dt, J=13.3, 2.9 Hz,1H).

Intermediate B-5: (1S,4R,6R)-tert-butyl6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate

To a solution of intermediate B-7 (3.41 g, 16.8 mmol) in EtOH (168 mL)was added Boc₂O (5.49 g, 25.2 mmol) and 20 wt % Pd(OH)₂/C (2.36 g, 3.36mmol). The reaction mixture was stirred under an atmosphere of H₂(balloon) at room temperature overnight. Then, the reaction mixture wasfiltered through a pad of Celite and washed with EtOAc. The filtrate wasconcentrated to a clear oil, which was further purified by silica gelchromatography (10-60% EtOAc in hexanes), to give intermediate B-5 as awhite solid (3.1 g, 1.5 mmol, 87%). [α]^(D) ₂₀−11.2 (c 0.0065, MeOH). MS(ESI) mass calcd. for C₁₁H₁₉NO₃, 213.1. m/z found 158.1 [M+2H-tBu]⁺. ¹HNMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ4.39-4.12 (m, 2H), 3.35 (br. s, 1H), 3.08 (dd, J=9.4, 1.4 Hz, 1H),2.56-1.39 (m, 14H), 1.15-0.99 (m, 1H).

Racemic Route (2-azabicyclo[2.2.1]heptan-6-ol) Intermediate B-8:(R/S)-tert-butyl 6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate

Intermediate B-8 was prepared from commercially available(R/S)-tert-butyl 6-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylatefollowing the procedure of R. Nencka et. al. [Tetrahedron 2012, 68,1286-1298]. MS (ESI) mass calcd. for C₁₁H₁₉NO₃, 213.1. m/z found 158.1[M+2H-tBu]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 4.39-4.08 (m, 2H), 3.36(br.s, 1H), 3.10 (dd, J=9.6, 1.4 Hz, 1H), 2.56-1.41 (m, 14H), 1.17-1.01(m, 1H).

Enantiopure Route (2-azabicyclo[2.2.1]heptan-6-amine) Intermediate B-9:(1S,4R)-tert-butyl6-(hydroxyimino)-2-azabicyclo[2.2.1]heptane-2-carboxylate

To a flask containing Intermediate B-4 (1.0 g, 4.7 mmol) dissolved inEtOH (20 mL) was added NEt₃ (2.0 ml, 14.4 mmol), and hydroxylaminehydrochloride (789 mg, 2.40 mmol) and the reaction mixture was broughtto reflux. Upon completion, the reaction mixture was concentrated,diluted with H₂O, and the aqueous layer extracted with EtOAc (3×). Thecombined organics were then washed with H₂O, brine, dried with MgSO₄,filtered, and concentrated to provide intermediate B-9 as an off-whitesolid (1.018 g) which was used without further purification. MS (ESI)mass calcd. for C₁₁H₁₈N₂O₃, 226.1. m/z found 171.1 [M+2H-tBu]⁺. ¹H NMR(500 MHz, Chloroform-d) δ 7.71 and 7.41 (2s, 1H), 4.62 and 4.48 (2s,1H), 3.40-3.33 (m, 1H), 3.15-2.96 (m, 1H), 2.79-2.70 (m, 1H), 2.54-2.43(m, 1H), 2.29-2.19 (m, 1H), 1.87-1.64 (m, 1H), 1.61-1.53 (m, 1H), 1.45(s, 9H).

Intermediate B-10: (1S,4S,6R)-tert-butyl6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate

A mixture of NiCl₂ (1.15 g, 8.84 mmol) and intermediate B-9 (1.0 g, 4.4mmol) in MeOH (30 mL) was cooled to −35° C. and NaBH₄ (3.34 g, 88.4mmol) was added portion wise to the reaction mixture over 30 min. Uponcomplete addition of NaBH₄, the reaction mixture was stirred for anadditional 25 min and then warmed to room temperature. After 30 min atroom temperature the reaction mixture was quenched with H₂O andconcentrated under reduced pressure to a dark brown residue, which wasre-dissolved in a mixture of DCM and 15% aqueous NaOH solution, and theaqueous layer extracted with DCM (3×). The combined organics were driedwith MgSO₄, filtered, and concentrated to provide intermediate B-10 (209mg). 5 N NH₄OH solution was then added to the aqueous layer along withDCM, NaCl, and Celite and after several minutes of stirring the mixturewas filtered to remove solids. The filtrate was then transferred to aseparatory funnel, the layers separated, and the aqueous layer extractedwith DCM (2×). The combined organics were dried with MgSO₄, filtered,and concentrated to provide additional intermediate B-10 (582 mg) whichwas combined with the above fraction to provide intermediate B-10 (791mg) as a brown oil which was used without further purification. MS (ESI)mass calcd. for C₁₁H₂₀N₂O₂, 212.2. m/z found 213.1 [M+H]⁺. ¹H NMR (500MHz, Chloroform-d) δ 4.13-3.92 (m, 1H), 3.41-3.27 (m, 2H), 2.99 (dd,J=24.3, 9.6 Hz, 1H), 2.51-2.39 (m, 1H), 2.16-2.05 (m, 1H), 1.68-1.57 (m,1H), 1.47 (s, 10H), 1.22-1.07 (m, 2H), 0.85-0.74 (m, 1H).

Route A (2-azabicyclo[2.2.1]heptan-6-ol and2-azabicyclo[2.2.2]octan-6-amine) Intermediate C-1:(R/S)-2-benzyl-2-azabicyclo[2.2.2]oct-5-ene

Intermediate C-1 was prepared according to the procedure of S. Larsen etal. [J. Am. Chem. Soc. 1985, 107, 1768-1769]. To a solution ofphenylmethanamine (3.92 g, 27.3 mmol) in H₂O (5 mL) was added aqueousformaldehyde (2.03 mL, 27.3 mmol, 37 wt. % in H₂O). After 2 minutes,1,3-cyclohexadiene (2 mL, 21 mmol) was added and the reaction mixturewas heated to 55° C. for 4 days. The reaction mixture was cooled to roomtemperature and diluted with H₂O and extracted with Et₂O (2×). Theorganic layer was discarded and the aqueous layer was basified withsolid KOH and further extracted with Et₂O (2×). The organic layer waswashed with brine, dried with MgSO₄, filtered, and concentrated. Theconcentrate was further purified by silica gel chromatography (100% DCMto 100% MeOH (with 10% 2 M NH₃) in DCM) to give intermediate C-1 as abrown oil, which contained minor impurities. Intermediate C-1 was usedwithout further purification. MS (ESI) mass calcd. for C₁₄H₁₂N, 199.1.m/z found 200.1 [M+H]⁺.

Intermediate C-2: (R/S)-2-benzyl-2-azabicyclo[2.2.2]octan-6-ol

Intermediate C-2 was synthesized according to the procedure of F.Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191] on a similarsubstrate. A 1 M solution of BH₃-THF (1 M BH₃-THF in THF, 1.11 L, 1.11mol) was added dropwise via addition funnel to a stirred solution ofintermediate C-1 (37 g, 186 mmol) in THF (250 mL) at 0° C. Upon completeaddition of BH₃-THF, the reaction mixture was stirred at 0° C. for 3 h.Then, excess BH₃ was quenched with a solution of THF-H₂O. A 4 M NaOH(100 mL) solution was added followed by the dropwise addition of H₂O₂(30% w/w in H₂O, 100 mL), and the reaction mixture was warmed to 40° C.and stirred overnight. The biphasic mixture was then cooled to roomtemperature and K₂CO₃ added portionwise. The resulting mixture wasconcentrated under reduced pressure to remove THF. Solid NaCl was addedto the remaining aqueous layer and the crude mixture extracted withEtOAc (3×). The combined organics were then washed with brine, driedwith Na₂SO₄, filtered, and concentrated to give a yellow-orange oil,which was further purified by silica gel chromatography (0-100% EtOAc inhexanes followed by 10% MeOH (with 10% 2 M NH₃) in DCM) to giveintermediate C-2 as a yellow oil (20.7 g, 95.3 mmol, 51%), whichcontained minor impurities. Intermediate C-2 was used without furtherpurification. MS (ESI) mass calcd. for C₁₄H₁₉NO, 217.2. m/z found 218.2[M+H]⁺.

Intermediate C-3: (R/S)-tert-Butyl6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

To a solution of intermediate C-2 (20.7 g, 95.3 mmol) in EtOH (477 mL)was added Boc₂O (27.1 g, 124 mmol) and 10 wt % Pd/C wet Degussa (5 g,4.77 mmol). The reaction mixture was stirred under an atmosphere of H₂(balloon) at room temperature for 48 h. Analysis of the crude reactionmixture showed that the majority of the mixture was the deprotectedamine, 2-azabicyclo[2.2.2]octan-6-ol. An additional equivalent of Boc₂O(27.1 g, 124 mmol) was added, and the reaction mixture was stirred atroom temperature overnight. Then, the reaction mixture was filteredthrough a pad of Celite and washed with EtOAc. The filtrate wasconcentrated to a yellow oil to give intermediate C-3, which was usedwithout further purification. MS (ESI) mass calcd. for C₁₂H₂₁NO₃, 227.2.m/z found 172.2 [M+2H-tBu]⁺.

Intermediate C-4A: (R/S)-tert-Butyl6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate

To a solution of intermediate C-3 (21.6 g, 95.0 mmol) in EtOAc (380 mL)was added IBX (31.9 g, 114 mmol), and the heterogeneous reaction mixturewas stirred at 80° C. overnight. Upon completion, the reaction mixturewas then filtered through Celite, washed with EtOAc and concentrated.The crude reaction mixture was re-dissolved in EtOAc and washed oncewith a 5% aqueous Na₂CO₃ solution. The aqueous layer was furtherextracted with EtOAc (2×) and the combined organics were washed withbrine, dried with Na₂SO₄, filtered, and concentrated to a brown residue.The concentrate was further purified by silica gel chromatography (0-35%EtOAc in hexanes), to give intermediate C-4A as a yellow solid. MS (ESI)mass calcd. for C₁₂H₁₉NO₃, 225.1. m/z found 170.1 [M+2H-tBu]⁺.Analytical HPLC using a XBridge C18 column (5 μm, 100×4.6 mm), mobilephase of 10-100% ACN in 20 mM NH₄OH over 2 min and then hold at 100% ACNfor 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.). R_(t)=1.91min at 280 nm.

Intermediate C-4B: (1S,4R)-tert-butyl6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate

The title compound was obtained as a single enantiomer by Chiral SFCpurification of Intermediate C-4A performed using a Chiralpak IC column(5 μm, 250×20 mm), mobile phase of 20% iPrOH: 80% CO₂, and a flow rateof 80 mL/min (Temperature=35° C.). Elution was monitored followingabsorbance at 250 nm. The enantiomeric purity was confirmed byanalytical SFC using a Chiralpak IC column (5 μm, 150×4.6 mm), mobilephase of 20% iPrOH+(0.3% iPrNH₂): 80% CO₂, and a flow rate of 3 mL/minover 7 minutes (Temperature=35° C.). Elution was monitored followingabsorbance at 250 nm. Enantiopurity 100%, which elutes at one peak (1.56min retention time). MS (ESI) mass calcd. for C₁₂H₁₉NO₃, 225.1. m/zfound 170.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound presentas a mixture of rotamers) δ 4.42-4.15 (m, 1H), 3.62-3.34 (m, 2H),2.49-2.32 (m, 3H), 2.21-2.06 (m, 1H), 1.97-1.85 (m, 1H), 1.79-1.68 (m,1H), 1.66-1.56 (m, 1H), 1.45 (s, 9H).

Intermediate C-4C: (1R,4S)-tert-butyl6-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate

The title compound was obtained as a single enantiomer by Chiral SFCpurification of Intermediate C-4A performed using a Chiralpak IC column(5 μm, 250×20 mm), mobile phase of 20% iPrOH: 80% CO₂, and a flow rateof 80 mL/min (Temperature=35° C.). Elution was monitored followingabsorbance at 250 nm. The enantiomeric purity was confirmed byanalytical SFC using a Chiralpak IC column (5 μm, 150×4.6 mm), mobilephase of 20% iPrOH+(0.3% iPrNH₂): 80% CO₂, and a flow rate of 3 mL/minover 7 minutes (Temperature=35° C.). Elution was monitored followingabsorbance at 250 nm. Enantiopurity 100%, which elutes at one peak (2.18min retention time). MS (ESI) mass calcd. for C₁₂H₁₉NO₃, 225.1. m/zfound 170.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound presentas a mixture of rotamers) δ 4.41-4.13 (m, 1H), 3.57-3.31 (m, 2H),2.46-2.31 (m, 3H), 2.22-2.08 (m, 1H), 1.96-1.86 (m, 1H), 1.83-1.68 (m,1H), 1.67-1.56 (m, 1H), 1.45 (s, 9H).

Intermediate C-5A: (R/S)-tert-Butyl6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

A 1 M solution of L-Selectride (1 M in THF, 1.7 mL, 1.7 mmol) was addedto a solution of intermediate C-4A (150 mg, 0.666 mmol) in dry THF (3mL) at −78° C., and the reaction mixture was stirred at that temperaturefor 3 h. Then, the reaction mixture was warmed to 0° C. and a 3 M NaOH(0.71 mL) solution was added followed by a solution of H₂O₂ (30% w/w inH₂O, 0.37 mL). The resulting mixture was warmed to room temperature andstirred for 2 h. The biphasic mixture was then concentrated in vacuo toremove THF and the aqueous layer extracted with DCM (3×). The combinedorganics were washed with brine, dried with Na₂SO₄, filtered, andconcentrated to an oil, which was further purified by silica gelchromatography (10-100% EtOAc in hexanes), to give intermediate C-5A asa white solid (114 mg, 0.502 mmol, 75%). MS (ESI) mass calcd. forC₁₂H₂₁NO₃, 227.2. m/z found 172.2 [M+2H-tBu]⁺. ¹H NMR (500 MHz,Methanol-d₄) δ 3.97-3.86 (m, 2H), 3.38-3.20 (m, 2H), 2.09-2.00 (m, 1H),1.96-1.87 (m, 1H), 1.87-1.79 (m, 1H), 1.62-1.48 (m, 3H), 1.46 (d, J=4.9Hz, 9H), 1.43-1.37 (m, 1H).

Intermediate C-5B: (1S,4R,6R)-tert-butyl6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

Intermediate C-5B was prepared analogous to Intermediate C-5Asubstituting racemic Intermediate C-4A for enantiopure IntermediateC-4B. MS (ESI) mass calcd. for C₁₂H₂₁NO₃, 227.2. m/z found 172.1[M+2H-tBu]⁺.

Intermediate C-6A: (R/S)-tert-butyl6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate

To a flask containing Intermediate C-4A (324 mg, 1.44 mmol) dissolved inEtOH (5 mL) was added NEt₃ (1 ml, 7.2 mmol), and hydroxylaminehydrochloride (300 mg, 4.32 mmol) and the reaction mixture was heated to70° C. overnight. Upon completion, the reaction mixture was cooled toroom temperature, concentrated, diluted with H₂O, and the aqueous layerextracted with EtOAc (3×). The combined organics were then dried withMgSO₄, filtered, and concentrated to provide intermediate C-6A as alight purple solid (351 mg) which was used without further purification.MS (ESI) mass calcd. for C₁₂H₂₀N₂O₃, 240.2. m/z found 184.1 [M+2H-tBu]⁺.

Intermediate C-6B: (1S,4R)-tert-butyl6-(hydroxyimino)-2-azabicyclo[2.2.2]octane-2-carboxylate

Intermediate C-6B was prepared analogous to Intermediate C-6Asubstituting racemic Intermediate C-4A for enantiopure IntermediateC-4B. MS (ESI) mass calcd. for C₁₂H₂₀N₂O₃, 240.2. m/z found 241.2[M+H]⁺.

Intermediate C-7A: (R/S)-tert-butyl6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate

A mixture of NiCl₂ (373 mg, 2.88 mmol) and intermediate C-6A (346 mg) inMeOH (12 mL) was cooled to −35° C. and NaBH₄ (1.09 g, 28.8 mmol) wasadded portion wise to the reaction mixture. Upon complete addition ofNaBH₄, the reaction mixture was warmed to room temperature. After 2 h atroom temperature the reaction mixture was quenched with H₂O. Celite wasadded and the crude reaction mixture was stirred for 30 min. The crudereaction mixture was filtered and the filtrate concentrated underreduced pressure to a dark brown residue, which was re-dissolved in amixture of DCM and 15% aqueous NaOH solution. The aqueous layer wasextracted with DCM (3×). The combined organics were filtered throughCelite, dried with MgSO₄, filtered, and concentrated to provideintermediate C-7A (308 mg) as a brown oil which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₂₂N₂O₂, 226.2. m/z found227.2 [M+H]⁺.

Intermediate C-7B: (1S,4R,6R)-tert-butyl6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate

Intermediate C-7B was prepared analogous to Intermediate C-7Asubstituting racemic Intermediate C-6A for enantiopure IntermediateC-6B. MS (ESI) mass calcd. for C₁₂H₂₂N₂O₂, 226.2. m/z found 227.2[M+H]⁺.

Alternative routes (2-azabicyclo[2.2.1]heptan-6-ol) Intermediate C-8:(R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]oct-5-ene

Intermediate C-8 was prepared according to the procedure of C. Chiu etal. [Synthetic Communications 1996, 26, 577-584] on a similar substrate.To a solution of H₂O (5.4 mL) and 12 M HCl (5 mL) was added(+)-α-methyl-benzylamine (6.95 mL, 54.6 mmol), and the reaction mixturewas stirred at room temperature for 5 minutes. Then, aqueousformaldehyde (4.06 mL, 54.6 mmol, 37 wt. % in H₂O) and1,3-cyclohexadiene (4 mL, 42 mmol) were added and the reaction mixtureheated to 55° C. for 4 days. The reaction mixture was cooled to roomtemperature and diluted with H₂O and the crude reaction mixtureextracted with Et₂O (2×). The aqueous phase was basified with KOH,extracted with Et₂O (2×), saturated with solid NaCl, and extracted oncemore with Et₂O. The combined organics were dried with Na₂SO₄, filtered,and concentrated to give an orange oil, which was further purified bysilica gel chromatography (0-10% MeOH (with 10% 2 M NH₃) in DCM) to giveintermediate C-8 as a yellow-orange oil (ca. 3:1 dr). Intermediate C-8was carried forward as a mixture of diastereoisomers. MS (ESI) masscalcd. for C₁₅H₁₉N, 213.2. m/z found 214.2 [M+H]⁺.

Intermediate C-9:(R/S)-2-((R)-1-phenylethyl)-2-azabicyclo[2.2.2]octan-6-ol

Intermediate C-9 was synthesized according to the procedure of F.Carroll et al. [J. Med. Chem. 1992, 35, 2184-2191] on a similarsubstrate. A 1 M solution of BH₃-THF (1 M BH₃-THF in THF, 68 mL, 68mmol) was added dropwise via addition funnel to a stirred solution ofintermediate C-8 (2.88 g, 13.5 mmol) in THF (42 mL) at 0° C. Uponcomplete addition of BH₃-THF, the reaction mixture was stirred at 0° C.for 2 h. Then, excess BH₃ was quenched with a solution of THF-H₂O. A 4 MNaOH (8 mL) solution was added followed by the dropwise addition of H₂O₂(30% w/w in H₂O, 8 mL), and the reaction mixture was warmed to 40° C.and stirred for 2 h. The biphasic mixture was then cooled to roomtemperature and K₂CO₃ added in one portion. The resulting mixture wasconcentrated under reduced pressure to remove THF and re-dissolved inDCM. The crude reaction mixture was washed with H₂O and the aqueousphase extracted with DCM (3×). The combined organics were then washedwith brine, dried with Na₂SO₄, filtered, and concentrated and theconcentrate was further purified by silica gel chromatography (0-10%MeOH (with 10% 2 M NH₃) in DCM) to give intermediate C-9 as anorange-brown foam (1.35 g, 5.84 mmol, 43%). MS (ESI) mass calcd. forC₁₅H₂₁NO, 231.2. m/z found 232.2 [M+H]⁺.

Intermediate C-10: (R/S)-tert-butyl6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

Intermediate C-10 was prepared analogous to Intermediate C-3substituting racemic Intermediate C-2 for schlemic Intermediate C-9. MS(ESI) mass calcd. for C₁₂H₂₁NO₃, 227.2. m/z found 172.2 [M+2H-tBu]⁺.Intermediate C-10 can be carried forward to Intermediate C-4A, which canbe obtained as a single enantiomer (Intermediate C-4B or C-4C) by ChiralSFC purification as described above.

Intermediate C-11:(R/S)-2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one

Intermediate C-11 was synthesized according to the procedure in U.S.Pat. No. 3,674,793. A mixture of 7-oxabicyclo[4.1.0]heptane-3-carboxylicacid methyl ester (268.0 g, 1.72 mol) and benzylamine (170.0 g, 1.58mol) in ethanol (1.3 L) was heated to reflux for 20 h and the reactionmixture was evaporated. The oily residue was stirred at 200° C. for 2 hto distill off low-boiling byproducts. The resulting oil was cooled toroom temperature, diluted with a solution of sodium hydroxide (51.0 g,1.27 mol) in methanol (1.0 L) and heated to reflux for 10 min. Thereaction mixture was cooled to room temperature and diluted with amixture of brine (1.5 L) and water (750 mL). The aqueous layer wasextracted with dichloromethane (3×) and the combined organic layers weredried with MgSO₄, filtered, and concentrated. The oily residue wastriturated with diisopropyl ether (400 mL) to give intermediate C-11(190.0 g, 0.82 mol, 48%) as a white solid. MS (ESI) mass calcd. forC₁₄H₁₇NO₂, 231.1. m/z found 232.1 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ7.43-7.12 (m, 5H), 4.99 (d, J=3.3 Hz, 1H), 4.48 (d, J=14.7 Hz, 1H), 4.39(d, J=14.7 Hz, 1H), 3.76-3.61 (m, 1H), 3.31-3.23 (m, 1H), 2.38-2.24 (m,1H), 2.15-1.91 (m, 2H), 1.79-1.51 (m, 2H), 1.45-1.16 (m, 2H).

Intermediate C-2: 2-benzyl-2-azabicyclo[2.2.2]octan-6-ol

To a suspension of lithium aluminum hydride (54.4 g, 1.43 mol) in THF(180 mL) under argon at 0° C. was added a solution of intermediate C-11(170.0 g, 716.4 mmol) dropwise as a solution in THF (720 mL). Thereaction mixture was allowed to warm to room temperature, then carefullyheated to 60° C. and stirred for 2 h. The resulting suspension wascooled to 0° C. and diluted with diethyl ether (540 mL). To thissuspension was added sodium sulfate decahydrate (450 g) in smallportions. The mixture was stirred at room temperature for 16 h. Thesuspension was filtered and the filtrate evaporated. The residue wastriturated with hexane (100 mL) to give intermediate C-2 (130.2 g, 0.60mol, 84%) as a white solid. MS (ESI) mass calcd. for C₁₄H₁₉NO, 217.2.m/z found 218.3 [M+H]⁺. ¹H NMR (300 MHz, DMSO-d₆) δ 7.41-7.25 (m, 4H),7.25-7.10 (m, 1H), 4.50 (d, J=3.6 Hz, 1H), 3.97-3.86 (m, 1H), 3.71 (d,J=14.7 Hz, 1H), 3.66 (d, J=14.4 Hz, 1H), 2.61 (d, J=9.3 Hz, 1H),2.48-2.32 (m, 2H), 1.94 (t, J=11.1 Hz, 1H), 1.82-1.66 (m, 2H), 1.66-1.56(m, 1H), 1.52-1.37 (m, 2H), 1.32-1.15 (m, 1H). Intermediate C-2 can becarried forward to Intermediate C-4A, which can be obtained as a singleenantiomer (Intermediate C-4B or C-4C) by Chiral SFC purification asdescribed above.

Example 1(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (R/S)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-8 (100 mg, 0.469 mmol) dissolved in DMF (3 mL) wasadded NaH (28 mg, 0.70 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyrazine (0.087 mL, 0.70 mmol) wasthen added and the mixture heated to 90° C. After heating at 90° C. for3.5 h, the mixture was cooled to room temperature, quenched withsaturated NH₄Cl solution, and diluted with EtOAc and H₂O. The aqueouslayer was extracted with EtOAc (3×). The combined organics were washedwith H₂O, brine, dried with MgSO₄, filtered and concentrated.Purification via silica gel chromatography (0-20% EtOAc in hexanes) gavethe title compound (151 mg, 0.420 mmol, 90%). MS (ESI) mass calcd. forC₁₆H₂₀F₃N₃O₃, 359.1. m/z found 304.1 [M+2H-tBu]⁺. ¹H NMR (400 MHz,Chloroform-d. compound present as a mixture of rotamers) δ 8.46-8.41 (m,1H), 8.27-8.24 and 8.16-8.12 (2m, 1H), 5.45-5.30 (m, 1H), 4.63-4.48 (m,1H), 3.48-3.33 (m, 1H), 3.28-3.13 (m, 1H), 2.67-2.54 (m, 1H), 2.32-2.19(m, 1H), 1.85-1.04 (m, 12H).

Step B:(R/S)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (151 mg, 0.42 mmol) in EtOAc (1 mL) wasadded 4 M HCl in dioxane (6 mL). After 3.25 h, the reaction wasconcentrated to give the title compound of step B which was used withoutfurther purification. MS (ESI) mass calcd. for C₁₁H₁₂F₃N₃O, 259.1. m/zfound 260.1 [M+H]⁺.

Step C:(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (43 mg) and intermediate A-1 (24 mg,0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.4 mL, 2.32 mmol) and HATU(48 mg, 0.13 mmol). Upon completion of the reaction, purification wasperformed using Agilent Prep Method X to give the title compound (9 mg).MS (ESI) mass calcd. for C₂₀H₁₂F₃N₆O₂, 430.1. m/z found 431.1 [M+H]⁺. ¹HNMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers(0.80:0.20), major rotamer reported) δ 8.25 (s, 1H), 8.02-7.98 (m, 1H),7.87-7.79 (m, 3H), 7.32 (ddd, J=8.2, 7.4, 1.5 Hz, 1H), 7.04 (dd, J=7.7,1.5 Hz, 1H), 6.81 (t, J=7.5 Hz, 1H), 4.97 (dt, J=10.2, 3.3 Hz, 1H),4.03-3.96 (m, 1H), 3.62 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5Hz, 1H), 2.68-2.63 (m, 1H), 2.27-2.18 (m, 1H), 1.48 (dt, J=13.6, 3.6 Hz,1H), 1.40 (d, J=10.6 Hz, 1H), 1.33-1.25 (m, 1H).

Example 2(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 1 substituting intermediate A-1 withintermediate A-20. MS (ESI) mass calcd. for C₂₀H₁₈F₃N₇O₂, 445.1. m/zfound 446.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.78:0.22), major rotamer reported) δ 8.30-8.27 (m,1H), 8.05-8.00 (m, 2H), 7.83 (s, 2H), 7.11-7.07 (m, 1H), 5.01 (dt,J=10.2, 3.2 Hz, 1H), 4.27-4.23 (m, 1H), 3.70 (dt, J=11.0, 3.2 Hz, 1H),3.49 (dd, J=11.0, 1.4 Hz, 1H), 2.72-2.67 (m, 1H), 2.30-2.21 (m, 4H),1.60-1.48 (m, 3H).

Example 3(R/S)-(3-ethoxyisoquinolin-4-yl)((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 1 substituting intermediate A-1 withintermediate A-21. MS (ESI) mass calcd. for C₂₃H₂₁F₃N₄O₃, 458.2. m/zfound 459.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers, major rotamer reported) δ 8.72 (d, J=0.8 Hz, 1H),7.77-7.72 (m, 1H), 7.71-7.68 (m, 1H), 7.64-7.58 (m, 2H), 7.52-7.47 (m,1H), 7.30 (ddd, J=8.1, 6.8, 1.1 Hz, 1H), 4.87 (dt, J=10.2, 3.4 Hz, 1H),4.68-4.39 (m, 3H), 3.87 (dt, J=11.1, 3.2 Hz, 1H), 3.56 (dd, J=11.1, 1.6Hz, 1H), 2.83-2.77 (m, 1H), 2.35-2.26 (m, 1H), 2.01-1.95 (m, 1H),1.84-1.75 (m, 1H), 1.56-1.38 (m, 4H).

Example 4(R/S)-5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 1 substituting intermediate A-1 withintermediate A-19. MS (ESI) mass calcd. for C₂₀H₁₈F₃N₂O₂, 445.1. m/zfound 446.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.34 (d,J=1.3 Hz, 1H), 8.00-7.95 (m, 2H), 7.84-7.80 (m, 2H), 7.62-7.59 (m, 1H),5.10 (dt, J=10.3, 3.2 Hz, 1H), 4.27-4.24 (m, 1H), 3.71 (dt, J=11.0, 3.2Hz, 1H), 3.49 (dd, J=11.0, 1.5 Hz, 1H), 2.76-2.70 (m, 1H), 2.34-2.22 (m,4H), 1.71-1.54 (m, 3H).

Example 5(R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (R/S)-tert-butyl6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-8 (200 mg, 0.94 mmol) dissolved in DMF (5 mL) wasadded NaH (56 mg, 1.41 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyridine (340 mg, 1.87 mmol) wasthen added and the mixture heated to 80° C. After heating at 80° C. for5.75 h, the mixture was cooled to room temperature, quenched withsaturated NH₄Cl solution, diluted with H₂O, and the aqueous layerextracted with EtOAc (3×). The combined organics were washed with H₂O,brine, dried with MgSO₄, filtered and concentrated. Purification viasilica gel chromatography (0-30% EtOAc in hexanes) gave the titlecompound (300 mg, 0.84 mmol, 89%). MS (ESI) mass calcd. forC₁₂H₂₁F₃N₂O₃, 358.2. m/z found 359.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d) δ 8.47-8.37 (m, 1H), 7.84-7.69 (m, 1H), 6.87-6.68 (m, 1H),5.45-5.29 (m, 1H), 4.63-4.52 (m, 1H), 3.47-3.34 (m, 1H), 3.26-3.11 (m,1H), 2.66-2.52 (m, 1H), 2.31-2.16 (m, 1H), 1.80-1.09 (series of m, 12H).

Step B:(R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (300 mg, 0.84 mmol) in EtOAc (1 mL) wasadded 4 M HCl in dioxane (5 mL). After 7 h, the reaction wasconcentrated to give the title compound of step B (243 mg) which wasused without further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O,258.1. m/z found 259.1 [M+H]⁺.

Step C:(R/S)-(5-(4-fluorophenyl)-2-methylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (30 mg) and intermediate A-14 (24 mg,0.10 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(38 mg, 0.10 mmol). Upon completion, the reaction was diluted with H₂Oand the aqueous layer extracted with EtOAc (3×). The combined organicswere washed with H2O, brine, dried with MgSO4, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (40.3 mg). MS (ESI)mass calcd. for C₂₃H₁₉F4N₃O₂S, 477.1. m/z found 478.1 [M+H]+. 1H NMR(400 MHz, Chloroform-d, Compound present as a mixture of rotamers(0.85:0.15), major rotamer reported) δ 8.19-8.14 (m, 1H), 7.63-7.57 (m,1H), 7.49-7.41 (m, 2H), 7.12-7.01 (m, 2H), 6.61-6.54 (m, 1H), 5.03 (dt,J=10.3, 3.2 Hz, 1H), 4.64-4.58 (m, 1H), 3.56-3.51 (m, 2H), 2.66-2.58 (m,1H), 2.44 (s, 3H), 2.26-2.15 (m, 1H), 1.53 (d, J=10.8 Hz, 1H), 1.45-1.35(m, 2H).

Example 6(R/S)-(6-methylimidazo[2,1-b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 substituting intermediate A-14 withintermediate A-17. MS (ESI) mass calcd. for C₁₉H₁₇F₃N₄O₂S, 422.1. m/zfound 423.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.08 (br.s, 1H),7.54-7.37 (m, 2H), 6.68 (d, J=4.5 Hz, 1H), 6.53-6.41 (m, 1H), 5.22-5.08(m, 1H), 4.98-4.85 (m, 1H), 3.87-3.65 (m, 1H), 3.57-3.46 (m, 1H),2.77-2.71 (m, 1H), 2.39 (s, 3H), 2.36-2.24 (m, 1H), 2.04-1.95 (m, 1H),1.85 (d, J=10.5 Hz, 1H), 1.49 (dt, J=13.6, 3.5 Hz, 1H).

Example 7(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-1. MS (ESI) masscalcd. for C₂₁H₁₈F₃N₅O₂, 429.2. m/z found 430.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.02-7.99 (m, 1H), 7.87-7.74 (m, 4H), 7.35-7.29 (m, 1H),7.03 (dd, J=7.7, 1.5 Hz, 1H), 6.84-6.78 (m, 2H), 5.00 (dt, J=10.1, 3.3Hz, 1H), 4.07-4.03 (m, 1H), 3.61 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd,J=10.9, 1.5 Hz, 1H), 2.65-2.60 (m, 1H), 2.25-2.16 (m, 1H), 1.45-1.37 (m,2H), 1.33-1.25 (m, 1H).

Example 8(R/S)-(3-ethoxyisoquinolin-4-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-21 and additionalpurification using Shimadzu Prep Method X. MS (ESI) mass calcd. forC₂₄H₂₂F₃N₃O₃, 457.2. m/z found 458.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d) δ 8.71 (s, 1H), 7.81-7.76 (m, 1H), 7.71-7.68 (m, 1H), 7.61(d, J=8.2 Hz, 1H), 7.46 (ddd, J=8.4, 6.8, 1.3 Hz, 1H), 7.29-7.23 (buriedm, 1H), 7.10 (dd, J=8.7, 2.5 Hz, 1H), 6.11 (d, J=8.6 Hz, 1H), 4.91 (dt,J=10.3, 3.4 Hz, 1H), 4.68-4.66 (m, 1H), 4.65-4.58 (m, 1H), 4.49-4.40 (m,1H), 3.86 (dt, J=11.2, 3.2 Hz, 1H), 3.58 (dd, J=11.1, 1.7 Hz, 1H),2.84-2.76 (m, 1H), 2.36-2.24 (m, 1H), 1.99-1.94 (m, 1H), 1.80 (d, J=10.4Hz, 1H), 1.50 (dt, J=13.7, 3.8 Hz, 1H), 1.44 (t, J=7.1 Hz, 3H).

Example 9(R/S)-(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-19. MS (ESI) masscalcd. for C₂₁H₁₉F₃N₆O₂, 444.2. m/z found 445.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.93:0.07),major rotamer reported) δ 7.98-7.95 (m, 1H), 7.95-7.92 (m, 1H), 7.82 (s,2H), 7.71 (dd, J=8.8, 2.6 Hz, 1H), 7.67-7.64 (m, 1H), 6.88-6.83 (m, 1H),5.02 (dt, J=10.2, 3.2 Hz, 1H), 4.28-4.21 (m, 1H), 3.68 (dt, J=10.9, 3.2Hz, 1H), 3.45 (dd, J=11.0, 1.2 Hz, 1H), 2.71-2.64 (m, 1H), 2.28 (s, 3H),2.28-2.17 (m, 1H), 1.59-1.46 (m, 3H).

Example 10(R/S)-(7-ethoxyquinolin-8-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-25. MS (ESI) masscalcd. for C₂₄H₂₂F₃N₃O₃, 457.2. m/z found 458.2 [M+H]⁺. Analytical HPLCwas obtained on a Agilent 1100 Series using a XBridge C18 column (5 um,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.49 min (major rotamer) at 254 nm.

Example 11(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-2. MS (ESI) masscalcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found 459.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18),major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.14-8.10 (m, 1H),7.79 (dd, J=8.8, 2.6 Hz, 1H), 7.30-7.26 (m, 1H), 7.10-7.03 (m, 1H),6.95-6.81 (m, 3H), 5.06 (dt, J=10.2, 3.4 Hz, 1H), 4.27-4.23 (m, 1H),3.34-3.30 (m, 2H), 2.57-2.51 (m, 1H), 2.25-2.14 (m, 1H), 1.46-1.40 (m,1H), 1.36 (dt, J=13.6, 3.6 Hz, 1H), 0.94-0.87 (m, 1H).

Example 12(R/S)-(4-methoxy-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

To the title compound of Example 5 step B (20 mg) and intermediate A-15(15 mg, 0.066 mmol) was added DCM (0.8 mL) and DIPEA (0.05 mL, 0.29mmol). T₃P (0.11 mL, 0.18 mmol, 50% solution in DMF) was then addeddropwise and the mixture heated to 45° C. Upon completion the reactionwas quenched with saturated NaHCO₃ solution and the aqueous layerextracted with EtOAc (3×). The combined organics were washed saturatedNaHCO₃ solution, brine, dried with MgSO₄, filtered, and concentrated.Purification of the concentrate was performed using Agilent Prep MethodX to give the title compound (9.3 mg). MS (ESI) mass calcd. forC₂₄H₂₁F₃N₄O₃, 470.2. m/z found 471.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18),major rotamer reported) δ 8.78 (d, J=4.8 Hz, 2H), 8.11-8.09 (m, 1H),7.83-7.77 (m, 1H), 7.70 (d, J=2.6 Hz, 1H), 7.20 (t, J=4.9 Hz, 1H), 6.96(d, J=8.4 Hz, 1H), 6.87-6.80 (m, 1H), 6.45 (dd, J=8.4, 2.7 Hz, 1H), 5.03(dt, J=10.1, 3.3 Hz, 1H), 4.16-4.12 (m, 1H), 3.81 (s, 3H), 3.62 (dt,J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.4 Hz, 1H), 2.66-2.60 (m, 1H),2.26-2.16 (m, 1H), 1.45-1.35 (m, 2H), 1.29-1.17 (m, 1H).

Example 13(R/S)-4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-5. MS (ESI) masscalcd. for C₂₂H₂₀F₃N₅O₃, 459.1. m/z found 460.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12),major rotamer reported) δ 8.11-8.07 (m, 1H), 7.84-7.75 (m, 3H), 7.37 (d,J=2.5 Hz, 1H), 6.96 (d, J=8.5 Hz, 1H), 6.81 (d, J=8.7 Hz, 1H), 6.37 (dd,J=8.5, 2.5 Hz, 1H), 5.01 (dt, J=10.1, 3.3 Hz, 1H), 4.08-4.01 (m, 1H),3.80 (s, 3H), 3.58 (dt, J=10.9, 3.2 Hz, 1H), 3.39 (dd, J=10.9, 1.4 Hz,1H), 2.65-2.58 (m, 1H), 2.25-2.14 (m, 1H), 1.45-1.35 (m, 2H), 1.30-1.22(m, 1H).

An ORTEP of Example 13 is depicted in FIG. 1.

Example 14(R/S)-(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-10. MS (ESI) masscalcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/z found 448.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15),major rotamer reported) δ 8.09-8.05 (m, 1H), 7.85-7.78 (m, 4H), 7.00(ddd, J=9.0, 7.6, 2.9 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.78 (dd, J=8.1,2.9 Hz, 1H), 5.02 (dt, J=10.2, 3.3 Hz, 1H), 4.06-4.01 (m, 1H), 3.59 (dt,J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.66-2.60 (m, 1H),2.28-2.17 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.27 (m, 1H).

An ORTEP of Example 14 is depicted in FIG. 2.

Example 15(R/S)-2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-13. MS (ESI) masscalcd. for C₂₂H₂₀F₃N₅O₃, 459.2. m/z found 460.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.00-7.95 (m, 1H), 7.82 (s, 2H), 7.73 (d, J=10.6 Hz, 1H),7.46 (dd, J=8.2, 0.9 Hz, 1H), 7.28-7.21 (m, 1H), 6.75-6.71 (m, 1H), 6.42(dd, J=8.4, 0.9 Hz, 1H), 4.82 (dt, J=10.2, 3.4 Hz, 1H), 4.18-4.12 (m,1H), 3.63-3.58 (m, 1H), 3.57 (s, 3H), 3.37 (dd, J=11.0, 1.5 Hz, 1H),2.58-2.52 (m, 1H), 2.19-2.09 (m, 1H), 1.74-1.66 (m, 1H), 1.45-1.37 (m,1H), 1.32-1.23 (m, 1H).

Example 16(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-16. MS (ESI) masscalcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/z found 448.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.86:0.14),major rotamer reported) δ 8.14-8.09 (m, 1H), 7.89 (s, 2H), 7.83-7.78 (m,1H), 7.16 (ddd, J=9.9, 8.1, 1.6 Hz, 1H), 6.98-6.81 (m, 3H), 5.06 (dt,J=10.1, 3.3 Hz, 1H), 4.19-4.15 (m, 1H), 3.38-3.30 (m, 2H), 2.59-2.53 (m,1H), 2.26-2.16 (m, 1H), 1.50-1.43 (m, 1H), 1.39-1.30 (m, 1H), 1.19-1.10(m, 1H).

Example 17(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-22. MS (ESI) masscalcd. for C₂₂H₂₀F₃N₅O₂, 443.2. m/z found 444.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.85:0.15),major rotamer reported) δ 8.15-8.11 (m, 1H), 7.86-7.77 (m, 3H),7.24-7.19 (m, 1H), 6.99-6.82 (m, 3H), 5.09 (dt, J=10.1, 3.3 Hz, 1H),4.25-4.19 (m, 1H), 3.31-3.23 (m, 2H), 2.57-2.50 (m, 1H), 2.27-2.11 (m,4H), 1.53-1.47 (m, 1H), 1.37-1.28 (m, 1H), 1.27-1.21 (m, 1H).

Example 18(R/S)-(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-11. MS (ESI) masscalcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/z found 448.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.04-8.02 (m, 1H), 7.85-7.72 (m, 4H), 7.32-7.26 (m, 1H),6.92-6.88 (m, 1H), 6.61 (td, J=8.4, 1.0 Hz, 1H), 5.00-4.94 (m, 1H),4.03-4.00 (m, 1H), 3.65 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5Hz, 1H), 2.68-2.60 (m, 1H), 2.28-2.17 (m, 1H), 1.46-1.37 (m, 2H),1.31-1.25 (m, 1H).

Example 19(R/S)-(5-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-7. MS (ESI) masscalcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found 459.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.88:0.12),major rotamer reported) δ 8.77 (d, J=4.9 Hz, 2H), 8.22 (dd, J=8.8, 5.6Hz, 1H), 8.11-8.06 (m, 1H), 7.82 (dd, J=8.7, 2.5 Hz, 1H), 7.19 (t, J=4.9Hz, 1H), 6.98 (ddd, J=8.8, 7.9, 2.7 Hz, 1H), 6.85 (d, J=8.8 Hz, 1H),6.77 (dd, J=8.6, 2.7 Hz, 1H), 5.03 (dt, J=10.1, 3.4 Hz, 1H), 4.16-4.11(m, 1H), 3.66 (dt, J=10.8, 3.2 Hz, 1H), 3.42 (dd, J=10.8, 1.5 Hz, 1H),2.70-2.63 (m, 1H), 2.30-2.19 (m, 1H), 1.50-1.39 (m, 2H), 1.35-1.27 (m,1H).

Example 20(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-23. MS (ESI) masscalcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found 459.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16),major rotamer reported) δ 8.80 (d, J=4.8 Hz, 2H), 8.12-8.09 (m, 1H),7.93 (dd, J=9.9, 2.6 Hz, 1H), 7.83-7.78 (m, 1H), 7.25-7.21 (m, 1H), 7.01(dd, J=8.4, 5.6 Hz, 1H), 6.85-6.81 (m, 1H), 6.63-6.55 (m, 1H), 5.03 (dt,J=10.1, 3.3 Hz, 1H), 4.16-4.09 (m, 1H), 3.65 (dt, J=10.8, 3.3 Hz, 1H),3.46-3.36 (m, 1H), 2.69-2.62 (m, 1H), 2.29-2.17 (m, 1H), 1.48-1.37 (m,2H), 1.31-1.23 (m, 1H).

Example 21(R/S)-(2-(4H-1,2,4-triazol-4-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-9. MS (ESI) masscalcd. for C₂₁H₁₈F₃N₅O₂, 429.1. m/z found 430.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.84:0.16),major rotamer reported) δ 8.44 (s, 2H), 8.03-7.95 (m, 1H), 7.80 (dd,J=8.9, 2.5 Hz, 1H), 7.44-7.34 (m, 1H), 7.30-7.24 (m, 1H), 7.08-6.92 (m,2H), 6.83 (d, J=8.7 Hz, 1H), 5.04-4.94 (m, 1H), 3.90 (br.s, 1H),3.47-3.32 (m, 2H), 2.65-2.57 (m, 1H), 2.26-2.13 (m, 1H), 1.52-1.33 (m,2H), 1.05-0.86 (m, 1H).

Example 22(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 5 using intermediate A-20. MS (ESI) masscalcd. for C₂₁H₁₉F₃N₆O₂, 444.2. m/z found 445.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.82:0.18),major rotamer reported) δ 8.05-7.98 (m, 2H), 7.83 (s, 2H), 7.71-7.66 (m,1H), 7.10-7.05 (m, 1H), 6.86-6.80 (m, 1H), 5.01-4.93 (m, 1H), 4.28-4.22(m, 1H), 3.68 (dt, J=10.9, 3.2 Hz, 1H), 3.46 (dd, J=10.9, 1.2 Hz, 1H),2.67-2.62 (m, 1H), 2.28-2.16 (m, 4H), 1.53-1.42 (m, 3H).

Example 23(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

The title compound, absolute configuration confirmed by Example 25, wasobtained as a single enantiomer by Chiral SFC purification of Example 22performed using a Chiralpak IC column (5 um 250×21 mm), mobile phase of20% EtOH: 80% CO₂, and a flow rate of 40 mL/min (Temperature=40° C.).Elution was monitored following absorbance at 270 nm. The enantiomericpurity was confirmed by analytical SFC using a Chiralpak IC column (5 um250×4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 2mL/min over 45 minutes (Temperature=40° C.). Elution was monitoredfollowing absorbance at 270 nm (enantiopurity >98%) which elutes as twopeaks with an initial minor peak followed by a second major peak (due torotamers), 6.77 min and 23.40 min retention time). MS (ESI) mass calcd.for C₂₁H₁₉F₃N₆O₂, 444.2. m/z found 445.2 [M+H]⁺. ¹H NMR data is inagreement with Example 22.

Example 24(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

The title compound, absolute configuration confirmed by Example 25, wasobtained as a single enantiomer by Chiral SFC purification of Example 22performed using a Chiralpak IC column (5 um 250×21 mm), mobile phase of20% EtOH: 80% CO₂, and a flow rate of 40 mL/min (Temperature=40° C.).Elution was monitored following absorbance at 270 nm. The enantiomericpurity was confirmed by analytical SFC using a Chiralpak IC column (5 um250×4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flow rate of 2mL/min over 45 minutes (Temperature=40° C.). Elution was monitoredfollowing absorbance at 270 nm (enantiopurity >98%) which elutes as twopeaks with an initial minor peak followed by a second major peak (due torotamers), 7.75 min and 11.79 min retention time). MS (ESI) mass calcd.for C₂₁H₁₉F₃N₆O₂, 444.2. m/z found 445.2 [M+H]⁺. ¹H NMR data is inagreement with Example 22.

Example 25(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (422 mg, 1.98 mmol) dissolved in DMF (8 mL) wasadded NaH (119 mg, 2.97 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyridine (718 mg, 3.96 mmol) wasthen added and the mixture heated to 80° C. After heating at 80° C. for4.75 h, the mixture was cooled to room temperature, quenched withsaturated NH₄Cl solution, diluted with H₂O, and the aqueous layerextracted with EtOAc (3×). The combined organics were washed with H₂O,brine, dried with MgSO₄, filtered and concentrated. Purification viasilica gel chromatography (0-25% EtOAc in hexanes) gave the titlecompound (622 mg, 1.74 mmol, 88%). MS (ESI) mass calcd. forC₁₂H₂₁F₃N₂O₃, 358.2. m/z found 359.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, compound present as a mixture of rotamers (0.75:0.25)) δ8.44-8.37 (m, 1H), 7.80-7.74 (m, 0.75H), 7.73-7.66 (m, 0.25H), 6.82-6.77(m, 0.75H), 6.73-6.68 (m, 0.25H), 5.44-5.37 (m, 0.25H), 5.34 (dt,J=10.1, 3.2 Hz, 0.75H), 4.58-4.53 (m, 1H), 3.44-3.34 (m, 1H), 3.20 (dd,J=9.6, 1.3 Hz, 0.75H), 3.13 (d, J=9.5 Hz, 0.25H), 2.61-2.52 (m, 1H),2.29-2.15 (m, 1H), 1.79-1.58 (m, 2H), 1.47-1.23 (m, 3H), 1.12 (s, 7H).

Step B:(1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (622 mg, 1.74 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (10 mL). After 2 h, the reaction wasconcentrated to give the title compound of step B (507 mg) which wasused without further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O,258.1. m/z found 259.1 [M+H]⁺.

Step C:(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanoneTo the title compound of step B (100 mg) and intermediate A-20 (84 mg,0.37 mmol) in DMF (4 mL) was added DIPEA (0.3 mL, 1.74 mmol) and HATU(142 mg, 0.37 mmol). Upon completion, the reaction was diluted with H₂Oand the aqueous layer extracted with EtOAc (3×). The combined organicswere washed with H₂O, brine, dried with MgSO₄, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (112 mg). Theenantiomeric purity was confirmed by analytical SFC using a Chiralpak ICcolumn (Sum 250×4.6 mm), mobile phase of 20% EtOH: 80% CO₂, and a flowrate of 2 mL/min over 45 minutes (Temperature=40° C.). Elution wasmonitored following absorbance at 270 nm (100% single enantiomer) whichelutes as two peaks with an initial minor peak followed by a secondmajor peak (due to rotamers), 7.69 min and 11.90 min retention time). MS(ESI) mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2. m/z found 445.2 [M+H]⁺. ¹HNMR data is in agreement with Example 22.

Example 26(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-23. MS (ESI) mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/zfound 459.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.85:0.15), major rotamer reported) δ 8.80 (d,J=4.8 Hz, 2H), 8.13-8.07 (m, 1H), 7.95-7.90 (m, 1H), 7.84-7.78 (m, 1H),7.23 (t, J=4.8 Hz, 1H), 7.01 (dd, J=8.4, 5.6 Hz, 1H), 6.87-6.81 (m, 1H),6.59 (ddd, J=8.5, 7.9, 2.7 Hz, 1H), 5.03 (dt, J=10.1, 3.3 Hz, 1H),4.15-4.10 (m, 1H), 3.65 (dt, J=10.8, 3.2 Hz, 1H), 3.44-3.38 (m, 1H),2.69-2.62 (m, 1H), 2.29-2.18 (m, 1H), 1.48-1.37 (m, 2H), 1.34-1.23 (m,1H).

Example 27(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-2. MS (ESI) mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/zfound 459.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.14-8.08 (m, 1H), 7.79 (dd, J=8.8, 2.5 Hz, 1H),7.30-7.26 (m, 1H), 7.10-7.02 (m, 1H), 6.95-6.80 (m, 3H), 5.06 (dt,J=10.3, 3.4 Hz, 1H), 4.28-4.22 (m, 1H), 3.34-3.30 (m, 2H), 2.56-2.51 (m,1H), 2.25-2.15 (m, 1H), 1.45-1.40 (m, 1H), 1.36 (dt, J=13.6, 3.6 Hz,1H), 0.95-0.86 (m, 1H).

Example 28(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-19. MS (ESI) mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2. m/zfound 445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.86:0.14), major rotamer reported) δ 7.98-7.92 (m,2H), 7.83 (s, 2H), 7.75-7.69 (m, 1H), 7.67-7.63 (m, 1H), 6.89-6.83 (m,1H), 5.02 (dt, J=10.3, 3.2 Hz, 1H), 4.27-4.21 (m, 1H), 3.69 (dt, J=10.9,3.2 Hz, 1H), 3.51-3.42 (m, 1H), 2.70-2.64 (m, 1H), 2.33-2.16 (m, 4H),1.58-1.46 (m, 3H).

Example 29(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-3. MS (ESI) mass calcd. C₂₁H₁₉F₃N₆O₂, 444.2. m/z found445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.83:0.17), major rotamer reported) δ 8.06-8.02 (m,1H), 7.88 (s, 2H), 7.80 (dd, J=8.7, 2.5 Hz, 1H), 7.31-7.24 (m, 1H), 6.82(d, J=8.7 Hz, 1H), 6.61 (d, J=7.8 Hz, 1H), 4.98 (dt, J=10.1, 3.3 Hz,1H), 4.06-4.02 (m, 1H), 3.62 (dt, J=11.0, 3.2 Hz, 1H), 3.41 (dd, J=10.9,1.5 Hz, 1H), 2.68-2.61 (m, 1H), 2.56 (s, 3H), 2.27-2.14 (m, 1H),1.48-1.40 (m, 2H), 1.37-1.29 (m, 1H).

Example 30(3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-28. MS (ESI) mass calcd. C₂₀H₁₇F₃N₆O₂, 430.1. m/z found431.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.80:0.20), major rotamer reported) δ 8.17 (dd,J=8.4, 1.5 Hz, 1H), 7.95-7.91 (m, 1H), 7.88-7.81 (m, 3H), 7.72 (dd,J=8.7, 2.6 Hz, 1H), 7.20 (dd, J=8.3, 4.7 Hz, 1H), 6.86 (d, J=8.8 Hz,1H), 5.03 (dt, J=10.2, 3.2 Hz, 1H), 4.27-4.23 (m, 1H), 3.74-3.68 (m,1H), 3.47 (dd, J=11.0, 1.3 Hz, 1H), 2.71-2.66 (m, 1H), 2.29-2.19 (m,1H), 1.64-1.48 (m, 3H).

Example 31(3-fluoro-2-methoxyphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-18. MS (ESI) mass calcd. C₂₀H₁₈F₄N₂O₃, 410.1. m/z found411.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.83:0.17), major rotamer reported) δ 8.01-7.97 (m,1H), 7.74-7.71 (m, 1H), 6.92 (ddd, J=11.5, 8.1, 1.7 Hz, 1H), 6.79 (d,8.7 Hz, 1H), 6.67-6.49 (m, 2H), 5.07 (dt, J=10.1, 3.2 Hz, 1H), 4.43-4.38(m, 1H), 3.90 (d, J=1.7 Hz, 3H), 3.69 (dt, J=11.1, 3.3 Hz, 1H), 3.45(dd, J=11.1, 1.5 Hz, 1H), 2.76-2.70 (m, 1H), 2.33-2.21 (m, 1H),1.90-1.83 (m, 1H), 1.75-1.69 (m, 1H), 1.44 (dt, J=13.5, 3.6 Hz, 1H).

Example 32(3-methyl-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-27. MS (ESI) mass calcd. C₂₃H₂₀F₃N₃O₃, 443.1. m/z found444.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.81:0.19), major rotamer reported) δ 8.07-8.03 (m,1H), 7.81-7.73 (m, 2H), 7.30-7.25 (m, 1H), 7.18-7.13 (m, 1H), 6.91-6.80(m, 3H), 5.04 (dt, J=10.2, 3.2 Hz, 1H), 4.22-4.17 (m, 1H), 3.49-3.41 (m,1H), 3.40-3.33 (m, 1H), 2.63-2.57 (m, 1H), 2.44 (s, 3H), 2.26-2.16 (m,1H), 1.49 (d, J=10.4 Hz, 1H), 1.41-1.26 (m, 2H).

Example 33(3-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-33. MS (ESI) mass calcd. C₂₁H₁₇F₄N₅O₂, 447.1. m/z found448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.76:0.24), major rotamer reported) δ 8.20-8.15 (m,1H), 7.92-7.88 (m, 1H), 7.87-7.80 (m, 2H), 7.24-7.16 (m, 1H), 7.07-6.99(m, 1H), 6.92-6.85 (m, 2H), 5.14 (dt, J=9.9, 3.2 Hz, 1H), 4.28-4.24 (m,1H), 3.37-3.31 (m, 1H), 3.30-3.24 (m, 1H), 2.62-2.56 (m, 1H), 2.32-2.21(m, 1H), 1.42-1.31 (m, 2H), 0.94-0.89 (m, 1H).

Example 34(6-methyl-2-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-4. MS (ESI) mass calcd. C₂₁H₁₉F₃N₆O₂, 444.2. m/z found445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.87:0.13), major rotamer reported) δ 8.44 (d,J=1.2 Hz, 1H), 8.09-8.05 (m, 1H), 7.84-7.78 (m, 2H), 7.28 (d, J=7.8 Hz,1H), 6.88-6.83 (m, 1H), 6.65 (d, J=7.8 Hz, 1H), 5.05 (dt, J=10.1, 3.3Hz, 1H), 4.13-4.06 (m, 1H), 3.73 (dt, J=11.0, 3.2 Hz, 1H), 3.38 (dd,J=10.9, 1.5 Hz, 1H), 2.72-2.65 (m, 1H), 2.50 (s, 3H), 2.31-2.21 (m, 1H),1.73-1.67 (m, 1H), 1.51-1.40 (m, 2H).

Example 35(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-16. MS (ESI) mass calcd. C₂₁H₁₇F₄N₅O₂, 447.1. m/z found448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.85:0.15), major rotamer reported) δ 8.14-8.08 (m,1H), 7.89 (s, 2H), 7.80 (dd, J=8.7, 2.5 Hz, 1H), 7.16 (ddd, J=9.9, 8.2,1.6 Hz, 1H), 6.98-6.81 (m, 3H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.21-4.13(m, 1H), 3.39-3.30 (m, 2H), 2.60-2.52 (m, 1H), 2.26-2.15 (m, 1H),1.51-1.43 (m, 1H), 1.39-1.30 (m, 1H), 1.20-1.10 (m, 1H).

Example 36(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-1. MS (ESI) mass calcd. C₂₁H₁₈F₃N₅O₂, 429.1. m/z found430.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.87:0.13), major rotamer reported) δ 8.04-7.98 (m,1H), 7.89-7.74 (m, 4H), 7.36-7.28 (m, 1H), 7.02 (dd, J=7.7, 1.5 Hz, 1H),6.85-6.77 (m, 2H), 4.99 (dt, J=10.2, 3.3 Hz, 1H), 4.10-4.00 (m, 1H),3.61 (dt, J=10.9, 3.3 Hz, 1H), 3.40 (dd, J=10.9, 1.5 Hz, 1H), 2.67-2.58(m, 1H), 2.26-2.15 (m, 1H), 1.47-1.23 (m, 3H).

Example 37(3-ethoxy-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-8. MS (ESI) mass calcd. C₂₁H₂₂F₃N₃O₃, 421.2. m/z found422.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.83:0.17), major rotamer reported) δ 7.92-7.88 (m,1H), 7.71-7.66 (m, 1H), 6.92 (d, J=8.5 Hz, 1H), 6.87-6.82 (m, 2H), 5.00(dt, J=10.2, 3.3 Hz, 1H), 4.68-4.63 (m, 1H), 4.05-3.85 (m, 2H), 3.72(dt, J=11.0, 3.2 Hz, 1H), 3.51 (dd, J=11.0, 1.6 Hz, 1H), 2.74-2.68 (m,1H), 2.31-2.16 (m, 4H), 1.96-1.88 (m, 1H), 1.78-1.70 (m, 1H), 1.48 (dt,J=13.5, 3.6 Hz, 1H), 1.43-1.35 (m, 3H).

Example 38(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-6 and substituting purification by Agilent Prep Method Xby silica gel chromatography (15-80% EtOAc (with 10% MeOH) in hexanes).MS (ESI) mass calcd. C₂₃H₁₈F₄N₄O₂, 458.1. m/z found 459.1 [M+H]⁺. ¹H NMR(500 MHz, Chloroform-d, Compound present as a mixture of rotamers(0.78:0.22), major rotamer reported) δ 8.81 (d, J=4.9 Hz, 2H), 8.11-8.05(m, 1H), 8.05-8.00 (m, 1H), 7.77 (dd, J=8.7, 2.3 Hz, 1H), 7.31-7.27 (m,1H), 7.23 (t, J=4.8 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 6.72-6.64 (m, 1H),4.97 (dt, J=10.1, 3.4 Hz, 1H), 4.14-4.09 (m, 1H), 3.68 (dt, J=10.9, 3.2Hz, 1H), 3.46 (dd, J=10.9, 1.5 Hz, 1H), 2.65 (s, 1H), 2.28-2.18 (m, 1H),1.48-1.38 (m, 2H), 1.25-1.18 (m, 1H).

Example 39(2-methoxy-6-(1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-30. MS (ESI) mass calcd. C₂₃H₂₁F₃N₄O₃, 458.2. m/z found459.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers, major rotamer reported) δ 8.00 (s, 1H), 7.75 (dd,J=8.7, 2.6 Hz, 1H), 7.62-7.57 (m, 1H), 7.34-7.26 (m, 1H), 7.25-7.21 (m,1H), 6.76 (d, J=8.7 Hz, 1H), 6.53 (d, J=2.0 Hz, 1H), 6.46 (d, J=8.4 Hz,1H), 4.84 (dt, J=10.2, 3.4 Hz, 1H), 4.15 (s, 1H), 3.54-3.46 (m, 4H),3.34 (d, J=10.8 Hz, 1H), 2.49 (s, 1H), 2.19-2.07 (m, 1H), 1.55-1.22 (m,3H).

Example 40(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-24. MS (ESI) mass calcd. C₂₄H₂₁F₃N₄O₃, 470.2. m/z found471.1 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min and then holdat 100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45°C.). R_(t)=2.01 and 2.24 min (major rotamers) at 254 nm.

Example 41(2-(1,4-dimethyl-1H-pyrazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-31. MS (ESI) mass calcd. C₂₄H₂₃F₃N₄O₂, 456.2. m/z found457.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as amixture of rotamers (0.74:0.26), major rotamer reported) δ 7.95-7.90 (m,1H), 7.75 (dd, J=9.0, 1.7 Hz, 1H), 7.39 (s, 1H), 7.30-7.27 (m, 1H), 7.13(dd, J=7.7, 0.7 Hz, 1H), 7.03 (dd, J=7.7, 0.8 Hz, 1H), 6.91-6.87 (m,1H), 6.80 (d, J=8.8 Hz, 1H), 4.96-4.91 (m, 1H), 4.05-4.03 (m, 1H), 3.61(s, 3H), 3.39-3.35 (m, 1H), 3.34-3.29 (m, 1H), 2.54-2.49 (m, 1H),2.19-2.10 (m, 1H), 2.08 (s, 3H), 1.44-1.34 (m, 2H), 0.95-0.89 (m, 1H).

Example 42(1H-indol-7-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-29 and substituting purification by Agilent Prep Method Xby silica gel chromatography (0-60% EtOAc (with 10% MeOH) in hexanes).MS (ESI) mass calcd. C₂₁H₁₈F₃N₃O₂, 401.1. m/z found 402.1 [M+H]⁺. ¹H NMR(400 MHz, DMSO-d₆) δ 10.82 (s, 1H), 7.92 (br. s, 1H), 7.62 (dd, J=8.9,2.7 Hz, 1H), 7.32 (d, J=7.9 Hz, 1H), 7.21 (t, J=2.8 Hz, 1H), 6.93 (d,J=7.3 Hz, 1H), 6.69 (t, J=7.5 Hz, 1H), 6.57 (d, J=8.7 Hz, 1H), 6.32-6.25(m, 1H), 5.06 (dt, J=10.0, 3.1 Hz, 1H), 4.67 (br. s, 1H), 3.60-3.53 (m,1H), 3.52-3.44 (m, 1H), 2.70-2.62 (m, 1H), 2.29-2.17 (m, 1H), 2.06-1.99(m, 1H), 1.73 (d, J=10.2 Hz, 1H), 1.30 (dt, J=13.4, 3.5 Hz, 1H).

Example 43(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-10. MS (ESI) mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.2. m/zfound 448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.09-8.03 (m,1H), 7.84-7.81 (m, 1H), 7.81-7.78 (m, 3H), 7.05-6.95 (m, 1H), 6.82 (d,J=8.7 Hz, 1H), 6.78 (dd, J=8.1, 2.9 Hz, 1H), 5.01 (dt, J=10.1, 3.3 Hz,1H), 4.07-3.99 (m, 1H), 3.58 (dt, J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9,1.5 Hz, 1H), 2.67-2.60 (m, 1H), 2.29-2.17 (m, 1H), 1.46-1.37 (m, 2H),1.33-1.27 (m, 1H).

Example 44(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-12. MS (ESI) mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.2. m/zfound 448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.13-8.07 (m,1H), 7.83 (s, 2H), 7.81-7.78 (m, 1H), 7.63 (dd, J=9.5, 2.5 Hz, 1H), 7.02(dd, J=8.5, 5.9 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.52 (td, J=8.1, 2.5Hz, 1H), 5.01 (dt, J=10.2, 3.3 Hz, 1H), 4.03 (s, 1H), 3.63 (dt, J=11.0,3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.4 Hz, 1H), 2.68-2.61 (m, 1H), 2.28-2.16(m, 1H), 1.46-1.38 (m, 2H), 1.38-1.28 (m, 1H).

Example 45(2-bromo-3-fluorophenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-32. MS (ESI) mass calcd. for C₁₉H₁₅BrF₄N₂O₂, 458.0. m/zfound 459.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.82:0.18), major rotamer reported) δ 8.03 (s, 1H),7.78 (dd, J=8.7, 2.5 Hz, 1H), 6.94 (td, J=8.3, 1.5 Hz, 1H), 6.87-6.81(m, 1H), 6.73 (br. s, 1H), 6.63 (br. s, 1H), 5.15-5.06 (m, 1H), 4.23(br. s, 1H), 3.73 (dt, J=11.1, 3.3 Hz, 1H), 3.45 (dd, J=11.0, 1.6 Hz,1H), 2.80-2.71 (m, 1H), 2.37-2.25 (m, 1H), 1.99-1.89 (m, 1H), 1.84-1.71(m, 1H), 1.46 (dt, J=13.6, 3.6 Hz, 1H).

Example 46(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-11. MS (ESI) mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.2. m/zfound 448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.81:0.19), major rotamer reported) δ 8.05-8.00 (m,1H), 7.83 (s, 2H), 7.80-7.77 (m, 1H), 7.77-7.72 (m, 1H), 7.32-7.27 (m,1H), 6.89 (d, J=8.8 Hz, 1H), 6.60 (td, J=8.4, 1.0 Hz, 1H), 4.96 (dt,J=10.1, 3.4 Hz, 1H), 4.06-3.96 (m, 1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H),3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.69-2.60 (m, 1H), 2.28-2.16 (m, 1H),1.51-1.34 (m, 2H), 1.30-1.22 (m, 1H).

Example 47((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) wasadded NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1.0 mL)and 5-bromo-2-fluoropyridine (0.078 mL, 0.76 mmol) was then added andthe mixture heated to 70° C. After heating at 70° C. for 3.25 h, themixture was cooled to room temperature, quenched with saturated NH₄Clsolution, diluted with H₂O, and the aqueous layer extracted with EtOAc(3×). The combined organics were washed with H₂O, brine, dried withMgSO₄, filtered and concentrated. Purification via silica gelchromatography (0-25% EtOAc in hexanes) gave the title compound (149 mg,0.40 mmol, 85%). MS (ESI) mass calcd. for C₁₆H₂₁BrN₂O₃, 368.1. m/z found369.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, compound is present amixture of rotamers (0.75:0.25)) δ 8.20-8.11 (m, 1H), 7.63 (dd, J=8.8,2.6 Hz, 0.75H), 7.58 (dd, J=8.8, 2.6 Hz, 0.25H), 6.63 (dd, J=8.8, 0.7Hz, 0.75H), 6.57-6.52 (m, 0.25H), 5.29 (dt, J=9.8, 3.0 Hz, 0.25H), 5.22(dt, J=10.1, 3.2 Hz, 0.75H), 4.57-4.49 (m, 1H), 3.43-3.31 (m, 1H), 3.19(dd, J=9.5, 1.3 Hz, 0.75H), 3.15-3.09 (m, 0.25H), 2.59-2.50 (m, 1H),2.26-2.13 (m, 1H), 1.77-1.66 (m, 1H), 1.65-1.56 (m, 1H), 1.43 (s, 2H),1.41-1.23 (m, 1H), 1.16 (s, 7H).

Step B:(1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (149 mg, 0.404 mmol) in EtOAc (1.5 mL)was added 4M HCl in dioxane (5 mL). After 3.25 h, the reaction wasconcentrated to give the title compound of step B (128 mg) which wasused without further purification. MS (ESI) mass calcd. for C₁₁H₁₃BrN₂O,268.0. m/z found 269.0 [M+H]⁺.

Step C:((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone.To the title compound of step B (30 mg) and intermediate A-6 (24 mg,0.11 mmol) in DMF (1.5 mL) was added DIPEA (0.25 mL, 1.45 mmol) and HATU(41 mg, 0.11 mmol). Upon completion the reaction was diluted with H₂Oand the aqueous layer extracted with EtOAc (3×). The combined organicswere washed with H₂O, brine, dried with MgSO₄, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (20 mg). MS (ESI) masscalcd. C₂₂H₁₈BrFN₄O₂, 468.1. m/z found 469.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.79:0.21),major rotamer reported) δ 8.80 (d, J=4.8 Hz, 2H), 8.08 (d, J=8.0 Hz,1H), 7.77 (d, J=2.5 Hz, 1H), 7.64 (dd, J=8.8, 2.5 Hz, 1H), 7.39-7.30 (m,1H), 7.23 (t, J=4.9 Hz, 1H), 6.81-6.72 (m, 2H), 4.86 (dt, J=10.1, 3.3Hz, 1H), 4.11-4.02 (m, 1H), 3.65 (dt, J=10.9, 3.1 Hz, 1H), 3.44 (dd,J=10.8, 1.5 Hz, 1H), 2.66-2.59 (m, 1H), 2.25-2.15 (m, 1H), 1.42-1.34 (m,2H), 1.22-1.13 (m, 1H).

Example 48((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-2. MS (ESI) mass calcd. C₂₂H₁₈BrFN₄O₂, 468.1. m/z found469.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported)¹H NMR (400 MHz,Chloroform-d) δ 8.85 (d, J=4.9 Hz, 2H), 7.90-7.83 (m, 1H), 7.66 (dd,J=8.8, 2.5 Hz, 1H), 7.29-7.26 (m, 1H), 7.16-7.07 (m, 1H), 7.05-6.96 (m,1H), 6.91 (dd, J=7.5, 1.3 Hz, 1H), 6.67 (d, J=8.7 Hz, 1H), 4.96 (dt,J=10.1, 3.3 Hz, 1H), 4.27-4.16 (m, 1H), 3.34-3.24 (m, 2H), 2.52 (s, 1H),2.23-2.11 (m, 1H), 1.40 (d, J=10.8 Hz, 1H), 1.31 (dt, J=13.5, 3.6 Hz,1H), 0.98-0.87 (m, 1H).

Example 49(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-1. MS (ESI) mass calcd. C₂₀H₁₈BrN₅O₂, 439.1. m/z found440.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.89:0.11), major rotamer reported) δ 7.85 (dd,J=8.2, 1.1 Hz, 1H), 7.81 (s, 2H), 7.75 (dd, J=2.5, 0.7 Hz, 1H), 7.64(dd, J=8.7, 2.6 Hz, 1H), 7.41-7.35 (m, 1H), 7.05 (dd, J=7.7, 1.5 Hz,1H), 6.91 (td, J=7.6, 1.2 Hz, 1H), 6.65 (d, J=8.7 Hz, 1H), 4.89 (dt,J=10.2, 3.3 Hz, 1H), 4.05-3.97 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H),3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.63-2.56 (m, 1H), 2.23-2.12 (m, 1H),1.41-1.33 (m, 2H), 1.29-1.23 (m, 1H).

Example 50((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-20. MS (ESI) mass calcd. C₂₀H₁₉BrN₆O₂, 454.1. m/z found455.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers (0.85:0.15), major rotamer reported) δ 8.03 (d,J=8.4 Hz, 1H), 7.82 (s, 2H), 7.70 (dd, J=2.6, 0.7 Hz, 1H), 7.56 (dd,J=8.8, 2.6 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.66 (dd, J=8.6, 0.7 Hz,1H), 4.82 (dt, J=10.2, 3.3 Hz, 1H), 4.23-4.16 (m, 1H), 3.65 (dt, J=11.0,3.2 Hz, 1H), 3.43 (dd, J=10.9, 1.5 Hz, 1H), 2.63-2.58 (m, 1H), 2.30 (s,3H), 2.23-2.11 (m, 1H), 1.48-1.33 (m, 3H).

Example 51(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (101 mg, 0.474 mmol) dissolved in DMF (3 mL) wasadded NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1.0 mL)and 2-fluoro-3-(trifluoromethyl)pyridine (0.091 mL, 0.76 mmol) was thenadded and the mixture heated to 70° C. After heating at 70° C. for 3 h,the mixture was cooled to room temperature, quenched with saturatedNH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (3×). The combined organics were washed with H₂O,5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated.Purification via silica gel chromatography (0-35% EtOAc in hexanes) gavethe title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI)mass calcd. for C₁₇H₂₁F₃N₂O₃, 358.2. m/z found 303.1 [M+2H-tBu]⁺. ¹H NMR(400 MHz, Chloroform-d, Compound present as a mixture of rotamers,(0.68:0.0.32), major rotamer reported) δ 8.35-8.25 (m, 1H), 7.90-7.82(m, 1H), 6.96 (dd, J=7.5, 5.0 Hz, 1H), 5.32 (dt, J=10.1, 3.1 Hz, 1H),4.64-4.58 (m, 1H), 3.42 (dt, J=9.5, 3.1 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H),2.61-2.56 (m, 1H), 2.27-2.15 (m, 1H), 1.76-1.66 (m, 1H), 1.63 (br. s,1H), 1.48 (dt, J=13.5, 3.5 Hz, 1H), 1.08 (s, 9H).

Step B:(1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (3 mL). After 2 h, the reaction was concentratedto give the title compound of step B (76.5 mg) as a white solid and usedwithout further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O,258.1. m/z found 259.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (25 mg) and intermediate A-1 (18 mg,0.093 mmol) in DMF (0.8 mL) was added DIPEA (75 μL, 0.44 mmol) and HATU(36 mg, 0.093 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification via silica gelchromatography (0-60% EtOAc in hexanes) gave the title compound (29 mg).MS (ESI) mass calcd. C₂₁H₁₈F₃N₅O₂, 429.1. m/z found 430.1 [M+H]⁺. ¹H NMR(400 MHz, Chloroform-d, Compound present as a mixture of rotamers,(0.76:0.24), major rotamer reported) δ 7.93-7.82 (m, 4H), 7.81 (s, 2H),7.07 (dd, J=7.7, 1.5 Hz, 1H), 6.93-6.86 (m, 1H), 6.75 (td, J=7.6, 1.2Hz, 1H), 5.04 (dt, J=10.2, 3.4 Hz, 1H), 4.15-4.04 (m, 1H), 3.66 (dt,J=10.9, 3.3 Hz, 1H), 3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.60 (m, 1H),2.27-2.15 (m, 1H), 1.48 (dt, J=13.3, 3.6 Hz, 1H), 1.44-1.37 (m, 1H),1.36-1.28 (m, 1H).

Example 52(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 51 substituting intermediate A-1 withintermediate A-20. MS (ESI) mass calcd. C₂₁H₁₉F₃N₆O₂, 444.2. m/z found445.0 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as amixture of rotamers, (0.72:0.28), major rotamer reported) δ 8.01 (d,J=8.5 Hz, 1H), 7.83-7.78 (m, 4H), 7.05 (d, J=8.4 Hz, 1H), 6.85-6.78 (m,1H), 4.97 (dt, J=10.4, 3.3 Hz, 1H), 4.31 (br. s, 1H), 3.70 (dt, J=10.9,3.3 Hz, 1H), 3.42 (d, J=10.9 Hz, 1H), 2.66-2.62 (m, 1H), 2.23-2.14 (m,1H), 2.10 (s, 3H), 1.58-1.15 (m, 3H).

Example 53(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (9 mL) was addedPd(OAc)₂ (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) atroom temperature and the reaction mixture was purged with N₂ for 5 min.Then, 2-chloro-5-(trifluoromethyl)pyridine (159 mg, 0.874 mmol),intermediate B-10 (204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol)were added and the reaction mixture heated to 70° C. overnight. Uponcompletion of the reaction, the mixture was cooled to room temperature,filtered through Celite and the filter pad washed with EtOAc. Thefiltrate was concentrated in vacuo and the crude residue subjecteddirectly to silica gel chromatography (0-50% EtOAc in hexanes) to givethe title compound of step A (198 mg, 0.554 mmol, 63%). MS (ESI) masscalcd. for C₁₂H₂₂F₃N₃O₂, 357.2. m/z found 358.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.33 (s, 1H), 7.55 (d, J=8.8 Hz, 1H), 6.37 (d, J=8.8 Hz,1H), 5.11-4.97 (m, 1H), 4.41 (s, 1H), 4.27-4.18 (m, 1H), 3.44-3.36 (m,1H), 3.08 (d, J=9.7 Hz, 1H), 2.62-2.55 (m, 1H), 2.39-2.26 (m, 1H),1.68-1.61 (m, 1H), 1.45-1.43 (m, 1H), 1.48 and 1.22 (two s, 9H).

Step B: Step B:(1S,4R,6R)—N-(5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (198 mg, 0.554 mmol) in EtOAc (3 mL) wasadded 4M HCl in dioxane (14 mL). After 1 h, the reaction wasconcentrated to give the title compound of step B (183 mg), which wasused without further purification. MS (ESI) mass calcd. for C₁₂H₁₄F₃N₃,257.1. m/z found 258.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (30 mg) and intermediate A-1 (19 mg,0.10 mmol) in DMF (1 mL) was added DIPEA (94 μL, 0.55 mmol) and HATU (38mg, 0.10 mmol), and the reaction mixture was stirred at room temperaturefor 1 h. The reaction was quenched by the addition of H₂O and theaqueous layer was extracted with 4:1 EtOAc/hexanes (3×X). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification via silica gelchromatography (25-100% EtOAc (with 10% MeOH) in hexanes) gave the titlecompound (20 mg). MS (ESI) mass calcd. C₂₁H₁₉F₃N₆O, 428.2. m/z found429.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆, Compound presents as a mixtureof rotamers, major rotamer reported) δ 8.10 (s, 2H), 7.94-7.77 (m, 1H),7.70 (d, J=8.1 Hz, 1H), 7.67-7.49 (m, 2H), 7.28 (td, J=7.7, 1.5 Hz, 1H),6.96-6.82 (m, 1H), 6.77-6.56 (m, 2H), 3.96 (br. s, 1H), 3.64 (br. s,1H), 3.33-3.25 (m, 1H), 3.23-3.14 (m, 1H), 2.15-2.00 (m, 1H), 1.44-1.33(m, 1H), 1.23-1.03 (m, 2H), *1H buried under DMSO-d₆ peak.

Example 54(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-20 and substituting purification by silica gelchromatography with Agilent Prep Method X. MS (ESI) mass calcd.C₂₁H₂₀F₃N₇O, 443.2. m/z found 444.2 [M+H]⁺. Analytical HPLC was obtainedon a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm),mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.).R_(t)=5.92 min (major rotamer) at 254 nm.

Example 55(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-22 and substituting purification by silica gelchromatography with Agilent Prep Method X. MS (ESI) mass calcd.C₂₂H₂₁F₃N₆O, 442.2. m/z found 443.2 [M+H]⁺. Analytical HPLC was obtainedon a Agilent 1100 Series using a XBridge C18 column (5 um, 100×4.6 mm),mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.).R_(t)=6.85 min (major rotamer) at 254 nm.

Example 56(7-ethoxyquinolin-8-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-25 and substituting purification by silica gelchromatography with Agilent Prep Method X. MS (ESI) mass calcd.C₂₄H₂₃F₃N₄O₂, 456.2. m/z found 457.2 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 um,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.45 min (major rotamer) at 254 nm.

Example 57(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-10. MS (ESI) mass calcd. C₂₁H₁₈F₄N₆O, 446.1. m/z found447.1 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄) δ 7.95 (s, 2H), 7.91-7.84(m, 1H), 7.81 (dd, J=9.0, 4.7 Hz, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.12-7.02(m, 1H), 6.78-6.67 (m, 1H), 6.67-6.47 (m, 1H), 4.02-3.91 (m, 1H), 3.85(br. s, 1H), 3.42 (dt, J=11.1, 3.2 Hz, 1H), 3.30-3.27 (m, 1H), 2.63-2.55(m, 1H), 2.26-2.14 (m, 1H), 1.51-1.40 (m, 1H), 1.28-1.16 (m, 2H).

Example 58(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-7 and substituting purification by silica gelchromatography with Agilent Prep Method X. MS (ESI) mass calcd.C₂₃H₁₉F₄N₅O, 457.2. m/z found 458.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆,Compound presents as a mixture of rotamers (0.90:0.10), major rotamerreported) δ 8.87 (d, J=4.9 Hz, 2H), 8.03 (dd, J=8.8, 5.6 Hz, 1H), 7.88(br. s, 1H), 7.64-7.49 (m, 2H), 7.45 (t, J=4.9 Hz, 1H), 7.04 (td, J=8.6,2.8 Hz, 1H), 6.70-6.53 (m, 2H), 3.96 (br. s, 1H), 3.73 (br. s, 1H),3.23-3.13 (m, 1H), 2.15-2.02 (m, 1H), 1.37 (d, J=9.7 Hz, 1H), 1.21-0.99(m, 3H). *1H buried under DMSO-d₆ peak.

Example 59(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-10 (44 mg) and 2-chloro-5-(trifluoromethyl)pyrazine(45 mg, 0.25 mmol) dissolved in DMF (2 mL) was added K₂CO₃ (43 mg, 0.31mmol) and the mixture heated to 70° C. After heating at 70° C. for 3.5h, the mixture was cooled to room temperature, diluted with H₂O, and theaqueous layer extracted with EtOAc (3×). The combined organics werewashed with H₂O, brine, dried with MgSO₄, filtered and concentrated.Purification via silica gel chromatography (0-45% EtOAc in hexanes) gavethe title compound (31 mg, 0.087 mmol, 42%). MS (ESI) mass calcd. forC₁₆H₂₁F₂N₄O₂, 358.2. m/z found 303.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz,Chloroform-d) δ 8.38-8.25 (m, 1H), 7.93-7.76 (m, 1H), 6.25-6.12 and5.57-5.44 (2m, 1H), 4.50-4.38 (m, 1H), 4.34-4.11 (m, 1H), 3.46-3.33 (m,1H), 3.16-3.01 (m, 1H), 2.66-2.57 (m, 1H), 2.42-2.29 (m, 1H), 1.95-0.80(m, 12H).

Step B:(1S,4R,6R)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (31 mg, 0.087 mmol) in EtOAc (0.5 mL)was added 4M HCl in dioxane (4 mL). After 1.5 h additional 4 M HCl indioxane (2 mL) was added. After an additional 1.25 h, the reaction wasconcentrated to give the title compound of step B (31 mg) which was usedwithout further purification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄,258.1. m/z found 259.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (29 mg) and intermediate A-1 (18 mg,0.096 mmol) in DMF (2.0 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(37 mg, 0.096 mmol). Upon completion the reaction was diluted with H₂Oand the aqueous layer extracted with EtOAc (3×). The combined organicswere washed with H₂O, brine, dried with MgSO₄, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (8 mg). MS (ESI) masscalcd. C₂₀H₁₈F₃N₇O, 429.2. m/z found 430.2 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 um,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.27 min (major rotamer) at 254 nm.

Example 60(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (218 mg, 1.03 mmol) inMeCN (5 mL) was added 2-chloro-5-(trifluoromethyl)pyrimidine (225 mg,1.23 mmol) and Et₃N (0.21 mL, 1.54 mmol), and the reaction mixture wassealed and heated to 90° C. overnight. Upon completion of the reaction,the mixture was cooled to room temperature and diluted with H₂O. Thereaction mixture was extracted with EtOAc (3×). The combined organicswere concentrated and the concentrate subjected directly to silica gelchromatography (0-50% EtOAc in hexanes) to give the title compound ofstep A (263 mg, 0.734 mmol, 71%). MS (ESI) mass calcd. for C₁₆H₂₁F₃N₄O₂;358.2. m/z found 303.1 [M+2H-tBu]⁺. ¹H NMR (400 MHz, Chloroform-d,Compound present as a mixture of rotamers) δ 8.54-8.36 (m, 2H),6.18-6.09 and 5.82-5.71 (two m, 1H), 4.49-4.36 (m, 1H), 4.34-4.23 (m,1H), 3.45-3.31 (m, 1H), 3.12 (3.00, 1H), 2.63-2.55 (m, 1H), 2.38-2.27(m, 1H), 1.77-1.18 (m, 12H), 1.12-1.02 (m, 1H).

Step B:(1S,4R,6R)—N-(5-(trifluoromethyl)pyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (263 mg, 0.73 mmol) in EtOAc (2 mL) wasadded 4M HCl in dioxane (6 mL), and the reaction mixture was stirred atroom temperature for 5 h. The reaction was concentrated to give thetitle compound of step B (230 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄, 258.1. m/z found259.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (35 mg) and intermediate A-1 (25 mg,0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(50 mg, 0.13 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Agilient Prep Method X to give the title compound (34mg). MS (ESI): mass calcd. for C₂₀H₁₈F₃N₇O, 429.2. m/z found, 430.9[M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using aXBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rateof 1 mL/min (Temperature=30° C.). R_(t)=6.18 min (major rotamer) at 254nm.

Example 61(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉F₃N₈O, 444.2. m/zfound, 445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.23 (s,1H), 8.16 (d, J=8.4 Hz, 1H), 7.92 (s, 1H), 7.86 (s, 2H), 7.73 (s, 1H),7.32 (d, J=8.4 Hz, 1H), 4.34-4.29 (m, 1H), 4.19-4.11 (m, 1H), 3.72 (dt,J=11.0, 3.2 Hz, 1H), 3.33 (dd, J=11.1, 1.6 Hz, 1H), 2.83-2.77 (m, 1H),2.60 (s, 3H), 2.49-2.39 (m, 1H), 2.00-1.93 (m, 1H), 1.75-1.69 (m, 1H),1.21 (dt, J=13.2, 3.6 Hz, 1H).

Example 62(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉F₃N₈O, 444.2. m/zfound, 445.9 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.73:0.27), major rotamer reported) δ 8.52-8.44 (m,1H), 8.36-8.30 (m, 1H), 8.21 (d, J=8.5 Hz, 1H), 7.99 (s, 2H), 7.39 (d,J=8.5 Hz, 1H), 4.24-4.15 (m, 1H), 4.12-4.00 (m, 1H), 3.60 (dt, J=11.1,3.3 Hz, 1H), 3.35-3.32 (m, 1H), 2.75-2.70 (m, 1H), 2.48 (s, 3H),2.43-2.30 (m, 1H), 1.76-1.62 (m, 2H), 1.39-1.29 (m, 1H).

Example 63(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 64(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 65(4-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 66(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O, 457.2. m/zfound, 458.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.90 (d,J=5.0 Hz, 2H), 7.93 (s, 1H), 7.57 (dd, J=8.9, 2.5 Hz, 1H), 7.49 (t,J=5.0 Hz, 1H), 7.10-7.03 (m, 1H), 6.91-6.83 (m, 1H), 6.84-6.76 (m, 1H),6.60-6.52 (m, 1H), 4.17 (s, 1H), 4.14-4.03 (m, 1H), 3.23 (s, 2H),2.57-2.49 (m, 1H), 2.27-2.17 (m, 1H), 1.54 (d, J=11.3 Hz, 1H), 1.26-1.17(m, 1H), 1.04 (d, J=10.0 Hz, 1H).

Example 67(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.83:0.17), major rotamer reported) δ 8.89 (d,J=4.9 Hz, 2H), 8.12 (s, 1H), 7.72 (d, J=1.4 Hz, 1H), 7.37 (t, J=5.0 Hz,1H), 7.18-7.11 (m, 1H), 7.07 (d, J=7.5 Hz, 1H), 4.52 (s, 1H), 4.41-4.28(m, 1H), 3.59-3.48 (m, 1H), 3.24 (d, J=11.6 Hz, 1H), 2.79-2.69 (m, 1H),2.49-2.38 (m, 1H), 1.81-1.71 (m, 2H), 1.15-1.05 (m, 1H). 1H buried undersolvent.

Example 68(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (600 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d,J=4.9 Hz, 2H), 8.55-8.50 (m, 1H), 8.24-8.19 (m, 1H), 7.49 (t, J=5.0 Hz,1H), 7.16-7.08 (m, 1H), 7.06-6.96 (m, 1H), 6.89 (d, J=7.8 Hz, 1H), 4.16(s, 1H), 4.14-4.07 (m, 1H), 3.28-3.26 (m, 1H), 3.26-3.21 (m, 1H),2.58-2.52 (m, 1H), 2.24-2.14 (m, 1H), 1.54 (d, J=10.0 Hz, 1H), 1.34-1.28(m, 1H), 1.09-1.01 (m, 1H).

Example 69(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 70(3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 71(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 72(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 73(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-2. The enantiomeric purity of the title compound wasconfirmed by analytical SFC using a Chiralpak AZ-H column (5 μm, 250×4.6mm), mobile phase of 35% EtOH+(0.2% TEA): 65% CO₂, and a flow rate of 2mL/min over 45 minutes (Temperature=40° C.). Elution was monitoredfollowing absorbance at 220 nm Enantiopurity 100%, which elutes as amajor peak (R_(t)=10.8 min) MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂,472.2. m/z found, 473.2 [M+H]⁺. Analytical HPLC was obtained on aAgilent 1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm),mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at100% ACN for 3 min, at a flow rate of 1 mL/min (Temperature=30° C.).R_(t)=7.18 min (major rotamer) at 254 nm.

Example 74(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 77 substituting intermediate A-40 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O₂, 473.2. m/zfound, 474.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.39 min(major rotamer) at 254 nm.

Example 75(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 76(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (196 mg, 0.862 mmol) dissolved in DMF (7 mL) wasadded NaH (69 mg, 1.7 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyridine (250 mg, 1.38 mmol) wasthen added and the mixture stirred at room temperature for 90 min. Thereaction mixture was quenched with saturated NH₄Cl solution, and dilutedwith EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered and concentrated. Purification via silica gel chromatography(0-50% EtOAc in hexanes) gave the title compound (250 mg, 0.671 mmol,78%). MS (ESI) mass calcd. for C₁₈H₂₃F₃N₂O₃, 372.2. m/z found 373.0[M+H]⁺.

Step B:(1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (250 mg, 0.671 mmol) in EtOAc (8 mL) wasadded 4 M HCl in dioxane (0.84 mL), and the reaction mixture was stirredat room temperature overnight. The reaction was then concentrated togive the title compound of step B which was used without furtherpurification. MS (ESI) mass calcd. for C₁₃H₁₅F₃N₂O, 272.1. m/z found273.1 [M+H]⁺.

Step C:(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (35 mg) and intermediate A-40 (75 mg,0.15 mmol, 42% purity) in DMF (1 mL) was added DIPEA (0.13 mL, 0.77mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirredat room temperature overnight. The reaction mixture was diluted withMeOH and subjected directly to purification using Agilent Prep Method Xto give the title compound (28 mg). MS (ESI): mass calcd. forC₂₂H₂₁F₃N₆O₂, 458.2. m/z found, 459.2 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=7.14 min (major rotamer) at 254 nm.

Example 77(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) wasadded NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyrazine (45 μL, 0.37 mmol) was thenadded and the mixture stirred at room temperature for 1 h. The reactionmixture was quenched with saturated NH₄Cl solution, and diluted withEtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered, and concentrated. Purification via silica gel chromatography(0-50% EtOAc in hexanes) gave the title compound (75 mg, 0.20 mmol,88%). MS (ESI) mass calcd. for C₁₂H₂₂F₃N₃O₃, 373.1. m/z found 317.9[M+2H-tBu]⁺.

Step B:(1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (75 mg, 0.20 mmol) in EtOAc (3 mL) wasadded 4M HCl in dioxane (0.25 mL), and the reaction mixture was stirredat room temperature overnight. Analysis of the reaction mixture showedunreacted starting material. An additional equivalent of 4M HCl indioxane (0.25 mL) was added and the reaction mixture stirred at roomtemperature overnight. The reaction was concentrated to give the titlecompound of step B (55 mg), which was used without further purification.MS (ESI) mass calcd. for C₁₂H₁₄F₃N₃O, 273.1. m/z found 274.1 [M+H]⁺.

Step C:(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (27 mg) and intermediate A-40 (58 mg,0.12 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.59 mmol) and HATU(41 mg, 0.11 mmol), and the reaction mixture was stirred at roomtemperature overnight. The reaction was diluted with MeOH and the crudereaction mixture subjected directly to purification via Agilent PrepMethod X to give the title compound (5.2 mg). MS (ESI): mass calcd. forC₂₁H₂₀F₃N₇O₂, 459.2. m/z found, 460.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ8.28-8.24 (m, 1H), 8.15-8.11 (m, 1H), 8.08-8.02 (m, 1H), 7.83-7.79 (s,2H), 7.13-7.09 (d, J=8.3 Hz, 1H), 5.03-4.94 (m, 1H), 3.84-3.75 (m, 2H),3.68-3.58 (m, 1H), 2.77-2.63 (m, 1H), 2.29-2.24 (s, 3H), 2.25-2.18 (m,3H), 1.93-1.81 (m, 1H), 1.71-1.62 (m, 1H), 1.50-1.43 (m, 1H).

Example 78(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 79(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 80(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 472.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.44 min(major rotamer) at 254 nm.

Example 81(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 82(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 83(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octane-2-carboxylate.To a microwave vial containing intermediate C-7B (193 mg, 0.853 mmol) inMeCN (4 mL) was added 2-chloro-5-(trifluoromethyl)pyrazine (0.1 mL, 0.82mmol) and Et₃N (0.14 mL, 1.02 mmol), and the reaction mixture was sealedand heated to reflux bench top overnight. Upon completion of thereaction, the crude reaction mixture was concentrated and subjecteddirectly to silica gel chromatography (0-50% EtOAc in hexanes) to givethe title compound of step A (245 mg, 0.658 mmol, 77%) MS (ESI) masscalcd. for C₁₇H₂₃F₃N₄O₂; 372.2. m/z found 373.2 [M+H]⁺.

Step B:(1S,4R,6R)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine.xHCl.To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (8 mL) wasadded 4M HCl in dioxane (0.82 mL), and the reaction mixture was stirredat room temperature overnight. The reaction was concentrated to give thetitle compound of step B (179 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₅F₃N₄, 272.1. m/z found273.1 [M+H]⁺.

Step C:(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (35 mg) and intermediate A-40 (75 mg,0.15 mmol, 42% purity) in DMF (1.3 mL) was added DIPEA (0.13 mL, 0.77mmol) and HATU (54 mg, 0.14 mmol), and the reaction mixture was stirredat room temperature overnight. The reaction was diluted with MeOH andthe crude reaction mixture subjected directly to purification viaAgilent Prep Method X to give the title compound (26 mg). MS (ESI): masscalcd. for C₂₁H₂₁F₃N₈O, 458.2. m/z found, 459.2 [M+H]⁺. Analytical HPLCwas obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=5.97 min (major rotamer) at 254 nm.

Example 84(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 85(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-(6-²H)-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 27 where the reduction of intermediate B-5is carried out with NaBD₄ instead of L-Selectride. MS (ESI): mass calcd.for C₂₃H₁₂DF₄N₄O₂, 459.1. m/z found, 460.1 [M+H]⁺. ¹H NMR (500 MHz,Methanol-d₄, Compound present as a mixture of rotamers (0.83:0.17),major rotamer reported) δ 8.91 (d, J=5.0 Hz, 2H), 8.19-8.13 (m, 1H),7.96 (dd, J=8.7, 2.6 Hz, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.18-7.13 (m, 1H),7.06-6.97 (m, 2H), 6.88 (dd, J=7.6, 1.1 Hz, 1H), 4.33-4.23 (m, 1H),3.27-3.24 (m, 2H), 2.59-2.53 (m, 1H), 2.30-2.21 (m, 1H), 1.54 (d, J=10.6Hz, 1H), 1.37 (dd, J=13.5, 3.6 Hz, 1H), 1.01-0.91 (m, 1H).

Example 86(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]-(3-²H,²H)-heptan-2-yl)methanone

Prepared analogous to Example 27 where the Diels-Alder reaction tointermediate B-1 is carried out with formaldehyde-d₂ instead offormaldehyde. MS (ESI): mass calcd. for C₂₃H₁₆D₂F₄N₄O₂, 460.1. m/zfound, 461.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.15-8.09 (m, 1H), 7.79 (dd, J=8.8, 2.5 Hz, 1H),7.30-7.27 (m, 1H), 7.10-7.03 (m, 1H), 6.96-6.86 (m, 2H), 6.84 (d, J=8.7Hz, 1H), 5.07 (dt, J=10.1, 3.3 Hz, 1H), 4.31-4.19 (m, 1H), 2.56-2.48 (m,1H), 2.27-2.12 (m, 1H), 1.46-1.40 (m, 1H), 1.36 (dt, J=13.6, 3.6 Hz,1H), 0.96-0.86 (m, 1H).

Example 87(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-39. MS (ESI): mass calcd. for C₂₀H₁₇F₃N₆O₂, 430.1. m/zfound, 431.2 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.43 (dd,J=4.8, 1.8 Hz, 1H), 8.18-8.11 (m, 1H), 8.11-8.02 (m, 2H), 7.95 (dd,J=8.6, 2.5 Hz, 1H), 7.71-7.55 (m, 1H), 7.12-6.90 (m, 2H), 5.08 (dt,J=10.1, 3.2 Hz, 1H), 4.01 (s, 1H), 3.57 (dt, J=11.1, 3.2 Hz, 1H), 3.35(dd, J=11.1, 1.7 Hz, 1H), 2.75-2.64 (m, 1H), 2.37-2.24 (m, 1H), 1.57 (d,J=10.4 Hz, 1H), 1.53-1.35 (m, 2H).

Example 88(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-38. MS (ESI): mass calcd. for C₂₁H₁₉F₃N₆O₂, 444.2. m/zfound, 445.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.90:0.10), major rotamer reported) δ 8.26-8.21 (m,1H), 8.19-8.14 (m, 1H), 8.05 (s, 2H), 7.98 (dd, J=8.7, 2.6 Hz, 1H),7.50-7.46 (m, 1H), 6.99 (d, J=8.8 Hz, 1H), 5.06 (dt, J=10.4, 3.2 Hz,1H), 4.05-3.97 (m, 1H), 3.54 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (dd, J=11.1,1.6 Hz, 1H), 2.68-2.62 (m, 1H), 2.32-2.19 (m, 1H), 2.08 (s, 3H), 1.56(d, J=10.7 Hz, 1H), 1.47-1.35 (m, 2H).

Example 89(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-34. MS (ESI): mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/zfound, 459.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.85-8.80(m, 2H), 8.17 (dd, J=8.1, 1.3 Hz, 1H), 8.09-8.03 (m, 1H), 7.95 (dd,J=8.8, 2.6 Hz, 1H), 7.39-7.31 (m, 1H), 7.05-6.96 (m, 2H), 6.92 (td,J=7.5, 1.2 Hz, 1H), 5.11 (dt, J=10.2, 3.3 Hz, 1H), 4.16-4.10 (m, 1H),3.61 (dt, J=10.9, 3.2 Hz, 1H), 3.35-3.33 (m, 1H), 2.74-2.65 (m, 1H),2.36-2.26 (m, 1H), 1.59-1.53 (m, 1H), 1.46 (dt, J=13.4, 3.7 Hz, 1H),1.41-1.32 (m, 1H).

Example 90(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-35. MS (ESI): mass calcd. for C₂₃H₁₇F₅N₄O₂, 476.1. m/zfound, 477.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.88 (d,J=0.7 Hz, 2H), 8.21-8.15 (m, 1H), 7.96 (dd, J=8.8, 2.6 Hz, 1H),7.19-7.13 (m, 1H), 7.07-6.99 (m, 2H), 6.91 (dd, J=7.6, 0.9 Hz, 1H), 5.17(dt, J=10.2, 3.3 Hz, 1H), 4.31-4.21 (m, 1H), 3.35-3.32 (m, 1H),3.27-3.23 (m, 1H), 2.63-2.59 (m, 1H), 2.32-2.25 (m, 1H), 1.65-1.56 (m,1H), 1.39 (dt, J=13.6, 3.6 Hz, 1H), 1.20-1.05 (m, 1H).

Example 91(2-(5-fluoropyrimidin-2-yl)-3-methylphenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-36. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 473.1 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.81:0.19), major rotamer reported) δ 8.85 (d,J=0.8 Hz, 2H), 8.21-8.10 (m, 1H), 7.96 (dd, J=8.8, 2.6 Hz, 1H),7.25-7.18 (m, 1H), 7.08-6.96 (m, 1H), 6.96-6.79 (m, 2H), 5.17 (dt,J=10.2, 3.3 Hz, 1H), 4.33-4.23 (m, 1H), 3.27-3.16 (m, 2H), 2.58 (s, 1H),2.33-2.22 (m, 4H), 1.62-1.56 (m, 1H), 1.37 (dt, J=13.5, 3.6 Hz, 1H),1.21-1.02 (m, 1H).

Example 92(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-41. MS (ESI): mass calcd. for C₂₃H₂₀F₃N₅O₂, 455.2. m/zfound, 456.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.87 (d,J=4.9 Hz, 2H), 8.47 (d, J=8.2 Hz, 1H), 8.05-7.99 (m, 1H), 7.86 (dd,J=8.8, 2.5 Hz, 1H), 7.42 (t, J=4.9 Hz, 1H), 7.22 (d, J=8.2 Hz, 1H),6.91-6.87 (m, 1H), 4.99 (dt, J=10.3, 3.4 Hz, 1H), 4.32-4.25 (m, 1H),3.66 (dt, J=10.9, 3.2 Hz, 1H), 3.39 (dd, J=10.9, 1.6 Hz, 1H), 2.71-2.66(m, 1H), 2.33-2.24 (m, 1H), 2.19 (s, 3H), 1.62-1.54 (m, 1H), 1.49 (dt,J=13.4, 3.7 Hz, 1H), 1.44-1.32 (m, 1H).

Example 93(3-phenylpyrazin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-43. MS (ESI): mass calcd. for C₂₃H₁₉F₃N₄O₂, 440.1. m/zfound, 441.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.52 (d, J=2.4 Hz, 1H),8.04-8.01 (m, 1H), 7.93 (d, J=2.5 Hz, 1H), 7.89 (dd, J=8.8, 2.7 Hz, 1H),7.75-7.71 (m, 2H), 7.56-7.53 (m, 3H), 6.91-6.84 (m, 1H), 4.95 (dt,J=10.3, 3.3 Hz, 1H), 4.11-3.99 (m, 1H), 3.38-3.34 (m, 2H), 2.57-2.52 (m,1H), 2.27-2.12 (m, 1H), 1.45-1.35 (m, 2H), 0.68-0.59 (m, 1H).

Example 94(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (50 mg, 0.23 mmol) dissolved in DMF (1 mL) was addedNaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil). After 5 minutesthe sides of the flask were rinsed with additional DMF (1 mL) and2-fluoro-6-(trifluoromethyl)pyridine (0.045 mL, 0.38 mmol) was thenadded and the mixture stirred overnight at room temperature. The mixturewas quenched with saturated NH₄Cl solution, diluted with EtOAc and H₂O.The aqueous layer was extracted with EtOAc (3×). The combined organicswere washed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄,filtered, and concentrated. Purification via silica gel chromatography(0-40% EtOAc in hexanes) gave the title compound (29 mg, 0.080 mmol,34%) as a clear oil. MS (ESI) mass calcd. for C₁₂H₂₁F₃N₂O₃, 358.2. m/zfound 303.1 [M+2H-tBu]⁺.

Step B:(1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (28 mg, 0.078 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (0.1 mL). After 4 h, the reaction wasconcentrated to give the title compound of step B (23 mg) as a pinksolid and used without further purification. MS (ESI) mass calcd. forC₁₂H₁₃F₃N₂O, 258.1. m/z found 259.1 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (23 mg) and intermediate A-2 (25 mg,0.094 mmol) in DMF (1.1 mL) was added DIPEA (81 μL, 0.47 mmol) and HATU(33 mg, 0.086 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (15mg). MS (ESI): mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found, 459.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers, (0.84:0.16), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H),7.95-7.88 (m, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.33 (d, J=7.5 Hz, 1H),7.17-7.10 (m, 2H), 7.05-6.99 (m, 1H), 6.86 (dd, J=7.9, 1.0 Hz, 1H), 5.12(dt, J=10.2, 3.3 Hz, 1H), 4.29-4.25 (m, 1H), 3.26 (t, J=3.0 Hz, 1H),3.25 (s, 1H), 2.58 (s, 1H), 2.32-2.24 (m, 1H), 1.60 (d, J=10.1 Hz, 1H),1.38 (dt, J=13.5, 3.6 Hz, 1H), 1.11-1.05 (m, 1H).

Example 95(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) wasadded NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2-chloro-4-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was thenadded and the mixture heated to 70° C. After heating at 70° C. for 3 h,the mixture was cooled to room temperature, quenched with saturatedNH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (3×). The combined organics were washed with H₂O,5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated.Purification via silica gel chromatography (0-40% EtOAc in hexanes) gavethe title compound (16 mg, 0.045 mmol, 10%) as a yellow-brown solid. MS(ESI) mass calcd. for C₁₇H₂₁F₃N₂O₃, 358.2. m/z found 359.1 [M+H]⁺. ¹HNMR (400 MHz, Chloroform-d) δ 8.34-8.23 (m, 1H), 7.12-7.04 (m, 1H),7.01-6.92 (m, 1H), 5.35 (dt, J=10.1, 3.2 Hz, 1H), 4.56-4.49 (m, 1H),3.41 (dt, J=9.5, 3.1 Hz, 1H), 3.27-3.17 (m, 1H), 2.60-2.55 (m, 1H),2.28-2.16 (m, 1H), 1.80-1.71 (m, 1H), 1.68-1.62 (m, 1H), 1.53-0.93 (m,10H).

Step B:(1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (16 mg, 0.045 mmol) in EtOAc (0.1 mL)was added 4M HCl in dioxane (0.1 mL). After 3 h, the reaction wasconcentrated to give the title compound of step B (16 mg) and usedwithout further purification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O,258.1. m/z found 259.2 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((4-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (16 mg) and intermediate A-2 (13 mg,0.060 mmol) in DMF (0.6 mL) was added DIPEA (56 μL, 0.33 mmol) and HATU(23 mg, 0.060 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (3.4mg). MS (ESI): mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found, 459.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers, (0.80:0.20), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H),8.07 (d, J=5.3 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.20-7.11 (m, 3H),7.03-6.97 (m, 1H), 6.91-6.87 (m, 1H), 5.16 (dt, J=10.2, 3.3 Hz, 1H),4.28-4.23 (m, 1H), 3.28-3.24 (m, 2H), 2.61-2.54 (m, 1H), 2.32-2.20 (m,1H), 1.56 (d, J=10.6 Hz, 1H), 1.38 (dt, J=13.6, 3.6 Hz, 1H), 1.04-0.96(m, 1H).

Example 96(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) wasadded NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2-fluoro-3-(trifluoromethyl)pyridine (0.10 mL, 0.76 mmol) was thenadded and the mixture heated to 70° C. After heating at 70° C. for 3 h,the mixture was cooled to room temperature, quenched with saturatedNH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (3×). The combined organics were washed with H₂O,5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated.Purification via silica gel chromatography (0-35% EtOAc in hexanes) gavethe title compound (87 mg, 0.24 mmol, 51%) as a white solid. MS (ESI)mass calcd. for C₁₂H₂₁F₃N₂O₃, 358.2. m/z found 303.1 [M+2H-tBu]⁺. ¹H NMR(400 MHz, Chloroform-d) δ 8.35-8.25 (m, 1H), 7.90-7.82 (m, 1H), 6.96(dd, J=7.5, 5.0 Hz, 1H), 5.32 (dt, J=10.1, 3.1 Hz, 1H), 4.64-4.58 (m,1H), 3.42 (dt, J=9.5, 3.1 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H), 2.61-2.56 (m,1H), 2.27-2.15 (m, 1H), 1.76-1.66 (m, 2H), 1.48 (dt, J=13.5, 3.5 Hz,1H), 1.08 (s, 9H).

Step B:(1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (86 mg, 0.24 mmol) in EtOAc (0.9 mL) wasadded 4M HCl in dioxane (3 mL). After 2 h, the reaction was concentratedto give the title compound of step B (77 mg) and used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₃F₃N₂O, 258.1. m/z found259.1 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (28 mg) and intermediate A-2 (23 mg,0.11 mmol) in DMF (1 mL) was added DIPEA (98 μL, 0.57 mmol) and HATU (40mg, 0.11 mmol), and the reaction mixture was stirred at room temperaturefor 1 h. The reaction was quenched by the addition of H₂O and theaqueous layer was extracted with EtOAc (3×). The combined organics werewashed with H₂O, 5% aqueous LiCl, brine, dried with Na₂SO₄, filtered,and concentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (5.4 mg). MS (ESI):mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/z found, 459.1 [M+H]⁺. ¹H NMR(500 MHz, Methanol-d₄, Compound present as a mixture of rotamers,(0.86:0.14), major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 8.05-8.01(m, 2H), 7.49 (t, J=5.0 Hz, 1H), 7.17-7.11 (m, 1H), 7.08-7.04 (m, 1H),6.96-6.90 (m, 1H), 6.77 (dd, J=7.6, 1.1 Hz, 1H), 5.20 (dt, J=10.2, 3.3Hz, 1H), 4.32-4.28 (m, 1H), 3.29-3.26 (m, 1H), 3.25-3.20 (m, 1H),2.60-2.54 (m, 1H), 2.29-2.21 (m, 1H), 1.53 (d, J=10.4 Hz, 1H), 1.40 (dt,J=13.6, 3.6 Hz, 1H), 0.95-0.89 (m, 1H).

Example 97(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (70 mg, 0.33 mmol) and2,3-difluoro-5-(trifluoromethyl)pyridine (90 mg, 0.49 mmol) dissolved inDMF (3 mL) was added NaH (18 mg, 0.46 mmol, 60% dispersion in mineraloil) and the reaction mixture was stirred overnight at room temperatureafter which analysis of the reaction mixture showed mainly startingmaterial. Additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL)was then added and the reaction mixture heated to 70° C. and stirredovernight after which analysis of the reaction mixture still showedstarting material remaining Additional2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) was again added andthe reaction mixture was heated at 70° C. for an additional 4.5 hoursbefore additional 2,3-difluoro-5-(trifluoromethyl)pyridine (0.05 mL) wasadded and the reaction stirred overnight. After this time analysis stillshowed incomplete conversion however the reaction was cooled to roomtemperature and quenched with H₂O. The aqueous layer was extracted withEtOAc (3×) and the combined organics were washed with 5% aqueous LiCl,brine, dried with Na₂SO₄, filtered, and concentrated. Purification viasilica gel chromatography (0-25% EtOAc in hexanes) gave the titlecompound. MS (ESI) mass calcd. for C₁₇H₂₀F₄N₂O₃, 376.1. m/z found 321.1[M+2H-tBu]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as amixture of rotamers (0.67:0.33), major rotamer reported) δ 8.21-8.18 (m,1H), 7.51 (dd, J=9.5, 2.1 Hz, 1H), 5.37 (dt, J=10.1, 3.2 Hz, 1H),4.57-4.50 (m, 1H), 3.41 (dt, J=9.5, 3.1 Hz, 1H), 3.22 (dd, J=9.5, 1.4Hz, 1H), 2.62-2.57 (m, 1H), 2.30-2.19 (m, 1H), 1.77-1.73 (m, 1H),1.67-1.63 (m, 1H), 1.48 (dt, J=13.7, 3.6 Hz, 1H), 1.12 (s, 9H).

Step B:(1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (130 mg, 0.345 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (3 mL) and the reaction mixture was stirred atroom temperature overnight. The reaction was concentrated to give thetitle compound of step B (114 mg) as a yellow oil and used withoutfurther purification. MS (ESI) mass calcd. for C₁₂H₁₂F₄N₂O, 276.1. m/zfound 277.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (28.5 mg) and intermediate A-1 (19 mg,0.1 mmol) in DMF (0.9 mL) was added DIPEA (0.13 mL, 0.73 mmol) and HATU(38 mg, 0.1 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (18mg). MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/z found, 448.2[M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture ofrotamers (0.81:0.19), major rotamer reported) δ 7.87 (s, 1H), 7.81 (s,2H), 7.57-7.50 (m, 2H), 7.37-7.30 (m, 2H), 6.96 (t, J=7.5 Hz, 1H), 5.05(dt, J=10.1, 3.4 Hz, 1H), 4.03 (s, 1H), 3.64 (dt, J=11.0, 3.2 Hz, 1H),3.42 (dd, J=10.9, 1.4 Hz, 1H), 2.72-2.62 (m, 1H), 2.36-2.20 (m, 1H),1.51-1.36 (m, 3H).

Example 98(1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 97 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O₂, 462.1. m/zfound, 463.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.79:0.21), major rotamer reported) δ 8.00 (d,J=8.4 Hz, 1H), 7.81 (s, 2H), 7.72-7.69 (m, 1H), 7.39 (dd, J=9.4, 2.1 Hz,1H), 7.07 (d, J=8.4 Hz, 1H), 4.96 (dt, J=10.3, 3.3 Hz, 1H), 4.47-4.40(m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.48 (dd, J=11.0, 1.4 Hz, 1H),2.72-2.64 (m, 1H), 2.29-2.21 (m, 4H), 1.66-1.61 (m, 1H), 1.57-1.50 (m,2H).

Example 99((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 97 substituting intermediate A-1 withintermediate A-37. MS (ESI): mass calcd. for C₂₃H₁₈F₄N₄O₂, 458.1. m/zfound, 459.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.79 (d,J=4.8 Hz, 2H), 8.21-8.18 (m, 1H), 7.89-7.84 (m, 1H), 7.57-7.52 (m, 1H),7.36-7.29 (m, 1H), 7.29-7.26 (m, 1H), 7.20 (t, J=4.8 Hz, 1H), 7.01 (td,J=7.5, 1.3 Hz, 1H), 5.06 (dt, J=10.0, 3.3 Hz, 1H), 4.17-4.11 (m, 1H),3.69 (dt, J=10.8, 3.2 Hz, 1H), 3.43 (dd, J=10.8, 1.5 Hz, 1H), 2.72-2.65(m, 1H), 2.37-2.23 (m, 1H), 1.51-1.43 (m, 2H), 1.42-1.30 (m, 1H).

Example 100(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 97 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₂F₅N₄O₂, 476.1. m/zfound, 477.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.85 (d,J=4.8 Hz, 2H), 8.00-7.94 (m, 1H), 7.55 (dd, J=9.5, 2.1 Hz, 1H),7.30-7.27 (m, 1H), 7.19 (dd, J=7.1, 1.7 Hz, 1H), 7.13-7.03 (m, 2H), 5.10(dt, J=10.0, 3.3 Hz, 1H), 4.31-4.24 (m, 1H), 3.45-3.29 (m, 2H),2.65-2.53 (m, 1H), 2.35-2.23 (m, 1H), 1.48 (d, J=9.9 Hz, 1H), 1.40 (dt,J=13.6, 3.7 Hz, 1H), 1.18-0.99 (m, 1H).

Example 101(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (101 mg, 0.47 mmol) dissolved in DMF (3 mL) wasadded NaH (38 mg, 0.95 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2-chloro-5-methylpyridine (0.08 mL, 0.76 mmol) was then added andthe mixture heated to 70° C. After heating at 70° C. for 3 h, themixture was cooled to room temperature, quenched with saturated NH₄Clsolution, diluted with EtOAc and H₂O. The aqueous layer was extractedwith EtOAc (3×). The combined organics were washed with H₂O, 5% aqueousLiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purificationvia silica gel chromatography (0-35% EtOAc in hexanes) gave the titlecompound (16 mg, 0.053 mmol, 11%) as a white solid. MS (ESI) mass calcd.for C₁₂H₂₄N₂O₃, 304.2. m/z found 305.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 7.97-7.89 (m, 1H), 7.37 (dd, J=8.4, 2.5 Hz, 1H), 6.61 (d,J=8.5 Hz, 1H), 5.25 (dt, J=10.1, 3.2 Hz, 1H), 4.56-4.48 (m, 1H), 3.38(dt, J=9.5, 3.1 Hz, 1H), 3.19 (d, J=9.5 Hz, 1H), 2.59-2.52 (m, 1H), 2.23(s, 3H), 2.20-2.14 (m, 1H), 1.76-1.68 (m, 1H), 1.65-1.60 (m, 1H), 1.35(dt, J=13.4, 3.6 Hz, 1H), 1.14 (s, 9H).

Step B:(1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (16 mg, 0.053 mmol) in EtOAc (0.1 mL)was added 4M HCl in dioxane (0.1 mL). After 3 h, the reaction wasconcentrated to give the title compound of step B (15 mg) and usedwithout further purification. MS (ESI) mass calcd. for C₁₂H₁₆N₂O, 204.1.m/z found 205.2 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (16 mg) and intermediate A-2 (16 mg,0.07 mmol) in DMF (1 mL) was added DIPEA (69 μL, 0.40 mmol) and HATU (28mg, 0.073 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (6 mg).MS (ESI): mass calcd. for C₂₃H₂₁FN₄O₂, 404.2. m/z found, 405.1 [M+H]⁺.¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers,(0.85:0.15), major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 7.69-7.65(m, 1H), 7.52 (dd, J=8.4, 2.5 Hz, 1H), 7.48 (t, J=4.9 Hz, 1H), 7.21-7.14(m, 1H), 7.07-7.00 (m, 1H), 6.92 (dd, J=7.6, 1.1 Hz, 1H), 6.74 (d, J=8.4Hz, 1H), 5.02 (dt, J=10.1, 3.3 Hz, 1H), 4.25-4.19 (m, 1H), 3.26-3.18 (m,2H), 2.57-2.53 (m, 1H), 2.25 (s, 3H), 2.24-2.19 (m, 1H), 1.56-1.51 (m,1H), 1.34-1.28 (m, 1H), 1.08-1.02 (m, 1H).

Example 102(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate. Tointermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) was addedNaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5 minutesthe sides of the flask were rinsed with additional DMF (1 mL) and2-fluoropyridine (0.10 mL, 1.13 mmol) was then added and the mixtureheated to 70° C. After heating at 70° C. for 7 h, the mixture was cooledto room temperature, quenched with saturated NH₄Cl solution, dilutedwith EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, 5% aqueous LiCl, brine, driedwith Na₂SO₄, filtered, and concentrated. Purification via silica gelchromatography (0-30% EtOAc in hexanes) gave the title compound (73 mg,0.25 mmol, 36%) as a colorless solid. MS (ESI) mass calcd. forC₁₆H₂₂N₂O₃, 290.2. m/z found 291.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.11 (ddd, J=5.1, 2.0, 0.8 Hz, 1H), 7.59-7.50 (m, 1H),6.89-6.80 (m, 1H), 6.70 (dt, J=8.4, 0.9 Hz, 1H), 5.29 (dt, J=10.1, 3.2Hz, 1H), 4.61-4.49 (m, 1H), 3.39 (dt, J=9.5, 3.1 Hz, 1H), 3.20 (dd,J=9.5, 1.3 Hz, 1H), 2.59-2.50 (m, 1H), 2.26-2.15 (m, 1H), 1.76-1.69 (m,1H), 1.67-1.63 (m, 1H), 1.38 (dt, J=13.3, 3.6 Hz, 1H), 1.12 (s, 9H).

Step B: (1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (73 mg, 0.25 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirredovernight. Then, the reaction was concentrated to give the titlecompound of step B (68 mg) and used without further purification. MS(ESI) mass calcd. for C₁₁H₁₄N₂O, 190.1. m/z found 191.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (23 mg) and intermediate A-1 (18 mg,0.094 mmol) in DMF (1 mL) was added DIPEA (0.17 mL, 0.99 mmol) and HATU(36 mg, 0.094 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (22mg). MS (ESI): mass calcd. for C₂₀H₁₉N₅O₂, 361.2. m/z found, 362.2[M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture ofrotamers, (0.90:0.10), major rotamer reported) δ 7.84 (dd, J=8.3, 1.2Hz, 1H), 7.82-7.77 (m, 3H), 7.60-7.54 (m, 1H), 7.36-7.28 (m, 1H), 7.16(dd, J=7.8, 1.5 Hz, 1H), 6.88 (td, J=7.6, 1.2 Hz, 1H), 6.82-6.77 (m,1H), 6.74 (d, J=8.3 Hz, 1H), 5.03 (dt, J=10.3, 3.2 Hz, 1H), 4.06-3.97(m, 1H), 3.60 (dt, J=10.9, 3.3 Hz, 1H), 3.39 (dd, J=10.8, 1.4 Hz, 1H),2.68-2.56 (m, 1H), 2.27-2.13 (m, 1H), 1.48-1.31 (m, 3H).

Example 103(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 102 substituting intermediate A-1 withintermediate A-3. MS (ESI): mass calcd. for C₂₀H₂₀N₆O₂, 376.2. m/zfound, 377.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.86 (s,2H), 7.82-7.78 (m, 1H), 7.60-7.54 (m, 1H), 7.40 (d, J=7.7 Hz, 1H),6.85-6.79 (m, 1H), 6.74-6.64 (m, 2H), 4.98 (dt, J=10.1, 3.2 Hz, 1H),4.05-3.97 (m, 1H), 3.61 (dt, J=10.9, 3.2 Hz, 1H), 3.40 (dd, J=10.8, 1.4Hz, 1H), 2.65-2.59 (m, 1H), 2.56 (s, 3H), 2.25-2.15 (m, 1H), 1.48-1.33(m, 3H).

Example 104(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 102 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₉FN₄O₂, 390.1. m/zfound, 391.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.84 (d,J=4.9 Hz, 2H), 7.92-7.85 (m, 1H), 7.63-7.56 (m, 1H), 7.28-7.24 (m, 2H),7.09-6.96 (m, 2H), 6.85-6.80 (m, 1H), 6.76 (dt, J=8.3, 0.9 Hz, 1H), 5.10(dt, J=10.0, 3.3 Hz, 1H), 4.26-4.15 (m, 1H), 3.34-3.30 (m, 2H),2.59-2.48 (m, 1H), 2.27-2.15 (m, 1H), 1.45 (d, J=11.0 Hz, 1H), 1.32 (dt,J=13.4, 3.6 Hz, 1H), 1.13-1.01 (m, 1H).

Example 105((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-3. MS (ESI): mass calcd. for C₂₀H₁₉BrN₆O₂, 454.1. m/zfound, 455.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.93:0.07), major rotamer reported) δ 7.87 (s,2H), 7.76 (d, J=2.6 Hz, 1H), 7.64 (dd, J=8.7, 2.6 Hz, 1H), 7.29 (d,J=7.8 Hz, 1H), 6.69 (d, J=7.7 Hz, 1H), 6.62 (d, J=8.7 Hz, 1H), 4.83 (dt,J=10.3, 3.3 Hz, 1H), 4.05-3.94 (m, 1H), 3.59 (dt, J=11.0, 3.2 Hz, 1H),3.38 (d, J=11.0 Hz, 1H), 2.66-2.56 (m, 4H), 2.23-2.10 (m, 1H), 1.44-1.33(m, 2H), 1.32-1.23 (m, 1H).

Example 106((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-16. MS (ESI): mass calcd. for C₂₀H₁₇BrFN₅O₂, 457.1. m/zfound, 458.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.90:0.10), major rotamer reported) δ 7.87 (s,2H), 7.85 (dd, J=2.6, 0.7 Hz, 1H), 7.66 (dd, J=8.7, 2.5 Hz, 1H),7.24-7.17 (m, 1H), 7.07-6.98 (m, 1H), 6.91 (dt, J=7.7, 1.2 Hz, 1H), 6.66(dd, J=8.8, 0.7 Hz, 1H), 4.95 (dt, J=10.1, 3.3 Hz, 1H), 4.19-4.10 (m,1H), 3.35-3.30 (m, 2H), 2.60-2.49 (m, 1H), 2.24-2.12 (m, 1H), 1.48-1.41(m, 1H), 1.31 (dt, J=13.5, 3.6 Hz, 1H), 1.21-1.09 (m, 1H).

Example 107((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-12. MS (ESI): mass calcd. for C₂₀H₁₇BrFN₅O₂, 457.1. m/zfound, 458.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.89:0.11), major rotamer reported) δ 7.85 (d,J=2.6 Hz, 1H), 7.82 (s, 2H), 7.71-7.61 (m, 2H), 7.05 (dd, J=8.5, 5.9 Hz,1H), 6.68-6.58 (m, 2H), 4.91 (dt, J=10.1, 3.3 Hz, 1H), 4.00 (s, 1H),3.61 (dt, J=10.9, 3.3 Hz, 1H), 3.38 (dd, J=10.9, 1.4 Hz, 1H), 2.69-2.59(m, 1H), 2.26-2.14 (m, 1H), 1.47-1.25 (m, 3H).

Example 108((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-10. MS (ESI): mass calcd. for C₂₀H₁₇BrFN₅O₂, 457.1. m/zfound, 458.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.91:0.09), major rotamer reported) δ 7.84-7.81(m, 2H), 7.80 (s, 2H), 7.68 (dd, J=8.8, 2.6 Hz, 1H), 7.07 (ddd, J=9.0,7.6, 2.9 Hz, 1H), 6.81 (dd, J=8.1, 2.9 Hz, 1H), 6.66 (d, J=8.8 Hz, 1H),4.90 (dt, J=10.2, 3.4 Hz, 1H), 4.04-4.00 (m, 1H), 3.56 (dt, J=11.0, 3.2Hz, 1H), 3.37 (dd, J=11.0, 1.5 Hz, 1H), 2.65-2.57 (m, 1H), 2.25-2.13 (m,1H), 1.50-1.32 (m, 2H), 1.32-1.23 (m, 1H).

Example 109((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-11. MS (ESI): mass calcd. for C₂₀H₁₇BrFN₅O₂, 457.1. m/zfound, 458.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.88:0.12), major rotamer reported) δ 7.83 (s,2H), 7.79-7.76 (m, 1H), 7.75 (dt, J=8.2, 1.0 Hz, 1H), 7.63 (dd, J=8.8,2.5 Hz, 1H), 7.39-7.31 (m, 1H), 6.76-6.66 (m, 2H), 4.85 (dt, J=10.1, 3.4Hz, 1H), 4.01-3.92 (m, 1H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.42 (dd,J=10.9, 1.5 Hz, 1H), 2.64-2.58 (m, 1H), 2.24-2.14 (m, 1H), 1.42-1.31 (m,2H), 1.30-1.17 (m, 1H).

Example 110((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-23. MS (ESI): mass calcd. for C₂₂H₁₈BrFN₄O₂, 468.1. m/zfound, 469.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Chloroform-d,Compound present as a mixture of rotamers, (0.88:0.12), major rotamerreported) δ 8.79 (d, J=4.9 Hz, 2H), 7.93 (dd, J=10.0, 2.7 Hz, 1H), 7.86(dd, J=2.6, 0.6 Hz, 1H), 7.67 (dd, J=8.8, 2.6 Hz, 1H), 7.22 (t, J=4.9Hz, 1H), 7.04 (dd, J=8.4, 5.6 Hz, 1H), 6.70-6.64 (m, 2H), 4.93 (dt,J=10.1, 3.3 Hz, 1H), 4.09-4.04 (m, 1H), 3.63 (dt, J=10.9, 3.1 Hz, 1H),3.43-3.34 (m, 1H), 2.66-2.59 (m, 1H), 2.26-2.15 (m, 1H), 1.46-1.33 (m,2H), 1.31-1.23 (m, 1H).

Example 111((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 47 substituting intermediate A-6 withintermediate A-7. MS (ESI): mass calcd. for C₂₂H₁₈BrFN₄O₂, 468.1. m/zfound, 469.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.76 (d,J=4.9 Hz, 2H), 8.23 (dd, J=8.8, 5.6 Hz, 1H), 7.83 (dd, J=2.6, 0.7 Hz,1H), 7.68 (dd, J=8.8, 2.6 Hz, 1H), 7.18 (t, J=4.9 Hz, 1H), 7.08-7.02 (m,1H), 6.81 (dd, J=8.6, 2.7 Hz, 1H), 6.68 (d, J=8.8 Hz, 1H), 4.93 (dt,J=10.0, 3.3 Hz, 1H), 4.14-4.06 (m, 1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H),3.40 (dd, J=10.7, 1.5 Hz, 1H), 2.69-2.61 (m, 1H), 2.30-2.15 (m, 1H),1.47-1.35 (m, 2H), 1.34-1.24 (m, 1H).

Example 112(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (150 mg, 0.70 mmol) dissolved in DMF (5 mL) wasadded NaH (37 mg, 0.91 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 5-chloro-2-fluoropyridine (0.11 mL, 1.13 mmol) was then added andthe mixture heated to 70° C. After heating at 70° C. for 7 h, themixture was cooled to room temperature, quenched with saturated NH₄Clsolution, diluted with EtOAc and H₂O. The aqueous layer was extractedwith EtOAc (3×). The combined organics were washed with H₂O, 5% aqueousLiCl, brine, dried with Na₂SO₄, filtered, and concentrated. Purificationvia silica gel chromatography (0-25% EtOAc in hexanes) gave the titlecompound (149 mg, 0.46 mmol, 65%) as a colorless solid. MS (ESI) masscalcd. for C₁₆H₂₁ClN₂O₃, 324.1. m/z found 325.1 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, only majorrotamer reported) δ 8.06 (d, J=2.6 Hz, 1H), 7.51 (dd, J=8.8, 2.7 Hz,1H), 6.66 (d, J=8.7 Hz, 1H), 5.22 (dt, J=10.1, 3.2 Hz, 1H), 4.52-4.49(m, 1H), 3.38 (dt, J=9.6, 3.1 Hz, 1H), 3.18 (dd, J=9.5, 1.3 Hz, 1H),2.58-2.54 (m, 1H), 2.23-2.12 (m, 1H), 1.75-1.68 (m, 1H), 1.64-1.59 (m,1H), 1.36 (dt, J=13.4, 3.6 Hz, 1H), 1.15 (s, 9H).

Step B:(1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (149 mg, 0.46 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 3 h. Then, the reaction was concentrated to givethe title compound of step B (129 mg) as a colorless solid and usedwithout further purification. MS (ESI) mass calcd. for C₁₁H₁₃ClN₂O,224.1. m/z found 225.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (32 mg) and intermediate A-1 (25 mg,0.14 mmol) in DMF (1 mL) was added DIPEA (0.25 mL, 1.5 mmol) and HATU(51 mg, 0.135 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (34mg). MS (ESI): mass calcd. for C₂₀H₁₈ClN₅O₂, 395.1. m/z found, 396.1[M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture ofrotamers, (0.89:0.11), major rotamer reported) δ 7.85 (dd, J=8.2, 1.1Hz, 1H), 7.81 (s, 2H), 7.67 (d, J=2.6 Hz, 1H), 7.53 (dd, J=8.8, 2.7 Hz,1H), 7.40-7.34 (m, 1H), 7.07 (dd, J=7.6, 1.5 Hz, 1H), 6.91 (td, J=7.5,1.2 Hz, 1H), 6.69 (d, J=8.8 Hz, 1H), 4.90 (dt, J=10.1, 3.3 Hz, 1H),4.07-3.97 (m, 1H), 3.59 (dt, J=10.9, 3.2 Hz, 1H), 3.38 (dd, J=10.8, 1.4Hz, 1H), 2.65-2.56 (m, 1H), 2.26-2.12 (m, 1H), 1.42-1.34 (m, 2H),1.31-1.23 (m, 1H).

Example 113((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 112 substituting intermediate A-1 withintermediate A-10. MS (ESI): mass calcd. for C₂₀H₁₇ClFN₅O₂, 413.1. m/zfound, 414.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.92:0.08), major rotamer reported) δ 7.85-7.79(m, 3H), 7.72 (d, J=2.7 Hz, 1H), 7.56 (dd, J=8.8, 2.7 Hz, 1H), 7.11-7.01(m, 1H), 6.81 (dd, J=8.2, 2.9 Hz, 1H), 6.70 (d, J=8.7 Hz, 1H), 4.91 (dt,J=10.1, 3.4 Hz, 1H), 4.11-3.98 (m, 1H), 3.56 (dt, J=10.9, 3.2 Hz, 1H),3.37 (dd, J=10.9, 1.5 Hz, 1H), 2.68-2.56 (m, 1H), 2.26-2.13 (m, 1H),1.47-1.32 (m, 2H), 1.32-1.22 (m, 1H).

Example 114((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 112 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉ClN₆O₂, 410.1. m/zfound, 411.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.04 (d,J=8.4 Hz, 1H), 7.83 (s, 2H), 7.61 (d, J=2.7 Hz, 1H), 7.44 (dd, J=8.8,2.7 Hz, 1H), 7.14 (d, J=8.4 Hz, 1H), 6.70 (d, J=8.8 Hz, 1H), 4.83 (dt,J=10.2, 3.3 Hz, 1H), 4.22-4.14 (m, 1H), 3.65 (dt, J=10.9, 3.2 Hz, 1H),3.43 (dd, J=11.0, 1.4 Hz, 1H), 2.63-2.58 (m, 1H), 2.29 (s, 3H),2.23-2.13 (m, 1H), 1.48-1.32 (m, 3H).

Example 115((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 112 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₈ClFN₄O₂, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.84:0.16), major rotamer reported) δ 8.90 (d,J=4.9 Hz, 2H), 7.80 (d, J=2.8 Hz, 1H), 7.69 (dd, J=8.8, 2.7 Hz, 1H),7.49 (t, J=5.0 Hz, 1H), 7.26-7.18 (m, 1H), 7.14-7.05 (m, 1H), 6.95-6.81(m, 2H), 5.02 (dt, J=10.1, 3.3 Hz, 1H), 4.29-4.20 (m, 1H), 3.28-3.17 (m,2H), 2.59-2.50 (m, 1H), 2.29-2.17 (m, 1H), 1.52 (d, J=10.6 Hz, 1H), 1.33(dt, J=13.5, 3.6 Hz, 1H), 1.04-0.89 (m, 1H).

Example 116((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 112 substituting intermediate A-1 withintermediate A-34. MS (ESI): mass calcd. for C₂₂H₁₈ClFN₄O₂, 424.1. m/zfound, 425.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.81 (d,J=0.6 Hz, 2H), 8.21-8.15 (m, 1H), 7.73-7.67 (m, 2H), 7.44-7.39 (m, 1H),7.02-6.99 (m, 2H), 6.85 (d, J=8.7 Hz, 1H), 5.00 (dt, J=10.2, 3.3 Hz,1H), 4.13-4.06 (m, 1H), 3.60 (dt, J=11.0, 3.2 Hz, 1H), 3.34-3.32 (m,1H), 2.71-2.64 (m, 1H), 2.31-2.22 (m, 1H), 1.58-1.50 (m, 1H), 1.41 (dt,J=13.3, 3.6 Hz, 1H), 1.38-1.33 (m, 1H).

Example 117((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 112 substituting intermediate A-1 withintermediate A-35. MS (ESI): mass calcd. for C₂₂H₁₇ClF₂N₄O₂, 442.1. m/zfound, 443.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.82:0.18), major rotamer reported) δ 8.87 (d,J=0.7 Hz, 2H), 7.82 (dd, J=2.7, 0.7 Hz, 1H), 7.70 (dd, J=8.8, 2.7 Hz,1H), 7.24-7.18 (m, 1H), 7.13-7.06 (m, 1H), 6.93 (dd, J=7.6, 1.4 Hz, 1H),6.87 (dd, J=8.8, 0.7 Hz, 1H), 5.06 (dt, J=10.1, 3.3 Hz, 1H), 4.26-4.20(m, 1H), 3.26-3.20 (m, 1H), 2.61-2.57 (m, 1H), 2.31-2.22 (m, 1H),1.61-1.55 (m, 1H), 1.35 (dt, J=13.5, 3.6 Hz, 1H), 1.17-1.09 (m, 1H). 1Hburied under solvent peak.

Example 118(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) wasadded NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2,5-difluoropyridine (0.11 mL, 1.22 mmol) was then added and themixture heated to 60° C. After heating at 60° C. for 3 h, the mixturewas cooled to room temperature, quenched with saturated NH₄Cl solution,diluted with EtOAc and H₂O. The aqueous layer was extracted with EtOAc(3×). The combined organics were washed with H₂O, 5% aqueous LiCl,brine, dried with Na₂SO₄, filtered, and concentrated. Purification viasilica gel chromatography (0-30% EtOAc in hexanes) gave the titlecompound (193 mg, 0.63 mmol, 67%) as a colorless solid. MS (ESI) masscalcd. for C₁₆H₂₁FN₂O₃, 308.2. m/z found 309.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, only majorrotamer reported) δ 7.95 (d, J=3.1 Hz, 1H), 7.37-7.30 (m, 1H), 6.67 (dd,J=9.0, 3.6 Hz, 1H), 5.21 (dt, J=10.2, 3.2 Hz, 1H), 4.53-4.50 (m, 1H),3.39 (dt, J=9.6, 3.1 Hz, 1H), 3.19 (dd, J=9.5, 1.4 Hz, 1H), 2.58-2.53(m, 1H), 2.24-2.12 (m, 1H), 1.77-1.69 (m, 1H), 1.64-1.59 (m, 1H), 1.36(dt, J=13.4, 3.6 Hz, 1H), 1.15 (s, 9H).

Step B:(1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (193 mg, 0.63 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 2 h. The reaction was concentrated to give thetitle compound of step B (182 mg) as an off-white solid and used withoutfurther purification. MS (ESI) mass calcd. for C₁₁H₁₃FN₂O, 208.1. m/zfound 209.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (32 mg) and intermediate A-1 (27 mg,0.13 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(48 mg, 0.13 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (31mg). MS (ESI): mass calcd. for C₂₀H₁₈FN₅O₂, 379.1. m/z found, 380.2[M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture ofrotamers, (0.88:0.12), major rotamer reported) δ 7.85 (dd, J=8.2, 1.1Hz, 1H), 7.81 (s, 2H), 7.60 (d, J=3.1 Hz, 1H), 7.39-7.31 (m, 2H), 7.12(dd, J=7.7, 1.5 Hz, 1H), 6.92 (td, J=7.6, 1.2 Hz, 1H), 6.70 (dd, J=9.0,3.6 Hz, 1H), 4.91 (dt, J=10.1, 3.3 Hz, 1H), 4.04-3.95 (m, 1H), 3.59 (dt,J=10.9, 3.2 Hz, 1H), 3.38 (dd, J=11.0, 1.4 Hz, 1H), 2.65-2.58 (m, 1H),2.24-2.13 (m, 1H), 1.44-1.20 (m, 3H).

Example 119((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 118 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉FN₆O₂, 394.2. m/zfound, 395.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.03 (d,J=8.4 Hz, 1H), 7.82 (s, 2H), 7.53 (d, J=3.1 Hz, 1H), 7.29-7.22 (m, 1H),7.13 (d, J=8.4 Hz, 1H), 6.71 (dd, J=9.0, 3.7 Hz, 1H), 4.84 (dt, J=10.3,3.2 Hz, 1H), 4.19-4.15 (m, 1H), 3.65 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd,J=10.8, 1.4 Hz, 1H), 2.63-2.58 (m, 1H), 2.30 (s, 3H), 2.23-2.13 (m, 1H),1.47-1.33 (m, 3H).

Example 120(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 118 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₈F₂N₄O₂, 408.1. m/zfound, 409.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.89:0.11), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 7.70 (d, J=3.1 Hz, 1H), 7.40-7.32 (m, 1H), 7.28-7.27 (m,1H), 7.15-7.05 (m, 1H), 7.06-6.94 (m, 2H), 6.72 (dd, J=9.0, 3.6 Hz, 1H),4.98 (dt, J=10.0, 3.3 Hz, 1H), 4.26-4.15 (m, 1H), 3.35-3.26 (m, 2H),2.60-2.48 (m, 1H), 2.25-2.14 (m, 1H), 1.42 (d, J=10.3 Hz, 1H), 1.30 (dt,J=13.4, 3.5 Hz, 1H), 1.00-0.92 (m, 1H).

Example 121(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (200 mg, 0.94 mmol) dissolved in DMF (3 mL) wasadded NaH (41 mg, 1.03 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2-chloro-5-(difluoromethyl)pyridine (0.15 mL, 1.22 mmol) was thenadded and the mixture heated to 60° C. After heating at 60° C. for 3 h,the mixture was cooled to room temperature, quenched with saturatedNH₄Cl solution, diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (3×). The combined organics were washed with H₂O,5% aqueous LiCl, brine, dried with Na₂SO₄, filtered, and concentrated.Purification via silica gel chromatography (0-20% EtOAc in hexanes) gavethe title compound (76 mg, 0.22 mmol, 24%) as a colorless solid. MS(ESI) mass calcd. for C₁₂H₂₂F₂N₂O₃, 340.2. m/z found 341.2 [M+H]⁺. ¹HNMR (400 MHz, Chloroform-d, Compound present as a mixture of rotamers,only major rotamer reported) δ 8.27-8.23 (m, 1H), 7.72 (dd, J=8.7, 2.5Hz, 1H), 6.83-6.46 (m, 2H), 5.32 (dt, J=10.1, 3.2 Hz, 1H), 4.57-4.52 (m,1H), 3.40 (dt, J=9.6, 3.1 Hz, 1H), 3.20 (dd, J=9.5, 1.3 Hz, 1H),2.61-2.55 (m, 1H), 2.26-2.15 (m, 1H), 1.77-1.71 (m, 1H), 1.67-1.60 (m,1H), 1.40 (dt, J=13.5, 3.8 Hz, 1H), 1.12 (s, 9H).

Step B:(1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (76 mg, 0.22 mmol) in EtOAc (4 mL) wasadded 4M HCl in dioxane (1 mL) and the reaction mixture was stirred atroom temperature for 2 h. The reaction was concentrated to give thetitle compound of step B (74 mg) as an off-white solid and used withoutfurther purification. MS (ESI) mass calcd. for C₁₂H₁₄F₂N₂O, 240.1. m/zfound 241.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (24 mg) and intermediate A-1 (20 mg,0.095 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(36 mg, 0.095 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (29mg). MS (ESI): mass calcd. for C₂₁H₁₉F₂N₅O₂, 411.2. m/z found, 412.2[M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present as a mixture ofrotamers, (0.89:0.11), major rotamer reported) δ 7.88-7.85 (m, 1H), 7.83(dd, J=8.3, 1.1 Hz, 1H), 7.81 (s, 2H), 7.77-7.70 (m, 1H), 7.34-7.28 (m,1H), 7.05 (dd, J=7.6, 1.5 Hz, 1H), 6.85-6.79 (m, 2H), 6.60 (t, J=56.0Hz, 1H), 5.00 (dt, J=10.2, 3.3 Hz, 1H), 4.09-3.99 (m, 1H), 3.60 (dt,J=11.0, 3.2 Hz, 1H), 3.40 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.56 (m, 1H),2.28-2.13 (m, 1H), 1.44-1.35 (m, 2H), 1.33-1.25 (m, 1H).

Example 122((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 121 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₁H₂₀F₂N₆O₂, 426.2. m/zfound, 427.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.86:0.14), major rotamer reported) δ 8.01 (d,J=8.4 Hz, 1H), 7.87-7.81 (m, 3H), 7.64 (dd, J=8.7, 2.4 Hz, 1H), 7.06 (d,J=8.4 Hz, 1H), 6.81 (d, J=8.6 Hz, 1H), 6.57 (t, J=56.0 Hz, 1H), 4.95(dt, J=10.4, 3.3 Hz, 1H), 4.25-4.17 (m, 1H), 3.67 (dt, J=11.0, 3.2 Hz,1H), 3.46 (dd, J=11.0, 1.4 Hz, 1H), 2.68-2.61 (m, 1H), 2.27-2.16 (m,4H), 1.50-1.40 (m, 3H).

Example 123((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 121 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₉F₃N₄O₂, 440.1. m/zfound, 441.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, (0.88:0.12), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 7.98-7.92 (m, 1H), 7.75 (dd, J=8.6, 2.4 Hz, 1H),7.29-7.26 (m, 1H), 7.09-7.02 (m, 1H), 6.96-6.88 (m, 2H), 6.83 (d, J=8.6Hz, 1H), 6.61 (t, J=55.9 Hz, 1H), 5.07 (dt, J=10.1, 3.3 Hz, 1H),4.27-4.20 (m, 1H), 3.35-3.28 (m, 2H), 2.59-2.51 (m, 1H), 2.25-2.12 (m,1H), 1.43 (d, J=10.3 Hz, 1H), 1.35 (dt, J=13.5, 3.5 Hz, 1H), 1.01-0.89(m, 1H).

Example 124(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (125 mg, 0.59 mmol) dissolved in DMF (5 mL) wasadded NaH (47 mg, 1.17 mmol, 60% dispersion in mineral oil). After 5minutes the sides of the flask were rinsed with additional DMF (1 mL)and 2-chloro-5-(trifluoromethyl)pyrazine (0.12 mL, 0.94 mmol) was thenadded and the reaction mixture stirred overnight at room temperature.Then, the mixture was quenched with saturated NH₄Cl solution, dilutedwith EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, 5% aqueous LiCl, brine, driedwith Na₂SO₄, filtered, and concentrated. Purification via silica gelchromatography (0-40% EtOAc in hexanes) gave the title compound (89 mg,0.25 mmol, 42%) as a colorless solid. MS (ESI) mass calcd. forC₁₆H₂₀F₃N₃O₃, 359.2. m/z found 304.0 [M+2H-tBu]⁺. ¹H NMR (500 MHz,Methanol-d₄) δ 8.60 (s, 1H), 8.35-8.26 (m, 1H), 5.49-5.39 (m, 1H),4.59-4.53 (m, 1H), 3.39 (dt, J=9.6, 3.2 Hz, 1H), 3.15 (d, J=9.5 Hz, 1H),2.67-2.62 (m, 1H), 2.37-2.22 (m, 1H), 1.80-1.73 (m, 3H), 1.08 (s, 9H).

Step B:(1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (89 mg, 0.25 mmol) in EtOAc (3 mL) wasadded 4M HCl in dioxane (0.3 mL) and the reaction mixture was stirred atroom temperature overnight. The reaction was concentrated to give thetitle compound of step B (80 mg) as a yellow oil and used withoutfurther purification. MS (ESI) mass calcd. for C₁₁H₁₂F₃N₃O, 259.1. m/zfound 260.1 [M+H]⁺.

Step C:(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (24 mg) and intermediate A-10 (20 mg,0.097 mmol) in DMF (1 mL) was added DIPEA (84 μL, 0.49 mmol) and HATU(34 mg, 0.089 mmol), and the reaction mixture was stirred at roomtemperature overnight. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Gilson Prep Method X to give the title compound (17 mg).MS (ESI): mass calcd. for C₂₀H₁₆F₄N₆O₂, 448.1. m/z found, 449.1 [M+H]⁺.¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers,(0.83:0.17), major rotamer reported) δ 8.40 (s, 1H), 8.23 (s, 1H), 7.96(s, 2H), 7.90 (dd, J=9.0, 4.7 Hz, 1H), 7.22-7.14 (m, 1H), 6.87 (d, J=8.1Hz, 1H), 5.10 (dt, J=10.2, 3.3 Hz, 1H), 4.02 (s, 1H), 3.52 (dt, J=10.9,3.3 Hz, 1H), 3.35 (dd, J=11.1, 1.6 Hz, 1H), 2.71-2.63 (m, 1H), 2.35-2.24(m, 1H), 1.59-1.51 (m, 1H), 1.49 (dt, J=13.5, 3.7 Hz, 1H), 1.46-1.21 (m,1H).

Example 125(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₈F₃N₇O₂, 445.1. m/zfound, 446.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.90:0.10), major rotamer reported) δ 8.28 (d,J=1.3 Hz, 1H), 8.19-8.14 (m, 2H), 8.00 (s, 2H), 7.29 (d, J=8.5 Hz, 1H),5.08 (dt, J=10.4, 3.2 Hz, 1H), 4.25-4.20 (m, 1H), 3.61 (dt, J=11.0, 3.2Hz, 1H), 3.41 (dd, J=11.0, 1.6 Hz, 1H), 2.75-2.67 (m, 1H), 2.36-2.27 (m,1H), 2.22 (s, 3H), 1.66-1.59 (m, 1H), 1.60-1.49 (m, 2H).

Example 126(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₅O₂, 459.1. m/zfound, 460.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.76:0.24), major rotamer reported) δ 8.91 (d,J=5.0 Hz, 2H), 8.42 (d, J=1.3 Hz, 1H), 8.26-8.23 (m, 1H), 7.50 (t, J=5.0Hz, 1H), 7.21-7.15 (m, 1H), 7.07-7.00 (m, 1H), 6.95 (dd, J=7.6, 1.2 Hz,1H), 5.14 (dt, J=10.2, 3.3 Hz, 1H), 4.33-4.24 (m, 1H), 3.29-3.27 (m,2H), 2.63-2.56 (m, 1H), 2.34-2.25 (m, 1H), 1.56 (d, J=11.1 Hz, 1H), 1.44(dt, J=13.7, 3.6 Hz, 1H), 1.05-0.91 (m, 1H).

Example 127(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-23. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₅O₂, 459.1. m/zfound, 460.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.80:0.20), major rotamer reported) δ 8.88 (d,J=4.9 Hz, 2H), 8.40 (s, 1H), 8.20 (s, 1H), 7.92 (dd, J=10.1, 2.7 Hz,1H), 7.46-7.41 (m, 1H), 7.08 (dd, J=8.4, 5.5 Hz, 1H), 6.66 (td, J=8.2,2.7 Hz, 1H), 5.09 (dt, J=10.2, 3.3 Hz, 1H), 4.11 (s, 1H), 3.60 (dt,J=11.0, 3.2 Hz, 1H), 3.36 (dd, J=11.0, 1.6 Hz, 1H), 2.74-2.65 (m, 1H),2.35-2.27 (m, 1H), 1.56-1.47 (m, 2H), 1.35-1.27 (m, 1H).

Example 128(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-7. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₅O₂, 459.1. m/zfound, 460.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 8.40 (s, 1H), 8.26 (dd, J=8.8, 5.5 Hz, 1H), 8.22 (s, 1H),7.39 (t, J=4.9 Hz, 1H), 7.15-7.09 (m, 1H), 6.78 (dd, J=8.6, 2.7 Hz, 1H),5.11 (dt, J=10.2, 3.4 Hz, 1H), 4.14 (s, 1H), 3.61 (dt, J=11.0, 3.2 Hz,1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.74-2.66 (m, 1H), 2.36-2.26 (m,1H), 1.58-1.54 (m, 1H), 1.52 (dt, J=13.6, 3.6 Hz, 1H), 1.40-1.33 (m,1H).

Example 129(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-6. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₅O₂, 459.1. m/zfound, 460.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.74:0.26), major rotamer reported) δ 8.88 (d,J=4.9 Hz, 2H), 8.35-8.33 (m, 1H), 8.17-8.12 (m, 2H), 7.43 (t, J=4.9 Hz,1H), 7.41-7.35 (m, 1H), 6.70-6.64 (m, 1H), 5.07 (dt, J=10.2, 3.4 Hz,1H), 4.13-4.10 (m, 1H), 3.64 (dt, J=11.0, 3.2 Hz, 1H), 3.39 (dd, J=11.0,1.6 Hz, 1H), 2.72-2.68 (m, 1H), 2.36-2.27 (m, 1H), 1.87-1.83 (m, 1H),1.55-1.53 (m, 1H), 1.32-1.25 (m, 1H).

Example 130(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 124 substituting intermediate A-10 withintermediate A-37. MS (ESI): mass calcd. for C₂₂H₁₈F₃N₅O₂, 441.1. m/zfound, 442.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, (0.85:0.15), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.38 (s, 1H), 8.16 (dd, J=8.0, 1.2 Hz, 1H), 8.11 (s, 1H),7.44-7.33 (m, 2H), 7.01 (dd, J=7.7, 1.4 Hz, 1H), 6.91 (t, J=7.5, 1.3 Hz,1H), 5.08 (dt, J=10.2, 3.3 Hz, 1H), 4.12 (s, 1H), 3.58 (dt, J=10.9, 3.2Hz, 1H), 3.37 (dd, J=10.9, 1.6 Hz, 1H), 2.73-2.66 (m, 1H), 2.35-2.22 (m,1H), 1.56-1.48 (m, 2H), 1.28-1.21 (m, 1H).

Example 131(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (106 mg, 0.497 mmol) and 2-chloro-5-methylpyrimidine(93 mg, 0.72 mmol) dissolved in DMF (2 mL) was added NaH (40 mg, 0.99mmol, 60% dispersion in mineral oil), and the reaction mixture wasstirred at room temperature for 2 h. Then, the mixture was quenched withH₂O, diluted with EtOAc and the aqueous layer extracted with EtOAc (3×).The combined organics were washed with H₂O, 5% aqueous LiCl, brine,dried with Na₂SO₄, filtered, and concentrated. Purification of theconcentrate via silica gel chromatography (0-60% EtOAc in hexanes) gavethe title compound (129 mg, 0.422 mmol, 85%) as a colorless solid. MS(ESI) mass calcd. for C₁₆H₂₃N₃O₃, 305.2. m/z found 306.2 [M+H]⁺. ¹H NMR(500 MHz, Chloroform-d, Compound present as a mixture of rotamers(0.68:0.32), major rotamer reported) δ 8.29 (s, 2H), 5.22-5.14 (m, 1H),4.59-4.51 (m, 1H), 3.37 (dt, J=9.5, 3.1 Hz, 1H), 3.20 (dd, J=9.4, 1.4Hz, 1H), 2.55-2.51 (m, 1H), 2.21 (s, 3H), 2.17-2.11 (m, 1H), 1.69-1.67(m, 1H), 1.63-1.59 (m, 1H), 1.54-1.47 (m, 1H), 1.07 (s, 9H).

Step B:(1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (129 mg, 0.422 mmol) in EtOAc (2 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 1 h. The reaction was concentrated to give thetitle compound of step B (147 mg) as a colorless solid and used withoutfurther purification. MS (ESI) mass calcd. for C₁₁H₁₅N₃O, 205.1. m/zfound 206.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (34 mg) and intermediate A-1 (29 mg,0.16 mmol) in DMF (0.8 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(59 mg, 0.16 mmol), and the reaction mixture was stirred at roomtemperature for 6 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (3×). The combinedorganics were washed with H₂O, 5% aqueous LiCl, brine, dried withNa₂SO₄, filtered, and concentrated. Purification of the concentrate wasperformed using Agilent Prep Method X to give the title compound (20mg). MS (ESI): mass calcd. for C₂₀H₂₀N₆O₂, 376.2. m/z found, 377.2[M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture ofrotamers (0.78:0.22), major rotamer reported) δ 8.11 (s, 2H), 7.83 (dd,J=8.2, 1.1 Hz, 1H), 7.80 (s, 2H), 7.30-7.26 (m, 1H), 7.20 (dd, J=7.7,1.5 Hz, 1H), 6.82 (t, J=7.6 Hz, 1H), 4.92 (dt, J=10.2, 3.3 Hz, 1H),4.15-3.99 (m, 1H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.41 (d, J=10.8 Hz,1H), 2.65-2.60 (m, 1H), 2.24-2.20 (m, 4H), 1.53 (dt, J=13.5, 3.4 Hz,1H), 1.41 (d, J=3.2 Hz, 2H).

Example 132(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 131 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₂₁N₇O₂, 391.2. m/zfound, 392.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.74:0.26), major rotamer reported) δ 8.04 (d,J=8.4 Hz, 1H), 8.03 (d, J=0.9 Hz, 2H), 7.80 (s, 2H), 7.07 (d, J=8.4 Hz,1H), 4.81 (dt, J=10.3, 3.4 Hz, 1H), 4.38-4.29 (m, 1H), 3.72 (dt, J=10.9,3.2 Hz, 1H), 3.46 (dd, J=10.9, 1.5 Hz, 1H), 2.67-2.65 (m, 1H), 2.25 (s,3H), 2.24-2.19 (m, 1H), 2.16 (s, 3H), 1.66-1.61 (m, 1H), 1.57-1.52 (m,1H), 1.51-1.47 (m, 1H).

Example 133(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 131 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₂₀FN₅O₂, 405.2. m/zfound, 406.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.75:0.25), major rotamer reported) δ 8.83 (d,J=4.9 Hz, 2H), 8.18 (d, J=0.9 Hz, 2H), 7.26-7.24 (m, 1H), 7.08 (dd,J=7.5, 1.2 Hz, 1H), 7.05-7.00 (m, 1H), 6.95-6.91 (m, 1H), 5.00 (dt,J=10.2, 3.3 Hz, 1H), 4.31-4.22 (m, 1H), 3.36-3.32 (m, 2H), 2.61-2.50 (m,1H), 2.22 (s, 3H), 1.52-1.41 (m, 2H), 1.12-1.07 (m, 1H). 1H buried underwater peak.

Example 134(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 131 substituting intermediate A-1 withintermediate A-47. MS (ESI): mass calcd. for C₂₂H₂₂N₆O₂, 402.2. m/zfound, 403.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.60:0.40), major rotamer reported) δ 8.76 (d,J=4.8 Hz, 2H), 8.28 (dd, J=2.2, 0.8 Hz, 1H), 8.03 (d, J=0.9 Hz, 2H),7.81 (dd, J=2.2, 0.8 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 4.88 (dt, J=10.3,3.4 Hz, 1H), 4.45-4.38 (m, 1H), 3.76 (dt, J=10.8, 3.2 Hz, 1H), 3.45 (dd,J=10.7, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.31 (s, 3H), 2.20 (s, 3H),1.74-1.53 (m, 3H). 1H buried under solvent.

Example 135(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (120 mg, 0.563 mmol) and 2-chloro-5-ethylpyrimidine(128 mg, 0.9 mmol), dissolved in DMF (4 mL), was added NaH (29 mg, 0.73mmol, 60% dispersion in mineral oil) and the mixture stirred at roomtemperature for 1 h. The reaction mixture was quenched with H₂O, dilutedwith EtOAc and the aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, 5% aqueous LiCl, brine, driedwith Na₂SO₄, filtered, and concentrated. Purification of the concentratevia silica gel chromatography (0-50% EtOAc in hexanes) gave the titlecompound (160 mg, 0.501 mmol, 89%) as a colorless solid. MS (ESI) masscalcd. for C₁₂H₂₅N₃O₃, 319.2. m/z found 320.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers, only majorrotamer reported) δ 8.34 (s, 2H), 5.21 (dt, J=10.3, 3.4 Hz, 1H),4.60-4.55 (m, 1H), 3.40 (dt, J=9.5, 3.1 Hz, 1H), 3.23 (dd, J=9.5, 1.4Hz, 1H), 2.61-2.55 (m, 3H), 2.22-2.15 (m, 1H), 1.75-1.69 (m, 1H),1.65-1.62 (m, 1H), 1.55 (dt, J=13.5, 3.8 Hz, 1H), 1.25-1.22 (m, 3H),1.09 (s, 9H).

Step B:(1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (160 mg, 0.501 mmol) in EtOAc (1.5 mL)was added 4M HCl in dioxane (4 mL) and the reaction mixture was stirredat room temperature for 1 h. Then, the reaction was concentrated to givethe title compound of step B (148 mg) as a colorless solid and usedwithout further purification. MS (ESI) mass calcd. for C₁₂H₁₂N₃O, 219.1.m/z found 220.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (37 mg) and intermediate A-1 (30 mg,0.16 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.6 mmol) and HATU (61mg, 0.16 mmol), and the reaction mixture was stirred at room temperaturefor 1 h. The reaction was quenched by the addition of H₂O and theaqueous layer was extracted with EtOAc (3×). The combined organics wereconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (33 mg). MS (ESI): masscalcd. for C₂₁H₂₂N₆O₂, 390.2. m/z found, 391.2 [M+H]⁺. ¹H NMR (400 MHz,Chloroform-d, Compound present as a mixture of rotamers (0.81:0.19),only major rotamer reported) δ 8.14-7.16 (m, 7H), 6.79 (t, J=7.6 Hz,1H), 4.92 (dt, J=10.3, 3.3 Hz, 1H), 4.05 (s, 1H), 3.62 (dt, J=10.9, 3.2Hz, 1H), 3.41 (d, J=10.8 Hz, 1H), 2.65-2.59 (m, 1H), 2.54 (q, J=7.6 Hz,2H), 2.28-2.12 (m, 1H), 1.85-1.76 (m, 1H), 1.70-1.63 (m, 1H), 1.53 (dt,J=13.3, 3.2 Hz, 1H), 1.26 (t, J=7.6 Hz, 3H).

Example 136((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 135 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₁H₂₃N₇O₂, 405.2. m/zfound, 406.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.69:0.31), only major rotamer reported) δ8.08-8.01 (m, 3H), 7.80 (s, 2H), 7.05 (d, J=8.5 Hz, 1H), 4.82 (dt,J=10.3, 3.4 Hz, 1H), 4.47-4.30 (m, 1H), 3.73 (dt, J=10.8, 3.2 Hz, 1H),3.47 (dd, J=10.9, 1.5 Hz, 1H), 2.70-2.65 (m, 1H), 2.55-2.45 (m, 2H),2.27-2.16 (m, 4H), 1.65 (dt, J=13.3, 3.7 Hz, 1H), 1.64-1.47 (m, 2H),1.27-1.18 (m, 3H).

Example 137((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 135 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₂FN₅O₂, 419.2. m/zfound, 420.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.78:0.22), only major rotamer reported) δ 8.84(d, J=4.9 Hz, 2H), 8.20 (s, 2H), 7.07 (dd, J=7.5, 1.2 Hz, 1H), 7.01-6.97(m, 1H), 6.94-6.89 (m, 1H), 5.00 (dt, J=10.1, 3.3 Hz, 1H), 4.31-4.22 (m,1H), 3.37-3.29 (m, 2H), 2.57 (q, J=7.6 Hz, 3H), 2.25-2.16 (m, 1H),1.53-1.44 (m, 2H), 1.27 (t, J=7.6 Hz, 3H), 1.15-1.06 (m, 1H). 1H buriedunder solvent.

Example 138((1S,4R,6R)-6-((5-ethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 135 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₃H₂₄N₆O₂, 416.2. m/zfound, 417.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.63:0.37), only major rotamer reported) δ 8.74(d, J=4.8 Hz, 2H), 8.38 (d, J=8.1 Hz, 1H), 8.00 (s, 2H), 7.17 (t, J=4.8Hz, 1H), 7.04 (d, J=8.2 Hz, 1H), 4.81 (dt, J=10.4, 3.4 Hz, 1H),4.51-4.46 (m, 1H), 3.80 (dt, J=10.8, 3.2 Hz, 1H), 3.47 (dd, J=10.6, 1.4Hz, 1H), 2.72-2.66 (m, 1H), 2.48 (q, J=7.6 Hz, 2H), 2.28-2.17 (m, 4H),1.67 (dt, J=13.3, 3.7 Hz, 1H), 1.61-1.54 (m, 2H), 1.21 (t, J=7.7 Hz,3H).

Example 139(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (106 mg, 0.457 mmol) and3-chloro-6-(trifluoromethyl)pyridazine (120 mg, 0.66 mmol) dissolved inDMF (2 mL) was added NaH (40 mg, 0.99 mmol, 60% dispersion in mineraloil), and the reaction mixture was stirred at room temperature for 2 h.Then, the mixture was quenched with saturated NH₄Cl solution, dilutedwith EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, 5% aqueous LiCl, brine, driedwith Na₂SO₄, filtered, and concentrated. Purification of the concentratevia silica gel chromatography (0-50% EtOAc in hexanes) gave the titlecompound (189 mg) as an off-white solid. MS (ESI) mass calcd. forC₁₆H₂₀F₃N₃O₃, 359.2. m/z found 304.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz,Chloroform-d, Compound present as a mixture of rotamers, (0.74:0.26),major rotamer reported) δ 7.70 (d, J=9.2 Hz, 1H), 7.07 (d, J=9.2 Hz,1H), 5.59 (dt, J=10.1, 3.1 Hz, 1H), 4.76-4.67 (m, 1H), 3.43 (dt, J=9.6,3.1 Hz, 1H), 3.23-3.17 (m, 1H), 2.64-2.60 (m, 1H), 2.34-2.26 (m, 1H),1.81-1.76 (m, 1H), 1.68-1.65 (m, 1H), 1.50-1.45 (m, 1H), 1.10 (s, 9H).

Step B:(1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (189 mg, 0.53 mmol) in EtOAc (2 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 6 h. The reaction was concentrated to give thetitle compound of step B (146 mg) as an off-white solid and used withoutfurther purification. MS (ESI) mass calcd. for C₁₁H₁₂F₃N₃O, 259.1. m/zfound 260.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (34 mg) and intermediate A-1 (24 mg,0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(48 mg, 0.126 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. Analysis of the reaction mixture showed unreactedstarting material and additional intermediate A-1 (10 mg) was added. Thereaction mixture was stirred for an additional 15 minutes at roomtemperature. The reaction was then quenched by the addition of H₂O andthe aqueous layer was extracted with EtOAc (3×). The combined organicswere concentrated and subjected directly to purification using AgilentPrep Method X to give the title compound (33 mg). MS (ESI): mass calcd.for C₂₀H₁₇F₃N₆O₂, 430.1. m/z found, 431.2 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.08 min (major rotamer) at 254 nm.

Example 140(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 139 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₈F₃N₇O₂, 445.1. m/zfound, 446.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.82:0.18), major rotamer reported) δ 8.04 (d,J=8.4 Hz, 1H), 7.81 (s, 2H), 7.62 (d, J=9.1 Hz, 1H), 7.15 (dd, J=9.2,0.7 Hz, 1H), 7.11 (d, J=8.5 Hz, 1H), 5.31 (dt, J=10.1, 3.3 Hz, 1H),4.46-4.41 (m, 1H), 3.70 (dt, J=11.0, 3.2 Hz, 1H), 3.47 (dd, J=11.0, 1.5Hz, 1H), 2.73-2.68 (m, 1H), 2.37-2.28 (m, 1H), 2.23 (s, 3H), 1.63-1.58(m, 1H), 1.57-1.49 (m, 2H).

Example 141(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 139 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₅O₂, 459.1. m/zfound, 460.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 7.73 (d, J=9.2 Hz, 1H), 7.28 (t, J=4.9 Hz, 1H), 7.15 (dd,J=9.2, 0.7 Hz, 1H), 7.12-7.09 (m, 1H), 7.09-7.04 (m, 1H), 6.98 (dd,J=7.5, 1.3 Hz, 1H), 5.39 (dt, J=9.9, 3.3 Hz, 1H), 4.40-4.31 (m, 1H),3.41-3.33 (m, 1H), 3.32 (dd, J=11.0, 1.3 Hz, 1H), 2.66-2.57 (m, 1H),2.41-2.33 (m, 1H), 1.53-1.48 (m, 1H), 1.38 (dt, J=13.7, 3.6 Hz, 1H),1.20-1.10 (m, 1H).

Example 142(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 139 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₂H₁₉F₃N₆O₂, 456.2. m/zfound, 457.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.78:0.22), major rotamer reported) δ 8.77 (d,J=4.8 Hz, 2H), 8.39 (d, J=8.1 Hz, 1H), 7.64 (d, J=9.2 Hz, 1H), 7.23-7.19(m, 2H), 7.09 (d, J=8.1 Hz, 1H), 5.34 (dt, J=10.1, 3.3 Hz, 1H),4.47-4.42 (m, 1H), 3.75 (dt, J=10.9, 3.2 Hz, 1H), 3.49 (dd, J=10.8, 1.3Hz, 1H), 2.75-2.70 (m, 1H), 2.38-2.28 (m, 1H), 2.20 (s, 3H), 1.58-1.51(m, 3H).

Example 143(6-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-3. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₇O, 443.2. m/zfound, 444.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=5.80 min(major rotamer) at 254 nm.

Example 144(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-16. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O, 446.1. m/zfound, 447.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-4 Compound present as amixture of rotamers, major rotamer reported) δ 8.00 (s, 2H), 7.91 (s,1H), 7.58 (dd, J=8.9, 2.6 Hz, 1H), 7.23-7.16 (m, 1H), 6.92-6.84 (m, 1H),6.80 (d, J=7.6 Hz, 1H), 6.64-6.53 (m, 1H), 4.15-3.93 (m, 2H), 3.27-3.18(m, 2H), 2.56-2.50 (m, 1H), 2.28-2.14 (m, 1H), 1.55 (d, J=10.2 Hz, 1H),1.29-1.09 (m, 2H).

Example 145(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-12. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O, 446.1. m/zfound, 447.1 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5 um,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min andthen hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min(Temperature=45° C.). R_(t)=2.05 min at 254 nm.

Example 146(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-11. MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O, 446.1. m/zfound, 447.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 7.98 (s, 2H), 7.78 (s,1H), 7.75 (dt, J=8.3, 0.9 Hz, 1H), 7.56 (dd, J=8.8, 2.4 Hz, 1H),7.35-7.27 (m, 1H), 6.66-6.56 (m, 1H), 6.49 (t, J=8.6 Hz, 1H), 3.98-3.89(m, 1H), 3.88-3.82 (m, 1H), 3.49 (dt, J=11.0, 3.2 Hz, 1H), 3.34-3.32 (m,1H), 2.63-2.55 (m, 1H), 2.27-2.15 (m, 1H), 1.44 (d, J=10.1 Hz, 1H),1.32-1.19 (m, 2H).

Example 147(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-6. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O, 457.2. m/zfound, 458.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H),8.06 (dd, J=7.9, 1.0 Hz, 1H), 7.83-7.73 (m, 1H), 7.56 (dd, J=8.9, 2.4Hz, 1H), 7.41 (t, J=4.9 Hz, 1H), 7.31-7.24 (m, 1H), 6.66-6.59 (m, 1H),6.58-6.53 (m, 1H), 3.99-3.90 (m, 2H), 3.55 (dt, J=10.9, 3.2 Hz, 1H),3.35-3.32 (m, 1H), 2.64-2.58 (m, 1H), 2.26-2.16 (m, 1H), 1.44 (d, J=10.4Hz, 1H), 1.33-1.26 (m, 1H), 1.19-1.13 (m, 1H).

Example 148(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-37. MS (ESI): mass calcd. for C₂₃H₂₀F₃N₅O, 439.2. m/zfound, 440.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d,J=4.9 Hz, 2H), 8.13 (dd, J=7.9, 1.2 Hz, 1H), 7.87-7.78 (m, 1H),7.65-7.54 (m, 1H), 7.38 (t, J=4.9 Hz, 1H), 7.29 (td, J=7.7, 1.4 Hz, 1H),6.98-6.87 (m, 1H), 6.87-6.76 (m, 1H), 6.66-6.49 (m, 1H), 4.08-3.92 (m,1H), 3.52 (dt, J=10.9, 3.3 Hz, 1H), 2.66-2.59 (m, 1H), 2.30-2.19 (m,1H), 1.54-1.45 (m, 1H), 1.35-1.19 (m, 3H). 1H buried under solvent peak.

Example 149(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-47. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O, 454.2. m/zfound, 455.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.89:0.11), only major rotamer reported) δ 8.82(d, J=4.9 Hz, 2H), 8.41-8.37 (m, 1H), 8.33 (dd, J=2.1, 0.9 Hz, 1H),8.26-8.22 (m, 1H), 7.70-7.58 (m, 1H), 7.45 (dd, J=8.9, 2.5 Hz, 1H), 7.28(t, J=4.9 Hz, 1H), 6.38 (d, J=8.8 Hz, 1H), 4.32-4.28 (m, 1H), 4.22-4.11(m, 1H), 3.72 (dt, J=10.9, 3.2 Hz, 1H), 3.32 (dd, J=10.9, 1.5 Hz, 1H),2.83-2.72 (m, 1H), 2.46-2.36 (m, 4H), 1.94-1.87 (m, 1H), 1.71 (d, J=10.0Hz, 1H), 1.20 (dt, J=13.0, 3.5 Hz, 1H).

Example 150(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O, 454.2. m/zfound, 455.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.91:0.09), only major rotamer reported) δ 8.79(d, J=4.9 Hz, 2H), 8.45 (d, J=8.1 Hz, 1H), 8.31-8.23 (m, 1H), 7.70-7.59(m, 1H), 7.47 (dd, J=8.8, 2.5 Hz, 1H), 7.29 (d, J=8.1 Hz, 1H), 7.24 (t,J=4.9 Hz, 1H), 6.44 (d, J=8.8 Hz, 1H), 4.26-4.21 (m, 1H), 4.13 (s, 1H),3.73 (dt, J=10.8, 3.2 Hz, 1H), 3.31 (dd, J=10.8, 1.5 Hz, 1H), 2.82-2.73(m, 1H), 2.62 (s, 3H), 2.51-2.37 (m, 1H), 1.98-1.85 (m, 1H), 1.70 (d,J=10.2 Hz, 1H), 1.20 (dt, J=13.5, 3.5 Hz, 1H).

Example 151(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-46. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O, 454.2. m/zfound, 455.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=5.33 min(major rotamer) at 254 nm.

Example 152(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-51. MS (ESI): mass calcd. for C₂₂H₁₉F₄N₅O₂, 461.1. m/zfound, 462.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 7.84 (s, 1H), 7.70 (dd,J=9.1, 2.6 Hz, 1H), 7.59-7.53 (m, 1H), 7.02 (dd, J=8.5, 5.3 Hz, 1H),6.72 (td, J=8.2, 2.6 Hz, 1H), 6.62-6.47 (m, 1H), 4.06-3.97 (m, 2H), 3.61(dt, J=11.1, 3.2 Hz, 1H), 3.41-3.35 (m, 1H), 2.76-2.67 (m, 1H), 2.44 (s,3H), 2.34-2.23 (m, 1H), 1.74-1.60 (m, 2H), 1.35-1.26 (m, 1H).

Example 153(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

To the title compound of example 53 (10 mg, 0.023 mmol) dissolved in DMF(0.5 mL) was added NaOtBu (2.5 mg, 0.026 mmol). After 5 minutes, MeI(1.5 μL, 0.025 mmol) was added and the reaction mixture as stirred atroom temperature overnight. Then, the mixture was diluted with EtOAc andH₂O. The aqueous layer was extracted with EtOAc (2×). The combinedorganics were washed with H₂O, dried with Na₂SO₄, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (3 mg) as a brownsolid. MS (ESI): mass calcd. for C₂₂H₂₁F₃N₆O, 442.2. m/z found, 443.1[M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.91:0.09), major rotamer reported) δ 8.06 (s, 1H), 7.95 (s,2H), 7.80 (d, J=8.3 Hz, 1H), 7.68-7.60 (m, 1H), 7.35-7.25 (m, 1H),7.00-6.90 (m, 1H), 6.82-6.75 (m, 1H), 6.65 (d, J=8.9 Hz, 1H), 4.58-4.46(m, 1H), 3.88 (s, 1H), 3.49-3.42 (m, 2H), 3.11 (s, 3H), 2.69 (s, 1H),2.09-1.98 (m, 1H), 1.99-1.88 (m, 1H), 1.49 (d, J=9.9 Hz, 1H), 1.27-1.17(m, 1H).

Example 154(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-16 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₂H₂₀F₄N₆O, 460.2. m/z found, 461.1 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.86:0.14), major rotamer reported) δ 7.98 (s, 3H), 7.76-7.70 (m, 1H),7.65 (dd, J=9.1, 2.5 Hz, 1H), 7.33-7.26 (m, 1H), 6.70 (d, J=9.1 Hz, 1H),6.59-6.50 (m, 1H), 4.49-4.40 (m, 1H), 3.99-3.93 (m, 1H), 3.51 (dt,J=11.4, 3.0 Hz, 1H), 3.43 (dd, J=11.4, 1.6 Hz, 1H), 3.09 (d, J=1.3 Hz,3H), 2.69 (s, 1H), 2.08-1.93 (m, 2H), 1.46 (d, J=9.7 Hz, 1H), 1.19-1.12(m, 1H).

Example 155(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-10 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₂H₂₀F₄N₆O, 460.2. m/z found, 461.1 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.93:0.07), major rotamer reported) δ 8.08 (s, 1H), 7.95 (s, 2H), 7.79(dd, J=9.0, 4.7 Hz, 1H), 7.63 (dd, J=9.1, 2.6 Hz, 1H), 7.07-6.99 (m,1H), 6.69 (dd, J=8.1, 2.9 Hz, 1H), 6.66 (d, J=9.1 Hz, 1H), 4.52-4.44 (m,1H), 3.92-3.87 (m, 1H), 3.44-3.40 (m, 2H), 3.10 (s, 3H), 2.70-2.65 (m,1H), 2.08-1.99 (m, 1H), 1.97-1.90 (m, 1H), 1.52-1.45 (m, 1H), 1.19-1.11(m, 1H).

Example 156((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-40 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₂H₂₂F₃N₇O, 457.2. m/z found, 458.1 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.93:0.07), major rotamer reported) δ 8.09 (d, J=8.4 Hz, 1H), 8.07 (s,1H), 7.97 (s, 2H), 7.66 (dd, J=9.1, 2.6 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H),6.68 (d, J=9.1 Hz, 1H), 4.72-4.63 (m, 1H), 3.95-3.87 (m, 1H), 3.54 (dt,J=11.4, 3.1 Hz, 1H), 3.51-3.42 (m, 1H), 3.12 (s, 3H), 2.77-2.69 (m, 1H),2.15 (s, 3H), 2.11-1.99 (m, 1H), 1.92-1.80 (m, 1H), 1.57 (d, J=10.4 Hz,1H), 1.47-1.38 (m, 1H).

Example 157(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-2 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₄H₂₁F₄N₅O, 471.2. m/z found, 472.1 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.90:0.10), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 8.20-8.12(m, 1H), 7.66 (dd, J=9.1, 2.6 Hz, 1H), 7.49 (t, J=4.9 Hz, 1H), 7.09-7.00(m, 1H), 6.87-6.80 (m, 1H), 6.72-6.66 (m, 2H), 4.62-4.53 (m, 1H),4.15-4.08 (m, 1H), 3.36 (dd, J=11.5, 1.6 Hz, 1H), 3.20 (dt, J=11.5, 3.2Hz, 1H), 3.10 (s, 3H), 2.66-2.57 (m, 1H), 2.08-1.98 (m, 1H), 1.90 (dt,J=13.8, 3.7 Hz, 1H), 1.54 (d, J=10.1 Hz, 1H), 0.95-0.87 (m, 1H).

Example 158(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-7 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₄H₂₁F₄N₅O, 471.2. m/z found, 472.2 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.91:0.09), major rotamer reported) δ 8.83 (d, J=4.9 Hz, 2H), 8.15 (dd,J=8.8, 5.5 Hz, 1H), 8.08 (s, 1H), 7.63 (dd, J=9.1, 2.6 Hz, 1H), 7.38 (t,J=4.9 Hz, 1H), 6.98 (ddd, J=8.8, 8.1, 2.7 Hz, 1H), 6.66 (d, J=9.1 Hz,1H), 6.58 (dd, J=8.4, 2.7 Hz, 1H), 4.55-4.45 (m, 1H), 4.02-3.95 (m, 1H),3.51 (dt, J=11.3, 3.1 Hz, 1H), 3.48-3.41 (m, 1H), 3.14 (s, 3H),2.75-2.67 (m, 1H), 2.10-2.00 (m, 1H), 1.99-1.92 (m, 1H), 1.49 (d, J=10.1Hz, 1H), 1.19-1.09 (m, 1H).

Example 159(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-6 followed by the alkylation step of Example 153. MS(ESI): mass calcd. for C₂₄H₂₁F₄N₅O, 471.2. m/z found, 472.2 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.85:0.15), major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H), 8.02 (dd,J=7.8, 1.0 Hz, 1H), 7.98 (s, 1H), 7.63 (dd, J=9.2, 2.6 Hz, 1H), 7.42 (t,J=4.9 Hz, 1H), 7.28-7.22 (m, 1H), 6.68 (d, J=9.2 Hz, 1H), 6.63-6.58 (m,1H), 4.48-4.40 (m, 1H), 4.08-4.00 (m, 1H), 3.55 (dt, J=11.3, 3.0 Hz,1H), 3.46-3.41 (m, 1H), 3.11-3.09 (m, 3H), 2.72-2.68 (m, 1H), 2.07-1.94(m, 2H), 1.48-1.42 (m, 1H), 1.07-1.02 (m, 1H).

Example 160(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

To the title compound of Example 66 (38 mg, 0.066 mmol) dissolved in DMF(1.3 mL) was added NaOtBu (7 mg, 0.072 mmol). After 5 minutes, EtI (5.5μL, 0.069 mmol) was added and the reaction mixture as stirred at roomtemperature overnight. Analysis of the reaction mixture showed thatstarting material (Example 66) still remained. NaH (5 mg, 0.13 mmol, 60%dispersion in mineral oil) and additional EtI (5.5 μL, 0.069 mmol) wereadded to the reaction flask, and the reaction mixture was stirred atroom temperature for 2 h. Then, the mixture was diluted with EtOAc andH₂O. The aqueous layer was extracted with EtOAc (2×). The combinedorganics were washed with H₂O, dried with Na₂SO₄, filtered, andconcentrated. Purification of the concentrate was performed usingAgilent Prep Method X to give the title compound (16 mg) as a whitesolid. MS (ESI): mass calcd. for C₂₅H₂₃F₄N₅O, 485.2. m/z found, 486.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.93:0.07), major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H),8.12 (s, 1H), 7.63 (dd, J=9.0, 2.6 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H),7.03-6.96 (m, 1H), 6.83-6.76 (m, 1H), 6.71-6.64 (m, 2H), 4.48-4.39 (m,1H), 4.13 (s, 1H), 3.88-3.75 (m, 1H), 3.36-3.32 (m, 2H), 3.16 (dt,J=11.4, 3.2 Hz, 1H), 2.61 (s, 1H), 2.14-2.05 (m, 1H), 1.83-1.75 (m, 1H),1.53 (d, J=10.1 Hz, 1H), 1.17 (t, J=7.0 Hz, 3H), 0.86-0.79 (m, 1H).

Example 161((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

To the title compound of Example 66 (30 mg, 0.053 mmol) dissolved in DMF(1 mL) was added NaH (6 mg, 0.16 mmol, 60% dispersion in mineral oil).After 10 minutes, (bromomethyl)cyclopropane (10 μL, 0.11 mmol) was addedand the reaction mixture as stirred at room temperature overnight. Then,the mixture was diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (2×). The combined organics were washed with H₂O,dried with Na₂SO₄, filtered, and concentrated. Purification of theconcentrate was performed using Gilson Prep Method X to give the titlecompound (19 mg) as a white solid. MS (ESI): mass calcd. forC₂₂H₂₅F₄N₅O, 511.2. m/z found, 512.3 [M+H]⁺. ¹H NMR (500 MHz,Methanol-d₄, Compound present as a mixture of rotamers (0.93:0.07),major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.13 (s, 1H), 7.61(dd, J=9.1, 2.6 Hz, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.02-6.95 (m, 1H),6.85-6.78 (m, 1H), 6.75 (d, J=9.1 Hz, 1H), 6.68 (dd, J=7.6, 1.1 Hz, 1H),4.51-4.41 (m, 1H), 4.20-4.10 (m, 1H), 3.85-3.73 (m, 1H), 3.28-3.23 (m,1H), 3.20-3.11 (m, 1H), 2.63-2.58 (m, 1H), 2.19-2.08 (m, 1H), 1.90-1.82(m, 1H), 1.57-1.51 (m, 1H), 1.29 (s, 1H), 0.99-0.90 (m, 1H), 0.86-0.77(m, 1H), 0.62-0.49 (m, 2H), 0.49-0.42 (m, 1H), 0.37-0.28 (m, 1H).

Example 162N-((1S,4R,6R)-2-(3-fluoro-2-(pyrimidin-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)acetamide

To the title compound of Example 66 (30 mg, 0.053 mmol) was added Ac₂O(0.1 mL, 1.05 mmol), and the reaction mixture as stirred at 100° C.overnight. Then, the mixture was concentrated and the concentrate waspurified directly using Gilson Prep Method X to give the title compound.MS (ESI): mass calcd. for C₂₅H₂₁F₄N₅O₂, 499.2. m/z found, 500.1 [M+H]⁺.¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture of rotamers(0.79:0.21), major rotamer reported) δ 9.02-8.98 (m, 1H), 8.89 (d, J=4.9Hz, 2H), 8.31 (dd, J=8.1, 2.5 Hz, 1H), 7.64-7.46 (m, 4H), 7.38-7.32 (m,1H), 4.55-4.48 (m, 1H), 4.38-4.33 (m, 1H), 3.08 (dt, J=11.1, 3.2 Hz,1H), 2.68 (d, J=11.2 Hz, 1H), 2.39 (s, 1H), 1.91-1.81 (m, 1H), 1.75 (s,3H), 1.52 (d, J=10.4 Hz, 1H), 0.96-0.90 (m, 1H), 0.69-0.61 (m, 1H).

Example 163(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

To the title compound of Example 66 (43 mg, 0.094 mmol) dissolved in DMF(2 mL) was added NaH (19 mg, 0.47 mmol, 60% dispersion in mineral oil).After 10 minutes, 2-chloroethyl methyl ether (26 μL, 0.28 mmol) wasadded and the reaction mixture as stirred at room temperature overnight.Analysis of the reaction mixture showed that starting material (Example66) still remained. NaH (19 mg, 0.47 mmol, 60% dispersion in mineraloil) and additional 2-chloroethyl methyl ether (26 μL, 0.28 mmol) wereadded to the reaction flask, and the reaction mixture was stirred at 50°C. for 3 h. Then, the mixture was diluted with EtOAc and H₂O. Theaqueous layer was extracted with EtOAc (2×). The combined organics werewashed with H₂O, dried with Na₂SO₄, filtered, and concentrated.Purification of the concentrate was performed using Gilson Prep Method Xto give the title compound (10 mg) as an off-white solid. MS (ESI): masscalcd. for C₂₆H₂₅F₄N₅O₂, 515.2. m/z found, 516.2 [M+H]⁺. ¹H NMR (500MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.92:0.08),major rotamer reported) δ 8.89 (d, J=5.0 Hz, 2H), 8.16 (s, 1H), 7.61(dd, J=9.1, 2.6 Hz, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.03-6.96 (m, 1H),6.84-6.77 (m, 1H), 6.74 (d, J=8.9 Hz, 1H), 6.71 (dd, J=7.6, 1.1 Hz, 1H),4.46-4.36 (m, 1H), 4.16 (s, 1H), 4.04-3.90 (m, 1H), 3.61-3.43 (m, 3H),3.38-3.32 (m, 3H), 3.16 (dt, J=12.1, 3.1 Hz, 1H), 2.65-2.56 (m, 1H),2.14-2.02 (m, 1H), 1.91-1.82 (m, 1H), 1.54 (d, J=10.3 Hz, 1H), 0.83 (d,J=10.3 Hz, 1H). 1H buried under solvent peak.

Example 164(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 165(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 166(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing 5-bromo-2-iodopyridine (669 mg, 2.36mmol) and degassed THF (12 mL) was added NaOtBu (453 mg, 4.71 mmol),Xantphos (98 mg, 0.17 mmol) and Pd₂(dba)₃ (86 mg, 0.094 mmol). Thereaction mixture was purged with N₂ for 10 minutes and then intermediateB-10 (500 mg, 2.36 mmol) was added and the reaction mixture heated to90° C. overnight. Upon completion of the reaction, the mixture wascooled to room temperature, filtered through Celite and washed withEtOAc. The filtrate was concentrated in vacuo and the crude residuesubjected directly to silica gel chromatography (0-60% EtOAc in hexanes)to give the title compound of step A (91 mg). Further flushing of thecolumn with 0-10% MeOH (with 10% 2 M NH₃) in DCM gave(1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine(483 mg). (1S,4S,6R)-tert-butyl6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate:MS (ESI) mass calcd. for C₁₆H₂₂BrN₃O₂, 367.1. m/z found 370.0 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄) δ 7.98 (d, J=2.5 Hz, 1H), 7.49 (dd, J=9.0,2.5 Hz, 1H), 6.51 (d, J=8.9 Hz, 1H), 4.46-4.41 (m, 1H), 4.12-4.05 (m,1H), 3.29-3.27 (m, 1H), 3.07 (d, J=9.6 Hz, 1H), 2.57-2.51 (m, 1H),2.27-2.18 (m, 1H), 1.70-1.67 (m, 2H), 1.18-1.09 (m, 10H).(1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine: ¹HNMR (500 MHz, Methanol-d₄) δ 8.11 (dd, J=2.5, 0.7 Hz, 1H), 7.58 (dd,J=8.9, 2.5 Hz, 1H), 6.65 (dd, J=8.9, 0.7 Hz, 1H), 4.44 (dd, J=3.1, 2.0Hz, 1H), 4.14-4.10 (m, 1H), 3.21 (dt, J=10.9, 3.4 Hz, 1H), 3.11 (dd,J=10.9, 1.8 Hz, 1H), 2.74-2.70 (m, 1H), 2.39-2.29 (m, 1H), 2.05-2.02 (m,1H), 1.90-1.83 (m, 1H), 1.38 (dt, J=13.4, 3.5 Hz, 1H).

Step B:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To (1S,4R,6R)—N-(5-bromopyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-aminefrom Step A (70 mg, 0.26 mmol) and intermediate A-1 (63 mg, 0.33 mmol)in DMF (2 mL) was added DIPEA (0.27 mL, 1.57 mmol) and HATU (109 mg,0.29 mmol), and the reaction mixture was stirred at room temperature for1 h. The reaction was quenched by the addition of H₂O and the aqueouslayer was extracted with EtOAc (2×). The combined organics wereconcentrated and subjected to purification via Gilson Prep Method X togive the title compound (42 mg) as an off-white powder. MS (ESI): masscalcd. for C₂₀H₁₉BrN₆O, 438.1. m/z found, 439.0 [M+H]⁺. ¹H NMR (500 MHz,Methanol-d₄, Compound present as a mixture of rotamers, major rotamerreported) δ 7.94 (s, 2H), 7.83 (d, J=7.8 Hz, 1H), 7.60-7.55 (m, 1H),7.50-7.43 (m, 1H), 7.40 (td, J=7.9, 1.5 Hz, 1H), 6.96 (s, 1H), 6.82 (s,1H), 6.46 (s, 1H), 3.85 (s, 2H), 3.50-3.41 (m, 1H), 3.28 (dd, J=11.1,1.6 Hz, 1H), 2.58 (s, 1H), 2.26-2.15 (m, 1H), 1.53-1.38 (m, 1H),1.35-1.24 (m, 1H), 1.23-1.14 (m, 1H).

Example 167((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 166 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₉BrFN₅O, 467.1. m/zfound, 470.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.81:0.19), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.07 (dd, J=8.0, 1.0 Hz, 1H), 7.52 (d, J=2.4 Hz, 1H),7.46-7.32 (m, 3H), 6.70-6.62 (m, 1H), 6.47 (d, J=9.4 Hz, 1H), 3.96-3.89(m, 1H), 3.87-3.78 (m, 1H), 3.53 (dt, J=10.9, 3.2 Hz, 1H), 2.62-2.55 (m,1H), 2.24-2.14 (m, 1H), 1.44-1.39 (m, 1H), 1.29-1.18 (m, 1H), 1.16-1.11(m, 1H). 1H buried under solvent peak

Example 168((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 166 substituting intermediate A-1 withintermediate A-6. MS (ESI): mass calcd. for C₂₂H₁₉BrFN₅O, 467.1. m/zfound, 468.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d,J=4.9 Hz, 2H), 7.69 (d, J=2.5 Hz, 1H), 7.48 (t, J=5.0 Hz, 1H), 7.45 (dd,J=8.9, 2.5 Hz, 1H), 7.17-7.10 (m, 1H), 6.99-6.92 (m, 1H), 6.81 (d, J=7.5Hz, 1H), 6.43 (d, J=8.9 Hz, 1H), 4.15 (s, 1H), 4.01-3.91 (m, 1H),3.25-3.18 (m, 2H), 2.52 (s, 1H), 2.27-2.15 (m, 1H), 1.52 (d, J=11.7 Hz,1H), 1.22-1.13 (m, 1H), 1.06 (d, J=10.2 Hz, 1H).

Example 169(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (3 mL) was addedPd(OAc)₂ (6 mg, 0.028 mmol) and racemic BINAP (17 mg, 0.028 mmol) atroom temperature and the reaction mixture was purged with N₂ for 5 min.Then, 2-bromo-5-chloropyridine (90 mg, 0.47 mmol), intermediate B-10(109 mg), and sodium tert-butoxide (63 mg, 0.66 mmol) were added and thereaction mixture heated to 90° C. overnight. Upon completion of thereaction, the mixture was cooled to room temperature, filtered throughCelite and washed with EtOAc. The filtrate was concentrated in vacuo andthe crude residue subjected directly to silica gel chromatography (0-10%MeOH (with 10% 2N NH₃) in DCM) to give the title compound of step A. MS(ESI) mass calcd. for C₁₆H₂₂ClN₃O₂, 323.1. m/z found 324.1 [M+H]⁺. ¹HNMR (500 MHz, Methanol-d₄) δ 7.90 (d, J=2.6 Hz, 1H), 7.39 (dd, J=8.9,2.7 Hz, 1H), 6.54 (d, J=9.0 Hz, 1H), 4.43 (s, 1H), 4.12-4.06 (m, 1H),3.30-3.27 (m, 1H), 3.09-3.05 (m, 1H), 2.57-2.50 (m, 1H), 2.28-2.17 (m,1H), 1.70-1.67 (m, 2H), 1.48-1.38 (m, 2H), 1.12 (s, 9H).

Step B:(1S,4R,6R)—N-(5-chloropyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (252 mg, 0.701 mmol) in EtOAc (9 mL) wasadded 4M HCl in dioxane (0.9 mL). After 1 h, the reaction wasconcentrated to give the title compound of step B (231 mg, 90% purity),which was used without further purification. MS (ESI) mass calcd. forC₁₁H₁₄ClN₃, 223.1. m/z found 224.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (40 mg) and intermediate A-1 (28 mg,0.15 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (56mg, 0.15 mmol), and the reaction mixture was stirred at room temperaturefor 1 h. The reaction was quenched by the addition of H₂O and theaqueous layer was extracted with EtOAc (4×). The combined organics wereconcentrated and the concentrate subjected directly to purification viaAgilent Prep Method X to give the title compound (30 mg). MS (ESI): masscalcd. for C₂₀H₁₉ClN₆O, 394.1. m/z found, 395.2 [M+H]⁺. Analytical HPLCwas obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.25 min (major rotamer) at 254 nm.

Example 170((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 169 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₉ClFN₅O, 423.1. m/zfound, 424.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.84:0.16), major rotamer reported) δ 8.89 (d,J=4.9 Hz, 2H), 7.83 (d, J=2.0 Hz, 1H), 7.33 (t, J=4.9 Hz, 1H), 7.21-7.13(m, 2H), 7.12-7.06 (m, 1H), 6.99 (d, J=7.2 Hz, 1H), 6.14 (d, J=8.9 Hz,1H), 4.42 (s, 1H), 4.24-4.13 (m, 1H), 3.46 (dt, J=11.1, 3.2 Hz, 1H),3.22 (dd, J=11.2, 1.6 Hz, 1H), 2.68-2.61 (m, 1H), 2.42-2.27 (m, 1H),1.71-1.66 (m, 1H), 1.58-1.52 (m, 1H), 1.09-0.99 (m, 1H).

Example 171((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 169 substituting intermediate A-1 withintermediate A-23. MS (ESI): mass calcd. for C₂₂H₁₉ClFN₅O, 423.1. m/zfound, 424.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.86 (d, J=4.9 Hz, 2H),7.88 (dd, J=10.1, 2.7 Hz, 1H), 7.58 (d, J=2.6 Hz, 1H), 7.44-7.35 (m,2H), 6.98-6.92 (m, 1H), 6.64-6.56 (m, 1H), 6.51-6.43 (m, 1H), 3.93 (s,1H), 3.91-3.86 (m, 1H), 3.52 (dt, J=10.9, 3.3 Hz, 1H), 3.30-3.28 (m,1H), 2.63-2.58 (m, 1H), 2.27-2.17 (m, 1H), 1.47 (d, J=10.0 Hz, 1H),1.33-1.26 (m, 1H), 1.24-1.17 (m, 1H).

Example 172((1S,4S,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 169 substituting intermediate A-1 withintermediate A-7. MS (ESI): mass calcd. for C₂₂H₁₉ClFN₅O, 423.1. m/zfound, 424.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.83 (d,J=4.8 Hz, 2H), 8.19 (dd, J=8.8, 5.5 Hz, 1H), 7.55 (d, J=2.6 Hz, 1H),7.39-7.32 (m, 2H), 7.08 (td, J=8.5, 2.7 Hz, 1H), 6.72-6.64 (m, 1H),6.50-6.42 (m, 1H), 3.95 (s, 1H), 3.92-3.86 (m, 1H), 3.50 (dt, J=11.0,3.2 Hz, 1H), 3.30-3.28 (m, 1H), 2.62-2.58 (m, 1H), 2.26-2.18 (m, 1H),1.46 (d, J=10.1 Hz, 1H), 1.28-1.17 (m, 2H).

Example 173(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (6 mL) was addedPd(OAc)₂ (25 mg, 0.038 mmol) and racemic BINAP (27 mg, 0.043 mmol) atroom temperature and the reaction mixture was purged with N₂ for 5 min.Then, 2-chloro-5-(difluoromethyl)pyridine (70 μL, 0.59 mmol),intermediate B-10 (137 mg), and sodium tert-butoxide (81 mg, 0.82 mmol)were added and the reaction mixture heated to 90° C. overnight. Uponcompletion of the reaction, the mixture was cooled to room temperature,filtered through Celite and washed with EtOAc. The filtrate wasconcentrated in vacuo and the crude residue subjected directly to silicagel chromatography (0-60% EtOAc in hexanes) to give the title compoundof step A (71 mg, 0.21 mmol, 36%). MS (ESI) mass calcd. forC₁₂H₂₃F₂N₃O₂, 339.2. m/z found 340.2 [M+H]⁺. ¹H NMR (500 MHz,Methanol-d₄) δ 8.12-8.07 (m, 1H), 7.56 (dd, J=8.6, 2.3 Hz, 1H),6.80-6.49 (m, 2H), 4.49-4.44 (m, 1H), 4.23-4.14 (m, 1H), 3.09 (d, J=9.5Hz, 1H), 2.59-2.54 (m, 1H), 2.31-2.18 (m, 1H), 1.74-1.68 (m, 2H),1.22-1.16 (m, 1H), 1.09 (s, 9H). 1H buried under solvent peak.

Step B:(1S,4R,6R)—N-(5-(difluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (71 mg, 0.21 mmol) in EtOAc (3 mL) wasadded 4M HCl in dioxane (0.3 mL). After 1 h, the reaction wasconcentrated to give the title compound of step B (65 mg), which wasused without further purification. MS (ESI) mass calcd. for C₁₂H₁₅F₂N₃,239.1. m/z found 240.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (33 mg) and intermediate A-1 (24 mg,0.13 mmol) in DMF (1.5 mL) was added DIPEA (0.11 mL, 0.63 mmol) and HATU(44 mg, 0.12 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Agilent Prep Method X to give the title compound (27mg). MS (ESI): mass calcd. for C₂₁H₂₀F₂N₆O, 410.2. m/z found, 411.1[M+H]⁺. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm),mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min and then hold at100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.).R_(t)=1.83 and 2.03 min (major rotamers) at 254 nm.

Example 174((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 173 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₀F₃N₅O, 439.2. m/zfound, 440.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.92:0.08), major rotamer reported) δ 8.89 (d,J=5.0 Hz, 2H), 7.81 (s, 1H), 7.53 (dd, J=8.8, 2.4 Hz, 1H), 7.48 (t,J=4.9 Hz, 1H), 7.10-7.02 (m, 1H), 6.91-6.82 (m, 1H), 6.82-6.51 (m, 3H),4.20-4.13 (m, 1H), 4.11-4.01 (m, 1H), 3.27-3.22 (m, 2H), 2.58-2.51 (m,1H), 2.29-2.18 (m, 1H), 1.55 (d, J=9.6 Hz, 1H), 1.25-1.17 (m, 1H), 1.11(d, J=9.5 Hz, 1H).

Example 175(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (4 mL) was addedPd(OAc)₂ (9 mg, 0.038 mmol) and racemic BINAP (24 mg, 0.038 mmol) atroom temperature and the reaction mixture was purged with N₂ for 5 min.Then, 2-chloro-5-methoxypyridine (75 μL, 0.63 mmol), intermediate B-10(148 mg, 0.695 mmol), and sodium tert-butoxide (85 mg, 0.89 mmol) wereadded and the reaction mixture heated to 90° C. overnight. Uponcompletion of the reaction, the mixture was cooled to room temperature,filtered through Celite and washed with EtOAc. The filtrate wasconcentrated in vacuo and the crude residue subjected directly to silicagel chromatography (0-10% MeOH (with 10% 2 N NH₃) in DCM) to give thetitle compound of step A (158 mg, 0.49 mmol, 90% purity, 70%) MS (ESI)mass calcd. for C₁₂H₂₅N₃O₃, 319.2. m/z found 320.3 [M+H]⁺. ¹H NMR (500MHz, Methanol-d₄) δ 7.65 (d, J=3.0 Hz, 1H), 7.18 (dd, J=9.1, 3.0 Hz,1H), 6.55 (d, J=9.1 Hz, 1H), 4.44-4.40 (m, 1H), 4.09-4.01 (m, 1H), 3.75(s, 3H), 3.30-3.26 (m, 1H), 3.07 (d, J=9.4 Hz, 1H), 2.57-2.49 (m, 1H),2.30-2.19 (m, 1H), 1.71-1.67 (m, 2H), 1.48-1.45 (m, 1H), 1.11 (s, 9H).

Step B:(1S,4R,6R)—N-(5-methoxypyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (176 mg, 0.49 mmol, 90% purity) in EtOAc(6 mL) was added 4M HCl in dioxane (0.6 mL). After 3 h, the reaction wasconcentrated to give the title compound of step B (150 mg), which wasused without further purification. MS (ESI) mass calcd. for C₁₂H₁₂N₃O,219.1. m/z found 220.2 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (30 mg) and intermediate A-1 (21 mg,0.11 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.55 mmol) and HATU(39 mg, 0.10 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound (17mg). MS (ESI): mass calcd. for C₂₁H₂₂N₆O₂, 390.2. m/z found, 391.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.87:0.13), major rotamer reported) δ 7.93 (s, 2H), 7.82 (d,J=8.1 Hz, 1H), 7.39-7.33 (m, 1H), 7.29 (d, J=2.4 Hz, 1H), 7.17-7.10 (m,1H), 7.02-6.92 (m, 1H), 6.85-6.69 (m, 1H), 6.57-6.38 (m, 1H), 3.93-3.80(m, 2H), 3.76 (s, 3H), 3.49-3.41 (m, 1H), 3.30-3.26 (m, 1H), 2.57 (s,1H), 2.27-2.16 (m, 1H), 1.53-1.43 (m, 1H), 1.41-1.26 (m, 1H), 1.20-1.12(m, 1H).

Example 176(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 175 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₂FN₅O₂, 419.2. m/zfound, 420.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.89 (d,J=5.0 Hz, 2H), 7.47 (t, J=4.9 Hz, 1H), 7.41 (d, J=3.0 Hz, 1H), 7.15-7.10(m, 1H), 7.11-7.07 (m, 1H), 6.94-6.88 (m, 1H), 6.82 (d, J=7.6 Hz, 1H),6.44 (d, J=9.1 Hz, 1H), 4.18-4.11 (m, 1H), 3.98-3.92 (m, 1H), 3.76 (s,3H), 3.23 (t, J=3.0 Hz, 1H), 3.22-3.20 (m, 1H), 2.55-2.50 (m, 1H),2.29-2.19 (m, 1H), 1.57 (d, J=11.2 Hz, 1H), 1.22-1.16 (m, 1H), 1.16-1.11(m, 1H).

Example 177(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (170 mg, 0.801 mmol) inDMF (2.5 mL) was added 2,3-difluoro-5-(trifluoromethyl)pyridine (176 mg,0.961 mmol) and Et₃N (0.17 mL, 1.20 mmol), and the reaction mixture wassealed and heated to 90° C. bench top overnight. Upon completion of thereaction, the mixture was cooled to room temperature and directlysubjected to silica gel chromatography (0-30% EtOAc in hexanes) to givethe title compound of step A (322 mg). MS (ESI) mass calcd. forC₁₇H₂₁F₄N₃O₂; 375.16. m/z found 376.0 [M+H]⁺. ¹H NMR (500 MHz,Chloroform-d, Compound present as a mixture of rotamers, major rotamerreported) δ 8.15 (s, 1H), 7.33-7.28 (m, 1H), 5.37-5.23 (m, 1H),4.42-4.34 (m, 2H), 3.44-3.39 (m, 1H), 3.11 (d, J=9.3 Hz, 1H), 2.64-2.60(m, 1H), 2.42-2.31 (m, 1H), 1.69-1.63 (m, 1H), 1.26 (s, 9H), 1.10-1.04(m, 1H).

Step B:(1S,4R,6R)—N-(3-fluoro-5-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (322 mg) in EtOAc (1 mL) was added 4MHCl in dioxane (3 mL), and the reaction mixture was stirred at roomtemperature for 2 h. The reaction was concentrated to give the titlecompound of step B (327 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₃F₄N₃, 275.1. m/z found276.0 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (40 mg) and intermediate A-1 (24 mg,0.126 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(48 mg, 0.13 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Agilent Prep Method X to give the title compound (26mg). MS (ESI): mass calcd. for C₂₁H₁₈F₄N₆O, 446.1. m/z found, 447.1[M+H]⁺. ¹H NMR (500 MHz, Methanol-4 Compound present as a mixture ofrotamers (0.87:0.13), major rotamer reported) δ 7.95 (s, 2H), 7.81 (d,J=8.2 Hz, 1H), 7.66 (s, 1H), 7.58-7.44 (m, 1H), 7.30 (t, J=7.8 Hz, 1H),7.04-6.95 (m, 1H), 6.83-6.72 (m, 1H), 4.11-4.03 (m, 1H), 3.88-3.79 (m,1H), 3.50-3.33 (m, 2H), 2.63-2.57 (m, 1H), 2.22-2.12 (m, 1H), 1.51-1.41(m, 2H), 1.29-1.18 (m, 1H). Analytical HPLC was obtained on a Agilent1100 Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phaseof 10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.81 min(major rotamer) at 254 nm.

Example 178((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 177 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₁H₁₉F₄N₇O, 461.2. m/zfound, 462.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-4 Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.14 (d,J=8.4 Hz, 1H), 7.98 (s, 2H), 7.84-7.78 (m, 1H), 7.43 (dd, J=11.1, 2.0Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 4.25-4.19 (m, 1H), 4.12-4.04 (m, 1H),3.56 (dt, J=11.0, 3.2 Hz, 1H), 3.35 (dd, J=10.9, 1.4 Hz, 1H), 2.72-2.67(m, 1H), 2.37 (s, 3H), 2.35-2.27 (m, 1H), 1.65-1.61 (m, 2H), 1.44-1.38(m, 1H).

Example 179(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 177 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₈F₅N₅O, 475.1. m/zfound, 476.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.90 (d,J=4.9 Hz, 2H), 7.80-7.73 (m, 1H), 7.52-7.46 (m, 2H), 7.08-7.01 (m, 1H),6.95-6.87 (m, 1H), 6.80 (d, J=7.7 Hz, 1H), 4.20 (s, 1H), 4.17-4.10 (m,1H), 3.33-3.32 (m, 1H), 3.19 (dt, J=11.1, 3.2 Hz, 1H), 2.57-2.49 (m,1H), 2.23-2.13 (m, 1H), 1.52 (d, J=9.8 Hz, 1H), 1.45-1.36 (m, 1H), 0.93(d, J=10.1 Hz, 1H).

Example 180((1S,4S,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 177 substituting intermediate A-1 withintermediate A-34. MS (ESI): mass calcd. for C₂₃H₁₈F₅N₅O, 475.1. m/zfound, 476.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.81 (d,J=0.6 Hz, 2H), 8.11 (d, J=7.3 Hz, 1H), 7.70-7.63 (m, 1H), 7.62-7.42 (m,1H), 7.32-7.22 (m, 1H), 7.01-6.90 (m, 1H), 6.90-6.79 (m, 1H), 4.16-4.08(m, 1H), 4.07-3.95 (m, 1H), 3.53 (dt, J=10.8, 3.2 Hz, 1H), 3.40 (dd,J=10.8, 1.6 Hz, 1H), 2.68-2.63 (m, 1H), 2.26-2.16 (m, 1H), 1.58-1.51 (m,1H), 1.51-1.45 (m, 1H), 1.38-1.28 (m, 1H).

Example 181((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Step A: (1S,4S)-tert-butyl6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (183 mg, 0.862 mmol) inMeCN (2 mL) was added 2-chlorobenzoxazole (0.12 mL, 1.03 mmol) and Et₃N(0.18 mL, 1.29 mmol), and the reaction mixture was sealed and heated to100° C. bench top overnight. Upon completion of the reaction, themixture was cooled to room temperature and diluted with H₂O. Thereaction mixture was extracted with EtOAc (3×). The combined organicswere concentrated and the concentrate subjected directly to silica gelchromatography (0-50% EtOAc in hexanes) to give the title compound ofstep A (199 mg, 0.604 mmol, 70%) MS (ESI) mass calcd. for C₁₈H₂₃N₃O₃;329.2. m/z found 330.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compoundpresent as a mixture of rotamers) δ 7.40-7.34 (m, 1H), 7.26-7.20 (m,1H), 7.20-7.12 (m, 1H), 7.07-6.99 (m, 1H), 5.88-5.78 and 5.29-5.19 (twom, 1H), 4.51-4.43 (m, 1H), 4.33-4.19 (m, 1H), 3.45-3.33 (m, 1H),3.15-3.04 (m, 1H), 2.64-2.57 (m, 1H), 2.46-2.31 (m, 1H), 1.80-0.99(series of m, 12H).

Step B:N-((1S,4R)-2-azabicyclo[2.2.1]heptan-6-yl)benzo[d]oxazol-2-amine.xHCl.To the title compound of step A (199 mg, 0.604 mmol) in EtOAc (1.5 mL)was added 4M HCl in dioxane (4 mL). After 1 h, the reaction wasconcentrated to give the title compound of step B (194 mg), which wasused without further purification. MS (ESI) mass calcd. for C₁₃H₁₅N₃O,229.1. m/z found 230.1 [M+H]⁺.

Step C:((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone.To the title compound of step B (40 mg) and intermediate A-40 (30 mg,0.15 mmol) in DMF (1 mL) was added DIPEA (0.13 mL, 0.75 mmol) and HATU(55 mg, 0.15 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Agilent Prep Method X to give the title compound (24mg). MS (ESI): mass calcd. for C₂₂H₂₁N₇O₂, 415.2. m/z found, 416.2[M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.81:0.19), major rotamer reported) δ 8.12-8.05 (m, 1H), 7.99(s, 2H), 7.26-7.21 (m, 1H), 7.16-7.08 (m, 3H), 7.08-7.01 (m, 1H),4.26-4.21 (m, 1H), 3.98-3.88 (m, 1H), 3.59 (dt, J=11.0, 3.2 Hz, 1H),3.35 (d, J=11.0 Hz, 1H), 2.76-2.68 (m, 1H), 2.40-2.28 (m, 1H), 2.09 (s,3H), 1.68-1.60 (m, 2H), 1.40-1.33 (m, 1H).

Example 182((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 181 substituting intermediate A-40 withintermediate A-16. MS (ESI): mass calcd. for C₂₂H₁₉FN₆O₂, 418.2. m/zfound, 419.2 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.00 (s, 2H),7.37-7.31 (m, 1H), 7.20-7.16 (m, 1H), 7.12 (d, J=7.1 Hz, 2H), 6.91 (d,J=8.2 Hz, 2H), 6.49-6.37 (m, 1H), 4.12 (s, 1H), 4.01-3.88 (m, 1H), 3.63(s, 1H), 3.27-3.22 (m, 1H), 2.60-2.54 (m, 1H), 2.31-2.21 (m, 1H), 1.59(d, J=10.3 Hz, 1H), 1.32-1.19 (m, 2H).

Example 183((1S,4S,6R)-6-(benzo[d]oxazol-2-ylamino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 181 substituting intermediate A-40 withintermediate A-2. MS (ESI): mass calcd. for C₂₄H₂₀FN₅O₂, 429.2. m/zfound, 430.2 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.91 (d,J=5.0 Hz, 2H), 7.49 (t, J=5.0 Hz, 1H), 7.30 (d, J=7.9 Hz, 1H), 7.21-7.06(m, 3H), 6.93 (d, J=7.5 Hz, 1H), 6.86-6.79 (m, 1H), 6.62-6.49 (m, 1H),4.27 (s, 1H), 4.05-3.97 (m, 1H), 3.29-3.28 (m, 1H), 3.27 (s, 1H),2.67-2.56 (m, 1H), 2.37-2.25 (m, 1H), 1.63 (d, J=10.2 Hz, 1H), 1.35-1.23(m, 2H).

Example 184(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S)-tert-butyl6-(p-tolylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylate. To amicrowave vial containing degassed dioxane (2 mL), intermediate B-10 (60mg, 0.28 mmol) and 4-bromotoluene (73 mg, 0.42 mmol) was added BrettPhosPalladacycle (11 mg, 0.014 mmol), BrettPhos (8 mg, 0.014 mmol) andsodium tert-butoxide (33 mg, 0.34 mmol). The reaction mixture was heatedto 90° C. bench top for 3 h. Upon completion of the reaction, themixture was cooled to room temperature and diluted with H₂O and EtOAc.The reaction mixture was extracted with EtOAc (3×) and the combinedorganics washed with brine, dried (Na₂SO₄), and filtered. The filtratewas concentrated in vacuo and the crude residue subjected directly tosilica gel chromatography (0-40% EtOAc in hexanes) to give the titlecompound of step A (68 mg, 0.22 mmol, 80%) MS (ESI) mass calcd. forC₁₈H₂₆N₂O₂, 302.2. m/z found 303.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄,Compound present as a mixture of rotamers, major rotamer reported) δ6.91 (d, J=8.1 Hz, 2H), 6.55 (d, J=8.3 Hz, 2H), 4.39 (s, 1H), 3.86-3.73(m, 1H), 3.27 (dt, J=9.4, 3.2 Hz, 1H), 3.05 (d, J=9.3 Hz, 1H), 2.52-2.48(m, 1H), 2.28-2.21 (m, 1H), 2.18 (s, 3H), 1.74-1.40 (m, 3H), 1.08 (s,9H).

Step B: (1S,4R)—N-(p-tolyl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl. Tothe title compound of step A (68 mg, 0.22 mmol) in EtOAc (3 mL) wasadded 4M HCl in dioxane (0.3 mL), and the reaction mixture was stirredat room temperature overnight. The reaction was concentrated to give thetitle compound of step B (70 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₃H₁₈N₂, 202.2. m/z found 203.3[M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (61 mg) and intermediate A-2 (71 mg,0.27 mmol, 82% purity) in DMF (2 mL) was added DIPEA (0.23 mL, 1.33mmol) and HATU (93 mg, 0.24 mmol), and the reaction mixture was stirredat room temperature for 1 h. The reaction was quenched by the additionof H₂O and the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound (31mg). MS (ESI): mass calcd. for C₂₄H₂₃FN₄O, 402.2. m/z found, 403.2[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.88:0.12), major rotamer reported) δ 8.88 (d, J=5.0 Hz, 2H),7.48 (t, J=5.0 Hz, 1H), 7.09-7.02 (m, 1H), 6.85-6.77 (m, 4H), 6.34-6.27(m, 2H), 4.10 (s, 1H), 3.73-3.64 (m, 1H), 3.29-3.11 (m, 2H), 2.57-2.48(m, 1H), 2.32-2.23 (m, 1H), 2.21 (s, 3H), 1.60 (d, J=10.1 Hz, 1H),1.26-1.19 (m, 1H), 1.15-1.09 (m, 1H).

Example 185(1H-indol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-29. MS (ESI): mass calcd. for C₂₁H₁₉F₃N₄O, 400.2. m/zfound, 401.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 7.53 (s, 1H), 7.32-7.25(m, 1H), 7.23 (d, J=3.1 Hz, 1H), 7.17 (dt, J=8.0, 1.0 Hz, 1H), 6.70-6.60(m, 2H), 6.37 (dd, J=3.1, 0.9 Hz, 1H), 6.33 (s, 1H), 4.59 (s, 1H),3.98-3.89 (m, 1H), 3.63 (dt, J=11.1, 3.3 Hz, 1H), 3.51 (dd, J=11.2, 1.6Hz, 1H), 2.76-2.66 (m, 1H), 2.33-2.20 (m, 1H), 2.05-1.95 (m, 1H),1.81-1.74 (m, 1H), 1.36-1.25 (m, 1H).

Example 186(1H-indazol-7-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 53 substituting intermediate A-1 withintermediate A-44. MS (ESI): mass calcd. for C₂₀H₁₈F₃N₅O, 401.1. m/zfound, 402.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.88 (s, 1H), 7.55(d, J=8.1 Hz, 1H), 7.52 (s, 1H), 7.22 (d, J=7.1 Hz, 1H), 7.09 (dd,J=8.9, 2.5 Hz, 1H), 6.89-6.80 (m, 1H), 6.11 (d, J=8.9 Hz, 1H), 4.76 (s,1H), 4.00-3.92 (m, 1H), 3.67-3.56 (m, 2H), 2.76-2.68 (m, 1H), 2.36-2.25(m, 1H), 2.17-2.08 (m, 1H), 1.83 (d, J=10.4 Hz, 1H), 1.33-1.22 (m, 1H).

Example 187(5-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-19. MS (ESI): mass calcd. for C₂₀H₁₉F₃N₈O, 444.2. m/zfound, 445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.32-8.26(m, 1H), 8.18 (s, 1H), 8.11-8.06 (m, 1H), 7.88 (s, 3H), 7.56 (s, 1H),4.31 (s, 1H), 4.26-4.12 (m, 1H), 3.72 (dt, J=11.0, 3.2 Hz, 1H), 3.35(dd, J=11.0, 1.7 Hz, 1H), 2.85-2.72 (m, 1H), 2.47-2.36 (m, 4H),1.98-1.89 (m, 1H), 1.72 (d, J=10.5 Hz, 1H), 1.21 (dt, J=13.4, 4.0 Hz,1H).

Example 188(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-39. MS (ESI): mass calcd. for C₁₉H₁₇F₃N₈O, 430.1. m/zfound, 431.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.36 (dd,J=4.8, 1.8 Hz, 1H), 8.07 (s, 2H), 7.98-7.83 (m, 2H), 7.61-7.48 (m, 1H),6.89-6.75 (m, 1H), 4.01-3.89 (m, 1H), 3.85-3.70 (m, 1H), 3.51 (dt,J=11.2, 3.2 Hz, 1H), 3.35 (dd, J=11.1, 1.7 Hz, 1H), 2.64 (s, 1H),2.30-2.19 (m, 1H), 1.57-1.47 (m, 1H), 1.43-1.32 (m, 1H), 1.32-1.21 (m,1H).

Example 189(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-42. MS (ESI): mass calcd. for C₂₁H₁₈F₃N₇O, 441.2. m/zfound, 442.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.85:0.15), major rotamer reported) δ 8.89 (d,J=4.9 Hz, 2H), 8.53 (dd, J=8.0, 1.6 Hz, 1H), 8.02 (d, J=4.8 Hz, 1H),7.94-7.86 (m, 2H), 7.44 (t, J=4.9 Hz, 1H), 7.37 (dd, J=8.0, 4.8 Hz, 1H),4.20-4.14 (m, 1H), 4.11-4.01 (m, 1H), 3.63 (dt, J=10.9, 3.2 Hz, 1H),3.35 (d, J=10.9 Hz, 1H), 2.77-2.68 (m, 1H), 2.36-2.30 (m, 1H), 1.70-1.54(m, 2H), 1.40-1.30 (m, 1H).

Example 190(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-47. MS (ESI): mass calcd. for C₂₂H₂₀F₃N₇O, 455.2. m/zfound, 456.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d,J=4.9 Hz, 2H), 8.33 (dd, J=2.1, 0.9 Hz, 1H), 7.90 (s, 1H), 7.89-7.88 (m,1H), 7.82 (s, 1H), 7.43 (t, J=4.9 Hz, 1H), 4.20-4.15 (m, 1H), 4.10-3.99(m, 1H), 3.60 (dt, J=10.9, 3.2 Hz, 1H), 3.35 (dd, J=11.0, 1.5 Hz, 1H),2.73-2.67 (m, 1H), 2.33 (s, 3H), 2.32-2.26 (m, 1H), 1.66-1.51 (m, 2H),1.38-1.31 (m, 1H).

Example 191(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₂H₂₀F₃N₇O, 455.2. m/zfound, 456.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.86:0.14), major rotamer reported) δ 7.37 (d,J=4.9 Hz, 2H), 6.88 (d, J=8.1 Hz, 1H), 6.45 (s, 1H), 6.33 (d, J=1.4 Hz,1H), 5.91 (t, J=4.9 Hz, 1H), 5.74 (d, J=8.1 Hz, 1H), 2.76-2.67 (m, 1H),2.59-2.48 (m, 1H), 2.11 (dt, J=11.0, 3.2 Hz, 1H), 1.83 (dd, J=10.9, 1.6Hz, 1H), 1.20-1.18 (m, 1H), 0.87-0.75 (m, 4H), 0.17-−0.00 (m, 2H),−0.13-−0.27 (m, 1H).

Example 192(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-16. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.35 min(major rotamer) at 254 nm.

Example 193(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-12. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.2 [M+H]⁺.]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.56 min(major rotamer) at 254 nm.

Example 194((5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-10. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.36 min(major rotamer) at 254 nm.

Example 195(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-11. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.41 min(major rotamer) at 254 nm.

Example 196(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-22. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₇O, 443.2. m/zfound, 444.2 [M+H]⁺.]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.61 min(major rotamer) at 254 nm.

Example 197(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-5. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₇O₂, 459.2. m/zfound, 460.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.30 min(major rotamer) at 254 nm.

Example 198(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-23. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.24 min(major rotamer) at 254 nm.

Example 199(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-7. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (600 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.84 (d,J=4.8 Hz, 2H), 8.19 (dd, J=8.8, 5.5 Hz, 1H), 7.95-7.87 (m, 2H), 7.38 (t,J=4.9 Hz, 1H), 7.04 (td, J=8.4, 2.7 Hz, 1H), 6.74-6.64 (m, 1H),4.04-3.93 (m, 2H), 3.54 (dt, J=11.0, 3.2 Hz, 1H), 3.36-3.33 (m, 1H),2.66-2.62 (m, 1H), 2.30-2.22 (m, 1H), 1.50 (d, J=10.0 Hz, 1H), 1.34-1.24(m, 2H).

Example 200(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-6. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.2 [M+H]⁺.]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.16 min(major rotamer) at 254 nm.

Example 201(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-37. MS (ESI): mass calcd. for C₂₂H₁₉F₃N₆O, 440.2. m/zfound, 441.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.12 (d, J=7.6 Hz, 1H), 7.94-7.87 (m, 1H), 7.86-7.78 (m,1H), 7.40 (t, J=4.9 Hz, 1H), 7.30 (td, J=7.7, 1.4 Hz, 1H), 7.02-6.92 (m,1H), 6.87-6.75 (m, 1H), 4.06-3.90 (m, 2H), 3.52 (dt, J=11.0, 3.1 Hz,1H), 3.36-3.33 (m, 1H), 2.67-2.60 (m, 1H), 2.31-2.20 (m, 1H), 1.47 (d,J=10.0 Hz, 1H), 1.32-1.26 (m, 1H), 1.25-1.15 (m, 1H).

Example 202(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-49. MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/zfound, 448.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, major rotamer reported) δ 8.30 (s, 1H), 8.11 (dd,J=8.8, 5.3 Hz, 1H), 7.99-7.89 (m, 1H), 7.85 (d, J=1.4 Hz, 1H), 7.80 (d,J=0.9 Hz, 1H), 7.29-7.26 (m, 1H), 7.21 (ddd, J=8.9, 7.9, 2.7 Hz, 1H),7.05 (dd, J=8.3, 2.6 Hz, 1H), 4.88 (s, 1H), 4.85-4.70 (m, 1H), 3.22 (dt,J=8.9, 2.9 Hz, 1H), 2.95 (dd, J=8.9, 1.5 Hz, 1H), 2.63-2.55 (m, 1H),2.49-2.31 (m, 1H), 1.90-1.75 (m, 2H), 1.18-1.11 (m, 1H).

Example 203(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-34. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.2 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.81 (s, 2H),8.12 (d, J=7.9 Hz, 1H), 7.97-7.87 (m, 1H), 7.86-7.76 (m, 1H), 7.29 (td,J=7.7, 1.4 Hz, 1H), 6.95 (d, J=7.5 Hz, 1H), 6.85-6.70 (m, 1H), 4.08-3.90(m, 2H), 3.55 (dt, J=10.9, 3.2 Hz, 1H), 3.38-3.32 (m, 1H), 2.66 (s, 1H),2.31-2.18 (m, 1H), 1.51 (d, J=10.0 Hz, 1H), 1.41-1.24 (m, 2H).

Example 204(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-35. MS (ESI): mass calcd. for C₂₂H₁₇F₅N₆O, 476.1. m/zfound, 477.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.88 (d,J=0.7 Hz, 2H), 7.96-7.89 (m, 2H), 7.11-7.03 (m, 1H), 6.93-6.81 (m, 2H),4.20 (s, 1H), 4.10-4.02 (m, 1H), 3.28-3.25 (m, 2H), 2.58 (s, 1H),2.32-2.19 (m, 1H), 1.57 (d, J=10.1 Hz, 1H), 1.32-1.21 (m, 1H), 1.15-1.02(m, 1H).

Example 205(3-phenylpyrazin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-43. MS (ESI): mass calcd. for C₂₂H₁₉F₃N₆O, 440.2. m/zfound, 441.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.48 (d, J=2.4 Hz, 1H),7.93 (s, 1H), 7.84 (s, 1H), 7.78 (d, J=2.4 Hz, 1H), 7.73-7.66 (m, 2H),7.56-7.50 (m, 3H), 3.90-3.82 (m, 1H), 3.81-3.73 (m, 1H), 3.34 (dd,J=11.3, 1.6 Hz, 1H), 3.27 (dt, J=11.3, 3.2 Hz, 1H), 2.53-2.48 (m, 1H),2.20-2.08 (m, 1H), 1.38-1.28 (m, 1H), 1.29-1.19 (m, 1H), 0.66-0.55 (m,1H).

Example 206[1,1′-biphenyl]-2-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 with[1,1′-biphenyl]-2-carboxylic acid. MS (ESI): mass calcd. forC₂₄H₂₁F₃N₄O, 438.2. m/z found, 439.2 [M+H]⁺. ¹H NMR (500 MHz,Methanol-d₄) δ 7.91 (br. s, 1H), 7.76 (br. s, 1H), 7.49-7.33 (m, 6H),7.25 (td, J=7.6, 1.4 Hz, 1H), 6.87 (dd, J=7.6, 1.3 Hz, 1H), 6.68 (td,J=7.5, 1.3 Hz, 1H), 3.93-3.72 (m, 2H), 3.25 (dd, J=11.2, 1.6 Hz, 1H),3.09 (dt, J=11.2, 3.2 Hz, 1H), 2.43-2.33 (m, 1H), 2.16-2.05 (m, 1H),1.26-1.11 (m, 3H).

Example 207(3-phenylfuran-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-45. MS (ESI): mass calcd. for C₂₂H₁₉F₃N₄O₂, 428.1. m/zfound, 429.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.93:0.07), major rotamer reported) δ 8.09-8.05 (m,1H), 7.74 (d, J=1.4 Hz, 1H), 7.43-7.36 (m, 4H), 7.36-7.31 (m, 1H), 7.06(d, J=1.8 Hz, 1H), 6.41 (d, J=1.8 Hz, 1H), 4.50-4.46 (m, 1H), 4.04-3.96(m, 1H), 3.49-3.45 (m, 2H), 2.64-2.58 (m, 1H), 2.28-2.20 (m, 1H),1.61-1.49 (m, 2H), 1.32-1.24 (m, 1H).

Example 208(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-2, followed by alkylation step of Example 153. MS (ESI):mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/z found, 473.2 [M+H]⁺. ¹H NMR (500MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.88:0.12),major rotamer reported) δ 8.90 (d, J=5.0 Hz, 2H), 8.18-8.16 (m, 1H),8.14-8.12 (m, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.10-7.01 (m, 1H), 6.91-6.83(m, 1H), 6.78 (dd, J=7.6, 1.2 Hz, 1H), 4.56-4.47 (m, 1H), 4.15-4.09 (m,1H), 3.37 (dd, J=11.5, 1.6 Hz, 1H), 3.22-3.16 (m, 4H), 2.63-2.59 (m,1H), 2.08-1.98 (m, 1H), 1.97-1.88 (m, 1H), 1.55-1.48 (m, 1H), 0.84-0.77(m, 1H).

Example 209(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 208 substituting intermediate A-2 withintermediate A-7. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 473.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.89:0.11), major rotamer reported) δ 8.84 (d,J=4.9 Hz, 2H), 8.18 (dd, J=8.8, 5.5 Hz, 1H), 8.15 (s, 1H), 8.09-8.04 (m,1H), 7.39 (t, J=4.9 Hz, 1H), 7.05-6.96 (m, 1H), 6.64 (dd, J=8.5, 2.7 Hz,1H), 4.51-4.41 (m, 1H), 4.03-3.95 (m, 1H), 3.54 (dt, J=11.3, 3.1 Hz,1H), 3.45 (dd, J=11.3, 1.6 Hz, 1H), 3.24 (s, 3H), 2.78-2.69 (m, 1H),2.13-1.97 (m, 2H), 1.57-1.46 (m, 1H), 1.23-1.11 (m, 1H).

Example 210((1S,4S,6R)-6-(methyl(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 208 substituting intermediate A-2 withintermediate A-37. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O, 454.2. m/zfound, 455.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 8.10 (dd, J=7.9, 1.2 Hz, 1H), 8.08 (s, 2H), 7.39 (t,J=4.9 Hz, 1H), 7.26 (td, J=7.7, 1.4 Hz, 1H), 6.92 (dd, J=7.6, 1.3 Hz,1H), 6.82 (td, J=7.5, 1.3 Hz, 1H), 4.50-4.43 (m, 1H), 3.99-3.92 (m, 1H),3.52 (dt, J=11.3, 3.1 Hz, 1H), 3.44 (dd, J=11.3, 1.5 Hz, 1H), 3.23 (s,3H), 2.76-2.67 (m, 1H), 2.12-1.91 (m, 2H), 1.52-1.42 (m, 1H), 1.19-1.07(m, 1H).

Example 211((1S,4S,6R)-6-((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 59 substituting intermediate A-1 withintermediate A-2, followed by alklyation step of Example 161. MS (ESI):mass calcd. for C₂₆H₂₄F₄N₆O, 512.2. m/z found, 513.2 [M+H]⁺. ¹H NMR (500MHz, Methanol-d₄, Compound present as a mixture of rotamers (0.93:0.07),major rotamer reported) δ 8.89 (d, J=4.9 Hz, 2H), 8.18 (br. s, 1H), 8.15(br. s, 1H), 7.49 (t, J=5.0 Hz, 1H), 7.04-6.98 (m, 1H), 6.89-6.81 (m,1H), 6.78 (dd, J=7.6, 1.2 Hz, 1H), 4.48-4.40 (m, 1H), 4.18-4.14 (m, 1H),3.84 (dd, J=16.1, 5.9 Hz, 1H), 3.39-3.33 (m, 2H), 3.14 (dt, J=11.4, 3.2Hz, 1H), 2.63-2.58 (m, 1H), 2.19-2.08 (m, 1H), 1.91-1.84 (m, 1H), 1.53(d, J=10.3 Hz, 1H), 1.01-0.92 (m, 1H), 0.77-0.70 (m, 1H), 0.65-0.52 (m,2H), 0.51-0.43 (m, 1H), 0.38-0.30 (m, 1H).

Example 212((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (300 mg, 1.41 mmol) inMeCN (3 mL) was added 2,5-dichloropyrazine (0.17 mL, 1.70 mmol) and Et₃N(0.30 mL, 2.12 mmol), and the reaction mixture was sealed and heated to90° C. bench top overnight. Upon completion of the reaction, the mixturewas cooled to room temperature and diluted with H₂O. The reactionmixture was extracted with EtOAc (3×). The combined organics wereconcentrated and the concentrate subjected directly to silica gelchromatography (0-60% EtOAc in hexanes) to give the title compound ofstep A (153 mg, 0.471 mmol, 33%) MS (ESI) mass calcd. for C₁₅H₂₁ClN₄O₂;324.1. m/z found 269.1 [M+2H-tBu]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.99(d, J=1.4 Hz, 1H), 7.71 (d, J=1.4 Hz, 1H), 4.45-4.39 (m, 1H), 4.16-4.12(m, 1H), 3.08 (d, J=10.1 Hz, 1H), 2.62-2.50 (m, 1H), 2.29-2.19 (m, 1H),1.74-1.64 (m, 2H), 1.22-1.16 (m, 1H), 1.11 (s, 9H). 1H buried undersolvent.

Step B:(1S,4R,6R)—N-(5-chloropyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (150 mg, 0.46 mmol) in EtOAc (5 mL) wasadded 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirredovernight. The reaction was concentrated to give the title compound ofstep B (137 mg), which was used without further purification. MS (ESI)mass calcd. for C₁₀H₁₃ClN₄, 224.1. m/z found 225.1 [M+H]⁺.

Step C:((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.To the title compound of step B (34 mg) and intermediate A-16 (28 mg,0.14 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.69 mmol) and HATU(48 mg, 0.13 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound (35mg). MS (ESI): mass calcd. for C₁₉H₁₇ClFN₇O, 413.1. m/z found, 414.0[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.92:0.08), major rotamer reported) δ 8.01 (s, 2H), 7.70-7.66(m, 1H), 7.62 (d, J=1.4 Hz, 1H), 7.33-7.27 (m, 1H), 7.02-6.93 (m, 1H),6.87 (d, J=7.7 Hz, 1H), 4.02 (s, 1H), 3.95-3.86 (m, 1H), 3.24-3.20 (m,2H), 2.53 (s, 1H), 2.27-2.15 (m, 1H), 1.52 (d, J=10.3 Hz, 1H), 1.22-1.05(m, 2H).

Example 2131S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 212 substituting intermediate A-16 withintermediate A-10. MS (ESI): mass calcd. for C₁₉H₁₇ClFN₇O, 413.1. m/zfound, 414.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.84 (dd,J=9.0, 4.7 Hz, 1H), 7.69-7.62 (m, 1H), 7.60 (d, J=1.4 Hz, 1H), 7.22-7.15(m, 1H), 6.81-6.70 (m, 1H), 3.92-3.74 (m, 1H), 3.48-3.39 (m, 1H),3.29-3.27 (m, 1H), 2.59 (s, 1H), 2.27-2.16 (m, 1H), 1.51-1.41 (m, 1H),1.29-1.16 (m, 2H). 1H buried under solvent peak.

Example 214((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 212 substituting intermediate A-16 withintermediate A-2. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.91 (d,J=5.0 Hz, 2H), 7.63 (dd, J=9.3, 1.5 Hz, 2H), 7.50 (t, J=5.0 Hz, 1H),7.19-7.12 (m, 1H), 7.01-6.93 (m, 1H), 6.85 (d, J=6.9 Hz, 1H), 4.15 (s,1H), 3.97-3.91 (m, 1H), 3.24-3.20 (m, 2H), 2.56-2.48 (m, 1H), 2.27-2.17(m, 1H), 1.50 (d, J=10.3 Hz, 1H), 1.22-1.15 (m, 1H), 0.94 (d, J=10.2 Hz,1H).

Example 215((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 212 substituting intermediate A-16 withintermediate A-37. MS (ESI): mass calcd. for C₂₁H₁₉ClN₆O, 406.1. m/zfound, 407.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.92:0.08), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 8.12 (d, J=8.0 Hz, 1H), 7.68-7.61 (m, 1H), 7.54-7.50 (m,1H), 7.43-7.34 (m, 2H), 6.97 (d, J=7.6 Hz, 1H), 6.95-6.85 (m, 1H), 3.94(s, 1H), 3.91-3.84 (m, 1H), 3.50 (dt, J=11.0, 3.2 Hz, 1H), 3.30-3.29 (m,1H), 2.66-2.58 (m, 1H), 2.28-2.17 (m, 1H), 1.51-1.42 (m, J=10.1 Hz, 1H),1.27-1.14 (m, 2H).

Example 216((1S,4S,6R)-6-((5-chloropyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 212 substituting intermediate A-16 withintermediate A-35. MS (ESI): mass calcd. for C₂₃H₁₈F₅N₅O, 475.1. m/zfound, 476.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.92:0.08), major rotamer reported) δ 8.87 (s, 2H),7.93 (s, 1H), 7.58 (dd, J=8.9, 2.5 Hz, 1H), 7.13-7.00 (m, 1H), 6.90-6.82(m, 1H), 6.82-6.75 (m, 1H), 6.65-6.54 (m, 1H), 4.17 (s, 1H), 4.13-4.04(m, 1H), 3.28-3.21 (m, 2H), 2.61-2.50 (m, 1H), 2.31-2.16 (m, 1H), 1.59(d, J=10.2 Hz, 1H), 1.27-1.08 (m, 2H).

Example 217(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (9 mL) was addedPd(OAc)₂ (24 mg, 0.035 mmol) and racemic BINAP (22 mg, 0.035 mmol) atroom temperature and the reaction mixture was purged with N₂ for 5 min.Then, 2-chloro-5-methylpyrazine (112 mg, 0.87 mmol), intermediate B-10(204 mg), and sodium tert-butoxide (121 mg, 1.22 mmol) were added andthe reaction mixture heated to 70° C. overnight. Upon completion of thereaction, the mixture was cooled to room temperature, filtered throughCelite and washed with EtOAc. The filtrate was concentrated in vacuo andthe crude residue subjected directly to silica gel chromatography(10-80% EtOAc in hexanes) to give the title compound of step A (139 mg,0.457 mmol, 52%). MS (ESI) mass calcd. for C₁₆H₂₄N₄O₂, 304.2. m/z found305.2 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 7.93-7.79 (m, 2H),4.45-4.40 (m, 1H), 4.16-4.12 (m, 1H), 3.09 (dd, J=9.5, 1.2 Hz, 1H),2.60-2.53 (m, 1H), 2.33 (s, 3H), 2.29-2.20 (m, 1H), 1.74-1.64 (m, 2H),1.20-1.15 (m, 1H), 1.08 (s, 9H). 1H buried under solvent.

Step B:(1S,4R,6R)—N-(5-methylpyrazin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (139 mg, 0.46 mmol) in EtOAc (5 mL) wasadded 4M HCl in dioxane (0.6 mL), and the reaction mixture was stirredat room temperature overnight. The reaction was concentrated to give thetitle compound of step B (140 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₁H₁₆N₄, 204.1. m/z found 205.2[M+H]⁺.

Step C:(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (31 mg) and intermediate A-16 (28 mg,0.13 mmol) in DMF (1 mL) was added DIPEA (0.12 mL, 0.67 mmol) and HATU(47 mg, 0.12 mmol), and the reaction mixture was stirred at roomtemperature overnight. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound (18mg). MS (ESI): mass calcd. for C₂₀H₂₀FN₇O, 393.2. m/z found, 394.2[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers, major rotamer reported) δ 8.00 (s, 2H), 7.80-7.75 (m, 1H),7.55-7.49 (m, 1H), 7.29-7.22 (m, 1H), 6.93-6.78 (m, 2H), 4.10-3.97 (m,1H), 3.97-3.89 (m, 1H), 3.25-3.20 (m, 2H), 2.53 (s, 1H), 2.33 (s, 3H),2.27-2.17 (m, 1H), 1.54 (d, J=10.1 Hz, 1H), 1.23-1.11 (m, 2H).

Example 218(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 217 substituting intermediate A-16 withintermediate A-10. MS (ESI): mass calcd. for C₂₀H₂₀FN₇O, 393.2. m/zfound, 394.5 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 7.95 (s, 2H), 7.82 (dd,J=9.0, 4.7 Hz, 1H), 7.78 (s, 1H), 7.50-7.45 (m, 1H), 7.19-7.11 (m, 1H),6.69 (s, 1H), 3.91-3.77 (m, 2H), 3.48-3.38 (m, 1H), 2.58 (s, 1H), 2.32(s, 3H), 2.27-2.18 (m, 1H), 1.50-1.38 (m, 1H), 1.29-1.14 (m, 2H). 1Hburied under solvent.

Example 219(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 217 substituting intermediate A-16 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₂₁FN₆O, 404.2. m/zfound, 405.5 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.90 (d,J=5.0 Hz, 2H), 7.75 (d, J=1.5 Hz, 1H), 7.55-7.52 (m, 1H), 7.49 (t, J=5.0Hz, 1H), 7.15-7.09 (m, 1H), 6.92-6.86 (m, 1H), 6.85-6.82 (m, 1H),4.18-4.13 (m, 1H), 4.01-3.93 (m, 1H), 3.27-3.20 (m, 2H), 2.53 (s, 1H),2.33 (s, 3H), 2.27-2.19 (m, 1H), 1.53 (d, J=10.3 Hz, 1H), 1.21-1.14 (m,1H), 1.06-1.00 (m, 1H).

Example 220((1S,4S,6R)-6-((5-methylpyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 217 substituting intermediate A-16 withintermediate A-37. MS (ESI): mass calcd. for C₂₂H₂₂N₆O, 386.2. m/zfound, 387.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 8.11 (d, J=7.9 Hz, 1H), 7.75 (s, 1H), 7.43 (s, 1H), 7.39(t, J=4.9 Hz, 1H), 7.33 (t, J=7.7 Hz, 1H), 6.96 (d, J=7.5 Hz, 1H),6.87-6.76 (m, 1H), 4.03-3.84 (m, 2H), 3.51 (dt, J=11.1, 3.2 Hz, 1H),2.67-2.57 (m, 1H), 2.33 (s, 3H), 2.28-2.14 (m, 1H), 1.48 (d, J=9.8 Hz,1H), 1.34-1.18 (m, 2H). 1H buried under solvent peak.

Example 221 methyl5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate

Step A: (1S,4S,6R)-tert-butyl6-((5-(methoxycarbonyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (100 mg, 0.471 mmol) inDMF (2 mL) was added methyl 5-chloropyrazine-2-carboxylate (98 mg, 0.57mmol) and Et₃N (0.1 mL, 0.72 mmol), and the reaction mixture was sealedand heated to 70° C. bench top overnight. After 14 hours, LCMS analysisof the reaction mixture showed incomplete conversion of the startingmaterial. The temperature was raised to 100° C. and the reaction mixtureheated overnight. Upon completion of the reaction, the mixture wascooled to room temperature and directly subjected to silica gelchromatography (0-50% EtOAc in hexanes) to give the title compound ofstep A (112 mg). MS (ESI) mass calcd. for C₁₂H₂₄N₄O₄; 348.2. m/z found349.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present as amixture of rotamers) δ 8.78-8.68 (m, 1H), 7.93-7.74 (m, 1H), 6.30-6.18and 5.90-5.77 (two m, 1H), 4.46-4.36 (m, 1H), 4.33-4.12 (m, 1H), 3.91(s, 3H), 3.41-3.30 (m, 1H), 3.11-2.99 (m, 1H), 2.63-2.51 (m, 1H),2.39-2.25 (m, 1H), 1.78-1.59 (m, 2H), 1.51-1.01 (m, 10H).

Step B: methyl5-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-ylamino)pyrazine-2-carboxylate.xHCl.To the title compound of step A (112 mg, 0.321 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (3 mL), and the reaction mixture was stirred atroom temperature for 2 h. The reaction was concentrated to give thetitle compound of step B (99 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₆N₄O₂, 248.1. m/z found249.1 [M+H]⁺.

Step C: methyl5-(((1S,4S,6R)-2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2-azabicyclo[2.2.1]heptan-6-yl)amino)pyrazine-2-carboxylate.To the title compound of step B (99 mg) and intermediate A-1 (70 mg,0.37 mmol) in DMF (2 mL) was added DIPEA (0.3 mL, 1.7 mmol) and HATU(129 mg, 0.339 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound. MS(ESI): mass calcd. for C₂₁H₂₁N₇O₃, 419.2. m/z found, 420.2 [M+H]⁺.Analytical HPLC was obtained on a Agilent 1100 Series using a XBridgeC18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mMNH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rate of1 mL/min (Temperature=30° C.). R_(t)=4.75 min (major rotamer) at 254 nm.

Example 222(2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-39. MS (ESI): mass calcd. for C₁₉H₁₇F₃N₈O, 430.1. m/zfound, 430.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=5.15 min(major rotamer) at 254 nm.

Example 223(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-16. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.9 [M+H]⁺. ¹H NMR (400 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.56 (d,J=3.2 Hz, 1H), 8.20 (d, J=3.1 Hz, 1H), 8.01 (s, 2H), 7.28-7.19 (m, 1H),7.06-6.95 (m, 1H), 6.93-6.85 (m, 1H), 4.10-3.99 (m, 2H), 3.29-3.26 (m,1H), 3.20 (dt, J=11.2, 3.2 Hz, 1H), 2.57-2.51 (m, 1H), 2.25-2.12 (m,1H), 1.54 (d, J=10.3 Hz, 1H), 1.39-1.28 (m, 1H), 1.23-1.08 (m, 1H).

Example 224(4-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-12. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 448.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.56 (s, 1H), 8.22-8.13(m, 1H), 7.98 (s, 2H), 7.64 (dd, J=9.6, 2.6 Hz, 1H), 7.12-6.99 (m, 1H),6.68-6.50 (m, 1H), 4.07-3.95 (m, 1H), 3.80 (s, 1H), 3.54-3.43 (m, 1H),3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.62 (s, 1H), 2.26-2.14 (m, 1H),1.52-1.42 (m, 1H), 1.38-1.29 (m, 2H).

Example 225(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-10. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 447.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported)) δ 8.52 (s, 1H), 8.17 (d,J=3.1 Hz, 1H), 7.95 (s, 2H), 7.85 (dd, J=9.0, 4.8 Hz, 1H), 7.16-7.06 (m,1H), 6.86-6.74 (m, 1H), 4.07-3.97 (m, 1H), 3.80 (s, 1H), 3.47-3.33 (m,2H), 2.65-2.54 (m, 1H), 2.25-2.15 (m, 1H), 1.47 (d, J=10.2 Hz, 1H),1.38-1.31 (m, 1H), 1.31-1.21 (m, 1H).

Example 226(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-11. MS (ESI): mass calcd. for C₂₀H₁₇F₄N₇O, 447.1. m/zfound, 447.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.18 min(major rotamer) at 254 nm.

Example 227(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-23. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.88 (d,J=4.9 Hz, 2H), 8.64-8.47 (m, 1H), 8.16 (d, J=3.1 Hz, 1H), 7.89 (dd,J=10.0, 2.7 Hz, 1H), 7.42 (t, J=4.9 Hz, 1H), 7.12-6.93 (m, 1H), 6.68 (s,1H), 4.09-3.85 (m, 2H), 3.53 (dt, J=10.9, 3.2 Hz, 1H), 3.36 (dd, J=10.9,1.6 Hz, 1H), 2.69-2.61 (m, 1H), 2.30-2.16 (m, 1H), 1.54-1.43 (m, 1H),1.41-1.34 (m, 1H), 1.33-1.23 (m, 1H).

Example 228(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous Example 60 substituting intermediate A-1 withintermediate A-7. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.91:0.09), major rotamer reported) δ 8.84 (d,J=4.8 Hz, 2H), 8.51 (s, 1H), 8.21 (dd, J=8.8, 5.5 Hz, 1H), 8.16 (d,J=3.1 Hz, 1H), 7.38 (t, J=4.9 Hz, 1H), 7.05 (td, J=8.3, 2.7 Hz, 1H),6.80-6.71 (m, 1H), 4.10-4.00 (m, 1H), 3.94 (s, 1H), 3.52 (dt, J=10.7,3.1 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.68-2.60 (m, 1H), 2.27-2.15(m, 1H), 1.49 (d, J=10.1 Hz, 1H), 1.41-1.33 (m, 1H), 1.33-1.23 (m, 1H).

Example 229(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-6. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H),8.56-8.51 (m, 1H), 8.12-8.04 (m, 2H), 7.42 (t, J=4.9 Hz, 1H), 7.36-7.30(m, 1H), 6.73-6.67 (m, 1H), 4.03-3.97 (m, 1H), 3.97-3.90 (m, 1H), 3.56(dt, J=10.9, 3.2 Hz, 1H), 3.36 (dd, J=10.9, 1.7 Hz, 1H), 2.65-2.60 (m,1H), 2.25-2.14 (m, 1H), 1.49-1.39 (m, 2H), 1.20-1.14 (m, 1H).

Example 230(2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-37. MS (ESI): mass calcd. for C₂₂H₁₉F₃N₆O, 440.2. m/zfound, 441.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.86 (d,J=4.9 Hz, 2H), 8.56-8.48 (m, 1H), 8.15 (d, J=8.0 Hz, 1H), 8.10 (s, 1H),7.39 (t, J=4.9 Hz, 1H), 7.36-7.28 (m, 1H), 7.01 (s, 1H), 6.95 (s, 1H),4.11-3.91 (m, 2H), 3.52 (dt, J=11.0, 3.3 Hz, 1H), 3.35 (dd, J=10.9, 1.6Hz, 1H), 2.64 (s, 1H), 2.28-2.16 (m, 1H), 1.56-1.44 (m, 1H), 1.41-1.16(m, 2H).

Example 231(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-34. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.82 (s, 2H),8.58-8.47 (m, 1H), 8.15 (d, J=7.8 Hz, 1H), 8.13-8.04 (m, 1H), 7.32 (t,J=7.6 Hz, 1H), 7.10-6.83 (m, 2H), 4.12-4.03 (m, 1H), 4.04-3.89 (m, 1H),3.56 (dt, J=10.9, 3.3 Hz, 1H), 3.36 (dd, J=10.9, 1.6 Hz, 1H), 2.70-2.62(m, 1H), 2.29-2.17 (m, 1H), 1.61-1.14 (m, 3H).

Example 232(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-50. MS (ESI): mass calcd. for C₂₁H₁₇F₄N₅O₂, 447.1. m/zfound, 447.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.15 min(major rotamer) at 254 nm.

Example 233(3-ethoxy-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 60 substituting intermediate A-1 withintermediate A-8. MS (ESI): mass calcd. for C₂₀H₂₂F₃N₅O₂, 421.2. m/zfound, 422.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.85:0.15), major rotamer reported) δ 8.47 (d,J=3.2 Hz, 1H), 8.11 (d, J=3.1 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.06 (d,J=8.9 Hz, 1H), 4.47-4.42 (m, 1H), 4.08-3.95 (m, 3H), 3.60 (dt, J=11.1,3.2 Hz, 1H), 3.38 (dd, J=11.1, 1.6 Hz, 1H), 2.77-2.69 (m, 1H), 2.36-2.28(m, 1H), 2.26 (s, 3H), 1.92-1.87 (m, 1H), 1.83-1.78 (m, 1H), 1.42-1.35(m, 4H).

Example 234((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing intermediate B-10 (305 mg, 1.44 mmol) inDMF (6 mL) was added 2,5-dichloropyrimidine (257 mg, 1.72 mmol) andDIPEA (0.99 mL, 5.75 mmol), and the reaction mixture was sealed andheated to 80° C. bench top overnight. Upon completion of the reaction,the mixture was cooled to room temperature and diluted with H₂O. Thereaction mixture was extracted with EtOAc (3×). The combined organicswere washed with 5% aqueous LiCl, dried (Na₂SO₄), filtered, andconcentrated. The concentrate was subjected directly to silica gelchromatography (10-90% EtOAc in hexanes) to give the title compound ofstep A (433 mg, 1.33 mmol, 93%). MS (ESI) mass calcd. for C₁₅H₂₁ClN₄O₂;324.1. m/z found 269.1 [M+2H-tBu]⁺.

Step B:(1S,4R,6R)—N-(5-chloropyrimidin-2-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (433 mg, 1.33 mmol) in EtOAc (7 mL) wasadded 4M HCl in dioxane (2 mL), and the reaction mixture was stirred atroom temperature overnight. The reaction was concentrated to give thetitle compound of step B (370 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₀H₁₃ClN₄, 224.1. m/z found225.1 [M+H]⁺.

Step C:((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.To the title compound of step B (30 mg) and intermediate A-16 (25 mg,0.12 mmol) in DMF (1 mL) was added DIPEA (0.10 mL, 0.61 mmol) and HATU(42 mg, 0.11 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Gilson Prep Method X to give the title compound (32mg). MS (ESI): mass calcd. for C₁₉H₁₂ClFN₂O, 413.1. m/z found, 414.0[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers (0.89:0.11), major rotamer reported) δ 8.35-8.20 (m, 1H), 8.00(s, 2H), 7.94-7.82 (m, 1H), 7.33-7.24 (m, 1H), 7.08-7.00 (m, 1H), 6.88(d, J=7.7 Hz, 1H), 4.01 (s, 1H), 3.98-3.92 (m, 1H), 3.27 (dd, J=11.1,1.6 Hz, 1H), 3.18 (dt, J=10.8, 3.0 Hz, 1H), 2.55-2.48 (m, 1H), 2.22-2.12(m, 1H), 1.52 (d, J=10.3 Hz, 1H), 1.30-1.22 (m, 1H), 1.18-1.10 (m, 1H).

Example 235((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-10. MS (ESI): mass calcd. for C₁₉H₁₇ClFN₇O, 413.1. m/zfound, 414.0 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄) δ 8.25 (s, 1H),8.14-8.01 (m, 1H), 7.95 (s, 2H), 7.85 (dd, J=9.0, 4.8 Hz, 1H), 7.17(ddd, J=9.0, 7.8, 2.9 Hz, 1H), 6.84-6.75 (m, 1H), 3.98-3.86 (m, 1H),3.85-3.75 (m, 1H), 3.44-3.38 (m, 1H), 3.36-3.32 (m, 1H), 2.63-2.54 (m,1H), 2.23-2.12 (m, 1H), 1.49-1.41 (m, 1H), 1.34-1.20 (m, 2H).

Example 236((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-2. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d,J=5.0 Hz, 2H), 8.35-8.15 (m, 1H), 8.02-7.85 (m, 1H), 7.49 (t, J=5.0 Hz,1H), 7.20-7.12 (m, 1H), 7.10-7.01 (m, 1H), 6.88 (d, J=7.9 Hz, 1H), 4.14(s, 1H), 4.05-3.95 (m, 1H), 3.26-3.21 (m, 1H), 2.56-2.48 (m, 1H),2.24-2.12 (m, 1H), 1.52 (d, J=9.5 Hz, 1H), 1.31-1.18 (m, 1H), 1.03 (d,J=10.1 Hz, 1H). 1H buried under solvent.

Example 237((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-23. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.87 (d, J=4.9 Hz, 2H),8.34-8.19 (m, 1H), 8.03-7.76 (m, 2H), 7.41 (t, J=4.9 Hz, 1H), 7.10-6.98(m, 1H), 6.80-6.67 (m, 1H), 4.01-3.85 (m, 2H), 3.51 (dt, J=11.0, 3.2 Hz,1H), 3.37-3.31 (m, 1H), 2.62 (s, 1H), 2.25-2.14 (m, 1H), 1.47 (d, J=9.9Hz, 1H), 1.37-1.20 (m, 2H).

Example 238((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-7. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.87:0.13), major rotamer reported) δ 8.84 (d,J=4.8 Hz, 2H), 8.29-8.19 (m, 2H), 7.86 (br. s, 1H), 7.38 (t, J=4.9 Hz,1H), 7.11 (td, J=8.5, 2.7 Hz, 1H), 6.79-6.70 (m, 1H), 3.98-3.88 (m, 2H),3.50 (dt, J=10.9, 3.2 Hz, 1H), 3.34 (dd, J=11.0, 1.7 Hz, 1H), 2.64-2.59(m, 1H), 2.24-2.15 (m, 1H), 1.47 (d, J=10.0 Hz, 1H), 1.35-1.19 (m, 2H).

Example 239((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-6. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min andthen hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min(Temperature=45° C.). R_(t)=1.85 and 2.12 min (major rotamers) at 254nm.

Example 240((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-37. MS (ESI): mass calcd. for C₂₁H₁₉ClN₆O, 406.1. m/zfound, 407.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.88:0.12), major rotamer reported) δ 8.85 (d,J=4.9 Hz, 2H), 8.29-8.18 (m, 1H), 8.14 (dt, J=8.0, 0.9 Hz, 1H),7.92-7.70 (m, 1H), 7.42-7.35 (m, 2H), 7.07-6.92 (m, 2H), 4.10-3.86 (m,2H), 3.50 (dt, J=10.8, 3.3 Hz, 1H), 3.35-3.32 (m, 1H), 2.65-2.59 (m,1H), 2.27-2.13 (m, 1H), 1.54-1.43 (m, 1H), 1.36-1.19 (m, 2H).

Example 241((1S,4S,6R)-6-((5-chloropyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 234 substituting intermediate A-16 withintermediate A-34. MS (ESI): mass calcd. for C₂₁H₁₈ClFN₆O, 424.1. m/zfound, 425.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.87:0.13), major rotamer reported) δ 8.81 (s, 2H),8.38-8.17 (m, 1H), 8.17-8.13 (m, 1H), 7.93-7.75 (m, 1H), 7.44-7.32 (m,1H), 7.11-6.91 (m, 2H), 4.06-3.86 (m, 2H), 3.54 (dt, J=10.8, 3.3 Hz,1H), 3.34 (dd, J=11.0, 1.7 Hz, 1H), 2.71-2.61 (m, 1H), 2.29-2.15 (m,1H), 1.59-1.46 (m, 1H), 1.45-1.27 (m, 2H).

Example 242(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a vial containing intermediate B-10 (100 mg, 0.471 mmol) in MeCN (2mL) was added 3-chloro-6-(trifluoromethyl)pyridazine (103 mg, 0.565mmol) and Et₃N (0.15 mL, 1.1 mmol), and the reaction mixture was sealedand heated to 90° C. bench top overnight. Upon completion of thereaction, the mixture was cooled to room temperature and subjecteddirectly to silica gel chromatography (0-50% EtOAc in hexanes) to givethe title compound of step A (143 mg), which contained a small amount ofimpurity. The title compound was carried forward as is to the next step.MS (ESI) mass calcd. for C₁₆H₂₁F₃N₄O₂; 358.2, m/z found 359.2 [M+H]⁺. ¹HNMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ7.45-7.33 (m, 1H), 6.71-6.56 (m, 1H), 6.12 and 5.60 (2 br. s, 1H),4.53-4.21 (m, 2H), 3.44-3.29 (m, 1H), 3.13-3.01 (m, 1H), 2.63-2.56 (m,1H), 2.50-2.28 (m, 1H), 1.77-1.06 (m, 12H).

Step B:(1S,4R,6R)—N-(6-(trifluoromethyl)pyridazin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (143 mg, 0.399 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (4 mL), and the reaction mixture was stirred atroom temperature for 1.5 h. The reaction was concentrated to give thetitle compound of step B (130 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₁H₁₃F₃N₄, 258.1. m/z found259.2 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (33 mg) and intermediate A-1 (21 mg,0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(42 mg, 0.11 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction was quenched by the addition of H₂Oand the aqueous layer was extracted with EtOAc (2×). The combinedorganics were concentrated and the concentrate subjected directly topurification via Agilent Prep Method X to give the title compound (26mg). MS (ESI): mass calcd. for C₂₀H₁₈F₃N₂O, 429.2. m/z found, 430.2[M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using aXBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rateof 1 mL/min (Temperature=30° C.). R_(t)=5.48 min (major rotamer) at 254nm.

Example 243(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 242 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₀H₁₉F₃N₈O, 444.2. m/zfound, 445.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.86:0.14), major rotamer reported) δ 8.18 (d,J=8.4 Hz, 1H), 7.86 (s, 2H), 7.36 (d, J=9.3 Hz, 1H), 7.33 (d, J=8.3 Hz,1H), 6.73 (d, J=9.3 Hz, 1H), 4.34-4.29 (m, 1H), 3.72 (dt, J=11.0, 3.2Hz, 1H), 3.32 (dd, J=11.0, 1.6 Hz, 1H), 2.84-2.76 (m, 1H), 2.62-2.44 (m,5H), 2.01-1.92 (m, 1H), 1.78-1.69 (m, 1H), 1.26 (dt, J=13.4, 3.4 Hz,1H).

Example 244(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 242 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₂H₂₀F₃N₇O, 455.2. m/zfound, 456.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.93:0.07), major rotamer reported) δ 8.79 (d,J=4.8 Hz, 2H), 8.48 (d, J=8.1 Hz, 1H), 8.16-7.96 (m, 1H), 7.37 (d, J=9.3Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.26-7.23 (m, 1H), 6.77 (d, J=9.2 Hz,1H), 4.27 (s, 1H), 3.74 (dt, J=10.9, 3.2 Hz, 1H), 3.33 (dd, J=10.8, 1.6Hz, 1H), 2.86-2.77 (m, 1H), 2.64-2.49 (m, 5H), 2.03-1.90 (m, 1H), 1.73(d, J=10.1 Hz, 1H), 1.27 (dt, J=13.2, 3.5 Hz, 1H).

Example 245(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridazin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 242 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₆O, 458.1. m/zfound, 459.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.85:0.15), major rotamer reported) δ 8.90 (d,J=4.9 Hz, 2H), 7.39 (t, J=5.0 Hz, 1H), 7.32-7.22 (m, 2H), 7.22-7.16 (m,1H), 7.11-7.06 (m, 1H), 6.47 (d, J=9.3 Hz, 1H), 4.67 (s, 1H), 3.55 (dt,J=11.1, 3.2 Hz, 1H), 3.26 (dd, J=11.0, 1.5 Hz, 1H), 2.79-2.69 (m, 1H),2.54-2.42 (m, 1H), 1.95-1.72 (m, 2H), 1.69-1.61 (m, 1H), 1.20-1.07 (m,1H).

Example 246(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Step A: (1S,4S,6R)-tert-butyl6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To a microwave vial containing degassed toluene (2 mL) was added5-bromo-2-(trifluoromethyl)pyridine (116 mg, 0.514 mmol), intermediateB-10 (120 mg) and racemic BINAP (13 mg, 0.021 mmol) at room temperatureand the reaction mixture was purged with N₂ for 5 min. Then, Pd(OAc)₂(14 mg, 0.021 mmol) and sodium tert-butoxide (71 mg, 0.72 mmol) wereadded and the reaction mixture heated to 70° C. overnight. Uponcompletion of the reaction, the mixture was cooled to room temperatureand the crude material subjected directly to silica gel chromatography(0-50% EtOAc in hexanes) to give the title compound of step A (184 mg).MS (ESI) mass calcd. for C₁₂H₂₂F₃N₃O₂, 357.2. m/z found 358.2 [M+H]⁺. ¹HNMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers) δ8.02 and 7.90 (two s, 1H), 7.46-7.35 (m, 1H), 6.88-6.81 and 6.77-6.68(two m, 1H), 5.39-5.29 and 4.72-4.62 (two m, 1H), 4.47-4.33 (m, 1H),3.87-3.72 (m, 1H), 3.41-3.31 (m, 1H), 3.11-2.99 (m, 1H), 2.64-2.56 (m,1H), 2.37-2.17 (m, 1H), 1.81-1.67 (m, 1H), 1.66-1.60 (m, 1H), 1.53-1.01(m, 11H).

Step B:(1S,4R,6R)—N-(6-(trifluoromethyl)pyridin-3-yl)-2-azabicyclo[2.2.1]heptan-6-amine.xHCl.To the title compound of step A (77 mg, 0.22 mmol) in EtOAc (0.6 mL) wasadded 4M HCl in dioxane (3 mL), and the reaction mixture was stirred atroom temperature for 2.5 h. The reaction was concentrated to give thetitle compound of step B (72 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₄F₃N₃, 257.1. m/z found258.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone.To the title compound of step B (36 mg) and intermediate A-1 (25 mg,0.13 mmol) in DMF (1 mL) was added DIPEA (0.2 mL, 1.2 mmol) and HATU (46mg, 0.12 mmol), and the reaction mixture was stirred at room temperaturefor 1.5 h. The reaction was quenched by the addition of H₂O and theaqueous layer was extracted with EtOAc (2×). The combined organics wereconcentrated and the concentrate subjected directly to purification viaGilson Prep Method X to give the title compound (29 mg). MS (ESI): masscalcd. for C₂₁H₁₉F₃N₆O, 428.2. m/z found, 429.2 [M+H]⁺. Analytical HPLCwas obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.07 min (major rotamer) at 254 nm.

Example 247(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4S,6R)-6-((6-(trifluoromethyl)pyridin-3-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 246 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O, 457.2. m/zfound, 458.1 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers (0.89:0.11), major rotamer reported) δ 8.91 (d,J=5.0 Hz, 2H), 7.87 (d, J=2.7 Hz, 1H), 7.50 (t, J=5.0 Hz, 1H), 7.31 (d,J=8.7 Hz, 1H), 7.06-6.99 (m, 1H), 6.87-6.80 (m, 2H), 6.73 (dd, J=8.7,2.8 Hz, 1H), 4.11 (s, 1H), 3.80-3.71 (m, 1H), 3.28-3.22 (m, 2H),2.60-2.52 (m, 1H), 2.34-2.25 (m, 1H), 1.59 (d, J=10.8 Hz, 1H), 1.24-1.18(m, 1H), 1.11 (d, J=10.3 Hz, 1H).

Example 248(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (R/S)-tert-butyl6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5A (50 mg, 0.22 mmol) dissolved in DMF (2 mL) wasadded NaH (18 mg, 0.44 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-(trifluoromethyl)pyridine (64 mg, 0.35 mmol) was thenadded and the mixture stirred at room temperature for 3 h. The reactionmixture was quenched with saturated NH₄Cl solution, and diluted withEtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered and concentrated. Purification via silica gel chromatography(0-40% EtOAc in hexanes) gave the title compound (67 mg, 0.18 mmol,82%). MS (ESI) mass calcd. for C₁₈H₂₃F₃N₂O₃, 372.2. m/z found 373.2[M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as a mixture ofrotamers, (0.68:0.32), major rotamer reported) δ 8.49-8.45 (m, 1H), 7.94(dd, J=8.8, 2.6 Hz, 1H), 6.90 (d, J=8.7, 0.8 Hz, 1H), 5.22 (dt, J=9.7,2.9 Hz, 1H), 4.48-4.41 (m, 1H), 3.42 (dt, J=10.9, 2.5 Hz, 1H), 3.25 (dt,J=11.0, 2.6 Hz, 1H), 2.27-2.18 (m, 1H), 2.09-2.04 (m, 1H), 1.97-1.87 (m,1H), 1.77-1.71 (m, 1H), 1.68-1.59 (m, 3H), 1.13 (s, 9H).

Step B:(R/S)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (67 mg, 0.18 mmol) in EtOAc (2 mL) wasadded 4 M HCl in dioxane (0.23 mL). After 3 h, the reaction wasconcentrated to give the title compound of step B which was used withoutfurther purification. MS (ESI) mass calcd. for C₁₃H₁₅F₃N₂O, 272.1. m/zfound 273.1 [M+H]⁺.

Step C:(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (46 mg) and intermediate A-2 (54 mg,0.20 mmol, 82% purity) in DMF (1.7 mL) was added DIPEA (0.18 mL, 1.01mmol) and HATU (71 mg, 0.19 mmol), and the reaction mixture was stirredat room temperature overnight. The reaction mixture was diluted with H₂Oand EtOAc. The aqueous layer was extracted with EtOAc (3×) and thecombined organics were concentrated and subjected directly topurification using Gilson Prep Method X to give the title compound (20mg). MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/z found, 473.1[M+H]⁺. Analytical HPLC using a XBridge C18 column (5 um, 100×4.6 mm),mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min and then hold at100% ACN for 2 min, at a flow rate of 2.5 mL/min (Temperature=45° C.).R_(t)=2.18 and 2.29 min (major rotamers) at 254 nm Enantiomers ofExample 248 can be separated by Chiral SFC purification using aChiralpak AZ-H column (5 μm 250×21 mm), mobile phase of 35% EtOH+(0.2%TEA): 65% CO₂, and a flow rate of 40 mL/min (Temperature=40° C.).

Example 249(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 248 substituting intermediate A-2 withintermediate A-16. MS (ESI): mass calcd. for C₂₂H₁₉F₄N₅O₂, 461.2. m/zfound, 461.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound present as amixture of rotamers, major rotamer reported) δ 8.25 (s, 1H), 8.11-7.95(m, 3H), 7.27 (t, J=9.3 Hz, 1H), 7.14-7.00 (m, 2H), 6.91 (d, J=7.8 Hz,1H), 5.14-5.06 (m, 1H), 3.82 (s, 1H), 3.60 (d, J=12.8 Hz, 1H), 3.24 (d,J=12.7 Hz, 1H), 2.34-2.24 (m, 1H), 2.11 (s, 1H), 1.81-1.41 (series of m,5H).

Example 250(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 248 substituting intermediate A-2 withintermediate A-23. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 472.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound is presentas a mixture of rotamers) δ 8.96-8.78 (m, 2H), 8.22-8.14 (m, 1H),8.04-7.97 (m, 1H), 7.92 (dd, J=10.1, 2.6 Hz, 1H), 7.49-7.42 (m, 1H),7.10-6.88 (m, 2H), 6.76-6.58 (m, 1H), 5.05-4.98 (m, 1H), 3.85-3.73 (m,1H), 3.69 (d, J=12.3 Hz, 1H), 3.55-3.48 (m, 1H), 2.33-2.24 (m, 1H),2.21-2.07 (m, 1H), 1.86-1.77 (m, 1H), 1.74-1.37 (m, 3H), 1.27-1.14 (m,1H).

Example 251(R/S)-(2-(5-fluoropyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 248 substituting intermediate A-2 withintermediate A-34. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 472.9 [M+H]⁺. ¹H NMR (500 MHz, Methanol-d₄, Compound is presentas a mixture of rotamers) δ 8.87-8.74 (m, 2H), 8.20-8.12 (m, 2H),8.05-7.93 (m, 1H), 7.65-7.55 (m, 1H), 7.38-7.30 (m, 1H), 7.09-6.86 (m,2H), 5.13-5.02 (m, 1H), 3.84-3.76 (m, 1H), 3.71-3.64 (m, 1H), 3.60-3.51(m, 1H), 2.35-2.26 (m, 1H), 2.22-2.13 (m, 1H), 1.87-1.76 (m, 1H),1.73-1.29 (m, 4H).

Example 252(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (R/S)-tert-butyl6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octane-2-carboxylate.To a microwave vial containing C-7A (308 mg, 1.36 mmol) in MeCN (5 mL)was added 2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) andEt₃N (0.28 mL, 2.04 mmol), and the reaction mixture was sealed andheated to 70° C. bench top overnight. Analysis of the reaction mixturestill showed unreacted starting material. Additional equivalents of2-chloro-5-(trifluoromethyl)pyrazine (0.20 mL, 1.63 mmol) and Et₃N (0.28mL, 2.04 mmol) were added, and the reaction mixture was heated again to70° C. bench top overnight. Upon completion of the reaction, the mixturewas cooled to room temperature and diluted with H₂O. The reactionmixture was extracted with EtOAc (3×). The combined organics wereconcentrated and the concentrate subjected directly to silica gelchromatography (0-30% EtOAc in hexanes) to give the title compound ofstep A (245 mg, 0.658 mmol, 48%) MS (ESI) mass calcd. for C₁₇H₂₃F₃N₄O₂;372.2. m/z found 371.1 [M+2H-tBu]⁺.

Step B:(R/S)—N-(5-(trifluoromethyl)pyrazin-2-yl)-2-azabicyclo[2.2.2]octan-6-amine.xHCl.To the title compound of step A (245 mg, 0.658 mmol) in EtOAc (1 mL) wasadded 4M HCl in dioxane (4 mL), and the reaction mixture was stirred atroom temperature for 3 h. The reaction was concentrated to give thetitle compound of step B (249 mg), which was used without furtherpurification. MS (ESI) mass calcd. for C₁₂H₁₅F₃N₄, 272.1. m/z found273.0 [M+H]⁺.

Step C:(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (50 mg) and intermediate A-40 (36 mg,0.18 mmol) in DMF (0.5 mL) was added DIPEA (0.15 mL, 0.87 mmol) and HATU(68 mg, 0.18 mmol), and the reaction mixture was stirred at roomtemperature for 3 h. The reaction was diluted with MeOH and the crudereaction mixture subjected directly to purification via Agilent PrepMethod X to give the title compound (25 mg). MS (ESI): mass calcd. forC₂₁H₂₁F₃N₈O, 458.2. m/z found, 458.9 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.45 min (major rotamer) at 254 nm.

Example 253(R/S)-(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252, isolated from Step C during HPLCpurification. MS (ESI): mass calcd. for C₂₁H₂₁F₃N₈O, 458.2. m/z found,459.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Seriesusing a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100%ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at aflow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.26 min (majorrotamer) at 254 nm.

Example 254(R/S)-(2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252 substituting intermediate A-40 withintermediate A-1. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₇O, 443.2. m/zfound, 443.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.65 min(major rotamer) at 254 nm.

Example 255(R/S)-(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252 substituting intermediate A-40 withintermediate A-16. MS (ESI): mass calcd. for C₂₁H₁₉F₄N₇O, 461.2. m/zfound, 461.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.65 min(major rotamer) at 254 nm.

Example 256(R/S)-(3-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252 substituting intermediate A-40 withintermediate A-22. MS (ESI): mass calcd. for C₂₂H₂₂F₃N₇O, 457.2. m/zfound, 458.0 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.96 min(major rotamer) at 254 nm.

Example 257(R/S)-(3-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252 substituting intermediate A-40 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 472.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.49 min(major rotamer) at 254 nm.

Example 258(R/S)-(4-fluoro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 252 substituting intermediate A-40 withintermediate A-23. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 472.9 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.57 min(major rotamer) at 254 nm.

Example 259(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-23. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.28 min(major rotamer) at 254 nm.

Example 260(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-7. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.59 min(major rotamer) at 254 nm.

Example 261(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-6. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.41 min(major rotamer) at 254 nm.

Example 262(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-34. MS (ESI): mass calcd. for C₂₄H₂₀F₄N₄O₂, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.83 min(major rotamer) at 254 nm.

Example 263(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-35. MS (ESI): mass calcd. for C₂₄H₁₉F₅N₄O₂, 490.1. m/zfound, 491.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.78 min(major rotamer) at 254 nm.

Example 264(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-47. MS (ESI): mass calcd. for C₂₄H₂₂F₃N₅O₂, 469.2. m/zfound, 470.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.999 min(major rotamer) at 254 nm.

Example 265(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 76 substituting intermediate A-40 withintermediate A-41. MS (ESI): mass calcd. for C₂₄H₂₂F₃N₅O₂, 469.2. m/zfound, 470.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.73 min(major rotamer) at 254 nm.

Example 266(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (52 mg, 0.23 mmol) dissolved in DMF (2 mL) wasadded NaH (18 mg, 0.46 mmol, 60% dispersion in mineral oil). After 5minutes 2,3-difluoro-5-(trifluoromethyl)pyridine (63 mg, 0.34 mmol) wasthen added and the mixture stirred at room temperature for 1 h. Thereaction mixture was quenched with saturated NH₄Cl solution, and dilutedwith EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered, and concentrated. Purification via silica gel chromatography(0-100% EtOAc in hexanes) gave the title compound (67 mg, 0.17 mmol,75%). MS (ESI) mass calcd. for C₁₈H₂₂F₄N₂O₃, 390.2. m/z found 336.1[M+2H-tBu]⁺.

Step B:(1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (67 mg, 0.17 mmol) in EtOAc (2 mL) wasadded 4 M HCl in dioxane (0.22 mL), and the reaction mixture was stirredat room temperature overnight. Analysis of the reaction mixture showedmostly starting material. Additional 4 M HCl in dioxane (0.5 mL) wasadded and the reaction mixture stirred at room temperature for 5 h. Thereaction mixture was then concentrated to give the title compound ofstep B (30 mg) which was used without further purification. MS (ESI)mass calcd. for C₁₃H₁₄F₄N₂O, 290.1. m/z found 291.1 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (30 mg) and intermediate A-2 (27 mg,0.12 mmol) in DMF (1 mL) was added DIPEA (0.11 mL, 0.62 mmol) and HATU(43 mg, 0.11 mmol). Upon completion of the reaction, purification wasperformed using Agilent Prep Method X to give the title compound (11mg). MS (ESI): mass calcd. for C₂₄H₁₉F₅N₄O₂, 490.2. m/z found, 491.1[M+H]⁺. Analytical HPLC was obtained on a Agilent 1100 Series using aXBridge C18 column (5 μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20mM NH₄OH over 8 min and then hold at 100% ACN for 3 min, at a flow rateof 1 mL/min (Temperature=30° C.). R_(t)=7.35 min (major rotamer) at 254nm.

Example 267(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) wasadded NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5minutes 2-chloro-5-methylpyridine (0.03 mL, 0.26 mmol) was then addedand the mixture stirred at room temperature for 2 h. Analysis of thereaction mixture showed only starting material was present. The reactionmixture was heated to 70° C. overnight. Analysis of the reaction mixtureshowed small amount of product formation. Additional NaH was added andthe reaction mixture heated to 70° C. over the weekend. The reactionmixture was quenched with saturated NH₄Cl solution, and diluted withEtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered and concentrated. Purification via silica gel chromatography(0-50% EtOAc in hexanes) gave the title compound (8 mg, 0.03 mmol, 15%).MS (ESI) mass calcd. for C₁₈H₂₆N₂O₃, 318.2. m/z found 319.2 [M+H]⁺.

Step B:(1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (8 mg, 0.03 mmol) in EtOAc (0.3 mL) wasadded 4 M HCl in dioxane (0.03 mL) and the reaction mixture was stirredat room temperature overnight. Analysis of the reaction mixture showedthat starting material still remained. Additional 4 M HCl in dioxane(0.25 mL) was added and the reaction mixture stirred at room temperaturefor 5 h. The reaction was concentrated to give the title compound ofstep B which was used without further purification. MS (ESI) mass calcd.for C₁₃H₁₈N₂O, 218.1. m/z found 219.2 [M+H]⁺.

Step C:(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (5 mg) and intermediate A-2 (6 mg, 0.03mmol) in DMF (0.3 mL) was added DIPEA (0.02 mL, 0.14 mmol) and HATU (10mg, 0.03 mmol), and the reaction mixture was stirred at room temperatureovernight. The reaction mixture was diluted with MeOH and the crudereaction mixture directly subjected to purification using Agilent PrepMethod X to give the title compound (1 mg). MS (ESI): mass calcd. forC₂₄H₂₃FN₄O₂, 418.2. m/z found, 419.2 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.35 min (major rotamer) at 254 nm.

Example 268(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate. Tointermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) was addedNaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5 minutes5-bromo-2-fluoropyridine (0.03 mL, 0.26 mmol) was then added and themixture stirred at room temperature for 2 h. The reaction mixture wasquenched with saturated NH₄Cl solution, and diluted with EtOAc and H₂O.The aqueous layer was extracted with EtOAc (3×). The combined organicswere washed with H₂O, brine, dried with MgSO₄, filtered andconcentrated. Purification via silica gel chromatography (0-100% EtOAcin hexanes) gave the title compound (63 mg, 0.16 mmol, 100%). MS (ESI)mass calcd. for C₁₂H₂₃BrN₂O₃, 382.1. m/z found 383.1 [M+H]⁺.

Step B:(1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (63 mg, 0.16 mmol) in EtOAc (2 mL) wasadded 4 M HCl in dioxane (0.21 mL) and the reaction mixture was stirredat room temperature overnight. Analysis of the reaction mixture showedthat starting material still remained. Additional 4 M HCl in dioxane(0.21 mL) was added and the reaction mixture stirred at room temperaturefor 5 h. The reaction was concentrated to give the title compound ofstep B which was used without further purification. MS (ESI) mass calcd.for C₁₂H₁₅BrN₂O, 282.0. m/z found 283.0 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (23 mg) and intermediate A-1 (47 mg,0.25 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.49 mmol) and HATU(34 mg, 0.09 mmol), and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with MeOH andthe crude reaction mixture directly subjected to purification usingAgilent Prep Method X to give the title compound (7.7 mg). MS (ESI):mass calcd. for C₂₁H₂₀BrN₅O₂, 453.1. m/z found, 454.1 [M+H]⁺. AnalyticalHPLC was obtained on a Agilent 1100 Series using a XBridge C18 column (5μm, 100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 minand then hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=7.51 min (major rotamer) at 254 nm.

Example 269((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 268 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₀BrFN₄O₂, 482.1. m/zfound, 483.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.10 min(major rotamer) at 254 nm.

Example 270(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (37 mg, 0.16 mmol) dissolved in DMF (1.4 mL) wasadded NaH (13 mg, 0.33 mmol, 60% dispersion in mineral oil). After 5minutes 5-chloro-2-fluoropyridine (0.03 mL, 0.26 mmol) was then addedand the mixture stirred at room temperature for 1.5 h. The reactionmixture was quenched with saturated NH₄Cl solution, and diluted withEtOAc and H₂O. The aqueous layer was extracted with EtOAc (3×). Thecombined organics were washed with H₂O, brine, dried with MgSO₄,filtered and concentrated. Purification via silica gel chromatography(0-50% EtOAc in hexanes) gave the title compound (52 mg, 0.15 mmol,94%). MS (ESI) mass calcd. for C₁₂H₂₃ClN₂O₃, 338.1. m/z found 339.2[M+H]⁺.

Step B:(1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (52 mg, 0.15 mmol) in EtOAc (2 mL) wasadded 4 M HCl in dioxane (0.19 mL) and the reaction mixture was stirredat room temperature overnight. The reaction was concentrated to give thetitle compound of step B which was used without further purification. MS(ESI) mass calcd. for C₁₂H₁₅ClN₂O, 238.1. m/z found 239.1 [M+H]⁺.

Step C:(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone.To the title compound of step B (18 mg) and intermediate A-1 (44 mg,0.23 mmol) in DMF (0.8 mL) was added DIPEA (0.08 mL, 0.45 mmol) and HATU(44 mg, 0.23 mmol), and the reaction mixture was stirred at roomtemperature overnight. The reaction mixture was diluted with MeOH andthe crude reaction mixture directly subjected to purification usingAgilent Prep Method X to give the title compound (16 mg). MS (ESI): masscalcd. for C₂₁H₂₀ClN₅O₂, 409.1. m/z found, 410.1 [M+H]⁺. Analytical HPLCwas obtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=7.35 min (major rotamer) at 254 nm.

Example 271((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 270 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₃H₂₀ClFN₄O₂, 438.1. m/zfound, 439.1 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.94 min(major rotamer) at 254 nm.

Example 272(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 77 substituting intermediate A-40 withintermediate A-34. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O₂, 473.1. m/zfound, 474.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.16 min(major rotamer) at 254 nm.

Example 273(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 77 substituting intermediate A-40 withintermediate A-35. MS (ESI): mass calcd. for C₂₃H₁₈F₅N₅O₂, 491.1. m/zfound, 492.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.29 min(major rotamer) at 254 nm.

Example 274(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-16. MS (ESI): mass calcd. for C₂₁H₁₉F₄N₇O, 461.2. m/zfound, 462.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.71 min(major rotamer) at 254 nm.

Example 275(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-1. MS (ESI): mass calcd. for C₂₁H₂₀F₃N₇O, 443.2. m/zfound, 444.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.67 min(major rotamer) at 254 nm.

Example 276(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1R,4S,6S)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-2 (step C), and substituting intermediate C-7B with itsenantiomer (step A), (1R,4S,6S)-tert-butyl6-amino-2-azabicyclo[2.2.2]octane-2-carboxylate. MS (ESI): mass calcd.for C₂₃H₂₀F₄N₆O, 472.2. m/z found, 472.9 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=6.39 min (major rotamer) at 254 nm.

Example 277(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-23. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.62 min(major rotamer) at 254 nm.

Example 278(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-7. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.44 min(major rotamer) at 254 nm.

Example 279(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-6. MS (ESI): mass calcd. for C₂₃H₂₀F₄N₆O, 472.2. m/zfound, 473.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.27 min(major rotamer) and 6.95 at 254 nm.

Example 280(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 83 substituting intermediate A-40 withintermediate A-37. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O, 454.2. m/zfound, 455.4 [M+H]⁺. Analytical HPLC using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 2 min andthen hold at 100% ACN for 2 min, at a flow rate of 2.5 mL/min(Temperature=45° C.). R_(t)=2.01 and 1.98 min (major rotamer) at 254 nm.

Example 281((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane-2-carboxylate.To intermediate C-5B (100 mg, 0.44 mmol) dissolved in DMF (4 mL) wasadded NaH (35 mg, 0.88 mmol, 60% dispersion in mineral oil). After 5minutes 3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (86 μL, 0.66 mmol)was then added and the mixture stirred at room temperature over theweekend. Analysis of the reaction mixture showed mostly startingmaterial. Additional NaH was added. Analysis still showed incompleteconversion, however the reaction mixture was quenched with saturatedNH₄Cl solution, and diluted with EtOAc and H₂O. The aqueous layer wasextracted with EtOAc (3×). The combined organics were washed with H₂O,brine, dried with MgSO₄, filtered, and concentrated. Purification viasilica gel chromatography (0-100% EtOAc in hexanes) gave the titlecompound (38 mg, 0.093 mmol, 21%). MS (ESI) mass calcd. forC₁₈H₂₂ClF₃N₂O₃, 406.1. m/z found 351.1 [M+2H-tBu]⁺.

Step B:(1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octane.xHCl.To the title compound of step A (38 mg, 0.093 mmol) in EtOAc (1.2 mL)was added 4 M HCl in dioxane (0.12 mL), and the reaction mixture wasstirred at room temperature overnight. Analysis of the reaction mixtureshowed that starting material was still present. Additional 4 M HCl indioxane (0.12 mL) was added and the reaction mixture stirred at roomtemperature overnight. The reaction mixture was then concentrated togive the title compound of step B (29 mg) which was used without furtherpurification. MS (ESI) mass calcd. for C₁₃H₁₄ClF₃N₂O, 306.1. m/z found307.1 [M+H]⁺.

Step C:((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.To the title compound of step B (27 mg) and intermediate A-2 (23 mg,0.11 mmol) in DMF (0.9 mL) was added DIPEA (0.09 mL, 0.53 mmol) and HATU(37 mg, 0.097 mmol), and the reaction mixture was stirred overnight atroom temperature. The crude reaction mixture was diluted with MeOH,syringe filtered, and subjected directly to purification using AgilentPrep Method X to give the title compound (11 mg). MS (ESI): mass calcd.for C₂₄H₁₉ClF₄N₄O₂, 506.1. m/z found, 507.1 [M+H]⁺. Analytical HPLC wasobtained on a Agilent 1100 Series using a XBridge C18 column (5 μm,100×4.6 mm), mobile phase of 10-100% ACN in 20 mM NH₄OH over 8 min andthen hold at 100% ACN for 3 min, at a flow rate of 1 mL/min(Temperature=30° C.). R_(t)=7.87 min (major rotamer) at 254 nm.

Example 282(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 77 substituting intermediate A-40 withintermediate A-47. MS (ESI): mass calcd. for C₂₃H₂₁F₃N₆O₂, 470.2. m/zfound, 471.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=6.77 min(major rotamer) at 254 nm.

Example 283((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 266 substituting intermediate A-2 withintermediate A-47. MS (ESI): mass calcd. for C₂₄H₂₁F₄N₅O₂, 487.2. m/zfound, 488.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=30° C.). R_(t)=7.38 min(major rotamer) at 254 nm.

Example 284((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (150 mg, 0.70 mmol) and 2,5-dichloropyrimidine (225mg, 1.51 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91 mmol,60% dispersion in mineral oil). After 3 h LCMS analysis showed that thereaction was incomplete and additional NaH (40 mg, 1.0 mmol, 60%dispersion in mineral oil) was added and the reaction mixture allowed tostir for an additional 45 min and then quenched with H2O. The aqueouslayer was extracted with EtOAc (3×). The combined organics were washedwith H₂O, 5% aqueous LiCl, dried with MgSO₄, filtered, and concentrated.Purification via silica gel chromatography (0-40% EtOAc in hexanes) gavethe title compound (211 mg, 0.65 mmol, 92%) as a colorless solid. MS(ESI) mass calcd. for C₁₅H₂₀ClN₃O₃, 325.1. m/z found 370.1 [M+2H-tBu]⁺.¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture ofrotamers, both rotamers reported) δ 8.44 and 8.39 (two s, 2H), 5.25-5.16(m, 1H), 4.68-4.65 and 4.56-4.52 (two m, 1H), 3.42-3.37 and 3.35-3.31(two m, 1H), 3.24-3.16 (m, 1H), 2.61-2.51 (m, 1H), 2.24-2.13 (m, 1H),1.77-1.40 (m, 3H), 1.35 and 1.12 (2s, 9H).

Step B:(1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane.xHCl.To the title compound of step A (211 mg, 0.65 mmol) in EtOAc (2 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 1.5 h. Then, the reaction was concentrated to givethe title compound of step B (155 mg) as an off-white solid and usedwithout further purification. MS (ESI) mass calcd. for C₁₀H₁₂ClN₃O,225.1. m/z found 226.1 [M+H]⁺.

Step C:((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone.To the title compound of step B (30 mg) and intermediate A-2 (27 mg,0.13 mmol) in DMF (0.4 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(48 mg, 0.13 mmol), and the reaction mixture was stirred at roomtemperature for 2 h. The reaction was diluted with MeOH, filtered, andpurified using Agilent Prep Method X to give the title compound (27 mg).MS (ESI): mass calcd. for C₂₁H₁₇ClFN₅O₂, 425.1. m/z found, 426.1 [M+H]⁺.¹H NMR (500 MHz, Chloroform-d, Compound present as a mixture of rotamers(0.72:0.28), major rotamer reported) δ 8.85 (d, J=4.9 Hz, 2H), 8.29 (s,2H), 7.29-7.26 (m, 1H), 7.12-6.97 (m, 3H), 4.95 (dt, J=10.1, 3.3 Hz,1H), 4.32-4.20 (m, 1H), 3.39-3.31 (m, 2H), 2.63-2.47 (m, 1H), 2.26-2.15(m, 1H), 1.50-1.39 (m, 2H), 1.07-0.97 (m, 1H).

Example 285((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 284 substituting intermediate A-2 withintermediate A-41. MS (ESI): mass calcd. for C₂₁H₁₉ClN₆O₂, 422.1. m/zfound, 423.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.63:0.37), major rotamer reported) δ 8.76 (d,J=4.8 Hz, 2H), 8.43-8.41 (m, 1H), 8.11 (s, 2H), 7.19 (t, J=4.9 Hz, 1H),7.12 (d, J=7.9 Hz, 1H), 4.79 (dt, J=10.3, 3.2 Hz, 1H), 4.48-4.39 (m,1H), 3.78 (dt, J=10.8, 3.0 Hz, 1H), 3.46 (dd, J=10.9, 1.4 Hz, 1H),2.72-2.64 (m, 1H), 2.30 (s, 3H), 2.26-2.18 (m, 1H), 1.67 (dt, J=13.5,3.6 Hz, 1H), 1.56-1.45 (m, 2H).

Example 286((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 287 substituting intermediate A-1 withintermediate A-40. MS (ESI): mass calcd. for C₂₃H₂₁N₇O₂, 427.2. m/zfound, 428.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.86 (dd, J=4.4,2.0 Hz, 1H), 8.06 (dd, J=7.9, 2.0 Hz, 1H), 7.92 (d, J=8.7 Hz, 1H), 7.86(d, J=8.4 Hz, 1H), 7.81 (s, 2H), 7.33 (dd, J=7.9, 4.4 Hz, 1H), 7.03 (d,J=8.8 Hz, 1H), 6.67 (d, J=8.4 Hz, 1H), 5.39 (dt, J=9.9, 3.1 Hz, 1H),4.54-4.43 (m, 1H), 3.71 (dt, J=11.0, 3.2 Hz, 1H), 3.49 (d, J=11.0 Hz,1H), 2.69-2.66 (m, 1H), 2.39-2.23 (m, 1H), 2.03 (s, 3H), 1.58-1.50 (m,3H).

Example 287((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Step A: (1S,4R,6R)-tert-butyl6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate.To intermediate B-5 (150 mg, 0.70 mmol) and 2-chloro-1,8-naphthyridine(225 mg, 1.37 mmol) dissolved in DMF (2 mL) was added NaH (37 mg, 0.91mmol, 60% dispersion in mineral oil). After 50 min the mixture wasquenched with H₂O and the aqueous layer was extracted with EtOAc (3×).The combined organics were washed with 5% aqueous LiCl, brine, driedwith MgSO₄, filtered, and concentrated. Purification via silica gelchromatography (0-100% EtOAc in hexanes) gave the title compound (200mg) as a colorless solid. MS (ESI) mass calcd. for C₁₉H₂₃N₃O₃, 341.2.m/z found 342.2 [M+H]⁺.

Step B:2-((1S,4R,6R)-2-azabicyclo[2.2.1]heptan-6-yloxy)-1,8-naphthyridine.xHCl.To the title compound of step A (200 mg, 0.59 mmol) in EtOAc (2 mL) wasadded 4M HCl in dioxane (4 mL) and the reaction mixture was stirred atroom temperature for 2 h. Then, the reaction was concentrated to givethe title compound of step B (192 mg) as a colorless solid and usedwithout further purification. MS (ESI) mass calcd. for C₁₄H₁₅N₃O₃,241.1. m/z found 242.1 [M+H]⁺.

Step C:((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.To the title compound of step B (30 mg) and intermediate A-1 (20 mg,0.11 mmol) in DMF (0.5 mL) was added DIPEA (0.1 mL, 0.58 mmol) and HATU(40 mg, 0.11 mmol), and the reaction mixture was stirred at roomtemperature for 1 h. The reaction mixture was diluted with MeOH,filtered, and purified using Agilent Prep Method X to give the titlecompound (22 mg). MS (ESI): mass calcd. for C₂₃H₂₀N₆O₂, 412.2. m/zfound, 413.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J=4.4,2.0 Hz, 1H), 8.11 (dd, J=7.9, 2.0 Hz, 1H), 8.05 (d, J=8.8 Hz, 1H),7.82-7.74 (m, 3H), 7.35 (dd, J=7.9, 4.4 Hz, 1H), 7.10 (dd, J=7.7, 1.5Hz, 1H), 7.03 (d, J=8.7 Hz, 1H), 7.00-6.92 (m, 1H), 6.54 (t, J=7.6 Hz,1H), 5.44 (dt, J=10.2, 3.2 Hz, 1H), 4.28-4.19 (m, 1H), 3.65 (dt, J=10.9,3.2 Hz, 1H), 3.43 (d, J=9.5 Hz, 1H), 2.72-2.62 (m, 1H), 2.45-2.31 (m,1H), 1.52-1.42 (m, 3H).

Example 288((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 121 substituting intermediate A-1 withintermediate A-47. MS (ESI): mass calcd. for C₂₃H₂₁F₂N₅O₂, 437.2. m/zfound, 438.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 8.77 (d, J=4.9 Hz,2H), 8.28-8.19 (m, 1H), 7.83-7.77 (m, 1H), 7.69 (dd, J=8.7, 2.4 Hz, 1H),7.66-7.64 (m, 1H), 7.21 (t, J=4.9 Hz, 1H), 6.91 (d, J=8.6 Hz, 1H), 6.59(t, J=56.1 Hz, 1H), 5.02 (dt, J=10.3, 3.4 Hz, 1H), 4.33-4.21 (m, 1H),3.70 (dt, J=10.8, 3.2 Hz, 1H), 3.46 (dd, J=10.7, 1.4 Hz, 1H), 2.72-2.63(m, 1H), 2.26 (s, 3H), 2.23-2.16 (m, 1H), 1.61-1.35 (m, 3H).

Example 289(2-methoxy-6-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-13. MS (ESI): mass calcd. for C₂₂H₂₀F₃N₅O₃, 459.2. m/zfound, 460.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=6.84 min(major rotamer) at 254 nm.

Example 290(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-46. MS (ESI): mass calcd. for C₂₃H₂₀F₃N₅O₂, 455.2. m/zfound, 456.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.87 (d,J=4.8 Hz, 2H), 8.47 (dd, J=2.1, 0.8 Hz, 1H), 8.18-8.10 (m, 1H), 7.80(dd, J=8.7, 2.5 Hz, 1H), 7.31-7.28 (m, 2H), 6.83-6.78 (m, 1H), 5.02 (dt,J=10.1, 3.3 Hz, 1H), 4.18-4.09 (m, 1H), 3.65 (dt, J=10.9, 3.2 Hz, 1H),3.43 (dd, J=10.9, 1.5 Hz, 1H), 2.70-2.60 (m, 1H), 2.28-2.18 (m, 1H),2.04 (s, 3H), 1.47-1.38 (m, 2H), 1.32-1.24 (m, 1H).

Example 291(4-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-51. MS (ESI): mass calcd. for C₂₂H₁₈F₄N₄O₃, 462.1. m/zfound, 463.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 8.10-8.01 (m, 1H),7.80 (dd, J=8.8, 2.5 Hz, 1H), 7.72 (dd, J=8.9, 2.6 Hz, 1H), 7.02 (dd,J=8.5, 5.4 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.76-6.68 (m, 1H), 5.06 (dt,J=10.1, 3.3 Hz, 1H), 4.14-4.08 (m, 1H), 3.77 (dt, J=11.0, 3.2 Hz, 1H),3.44 (dd, J=10.9, 1.5 Hz, 1H), 2.76-2.71 (m, 1H), 2.45 (s, 3H),2.35-2.22 (m, 1H), 1.73-1.66 (m, 1H), 1.59-1.55 (m, 1H), 1.46 (dt,J=13.6, 3.6 Hz, 1H).

Example 292(2-fluoro-6-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-50. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₃O₃, 447.1. m/zfound, 448.5 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=7.18 min(major rotamer) at 254 nm.

Example 293(5-fluoro-2-(oxazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-49. MS (ESI): mass calcd. for C₂₂H₁₇F₄N₃O₃, 447.1. m/zfound, 448.5 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 8.05-8.02 (m, 1H),7.92 (dd, J=8.7, 5.3 Hz, 1H), 7.80 (dd, J=8.6, 2.5 Hz, 1H), 7.69 (d,J=0.8 Hz, 1H), 7.21 (d, J=0.8 Hz, 1H), 6.99-6.92 (m, 1H), 6.81 (d, J=8.7Hz, 1H), 6.69 (dd, J=8.4, 2.7 Hz, 1H), 5.03 (dt, J=10.2, 3.3 Hz, 1H),4.16-4.08 (m, 1H), 3.74 (dt, J=11.0, 3.2 Hz, 1H), 3.44 (dd, J=10.9, 1.5Hz, 1H), 2.74-2.63 (m, 1H), 2.30-2.21 (m, 1H), 1.63-1.56 (m, 1H),1.55-1.49 (m, 1H), 1.45 (dt, J=13.5, 3.6 Hz, 1H).

Example 294(5-methyl-3-(1H-1,2,3-triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 with theN-1 isomer, 5-methyl-3-(1H-1,2,3-triazol-1-yl)picolinonitrile, fromintermediate A-19. MS (ESI): mass calcd. for C₂H₁₉F₃N₆O₂, 444.2. m/zfound, 445.6 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 8.12 (d, J=1.1 Hz,1H), 8.02-7.98 (m, 1H), 7.97-7.94 (m, 1H), 7.81 (d, J=1.1 Hz, 1H),7.78-7.76 (m, 1H), 7.72 (dd, J=8.8, 2.5 Hz, 1H), 6.74-6.69 (m, 1H), 4.99(dt, J=10.2, 3.3 Hz, 1H), 4.43-4.34 (m, 1H), 3.48 (dt, J=11.2, 3.1 Hz,1H), 3.41 (dd, J=11.2, 1.5 Hz, 1H), 2.66-2.60 (m, 1H), 2.34 (s, 3H),2.25-2.17 (m, 1H), 1.60-1.53 (m, 1H), 1.40 (dt, J=13.6, 3.6 Hz, 1H),1.34-1.27 (m, 1H).

Example 295(4-methoxy-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-15. MS (ESI): mass calcd. for C₂₄H₂₁F₃N₄O₃, 470.2. m/zfound, 471.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.78 (d,J=4.8 Hz, 2H), 8.14-8.06 (m, 1H), 7.79 (dd, J=8.7, 2.5 Hz, 1H), 7.70 (d,J=2.6 Hz, 1H), 7.19 (t, J=4.8 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.85-6.83(m, 1H), 6.45 (dd, J=8.4, 2.6 Hz, 1H), 5.04 (dt, J=10.1, 3.4 Hz, 1H),4.19-4.09 (m, 1H), 3.81 (s, 3H), 3.62 (dt, J=10.9, 3.2 Hz, 1H), 3.40(dd, J=10.8, 1.5 Hz, 1H), 2.65-2.59 (m, 1H), 2.27-2.15 (m, 1H),1.44-1.35 (m, 2H), 1.29-1.17 (m, 1H).

Example 296(3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-42. MS (ESI): mass calcd. for C₂₂H₁₈F₃N₅O₂, 441.1. m/zfound, 442.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.81:0.19), major rotamer reported) δ 8.78 (d,J=4.8 Hz, 2H), 8.47 (dd, J=8.0, 1.7 Hz, 1H), 7.97-7.90 (m, 1H), 7.83(dd, J=4.7, 1.7 Hz, 1H), 7.73 (dd, J=8.8, 2.6 Hz, 1H), 7.22 (t, J=4.9Hz, 1H), 7.15 (dd, J=8.0, 4.7 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 5.04 (dt,J=10.2, 3.4 Hz, 1H), 4.35-4.20 (m, 1H), 3.73 (dt, J=10.8, 3.2 Hz, 1H),3.47 (d, J=10.9 Hz, 1H), 2.72-2.65 (m, 1H), 2.30-2.13 (m, 1H), 1.60-1.44(m, 3H).

Example 297(2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-37. MS (ESI): mass calcd. for C₂₃H₁₉F₃N₄O₂, 440.1. m/zfound, 441.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.88:0.12), major rotamer reported) δ 8.78 (d,J=4.8 Hz, 2H), 8.17 (dd, J=8.0, 1.2 Hz, 1H), 8.06-8.00 (m, 1H), 7.78(dd, J=8.7, 2.5 Hz, 1H), 7.30 (td, J=7.7, 1.4 Hz, 1H), 7.19 (t, J=4.8Hz, 1H), 7.00 (dd, J=7.6, 1.3 Hz, 1H), 6.88 (td, J=7.5, 1.3 Hz, 1H),6.83 (d, J=8.7 Hz, 1H), 5.01 (dt, J=10.2, 3.4 Hz, 1H), 4.24-4.10 (m,1H), 3.64 (dt, J=10.9, 3.2 Hz, 1H), 3.41 (dd, J=10.8, 1.5 Hz, 1H),2.66-2.61 (m, 1H), 2.27-2.12 (m, 1H), 1.47-1.37 (m, 2H), 1.34-1.19 (m,1H).

Example 298(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 25 substituting intermediate A-20 withintermediate A-47. MS (ESI): mass calcd. for C₂₃H₂₀F₃N₅O₂, 455.2. m/zfound, 456.4 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d, Compound present asa mixture of rotamers (0.87:0.13), major rotamer reported) δ 8.78 (d,J=4.8 Hz, 2H), 8.27-8.21 (m, 1H), 7.95-7.92 (m, 1H), 7.74 (dd, J=8.4,2.7 Hz, 1H), 7.65-7.62 (m, 1H), 7.22 (t, J=4.8 Hz, 1H), 6.95-6.90 (m,1H), 5.03 (dt, J=10.3, 3.3 Hz, 1H), 4.32-4.27 (m, 1H), 3.71 (dt, J=10.9,3.2 Hz, 1H), 3.46 (dd, J=10.8, 1.4 Hz, 1H), 2.72-2.64 (m, 1H), 2.26 (s,3H), 2.25-2.18 (m, 1H), 1.59-1.45 (m, 3H).

Example 299((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 284 substituting intermediate A-2 withintermediate A-40. MS (ESI): mass calcd. for C₁₉H₁₈ClN₇O₂, 411.1. m/zfound, 412.3 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 nm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=5.23 min(major rotamer) at 254 nm.

Example 300(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Prepared analogous to Example 284 substituting intermediate A-2 withintermediate A-1. MS (ESI): mass calcd. for C₁₉H₁₇ClN₆O₂, 396.1. m/zfound, 397.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d, Compound present asa mixture of rotamers, major reported) δ 8.22 (s, 2H), 7.88-7.85 (m,1H), 7.81 (s, 2H), 7.40-7.31 (m, 1H), 7.17 (dd, J=7.7, 1.5 Hz, 1H), 6.90(t, J=7.5 Hz, 1H), 4.87 (dt, J=10.2, 3.3 Hz, 1H), 4.10-3.98 (m, 1H),3.63 (dt, J=10.9, 3.2 Hz, 1H), 3.42 (dd, J=10.9, 1.4 Hz, 1H), 2.66-2.60(m, 1H), 2.29-2.12 (m, 1H), 1.54 (dt, J=13.6, 3.5 Hz, 1H), 1.42-1.33 (m,2H).

Example 301((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Prepared analogous to Example 287 substituting intermediate A-1 withintermediate A-2. MS (ESI): mass calcd. for C₂₅H₂₀FN₅O₂, 441.2. m/zfound, 442.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=4.68 min at254 nm.

Example 302((1S,4R,6R)-6-((1,8-naphthyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Prepared analogous to Example 287 substituting intermediate A-1 withintermediate A-41. MS (ESI): mass calcd. for C₂₅H₂₂N₆O₂, 438.2. m/zfound, 439.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=4.33 min(major rotamer) at 254 nm.

Example 303(2-(pyridazin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 304(2-(pyridazin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 305(2-(pyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 306(2-(pyridin-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 307(2-(pyridin-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 308(2-(pyrazin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 309(2-(3-methylpyridin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 310(2-(5-methylisoxazol-3-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 311(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 312((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 313((1S,4R,6R)-6-((4,6-dimethylpyrimidin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 314(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 315((1S,4R,6R)-6-((5-(difluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 316(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 317(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 318((1S,4R,6R)-6-((5-(hydroxymethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 319((1S,4R,6R)-6-((5-(fluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 320(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 321(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 322(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 323(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 324(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 325(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 326(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 327(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 328(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 329(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 330(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 331(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 332[2,3′-bipyridin]-2′-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 333[2,2′-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 334(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 335(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 336(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 337(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 338(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 339(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 340(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 341(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 342(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 343(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 344(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 345(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 346(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 347(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 348(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 349(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 350(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 351(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 352(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 353(3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 354(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 355(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 356(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 357(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 358(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 359(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 360(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 361(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 362(2-(pyridazin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 363(2-(pyridazin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 364(2-(pyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 365(2-(pyridin-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 366(2-(pyridin-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 367(2-(pyrazin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 368(2-(3-methylpyridin-2-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 369(2-(5-methylisoxazol-3-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 370(2-(3,5-dimethylisoxazol-4-yl)phenyl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 371(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 372(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 373(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 374(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 375(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 376(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 377(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 378(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 379(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 380(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 381(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 382(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 383[2,3′-bipyridin]-2′-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 384[2,2′-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 385(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 386(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 387(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 388(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 389(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 390(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 391(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 392(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 393(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 394(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 395(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 396(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 397(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 398(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 399(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 400(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 401(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 402(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 403(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 404(3-(oxazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 405(2-(oxazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 406(5-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 407(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 408(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 409(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 410(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 411(3-(thiazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 412(2-(thiazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 413((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 414((1S,4S,6R)-6-((4,6-dimethylpyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 415(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 416((1S,4S,6R)-6-((5-(difluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 417(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 418(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 419(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 420(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Prepared analogous to Example 77 substituting intermediate A-40 withintermediate A-6. MS (ESI): mass calcd. for C₂₃H₁₉F₄N₅O₂, 473.2. m/zfound, 474.2 [M+H]⁺. Analytical HPLC was obtained on a Agilent 1100Series using a XBridge C18 column (5 μm, 100×4.6 mm), mobile phase of10-100% ACN in 20 mM NH₄OH over 8 min and then hold at 100% ACN for 3min, at a flow rate of 1 mL/min (Temperature=45° C.). R_(t)=6.79 min(major rotamer) at 254 nm.

Example 421(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 422(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 423(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 424(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 425(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 426(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 427(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 428(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 429((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 430(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 431(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 432(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 433((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 434((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 435((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 436((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 437((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 438((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 439(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 440(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 441((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 442((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 443((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 444((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 445((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 446((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 447((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 448((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 449((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 450((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 451((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 452(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 453((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 454(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 455(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 456(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 457(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 458(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 459(2-(5-fluoropyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 460(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 461(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 462(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 463(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 464(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 465(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 466(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 467((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 468((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 469((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 470((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 471((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 472((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 473((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 474((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 475((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 476((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 477((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 478((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 479((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 480((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 481((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 482((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 483((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(5-fluoropyrimidin-2-yl)phenyl)methanone

Example 484((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 485((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 486((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 487((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 488((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 489((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 490((1S,4R,6R)-6-((5-bromopyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 491(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 492(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 493(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 494(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 495(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 496(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 497(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 498(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 499(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 500(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 501(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 502(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 503(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 504(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 505(2-fluoro-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 506(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 507(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 508(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 509(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 510(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 511(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 512(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 513((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 514((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 515((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 516((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 517((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 518((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 519((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 520((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 521(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 522((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 523((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 524((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 525((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 526((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 527((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 528((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 529((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 530((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 531((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 532(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 533((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 534((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 535((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 536((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 537((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 538((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 539(5-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 540(4-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 541((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 542((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 543(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 544(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 545(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 546((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 547((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl)methanone

Example 548((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)methanone

Example 549((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone

Example 550((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 551((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(4-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 552((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 553((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 554(2-(2H-1,2,3-triazol-2-yl)phenyl)((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 555((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Example 556((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2-(pyrimidin-2-yl)phenyl)methanone

Example 557((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 558((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 559(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 560((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 561((1S,4R,6R)-6-((5-chloropyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)methanone

Example 562((1S,4R,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)methanone

Example 563(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 564(5-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 565(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 566(6-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 567(5-methyl-2-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 568(5-methyl-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 569(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 570((1S,4R,6R)-6-((5-chloropyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone

Example 571(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 572((1S,4R,6R)-6-((3-fluoro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone

Example 573((1S,4R,6R)-6-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-methoxy-6-(pyrimidin-2-yl)phenyl)methanone

Example 574(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 575(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 576(2-methoxy-6-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 577(3-fluoro-2-(pyrimidin-2-yl)phenyl)((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 578((1S,4R,6R)-6-((5-methylpyrazin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)(2-(pyrimidin-2-yl)phenyl)methanone

Example 579(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 580(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 581(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 582(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 583(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 584(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 585(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 586(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 587(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 588(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 589(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 590(4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 591[2,3′-bipyridin]-2′-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 592[2,2′-bipyridin]-3-yl((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 593(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 594(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 595(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 596(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 597(3,4′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 598(3-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 599(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 600(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 601(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 602(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 603(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 604(3-fluoro-4′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 605(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 606(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 607(5-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 608(6-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 609(6-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 610(5-methyl-2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 611(4-methyl-3-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 6123-(oxazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 613(2-(oxazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 6145-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 615(6-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 616(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 617(5-methyl-2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 618(4-methyl-3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 619(3-(thiazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 620(2-(thiazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 621(2-(1-methyl-1H-imidazol-2-yl)phenyl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 622(2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 623(3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 624(5-methyl-3-(1-methyl-1H-imidazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 625(6-methyl-2-(1-methyl-1H-imidazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 626(6-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 627(2-methyl-4-(pyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)oxy)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 628(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 629(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 630(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 631(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 632(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 633(5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 634[2,2′-bipyridin]-3-yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 635(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 636(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 637(3′,5-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 638(3′-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 639(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 640(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 641(3′-fluoro-5-methyl-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 642(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)methanone

Example 643(3-(5-fluoropyrimidin-2-yl)-5-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 644(2-(5-fluoropyrimidin-2-yl)-6-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 645(3-(5-fluoropyrimidin-2-yl)-6-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 646(2-(5-fluoropyrimidin-2-yl)-5-methylpyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 647(3-(5-fluoropyrimidin-2-yl)-4-methylpyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 648(5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 649(6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 650(6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 651(3-(5-fluoropyrimidin-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 652(2-(5-fluoropyrimidin-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 653(3,5′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 654(3′,6-dimethyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 655(3,6′-dimethyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 656(3-fluoro-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 657(3′-fluoro-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 658(3-fluoro-5′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 659(3′-fluoro-6-methyl-[2,2′-bipyridin]-3-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Example 660(3-fluoro-6′-methyl-[2,3′-bipyridin]-2′-yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin-2-yl)amino)-2-azabicyclo[2.2.2]octan-2-yl)methanone

Assays:

The in vitro affinity of the compounds of the invention for therat/human orexin 1 and human orexin 2 receptors was determined bycompetitive radioligand binding using[³H](1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)(Langmeadet al., 2004) and [³H]EMPA(n-ethyl-2[96-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethylacetamide), respectively (Langmead et al., 2004, British Journal ofPharmacology 141:340-346; Malherbe et al., 2004, British Journal ofPharmacology 156:1326-41).

The in vitro functional antagonism of the compounds on the human orexin1 and orexin 2 receptors was determined using fluorometric imaging platereader (FLIPR) based calcium assays.

Data are analyzed using pc-Sandy macro and graphed on Graphpad Prism 5.For analysis, each concentration point is averaged from triplicatevalues and the averaged values are plotted on Graphpad Prism. The IC50was determined by applying the following equation (GraphPad Prism 5.0,SanDiego) for one site competition where X=log (concentration) andY=specific binding. Top denotes the total[³H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)binding, bottom denotes the nonspecific[³H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)binding. Graphpad Prism calculates Ki value from IC50 and thepre-determined Kd values for[³H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)and [3H]-EMPA. The Ki for each compound is then uploaded into 3DX. Eachrun comprises individual compounds in triplicate. The data in Table 1and Table 2 represent averages from between 2-20 runs

Rat and Human Orexin 1 Receptor Radioligand Binding Studies

Human Embryonic Kidney 293 cells (HEK293) stably expressing rat orexin 1receptor (Genebank accession number NM_(—)001525) or Chinese ovary cells(CHO) stably expressing human orexin 1 receptor (Genebank accessionnumber NM_(—)001526) were grown to confluency in DMEM (Hyclone, cat #SH30022), 10% FBS, 1× Pen/Strep, 1× sodium pyruvate, 10 mM HEPES, 600μg/mL G418 and DMEM/F12 (Gibco, Cat #11039), 10% FBS, 1× Pen/Strep, 600μg/mL G418 media, respectively on 150 cm² tissue culture plates, washedwith 5 mM EDTA in PBS (HyClone Dulbecco's Phosphate Buffered Saline 1×with Calcium and Magnesium, Cat # SH30264.01, hereafter referred tosimply as PBS) and scraped into 50 ml tubes. After centrifugation (2KxG, 5 min at 4° C.), the supernatant was aspirated and the pelletsfrozen and stored at −80° C. Cells were resuspended in PBS in thepresence of 1 tablet of protease inhibitor cocktail (Roche, Cat.#11836145001) per 50 mL. Each cell pellet from a 15 cm plate wasresuspended in 10 mL, stored on ice, and homogenized for 45 sec prior toaddition to the reactions. Competition binding experiments in 96 wellpolypropylene plates were performed using[³H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)(Moraveck Corporation, specific activity=35.3 Ci/mmol), diluted to a 10nM concentration in PBS (4 nM final). Compounds were solubilized in 100%DMSO (Acros Organics, Cat. #61042-1000) and tested over a range of 7concentrations (from 0.1 nM to 10 μM). The final concentration of DMSOin the reactions is equal to or less than 0.1%. Total and nonspecificbinding was determined in the absence and presence of 10 μM almorexant.The total volume of each reaction is 200 μL (20 μL of diluted compounds,80 μL of[³H]-(1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-((S)-2-(5-phenyl-(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone)diluted in PBS and 100 μL of the cell suspension). Reactions were runfor 60 min at room temperature and terminated by filtration through GF/Cfilter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3%polyethylenimine using the cell harvester (PerkinElmer Filtermate). Theplates were washed 3 times by aspirating 30 ml PBS through the plates.Plates were dried in 55° C. oven for 60 min, scintillation fluid wasadded, and the radioactivity was counted on a Topcount (Packard).

IC₅₀ values (i.e. concentration of unlabelled compound required tocompete for 50% of specific binding to the radioligand) was calculatedusing the GraphPad Prism software (GraphPad Prism Software Inc., SanDiego, Calif.) with a fit to a sigmoidal dose-response curve. ApparentKi values were calculated as K_(i)=IC₅₀/(1+C/K_(d)), where C isconcentration of radioligand and K_(d)=4 nM for rat orexin 1 receptorand 6 nM for human orexin 1 receptor.

Human Orexin 2 Receptor Radioligand Binding Studies

HEK293 stably expressing human orexin 2 receptor (Genebank accessionnumber NM_(—)001526) were grown to confluency in DMEM (Hyclone, cat #SH30022), 10% FBS, 1× Pen/Strep, 1× NaPyruvate, 10 mM HEPES, 600 ug/mlG418 media on 150 cm² tissue culture plates, washed with 5 mM EDTA inPBS (HyClone Dulbecco's Phosphate Buffered Saline 1× with Calcium andMagnesium, Cat # SH30264.01, hereafter referred to simply as PBS) andscraped into 50 ml tubes. After centrifugation (2K xG, 5 min at 4° C.),the supernatant was aspirated and the pellets frozen and stored at −80°C. Cells were resuspended in PBS in the presence of 1 tablet of proteaseinhibitor cocktail (Roche, Cat. #11836145001) per 50 mL. Each cellpellet from a 15 cm plate was resuspended in 10 mL, stored on ice, andhomogenized for 45 sec just prior to addition to the reactions.Competition binding experiments in 96 well polypropylene plates wereperformed using [³H]-EMPA (Moraveck Corporation, specific activity=29.6Ci/mmol), diluted to a 5 nM concentration in PBS (2 nM finalconcentration). Compounds were solubilized in 100% DMSO (Acros Organics,Cat. #61042-1000) and tested over a range of 7 concentration (from 0.1nM to 10 μM). The final concentration of DMSO in the reactions is equalto or less than 0.1%. Total and nonspecific binding was determined inthe absence and presence of 10 μM almorexant. The total volume of eachreaction is 200 μL (20 μL of diluted compounds, 80 μL of [³H]-EMPAdiluted in PBS and 100 μL of the cell suspension). Reactions were runfor 60 min at room temperature and terminated by filtration through GF/Cfilter plates (PerkinElmer, Cat. #6005174) presoaked in 0.3%polyethylenimine using the cell harvester (PerkinElmer Filtermate). Theplates were washed 3 times by aspirating 30 ml PBS through the plates.Plates were dried in 55° C. oven for 60 min, scintillation fluid wasadded, and the radioactivity was counted on a Topcount (Packard).

IC₅₀ values (i.e. concentration of unlabelled compound required tocompete for 50% of specific binding to the radioligand) was calculatedusing the GraphPad Prism software (GraphPad Prism Software Inc., SanDiego, Calif.) with a fit to a sigmoidal dose-response curve. ApparentKi values were calculated as K_(i)=IC₅₀/(1+C/K_(d)), where C isconcentration of radioligand and K_(d)=2 nM.

Human Orexin 1 Receptor Ca²⁺ Mobilization Assay

CHO cells stably transfected with the human orexin 1 receptor (Genebankaccession number NM_(—)001526) were grown to confluency in DMEM/F12, 10%FBS, 1× pen-strep, 400 μg/ml G418. Cells were seeded on to 384-wellPackard viewplates at a density of 10,000 cells/well and incubatedovernight at 37° C., 5% CO2. The cells were dye-loaded with BD CalciumAssay kit (BD, cat #640178) in HBSS (Gibco, cat#14025-092) with 2.5 mMprobenecid and incubated at 37° C., 5% CO₂ for 45 min. Cells werepre-incubated with compounds (diluted in DMEM/F-12) for 15-30 minutesbefore agonist (orexin A, 10 nM) stimulation. Ligand-induced Ca²⁺release was measured using a Fluorometric Imaging Plate Reader (FLIPR,Molecular Devices, Sunnyvale, Calif.). Functional responses weremeasured as peak fluorescence intensity minus basal. The concentrationof agonist that produced a half-maximal response is represented by theEC₅₀ value. Antagonistic potency values were converted to apparentpK_(B) values using a modified Cheng-Prusoff correction. ApparentpK_(B)=−log IC₅₀/1+[conc agonist/EC₅₀].

Human Orexin 2 Receptor Ca²⁺ Mobilization Assay

PFSK-1 cells endogenously expressing the human orexin 2 receptor weregrown to confluency in RPMI1640 (Hyclone, cat#30027.02), 10% FBS, 1×pen-strep. Cells were seeded on to 384-well Packard viewplates at adensity of 5,000 cells/well and incubated overnight at 37° C., 5% CO2.The cells were dye-loaded with BD Calcium Assay kit (BD, cat #640178) inHBSS (Gibco, cat#14025-092) with 2.5 mM probenecid and incubated at 37°C., 5% CO₂ for 45 min. Cells were pre-incubated with compounds (dilutedin DMEM/F-12) for 15-30 minutes before agonist (orexin B, 100 nM)stimulation. Ligand-induced Ca²⁺ release was measured using aFluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale,Calif.). Functional responses were measured as peak fluorescenceintensity minus basal. The concentration of agonist that produced ahalf-maximal response is represented by the EC₅₀ value. Antagonisticpotency values were converted to apparent pK_(B) values using a modifiedCheng-Prusoff correction. Apparent pK_(B)=−log IC₅₀/1+[concagonist/EC₅₀].

Preferred compounds of the invention are set forth in the table below.Orexin receptor activity of certain compounds of the invention is alsoset forth in Table 1 below.

TABLE 1 rOX1 hOX1 hOX2 Ex. K_(i) K_(i) K_(i) No. Compound (nM) (nM) (nM)Compound Name  1

  74 120  4700 (R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  2

  200 342  10000 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  3

  63 123  8900 (R/S)-(3- ethoxyisoquinolin-4- yl)((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  4

  837 >10000 (R/S)-5-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  7

  21  12   800 (R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  8

  16  15  1450 (R/S)-(3- ethoxyisoquinolin-4- yl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  9

  56 101  2554 (R/S)-(5-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 10

  18  27   526 (R/S)-(7- ethoxyquinolin-8-yl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 11

  11  8  1475 (R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 12

  44  59 >10000 (R/S)-(4-methoxy-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 13

  52 109 >10000 (R/S)-4-methoxy-2- (2H-1,2,3-triazol-2-yl)phenyl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 14

  16  21   855 (R/S)-(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 15

  17  40   229 (R/S)-2-methoxy-6- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 16

   8  7  1000 (R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 17

   8  3   234 (R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 18

  25  23  1800 (R/S)-(2-fluoro-6-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 19

  18  9   945 (R/S)-(5-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 20

  15  15  2700 (R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 21

>10000 >10000 (R/S)-(2-(4H-1,2,4- triazol-4-yl)phenyl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 22

  25  23  1000 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 23

>10000 >10000 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 24

  20  16   692 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 25

  17  15   466 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 26

  12  15  2100 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 27

   4  4   767 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 28

  32  21  1600 (5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 29

  55  47 >10000 (6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 30

  19  22  1700 (3-(2H-1,2,3-triazol-2- yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 31

  707 >10000 (3-fluoro-2- methoxyphenyl)((1S,4R, 6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 32

   3  4   143 (3-methyl-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 33

  74  86  3500 (3-fluoro-2-(1H-1,2,3- triazol-1- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 34

  117 462  1100 (6-methyl-2-(1H-1,2,3- triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 35

   8  3   542 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 36

   5  11   322 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 37

  170 265  1800 (3-ethoxy-6- methylpyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 38

   8  8   690 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 39

  132  17   108 (2-methoxy-6-(1H- pyrazol-5- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 40

  16  9   340 (2-methoxy-6- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 41

 4399 >10000 (2-(1,4-dimethyl-1H- pyrazol-5- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 42

  184 175  5800 (1H-indol-7- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 43

  16  8   557 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 44

  22  42  2198 (4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 45

  60  55  1500 (2-bromo-3- fluorophenyl)((1S,4R, 6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 46

  10  12   650 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 47

   7  11   503 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2-yl)phenyl)methanone 48

   3  6   972 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 49

   6  6   507 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone50

   7  9   670 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 51

  294   676 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((3-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 52

  550  4000 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 53

   3  3   165 (2H-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 54

   5  6   132 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 55

   3  3   46 (3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 56

   8  10   192 (7-ethoxyquinolin-8- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 57

   6  5   252 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 58

   4  2   181 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 59

   6  9   213 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 60

(2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 61

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 62

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 63

(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 64

(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 65

(4-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 66

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 67

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 68

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 69

(2-(3-methyl-1,2,4- oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 70

(3-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 71

(4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 72

(3-(5- fluoropyrimidin-2-yl)- 5-methylpyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 73

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 74

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 75

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 76

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 77

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 78

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 79

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 80

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 81

(3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 82

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 83

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 84

(6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone

Preferred compounds of the invention are set forth in the table below.Orexin receptor activity of certain compounds of the invention is alsoset forth in Table 2 below.

TABLE 2 rOX1 hOX1 hOX2 Ex. K_(i) K_(i) K_(i) No. Compound (nM) (nM) (nM)Compound Name  1

74 120 4700 (R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  2

200 342 10000 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  3

63 123 8900 (R/S)-(3- ethoxyisoquinolin-4- yl)((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  4

837 >10000 (R/S)-5-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  5

25 18 779 (R/S)-(5-(4- fluorophenyl)-2- methylthiazol-4-yl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  6

>10000 >10000 (R/S)-(6- methylimidazo[2,1- b]thiazol-5-yl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  7

21 12 800 (R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  8

16 15 1450 (R/S)-(3- ethoxyisoquinolin-4- yl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  9

56 102 2575 (R/S)-(5-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  10

18 27 526 (R/S)-(7- ethoxyquinolin-8-yl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  11

11 9 1475 (R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  12

44 59 >10000 (R/S)-(4-methoxy-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- azabicyclo[2.2.1]heptan- 2-yl)methanone  13

52 109 >10000 (R/S)-4-methoxy-2- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  14

17 23 882 (R/S)-(5-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  15

17 40 229 (R/S)-2-methoxy-6- (2H-1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)- azabicyclo[2.2.1]heptan-2-yl)methanone  16

8 7 1000 (R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  17

8 3 234 (R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  18

25 23 1800 (R/S)-(2-fluoro-6-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  19

18 9 945 (R/S)-(5-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  20

15 15 2700 (R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  21

>10000 >10000 (R/S)-(2-(4H-1,2,3- triazol-4-yl)phenyl)(6- ((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  22

25 23 1000 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)(6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  23

>10000 >10000 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1R,4S,6S)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  24

20 16 692 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1R,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  25

14 15 483 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  26

12 15 2100 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  27

6 5 725 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  28

32 21 1600 (5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  29

55 47 >10000 (6-methyl-2-(2H-1,2,3- triaazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  30

19 22 1700 (3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  31

707 >10000 (3-fluoro-2- methoxyphenyl)((1S,4R, 6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  32

3 6 149 (3-methyl-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  33

74 86 3500 (3-fluoro-2-(1H-1,2,3- triazol-1- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  34

162 368 1050 (6-methyl-2-(1H-1,2,3- triazol-1-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  35

8 3 546 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  36

5 13 343 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  37

170 265 1800 (3-ethoxy-6- methylpyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  38

8 8 633 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  39

72 17 104 (2-methoxy-6-(1H- pyrazol-5- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  40

15 9 333 (2-methoxy-6- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  41

4400 >10000 (2-(1,4-dimethyl-1H- pyrazol-5- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  42

184 175 5800 (1H-indol-7- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  43

24 16 550 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  44

21 39 2333 (4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  45

60 55 1500 (2-bromo-3- fluorophenyl)((1S,4R, 6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  46

10 12 650 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  47

6 9 524 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2-yl)phenyl)methanone  48

4 5 903 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone  49

6 5 443 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone 50

7 10 578 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone  51

294 676 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((3-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  52

550 4000 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((3- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  53

3 4 169 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  54

6 5 126 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  55

3 3 46 (3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  56

8 10 192 (7-ethoxyquinolin-8- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  57

5 5 225 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  58

5 3 193 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  59

6 7 192 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  60

20 12 617 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  61

15 19 248 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  62

28 19 569 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  66

2 5 181 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  67

7 7 264 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  68

7 8 612 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  73

8 11 575 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  74

16 16 1800 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  76

4 3 211 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  77

9 13 1700 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  80

9 7 456 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  83

8 5 289 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  85

6 6 910 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- (6-²H)-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  86

7 9 946 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]- (3- ²H,²H)-heptan-2- yl)heptan- 2-yl)methanone  87

156 211 >10000 (2-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  88

45 36 >10000 (5-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  89

18 8 1100 (2-(5-fluoropyrimidin- 2- yl)phenyl)((1`S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  90

15 19 2150 (3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  91

8 6 331 (2-(5-fluoropyrimidin- 2-yl)-3- methylphenyl)((1S,4R, 6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  92

13 19 362 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  93

125 76 3100 (3-phenylpyrazin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  94

35 30 848 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((6-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  95

29 37 137 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((4-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  96

320 1700 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((3-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone  97

21 15 1100 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone  98

37 28 1200 ((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin-2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)methanone  99

11 10 725 ((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin-2-yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2-yl)phenyl)methanone 100

13 12 1600 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 101

26 11 710 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 102

404 1600 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone 103

>10000 >10000 (6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)((1S,4R,6R)-6- (pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 104

497 5000 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-(pyridin-2-yloxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone 105

119 337 >10000 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-2-(2H- 1,2,3-triazol-2-yl)pyridin-3- yl)methanone 106

3 4 436 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2- 1,2,3-triazol-2-yl)phenyl)methanone 107

16 26 1960 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 108

8 31 776 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 109

6 5 442 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 110

6 11 1200 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 111

5 5 458 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 112

8 10 459 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 113

17 14 984 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-5-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 114

11 23 668 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 115

7 8 852 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 116

11 12 939 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2-yl)phenyl)methanone 117

16 28 1600 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(5- fluoropyrimidin-2-yl)phenyl)methanone 118

133 105 1600 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 119

262 3600 ((1S,4R,6R)-6-((5- fluoropyridin-2-yl)oxy)- 2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 120

60 111 4100 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((5-fluoropyridin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 121

10 11 50 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(difluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 122

28 30 218 ((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 123

11 10 149 ((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2- methanone 124

200 109 4500 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 125

220 88 5500 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 126

27 22 4200 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 127

116 143 >10000 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromnethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 128

69 62 3800 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 129

53 47 4400 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 130

29 27 3500 (2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 131

140 132 2200 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 132

425 6800 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- methylpyrimidin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 133

60 102 4200 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((5-methylpyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 134

668 >10000 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-methylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone135

61 100 1200 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-ethylpyrimidin-2- yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 136

380 4700 ((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 137

39 65 1700 ((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 138

300 2700 ((1S,4R,6R)-6-((5- ethylpyrimidin-2- yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin-2-yl)methanone 139

208 150 3700 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((6-(trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 140

330 7700 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4R,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)oxy)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 141

208 348 >10000 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((6-(trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 142

376 7900 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((6-(trifluoromethyl)pyridazin- 3-yl)oxy)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 143

24 34 7300 (6-methyl-2-(2H-1,2,3- triazol-2-yl)pyridin-3-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 144

3 3 133 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 145

17 7 934 (4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 146

6 3 150 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 147

5 6 190 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 148

3 5 189 (2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 149

14 7 4600 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 150

13 9 88 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 151

21 47 5100 (5-methyl-2-(pyrimidin- 2-yl)pyridin-3- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 152

30 16 1600 (4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5-yl)phenyl)((1S,4S,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 153

3 3 342 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 154

4 6 329 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 155

5 3 303 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-(methyl(5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 156

7 5 274 ((1S,4S,6R)-6- (methyl(5- (trifluoromethyl)pyridin-2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)methanone 157

6 3 351 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 158

5 2 340 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 159

6 4 209 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 160

9 6 208 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 161

14 5 384 ((1S,4S,6R)-6- ((cyclopropylmethyl)(5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone 162

>10000 >10000 N-((1S,4S,6R)-2-(3- fluoro-2-(pyrimidin-2- yl)benzoyl)-2-azabicyclo[2.2.1]heptan- 6-yl)-N-(5- (trifluoromethyl)pyridin-2-yl)acetamide 163

19 12 962 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)-6-((2-methoxyethyl)(5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 166

2 4 236 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)-6-((5-bromopyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 167

2 6 239 ((1S,4S,6R)-6-((5- bromopyridin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 168

2 4 351 ((1S,4S,6R)-6-((5- bromopyridin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2-yl)phenyl)methanone 169

3 4 285 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)-6-((5-chloropyridin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 170

4 12 321 ((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 171

27 25 1900 ((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 172

8 7 400 ((1S,4S,6R)-6-((5- chloropyridin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 173

55 33 264 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(difluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 174

18 15 230 ((1S,4S,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 175

170 191 844 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 176

56 52 1300 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)-6-((5-methoxypyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 177

3 3 200 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((3-fluoro-5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 178

6 8 112 ((1S,4S,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin-2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H-1,2,3-triazol-2- yl)pyridin-2- yl)methanone 179

5 5 217 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)-6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 180

6 5 380 ((1S,4S,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin-2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2-yl)phenyl)methanone 181

5 8 163 ((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2-azabicyclo[2.2.1]heptan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 182

3 4 218 ((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 183

5 7 206 ((1S,4S,6R)-6- (benzo[d]oxazol-2- ylamino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 184

13 15 337 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)-6-(p-tolylamino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone 185

27 33 146 (1H-indol-7- yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyridin-2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)methanone 186

123 151 2700 (1H-indazol-7- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 187

28 30 1600 (5-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 188

191 210 >10000 (2-(2H-1,2,3-triazol-2- yl)pyridin-3-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 189

14 11 678 (3-(pyrimidin-2- yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone. 190

12 12 >10000 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2-yl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 191

15 13 163 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 192

8 7 249 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 193

40 65 2000 (4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 194

8 8 241 ((5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluorometjyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 195

9 8 199 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 196

6 4 60 (3-methyl-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 197

93 39 9700 (4-methoxy-2-(2H- 1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 198

11 9 1375 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 199

6 8 221 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 200

7 6 240 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 201

6 6 213 (2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 202

13 13 302 (5-fluoro-2-(oxazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 203

9 9 545 (2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 204

9 9 960 (3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 205

51 35 846 (3-phenylpyrazin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 206

8 10 103 [1,1′-biphenyl]-2- yl((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 207

143 127 611 (3-phenylfuran-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 208

7 6 846 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 209

9 5 753 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-(methyl(5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 210

6 5 502 ((1S,4S,6R)-6- (methyl(5- (trifluoromethyl)pyrazin-2-yl)amino)-2- azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2-yl)phenyl)methanone 211

31 16 1300 ((1S,4S,6R)-6- ((cyclopropylmethyl)(5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone 212

14 9 607 ((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 213

39 31 871 ((1S,4S,6R)-6-((5- chloropyrazin-5- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 214

13 14 708 ((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 215

12 13 435 ((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone 216

9 9 500 ((1S,4S,6R)-6-((5- chloropyrazin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(5- fluoropyrimidin-2-yl)phenyl)methanone 217

12 29 390 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 218

31 49 490 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 219

20 27 480 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)-6-((5-methylpyrazin-2- yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 220

11 17 284 ((1S,4S,6R)-6-((5- methylpyrazin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone 221

2100 3000 Methyl 5-(((1S,4S,6R)- 2-(2-(2H-1,2,3-triazol-2-yl)benzoyl)-2- azabicyclo[2.2.1]heptan- 6-ylamino)pyrazin-2-carboxylate 222

261 >10000 (2-(2H-1,2,3-triazol-2- yl)pyridin-3- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 223

11 6 619 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 224

37 33 1900 (4-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 225

20 16 800 (5-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 226

17 19 874 (2-fluoro-6-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4S,6R)-6-((5- (trifluoromethyl)pyrimidin- 2-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 227

12 13 3100 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 228

11 9 544 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 229

9 11 724 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 230

4 4 470 (2-(pyrimidin-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 231

9 12 1300 (2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 232

24 25 1352 (2-fluoro-6-(oxazol-2- yl)phenyl)((1S,4S,6R)- 6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 233

280 1100 (3-ethoxy-6- methylpyridin-2- yl)((1S,4S,6R)-6-((5-(trifluoromethyl)pyrimidin- 2-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 234

17 12 827 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 235

36 41 1300 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2-(2H- 1,2,3-triazol-2-yl)phenyl)methanone 236

10 9 1020 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 237

32 13 1900 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(4-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 238

20 8 991 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(5-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 239

23 41 726 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-fluoro-6- (pyrimidin-2-yl)phenyl)methanone 240

17 12 831 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-(pyrimidin-2- yl)phenyl)methanone 241

21 12 971 ((1S,4S,6R)-6-((5- chloropyrimidin-2- yl)(methyl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)(2-(5- fluoropyrimidin-2-yl)phenyl)methanone 242

89 113 2100 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((6-(trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 243

112 131 1800 (6-methyl-3-(2H-1,2,3- triazol-2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 244

114 143 1700 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2-yl)((1S,4S,6R)-6-((6- (trifluoromethyl)pyridazin- 3-yl)amino)-2-azabicyclo[2.2.1]heptan- 2-yl)methanone 245

65 53 4300 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((6-(trifluoromethyl)pyridazin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 246

194 155 843 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4S,6R)- 6-((6-(trifluoromethyl)pyridin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 247

26 31 939 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4S,6R)- 6-((6-(trifluoromethyl)pyridin- 3-yl)amino)-2- azabicyclo[2.2.1]heptan-2-yl)methanone 248

11 14 467 (R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 249

8 15 758 (R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)(phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 250

22 24 1800 (R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 251

18 11 760 (R/S)-(2-(5- fluoropyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyridiun- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 252

13 14 312 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2-yl)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 253

>10000 >10000 (R/S)-(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2-yl)((1S,4R,6S)-6-((5- (trifluoromethyl)pyrazin- 2-yl)amino)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 254

12 10 307 (R/S)-(2-(2H-1,2,3- triazol-2-yl)phenyl)(6- ((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 255

12 11 1000 (R/S)-(3-fluoro-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 256

20 10 348 (R/S)-(3-methyl-2-(2H- 1,2,3-triazol-2- yl)phenyl)(6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 257

21 24 741 (R/S)-(3-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 258

26 17 2600 (R/S)-(4-fluoro-2- (pyrimidin-2- yl)phenyl)(6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 259

16 19 865 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 260

11 10 294 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 261

21 9 400 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 262

10 10 550 (2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 263

11 9 1100 (3-fluoro-2-(5- fluoropyrimidin-2- yl)phenbyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 264

10 16 >10000 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 265

14 19 306 (6-methyl-3-(pyrimidin- 2-yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 266

11 11 654 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((3-fluoro-5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 267

26 19 1100 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)-6-((5-methylpyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone268

5 4 200 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-bromopyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone269

4 5 363 ((1S,4R,6R)-6-((5- bromopyridin-2- yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 270

4 3 200 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-chloropyridin-2- yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)methanone271

7 8 452 ((1S,4R,6R)-6-((5- chloropyridin-2- yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 272

23 11 1400 (2-(5-fluoropyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 273

44 16 3800 (3-fluoro-2-(5- fluoropyrimidin-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 274

11 8 534 (3-fluoro-2-(2H-1,2,3- triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 275

8 5 175 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 276

2700 >10000 (3-fluoro-2-(pyrimidin- 2- yl)phenyl)((1R,4S,6S)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 277

17 15 998 (4-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 278

14 7 243 (5-fluoro-2-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 279

11 13 177 (2-fluoro-6-(pyrimidin- 2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 280

7 4 189 (2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyrazin- 2-yl)amino)-2- azabicyclo[2.2.2]octan-2-yl)methanone 281

5 19 336 ((1S,4R,6R)-6-((3- chloro-5- (trifluoromethyl)pyridin-2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 282

81 65 >10000 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyrazin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 283

21 27 >10000 ((1S,4R,6R)-6-((3- fluoro-5- (trifluoromethyl)pyridin-2-yl)oxy)-2- azabicyclo[2.2.2]octan- 2-yl)(5-methyl-3-(pyrimidin-2-yl)pyridin- 2-yl)methanone 284

45 47 5600 ((1S,4R,6R)-6-((5- chloropyrimdin-2- yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)(3-fluoro-2- (pyrimidin-2-yl)phenyl)methanone 285

117 215 6000 ((1S,4R,6R)-6-((5- chloropyrimidin-2- yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin-2-yl)methanone 286

822 3100 ((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2-azabicyclo[2.2.2]octan- 2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2-yl)pyridin-2- yl)methanone 287

155 226 2700 ((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2-azabicyclo[2.2.2]octan- 2-yl)(2-(2H-1,2,3- triazol-2-yl)phenyl)methanone 288

29 39 5100 ((1S,4R,6R)-6-((5- (difluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)(5-methyl-3- (pyrimidin-2-yl)pyridin-2-yl)methanone 289

14 24 207 (2-methoxy-6-(2H- 1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 290

97 188 >10000 (5-methyl-2-(pyrimidin- 2-yl)pyridin-3-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 291

43 82 4200 (4-fluoro-2-(3-methyl- 1,2,4-oxadiazol-5-yl)phenyl)((1S,4R,6R)- 6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 292

19 40 673 (2-fluoro-6-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 293

16 26 535 (5-fluoro-2-(oxazol-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 294

166 580 1400 (5-methyl-3-(1H-1,2,3- triazol-1-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 295

19 34 5800 (4-methoxy-2- (pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 296

8 14 474 (3-(pyrimidin-2- yl)pyridin-2- yl)((1S,4R,6R)-6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 297

10 10 606 (2-(pyrimidin-2- yl)phenyl)((1S,4R,6R)- 6-((5-(trifluoromethyl)pyridin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 298

24 29 >10000 (5-methyl-3-(pyrimidin- 2-yl)pyridin-2-yl)((1S,4R,6R)-6-((5- (trifluoromethyl)pyridin- 2-yl)oxy)-2-azabicyclo[2.2.2]octan- 2-yl)methanone 299

(1S,4R,6R)-6-((5- chloropyrimidin-2- yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)(6-methyl-3-(2H- 1,2,3-triazol-2- yl)pyridin-2- yl)methanone 300

92 112 3700 (2-(2H-1,2,3-triazol-2- yl)phenyl)((1S,4R,6R)-6-((5-chloropyrimidin- 2-yl)oxy)-2- azabicyclo[2.2.2]octan-2-yl)methanone 301

((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan-2-yl)(3-fluoro-2- (pyrimidin-2- yl)phenyl)methanone 302

((1S,4R,6R)-6-((1,8- naphthyridin-2-yl)oxy)- 2- azabicyclo[2.2.2]octan-2-yl)(6-methyl-3- (pyrimidin-2-yl)pyridin- 2-yl)methanone

1. A compound of formula I

or an enantiomer or diastereomer thereof; or a pharmaceuticallyacceptable salt thereof; wherein X is N or CR₁; Y is N or CR₂; R₁ is H,alkoxy, halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl,isoxazolyl, oxadiazolyl, pyridyl, phenyl or pyrazolyl, whereintriazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted withup to two substituents selected from halo or alkyl; R₂ is H, alkyl,alkoxy, or halo; Z is NH, N—CH₃, N—CH₂CH₃, N—CH₂-cyclopropyl,N—C(═O)CH₃, N—CH₂CH₂OCH₃ or O; R₃ is H, alkyl, alkoxy, halo, triazolyl,thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl,pyridyl, phenyl or pyrazolyl, wherein triazolyl, thiazolyl, pyridazinyl,pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl, phenyl orpyrazolyl is optionally substituted with up to two substituents selectedfrom halo or alkyl; R₄ is H or alkyl; or R₃ and R₄, together with theatoms to which they are attached, form a 6-membered aryl ring or a 5- or6-membered heteroaryl ring; R₅ is phenyl, pyridyl, pyrazinyl,benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein thepyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl orpyrimidinyl is optionally substituted with up to two groups selectedfrom halo, alkoxy, hydroxymethyl or alkyl; and n is 1 or
 2. 2. Thecompound of claim 1, wherein Z is NH.
 3. The compound of claim 1,wherein Z is O.
 4. The compound of claim 1, wherein X is CR₁ and Y isCR₂.
 5. The compound of claim 1, wherein X is CR₁ and Y is N.
 6. Thecompound of claim 1, wherein X is N and Y is CR₂.
 7. The compound ofclaim 1, wherein R₁ is alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl,isoxazolyl, oxadiazolyl, or pyrazolyl.
 8. The compound of claim 7,wherein R₁ is alkoxy, halo, triazolyl, or pyrimidinyl.
 9. The compoundof claim 7, wherein pyrazolyl is methyl-pyrazolyl or dimethyl-pyrazolyl.10. The compound of claim 7, wherein oxadiazolyl is methyl-oxadiazolyl.11. The compound of claim 1, wherein R₂ is H.
 12. The compound of claim1, wherein R₂ is alkyl.
 13. The compound of claim 12, wherein alkyl is—CH₃.
 14. The compound of claim 1, wherein R₂ is alkoxy.
 15. Thecompound of claim 1, wherein R₂ is halo.
 16. The compound of claim 15,wherein halo is F.
 17. The compound of claim 1, wherein R₃ is H.
 18. Thecompound of claim 1, wherein R₃ is alkyl.
 19. The compound of claim 1,wherein R₃ is alkoxy.
 20. The compound of claim 1, wherein R₃ is halo.21. The compound of claim 1, wherein R₃ is triazolyl.
 22. The compoundof claim 1, wherein R₄ is H.
 23. The compound of claim 1, wherein R₄ isalkyl.
 24. The compound of claim 23, wherein alkyl is —CH₃.
 25. Thecompound of claim 1, wherein R₃ and R₄ together with the atoms to whichthey are attached, form a 6-membered aryl ring.
 26. The compound ofclaim 1, wherein R₃ and R₄ together with the atoms to which they areattached, form a 6-membered heteroaryl ring containing one N.
 27. Thecompound of claim 1, wherein R₃ and R₄ together with the atoms to whichthey are attached, form a 5-membered heteroaryl ring containing one N.28. The compound of claim 1, wherein R₅ is pyridyl, optionallysubstituted with halo or alkyl.
 29. The compound of claim 28, whereinalkyl is trihaloalkyl.
 30. The compound of claim 28, wherein R₅ ispyridyl optionally substituted with trifluoromethyl.
 31. The compound ofclaim 1, wherein R₅ is pyrazinyl, optionally substituted with halo oralkyl.
 32. The compound of claim 31, wherein alkyl is trihaloalkyl. 33.The compound of claim 31, wherein R₅ is pyrazinyl optionally substitutedwith trifluoromethyl.
 34. The compound of claim 1, wherein R₅ ispyrimidinyl, optionally substituted with halo or alkyl.
 35. The compoundof claim 34, wherein alkyl is trihaloalkyl.
 36. The compound of claim34, wherein R₅ is pyrimidinyl optionally substituted withtrifluoromethyl.
 37. The compound of claim 1, wherein n is
 1. 38. Thecompound of claim 1, wherein n is
 2. 39. A compound selected from thegroup consisting of


40. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound according to claim 1 and at least onepharmaceutically acceptable excipient.
 41. A method of treating asubject suffering from or diagnosed with a disease, disorder, or medicalcondition mediated by orexin receptor activity, comprising administeringto the subject an effective amount of a compound according to claim 1.42. The method of claim 41, wherein the disease, disorder, or medicalcondition mediated by orexin receptor activity is a disorder of thesleep-wake cycle, insomnia, restless legs syndrome, jet-lag, disturbedsleep, a sleep disorder secondary to neurological disorders, mania,depression, manic depression, schizophrenia, a pain syndromes,fibromyalgia, neuropathic pain, catatonia, Parkinson's disease,Tourette's syndrome, anxiety, delirium, dementia, overweight, obesity ora condition related to overweight or obesity, insulin resistance, typeII diabetes, hyperlipidemia, gallstones, angina, hypertension,breathlessness, tachycardia, infertility, sleep apnea, back and jointpain, varicose veins, osteoarthritis, hypertension, tachycardia,arrhythmias, angina pectoris, acute heart failure, ulcers, irritablebowel syndrome, diarrhea, gastroesophageal reflux, post-traumatic stressdisorder, panic disorders, attention deficit disorders, cognitivedeficiencies, or substance abuse.
 43. The method of claim 42 wherein thedisease, disorder, or medical condition is mood disorders,post-traumatic stress disorder, panic disorders, attention deficitdisorders, cognitive deficiencies, or substance abuse.
 44. A compound ofFormula IA:

or an enantiomer or diastereomer thereof; or a pharmaceuticallyacceptable salt thereof; wherein ring A is a heteroaryl ring selectedfrom furanyl, thiazolyl, imidazothiazolyl or pyrazinyl; R₁ is H, alkoxy,halo, triazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl,isoxazolyl, oxadiazolyl, pyridyl, phenyl, or pyrazolyl, whereintriazolyl, thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl,oxadiazolyl, pyridyl, phenyl or pyrazolyl is optionally substituted withup to two substituents selected from halo or alkyl; R₂ is H, alkyl,alkoxy, or halo; Z is NH, N—CH₃, N—CH₂CH₃, N—CH₂-cyclopropyl,N—C(═O)CH₃, N—CH₂CH₂OCH₃ or O; R₃ is H, alkyl, alkoxy, halo, triazolyl,thiazolyl, pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl,pyridyl, phenyl, or pyrazolyl, wherein triazolyl, thiazolyl,pyridazinyl, pyrimidinyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridyl,phenyl or pyrazolyl is optionally substituted with up to twosubstituents selected from halo or alkyl; R₄ is H or alkyl; or R₃ andR₄, together with the atoms to which they are attached, form a6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R₅ ispyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl orpyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl,naphthyridinyl or pyrimidinyl is optionally substituted with up to twosubstituents selected from halo, alkoxy, hydroxymethyl or alkyl; and nis 1 or
 2. 45. A compound selected from